WorldWideScience

Sample records for aripiprazole improves depressive

  1. Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression

    Directory of Open Access Journals (Sweden)

    Chiara Cecchelli

    2010-01-01

    Full Text Available Aripiprazole is the first medication approved by the FDA as an add-on treatment for MDD. The impact of aripiprazole on the response to HIV is unknown. The patient we report on was diagnosed HIV-positive in 1997 and has been treated with antiretroviral therapy since then. In 2008, we diagnosed resistant major depression, hypochondria, and panic disorder. On that occasion, blood tests showed a significantly reduced CD4 count and a positive viral load. We treated this patient with aripiprazole and citalopram. Mood, somatic symptoms, and occupational functioning progressively improved. The last blood examination showed an increase in the CD4 count and a negative viral load. On the basis of the present case study and the review of the literature concerning the effects of psychotropic agents on viral replication, we suggest that the use of aripiprazole in HIV-infected subjects warrants further research.

  2. Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression

    OpenAIRE

    Chiara Cecchelli; Giacomo Grassi; Stefano Pallanti

    2010-01-01

    Aripiprazole is the first medication approved by the FDA as an add-on treatment for MDD. The impact of aripiprazole on the response to HIV is unknown. The patient we report on was diagnosed HIV-positive in 1997 and has been treated with antiretroviral therapy since then. In 2008, we diagnosed resistant major depression, hypochondria, and panic disorder. On that occasion, blood tests showed a significantly reduced CD4 count and a positive viral load. We treated this patient with aripiprazole...

  3. Aripiprazole

    Science.gov (United States)

    ... legs difficulty breathing or swallowing tightening of the neck muscles tightness in the throat Aripiprazole may cause ... aripiprazole solution 6 months after you open the bottle or when the expiration date marked on the ...

  4. Aripiprazole Can Improve Apraxia of Eyelid Opening in Parkinson's Disease.

    Science.gov (United States)

    Tokisato, Kaori; Fukunaga, Kimiko; Tokunaga, Makoto; Watanabe, Susumu; Nakanishi, Ryoji; Yamanaga, Hiroaki

    2015-01-01

    We herein report three cases of Parkinson's disease associated with difficulty in eyelid opening, referred to as apraxia of eyelid opening (AEO), which improved after aripiprazole treatment. In case 1, aripiprazole was administered as a psychiatric treatment. It proved to be effective in AEO with blepharospasm. In case 2 and case 3, the patients experienced AEO without blepharospasm, and a significant improvement was observed after aripiprazole treatment. In this study, the aripiprazole dosage ranged between 3 and 9 mg/day. This is the first report of aripiprazole as a potentially effective treatment for AEO in Parkinson's disease. PMID:26631893

  5. A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression

    Directory of Open Access Journals (Sweden)

    Sugawara H

    2016-05-01

    Full Text Available Hiroko Sugawara,1,2 Kaoru Sakamoto,1 Tsuyoto Harada,3 Satoru Shimizu,4 Jun Ishigooka1 1Department of Psychiatry, Tokyo Women’s Medical University, 2Support Center for Women Health Care Professionals and Researchers, Tokyo Women’s Medical University, Shinjuku-ku, 3Department of Psychiatry, Tokyo Women’s Medical University Medical Center East, Arakawa-ku, 4Department of Research, Medical Research Institute, Tokyo Women’s Medical University, Shinjuku-ku, Tokyo, Japan Background: Several studies have evaluated the efficacy and tolerability of aripiprazole for augmentation of antidepressant therapy for treatment-resistant depression (TRD. Here, we investigated the efficacy of aripiprazole augmentation for TRD including both major depressive disorder and bipolar disorder and the clinical predictors of treatment efficacy in a Japanese population.  Methods: Eighty-five depressed Japanese patients who underwent aripiprazole augmentation therapy after failing to respond satisfactorily to antidepressant monotherapy were included in the study. Treatment responses were evaluated based on Clinical Global Impression Improvement scores assessed 8 weeks after initiation of aripiprazole administration. We compared demographic and diagnostic variables, psychiatric medication variables, and clinical variables between remission and nonremission groups.  Results: The aripiprazole augmentation remission rate was 36.5%. Multiple logistic regression analysis indicated that aripiprazole augmentation was significantly more effective for bipolar depression than for major depressive disorder, and both absence of comorbid anxiety disorders and current episode duration >3 months were significantly associated with the efficacy of aripiprazole augmentation.  Conclusion: Polarity of depression, comorbidity of anxiety disorders, and current episode duration may predict the efficacy of aripiprazole augmentation for TRD including both major depressive disorder and

  6. Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome.

    Science.gov (United States)

    Gerasch, Sarah; Kanaan, Ahmad Seif; Jakubovski, Ewgeni; Müller-Vahl, Kirsten R

    2016-01-01

    Gilles de la Tourette Syndrome (GTS) is characterized by motor and vocal tics, as well as associated comorbid conditions including obsessive-compulsive disorder (OCD), attention deficit/hyperactivity disorder (ADHD), depression, and anxiety which are present in a substantial number of patients. Although randomized controlled trials including a large number of patients are still missing, aripiprazole is currently considered as a first choice drug for the treatment of tics. The aim of this study was to further investigate efficacy and safety of aripiprazole in a group of drug-free, adult patients. Specifically, we investigated the influence of aripiprazole on tic severity, comorbidities, premonitory urge (PU), and quality of life (QoL). Moreover, we were interested in the factors that influence a patient's decision in electing for-or against- pharmacological treatment. In this prospective uncontrolled open-label study, we included 44 patients and used a number of rating scales to assess tic severity, PU, comorbidities, and QoL at baseline and during treatment with aripiprazole. Eighteen out of fortyfour patients decided for undergoing treatment for their tics with aripiprazole and completed follow-up assessments after 4-6 weeks. Our major findings were (1) aripiprazole resulted in significant reduction of tics, but did not affect PU; (2) aripiprazole significantly improved OCD and showed a trend toward improvement of other comorbidities including depression, anxiety, and ADHD; (3) neither severity of tics, nor PU or QoL influenced patients' decisions for or against treatment of tics with aripiprazole; instead patients with comorbid OCD tended to decide in favor of, while patients with comorbid ADHD tended to decide against tic treatment; (4) most frequently reported adverse effects were sleeping problems; (5) patients' QoL was mostly impaired by comorbid depression. Our results suggest that aripiprazole may improve associated comorbid conditions in addition to tics

  7. Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome.

    Science.gov (United States)

    Gerasch, Sarah; Kanaan, Ahmad Seif; Jakubovski, Ewgeni; Müller-Vahl, Kirsten R

    2016-01-01

    Gilles de la Tourette Syndrome (GTS) is characterized by motor and vocal tics, as well as associated comorbid conditions including obsessive-compulsive disorder (OCD), attention deficit/hyperactivity disorder (ADHD), depression, and anxiety which are present in a substantial number of patients. Although randomized controlled trials including a large number of patients are still missing, aripiprazole is currently considered as a first choice drug for the treatment of tics. The aim of this study was to further investigate efficacy and safety of aripiprazole in a group of drug-free, adult patients. Specifically, we investigated the influence of aripiprazole on tic severity, comorbidities, premonitory urge (PU), and quality of life (QoL). Moreover, we were interested in the factors that influence a patient's decision in electing for-or against- pharmacological treatment. In this prospective uncontrolled open-label study, we included 44 patients and used a number of rating scales to assess tic severity, PU, comorbidities, and QoL at baseline and during treatment with aripiprazole. Eighteen out of fortyfour patients decided for undergoing treatment for their tics with aripiprazole and completed follow-up assessments after 4-6 weeks. Our major findings were (1) aripiprazole resulted in significant reduction of tics, but did not affect PU; (2) aripiprazole significantly improved OCD and showed a trend toward improvement of other comorbidities including depression, anxiety, and ADHD; (3) neither severity of tics, nor PU or QoL influenced patients' decisions for or against treatment of tics with aripiprazole; instead patients with comorbid OCD tended to decide in favor of, while patients with comorbid ADHD tended to decide against tic treatment; (4) most frequently reported adverse effects were sleeping problems; (5) patients' QoL was mostly impaired by comorbid depression. Our results suggest that aripiprazole may improve associated comorbid conditions in addition to tics

  8. Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome

    Science.gov (United States)

    Gerasch, Sarah; Kanaan, Ahmad Seif; Jakubovski, Ewgeni; Müller-Vahl, Kirsten R.

    2016-01-01

    Gilles de la Tourette Syndrome (GTS) is characterized by motor and vocal tics, as well as associated comorbid conditions including obsessive-compulsive disorder (OCD), attention deficit/hyperactivity disorder (ADHD), depression, and anxiety which are present in a substantial number of patients. Although randomized controlled trials including a large number of patients are still missing, aripiprazole is currently considered as a first choice drug for the treatment of tics. The aim of this study was to further investigate efficacy and safety of aripiprazole in a group of drug-free, adult patients. Specifically, we investigated the influence of aripiprazole on tic severity, comorbidities, premonitory urge (PU), and quality of life (QoL). Moreover, we were interested in the factors that influence a patient's decision in electing for-or against- pharmacological treatment. In this prospective uncontrolled open-label study, we included 44 patients and used a number of rating scales to assess tic severity, PU, comorbidities, and QoL at baseline and during treatment with aripiprazole. Eighteen out of fortyfour patients decided for undergoing treatment for their tics with aripiprazole and completed follow-up assessments after 4–6 weeks. Our major findings were (1) aripiprazole resulted in significant reduction of tics, but did not affect PU; (2) aripiprazole significantly improved OCD and showed a trend toward improvement of other comorbidities including depression, anxiety, and ADHD; (3) neither severity of tics, nor PU or QoL influenced patients' decisions for or against treatment of tics with aripiprazole; instead patients with comorbid OCD tended to decide in favor of, while patients with comorbid ADHD tended to decide against tic treatment; (4) most frequently reported adverse effects were sleeping problems; (5) patients' QoL was mostly impaired by comorbid depression. Our results suggest that aripiprazole may improve associated comorbid conditions in addition to tics

  9. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data.

    Science.gov (United States)

    Preskorn, Sheldon H; Macaluso, Matthew

    2016-03-01

    This series of columns has 3 main goals: (1) to explain class warnings as used by the United States Food and Drug Administration, (2) to increase awareness of movement disorders that may occur in patients treated with antipsychotic medications, and (3) to understand why clinicians should refrain from immediately assuming a diagnosis of tardive dyskinesia/dystonia (TD) in patients who develop abnormal movements during treatment with antipsychotics. The first column in the series presented a patient who developed abnormal movements while being treated with aripiprazole as an augmentation strategy for major depressive disorder (MDD) and reviewed data concerning the historical background, incidence, prevalence, and risk factors for tardive and spontaneous dyskinesias, the clinical presentations of which closely resemble each other. The second column in the series reviewed the unique mechanism of action of aripiprazole and preclinical studies and an early-phase human translational study that suggest a low, if not absent, risk of TD with aripiprazole. This column reviews clinical trial data to assess whether those data support the conclusion that aripiprazole has a low to absent risk of causing TD when used as an augmentation strategy to treat MDD. To date, no randomized, placebo-controlled trials have established a definitive link between exposure to aripiprazole and TD in patients with MDD. One long-term, open-label, safety trial examined aripiprazole as an augmentation strategy in individuals with MDD and found a rare occurrence (4/987, 0.4%, the confidence interval of which overlaps with zero) of an adverse event termed TD. In all 4 cases, the observed movements resolved within weeks of aripiprazole discontinuation, suggesting that they were either amenable to treatment or represented an acute syndrome rather than TD. No cases of TD were reported in the registration trials for the MDD indication for aripiprazole. These data were presented in a pooled analysis of

  10. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report Data.

    Science.gov (United States)

    Macaluso, Matthew; Flynn, Alexandra; Preskorn, Sheldon

    2016-05-01

    This series of columns has 3 main goals: (1) to explain class warnings as used by the United States Food and Drug Administration, (2) to increase awareness of movement disorders that may occur in patients treated with antipsychotic medications, and (3) to understand why clinicians should refrain from immediately assuming a diagnosis of tardive dyskinesia/dystonia (TD) in patients who develop abnormal movements during treatment with antipsychotics. The first column in the series presented a patient who developed abnormal movements while being treated with aripiprazole as an augmentation strategy for major depressive disorder and reviewed data concerning the historical background, incidence, prevalence, and risk factors for tardive and spontaneous dyskinesias, the clinical presentations of which closely resemble each other. The second column in the series reviewed the unique mechanism of action of aripiprazole and reviewed preclinical studies and an early-phase human translational study that suggest a low, if not absent, risk of TD with aripiprazole. The third column in this series reviewed the registration trial data for aripiprazole across all of its indications and found a raw incidence of TD ranging from 0.004 (4 out of 987) in long-term studies of the drug as an augmentation strategy for major depressive disorder to 0.0016 (19 out of 11,897) based on all short-term (ie, weeks to <6 mo) and long-term (6 mo to 1 y) studies combined. This fourth column in the series reviews the "real-world" data on aripiprazole and assesses whether these data also support the conclusion that aripiprazole has a low to absent risk of causing TD. The "real-world" data consist of case reports from the medical literature and the United States Food and Drug Administration Adverse Event Reporting System (FAERS). We found 37 cases in the medical literature reporting what was termed TD in association with aripiprazole treatment as well as 27 case reports suggesting improvement in

  11. Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder.

    Science.gov (United States)

    Smagula, Stephen F; Wallace, Meredith L; Anderson, Stewart J; Karp, Jordan F; Lenze, Eric J; Mulsant, Benoit H; Butters, Meryl A; Blumberger, Daniel M; Diniz, Breno S; Lotrich, Francis E; Dew, Mary Amanda; Reynolds, Charles F

    2016-10-01

    Personalizing treatment for late-life depression requires identifying and integrating information from multiple factors that influence treatment efficacy (moderators). We performed exploratory moderator analyses using data from a multi-site, randomized, placebo-controlled, double-blind trial of aripiprazole augmentation. Patients (n = 159) aged ≥60 years had major depressive disorder that failed to remit with venlafaxine monotherapy. We examined effect sizes of 39 potential moderators of aripiprazole (vs. placebo) augmentation efficacy using the outcome of percentage reduction in depressive symptom after 12 weeks. We then incorporated information from the individually relevant variables in combined moderators. A larger aripiprazole treatment effect was related to: white race, better physical function, better performance on Trail-Making, attention, immediate, and delayed memory tests, greater psychomotor agitation and suicidality symptoms, and a history of adequate antidepressant pharmacotherapy. A smaller aripiprazole treatment effect was observed in patients with: more pain and more work/activity impairment and libido symptoms. Combining information from race and Trail-Making test performance (base combined moderator (Mb*)) produced a larger effect size (Spearman effect size = 0.29 (95% confidence interval (CI): 0.15, 0.42)) than any individual moderator. Adding other individually relevant moderators in the full combined moderator (Mf*) further improved effect size (Spearman effect size = 0.39 (95% CI: 0.25, 0.52)) and identified a sub-group benefiting more from placebo plus continuation venlafaxine monotherapy than adjunctive aripiprazole. Combining moderators can help clinicians personalize depression treatment. We found the majority of our patients benefited from adjunctive aripiprazole, but a smaller subgroup that is identifiable using clinical measures appeared to benefit more from continuation venlafaxine plus placebo. PMID:27438687

  12. Aripiprazole Improved Obsessive Compulsive Symptoms in Asperger's Disorder.

    Science.gov (United States)

    Celik, Gonca; Tahiroglu, Aysegul Yolga; Firat, Sunay; Avci, Ayşe

    2011-12-01

    There are many comorbid disorders associated with autism spectrum disorders in child and adolescent population. Although obsessive compulsive disorder and autism spectrum disorders (ASD) comorbidity has common in clinical practice, there are few reports about psychopharmacological treatment for obsessive compulsive symptoms in children with ASD in the literacy. We report a successful treatment case with aripiprazole in Asperger's Disorder with obsessive compulsive symptoms. The Yale Brown Obsessive Compulsive Scale was performed to assess symptom variety. This case report supports the effectiveness of aripiprazole in treatment of obsessive compulsive symptoms in Asperger's Disorder or ASDs. Aripiprazole may be beneficial to obsessive compulsive disorder comorbid autism spectrum disorders in child and adolescent age group. PMID:23429759

  13. Aripiprazole Improved Obsessive Compulsive Symptoms in Asperger's Disorder

    OpenAIRE

    Celik, Gonca; Tahiroglu, Aysegul Yolga; Firat, Sunay; AVCI, Ayşe

    2011-01-01

    There are many comorbid disorders associated with autism spectrum disorders in child and adolescent population. Although obsessive compulsive disorder and autism spectrum disorders (ASD) comorbidity has common in clinical practice, there are few reports about psychopharmacological treatment for obsessive compulsive symptoms in children with ASD in the literacy. We report a successful treatment case with aripiprazole in Asperger's Disorder with obsessive compulsive symptoms. The Yale Brown Obs...

  14. Aripiprazole salts. II. Aripiprazole perchlorate.

    Science.gov (United States)

    Freire, Eleonora; Polla, Griselda; Baggio, Ricardo

    2012-06-01

    The molecular structure of aripiprazole perchlorate (systematic name: 4-(2,3-dichlorophenyl)-1-{4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl}piperazin-1-ium perchlorate), C(23)H(28)Cl(2)N(3)O(2)(+)·ClO(4)(-), does not differ substantially from the recently published structure of aripiprazole nitrate [Freire, Polla & Baggio (2012). Acta Cryst. C68, o170-o173]. Both compounds have almost identical bond distances, bond angles and torsion angles. The two different counter-ions occupy equivalent places in the two structures, giving rise to very similar first-order `packing motifs'. However, these elemental arrangements interact with each other in different ways in the two structures, leading to two-dimensional arrays with quite different organizations.

  15. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 2: Preclinical and Early Phase Human Proof of Concept Studies.

    Science.gov (United States)

    Macaluso, Matthew; Flynn, Alexandra; Preskorn, Sheldon

    2016-01-01

    This series of columns has 3 main goals: (1) to explain class warnings as used by the United States Food and Drug Administration, (2) to increase awareness of movement disorders that may occur in patients treated with antipsychotic medications, and (3) to understand why clinicians should refrain from immediately assuming a diagnosis of tardive dyskinesia/dystonia (TD) in patients treated with antipsychotics. The first column in this series began with the case of a 76-year-old man with major depressive disorder who developed orofacial dyskinesias while being treated with aripiprazole as an antidepressant augmentation strategy. It was alleged that a higher than intended dose of aripiprazole (ie, 20 mg/d for 2 wk followed by 10 mg/d for 4 wk instead of the intended dose of 2 mg/d) was the cause of the dyskinetic movements in this man, and the authors were asked to review the case and give their opinion. The principal basis for this theory of causation was the class warning about TD in the package insert for aripiprazole. The rationale for concluding aripiprazole caused TD in the 76-year-old man led to this series of columns about aripiprazole, its potential--if any--to cause TD, and the presence of a class warning about TD in its package insert. The central point is to illustrate why class warnings exist and their implications for practice. The first column in this series focused on the historical background, incidence, prevalence, risk factors, and clinical presentations of tardive and spontaneous dyskinesias and concluded with a discussion of diagnostic considerations explaining why clinicians should avoid making a diagnosis of TD until a thorough differential diagnosis has been considered. This second column in the series reviews the pharmacology of aripiprazole and the preclinical and phase I translational human studies that suggest aripiprazole should have a low to nonexistent risk of causing TD compared with other antipsychotics. The third column in the series

  16. Aripiprazole-Induced Parkinsonism: Report of Two Cases

    OpenAIRE

    Çetin Kürşad Akpınar; Dursun Aygün; Hakan Doğru

    2015-01-01

    Aripiprazole is one of the recently introduced atypical antipsychotics used in the treatment of psychosis related to schizophrenia, depression, bipolar disorder, and Parkinson’s disease. Well-documented side effects associated with the use of aripiprazole include insomnia, anxiety, headache, nausea, vomiting, and somnolence. Aripiprazole is associated with infrequent extrapyramidal side effects. Parkinsonism is caused by some drugs that block dopamine receptors. The sign of dru...

  17. Low dosage of aripiprazole induced neuroleptic malignant syndrome after interaction with other neuroleptic drugs

    Directory of Open Access Journals (Sweden)

    Albino Petrone

    2013-09-01

    Full Text Available Aripiprazole is a 2nd generation antipsychotic medication, atypical neuroleptic used for treatment of schizophrenia improving symptoms such as hallucinations, delusions, and disorganized thinking. A potentially fatal symptom complex sometimes referred to as neuroleptic malignant syndrome (NMS has been reported in association with administration of antipsychotic drugs, including aripiprazole. Rare cases of NMS occurred during aripiprazole treatment in the worldwide clinical database. The disease is characterized by a distinctive clinical syndrome of mental status change, rigidity, fever, and dysautonomia. We report on a 63-year old woman with depression syndrome who developed neuroleptic malignant syndrome after twelve days of aripripazole 5 mg per day. Our case is added to the small number already described and suggests the need for caution when aripripazole is added to increase the effect of other antipsychotics.

  18. 阿立哌唑合并抗抑郁药治疗抑郁症的临床疗效及安全性研究%Study on the clinical effect and safety of aripiprazole combined with antidepressants in the treatment of depression

    Institute of Scientific and Technical Information of China (English)

    姜美俊

    2014-01-01

    目的:探讨阿立哌唑合并抗抑郁药(三环类抗抑郁剂阿米替林)治疗抑郁症的临床疗效及安全性。方法选择120例抑郁症患者随机分为研究组和对照组。对照组给予常规抗抑郁药物治疗,研究组在常规抗抑郁治疗基础上给予阿立哌唑。采用汉密尔顿抑郁量表和副反应量表对两组患者治疗前和治疗后进行评定。结果研究组治疗后的第1、2、4、6周汉密尔顿抑郁量表评分分别与对照组同期比较,差异有统计学意义(P0.05)。结论阿立哌唑能够提高抗抑郁药(三环类抗抑郁剂阿米替林)治疗抑郁症的临床治疗效果,可作为临床抗抑郁治疗的一种增效手段。%Objective To study clinical effect and safety of aripiprazole combined with antidepressants(tricyclic antidepressants amitriptyline) in the treatment of depression. Methods From January 2010 to December 2013, 120 patients with depression patients were selected and randomly divided into study group and control group , control group was given regular treatment of antidepressant drugs, study group was given aripiprazole combined with antidepressants(tricyclic antidepressants amitriptyline). The Hamilton Depression Scale (HAMD) and Treatment Emergent Symptom Scale (TESS) were used in the two group s of patients before and after treatment. Results Hamilton Depression Scale scores in the study group after treatment of the first week, second week, fourth week and sixth week of study group was compared with those in control group , the difference was statistically significant(P0.05). Conclusion Aripiprazole can improve the clinical efficacy of antidepressants (tricyclic antidepressants amitriptyline) in the treatment of depression, which can be one of the augmentations in the treatment of depression.

  19. Mania/hipomania induzida por aripiprazol Manic/hypomanic symptoms induced by aripiprazole

    Directory of Open Access Journals (Sweden)

    Márcio Gerhardt Soeiro de Souza

    2010-01-01

    Full Text Available Aripiprazol é um antipsicótico atípico (AAt frequentemente indicado para o tratamento agudo da mania, assim como para quadros mistos de transtorno bipolar (TB tipo I e para o tratamento de manutenção do TB tipo I. A potencial ação antidepressiva dos AAts possibilita que medicamentos dessa classe aumentem as chances do aparecimento de mania em indivíduos suscetíveis. Com o objetivo de sumarizar evidência que possibilite a discussão técnica desse tópico, aqui relatamos três casos de pacientes com TB com mania induzida por aripiprazol. Pacientes tinham diagnósticos e comorbidades diferentes e estavam em regime terapêutico também diferente. Mania foi temporalmente associada à introdução de aripiprazol. Melhora considerável aconteceu após a retirada do fármaco. Sugerimos que o aripiprazol, por meio da sua ação antidepressiva, seja fator de risco para virada maníaca e hipomaníaca. Recomendamos o uso associado de estabilizador de humor com potencial antimaníaco para prevenir eventual inversão de fase. Sugere-se, ainda, a provável eficácia antidepressiva do aripiprazol.Aripiprazole is an atypical antipsychotic often used as monotherapy or as add-on therapy in patients with manic episodes, as well as for bipolar disorders. The antidepressive effect of the atypical antipsychotic medications raises the possibility that these drugs may increase the risk of mania in susceptible individuals. With the aim of providing further evidence on this subject, herein we reported three patients with bipolar disorder and mania induced by aripiprazole. Patients had different final diagnosis as well as different comorbidities. Their therapeutic regimen was different as well. Onset of manias was temporarily associated with aripiprazole use and important improvement happened after the discontinuation of this drug. We suggest that aripiprazole, due to its antidepressant properties, is a risk factor for mania and hypomania. Mood stabilizer is

  20. Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder.

    Science.gov (United States)

    Woo, Young Sup; Bahk, Won-Myong; Park, Young-Min; Chung, Sangkeun; Yoon, Bo-Hyun; Won, Seunghee; Lee, Jeong Goo; Lee, Hwang-Bin; Kim, Won; Jeong, Jong-Hyun; Lee, Kwanghun; Kim, Moon-Doo

    2016-09-01

    We evaluated the effectiveness of aripiprazole among bipolar patients who had switched to this medication as a result of difficulty maintaining on their prestudy atypical antipsychotics (AAPs) because of subsyndromal mood symptoms or intolerance. This study included 77 bipolar patients who were in syndromal remission with an AAP as monotherapy or with an AAP combined with a mood stabilizer(s) who needed to switch from their present AAP because of subsyndromal symptoms or intolerance. At 24 weeks after switching to aripiprazole, the remission rates on the Montgomery-Åsberg Depression Rating Scale (MADRS) and on both the MADRS and the Young Mania Rating Scale were increased significantly in the full sample and in the inefficacy subgroup. In the inefficacy subgroup, the MADRS score change was significant during the 24 weeks of study. Total cholesterol and prolactin decreased significantly after switching to aripiprazole. The proportion of patients who had abnormal values for central obesity and hypercholesterolemia decreased significantly from baseline to week 24. These findings suggest that a change from the current AAP to aripiprazole was associated with improvement in subsyndromal mood symptoms and several lipid/metabolic or safety profile parameters in patients with bipolar disorder with tolerability concerns or subsyndromal mood symptoms. PMID:27487259

  1. TARDIVE DYSKINESIA AND OTHER EXTRAPYRAMIDAL SYMPTOMS ASSOCIATED WITH ARIPIPRAZOLE: A CASE SERIES

    Directory of Open Access Journals (Sweden)

    Nayana Sanjay

    2016-06-01

    Full Text Available BACKGROUND Aripiprazole is a third generation antipsychotic introduced in 2004 for treatment of Schizophrenia and bipolar disorders. It has partial agonist activity at dopamine D2 receptor and D2 antagonist activity under hyperdopaminergic condition. In addition, it is a partial agonist at serotonin 5HT1A receptor and antagonist at 5HT2A receptor. Because its pharmacological profile differs from other atypical antipsychotics, it was initially thought to produce lesser side effects and movement disorders. But over the years, there is a growing body of evidence in the form of case reports and case series of Aripiprazole induced movement disorders like Tardive dyskinesia, Parkinsonism, akathisia and dystonia. Of late it has been advocated for irritability associated with autism and as an augmenter for depressive disorder. It has lower potential for weight gain and sedation, as it has relatively low affinity for H1 [Histamine] receptor compared to clozapine, olanzapine and quetiapine. Based on this unique mechanism, it is claimed to have minimal or non-significant motor side effects like Tardive dyskinesia. We document a case series of 8 patients who developed Tardive dyskinesia, Parkinsonism and akathisia following treatment with Aripiprazole (ARP. METHODS This is both retrospective and observational study. Patients from outpatient and inpatient department of a tertiary psychiatric teaching hospital with an ICD-10 diagnosis of psychiatric disorder, who has experienced movement disorder while on treatment with Aripiprazole are included in this report. All these patients were under the care of authors as treating Psychiatrists. Rating scales like Abnormal Involuntary Movement Scale (AIMS, Naranjo’s Causality Scale, Barnes Akathisia Rating Scale (BARS and Simpson Angus extrapyramidal Scale (SAS were used. RESULTS Total of eight patients presented with various movement disorders associated with Aripiprazole, out of which three patients with tardive

  2. Treatment of refractory catatonic schizophrenia with low dose aripiprazole

    Directory of Open Access Journals (Sweden)

    Sasaki Tsuyoshi

    2012-05-01

    Full Text Available Abstract This case is of 54-year-old female with catatonic schizophrenia, characterized by treatment resistance to the pharmacotherapy with olanzapine, risperidone, flunitrazepam, and ECT. Olanzapine and risperidone and flunitrazepam did not improve her catatonic and psychotic symptoms, and induced the extrapyramidal symptoms. The effects of ECT did not continue even for a month. However, the treatment with low-dose aripiprazole dramatically improved the patient’s psychotic symptoms and extrapyramidal symptoms. The mechanisms underlying the effects of low-dose aripiprazole in this case remain unclear, but unlike other antipsychotics, aripiprazole is a dopamine D2 partial agonist. In this regard, our results suggest that aripiprazole has numerous advantages, especially in cases of stuporous catatonia and a defective general status.

  3. A control study of duloxetine combined with aripiprazol in the treatment of treatment-resistant depression%度洛西汀联合阿立哌唑治疗难治性抑郁症对照研究

    Institute of Scientific and Technical Information of China (English)

    邓良华; 莫翠英; 吴廷娟; 杨子民

    2014-01-01

    Objective To explore the efficacy and safety of duloxetine combined with aripiprazol in the treatment of treatment-resistant depression (TRD) .Meth-ods Ninety-three TRD patients were randomly divided into two groups ,research group (n=47) was trea-ted with oral duloxetine plus aripiprazol and control group (n=46) with single duloxetine for 8 weeks . Clinical efficacies were assessed with the Hamilton Depression Scale (HAMD) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 8th week ,obvious effective and effective rate were respectively 59 .1% and 77 .3% in research and 31 .1% and 42 .2% in control group , the former was significantly than the latter (χ2 = 7 .04 ,11 .35 ;P0 .05) .Conclusion Duloxetine plus aripiprazol takes effect more rapidly and has an evident effect and higher safety compared with single duloxetine in the treatment of T RD .%目的:探讨度洛西汀联合阿立哌唑治疗难治性抑郁症的临床疗效和安全性。方法将93例难治性抑郁症患者随机分为两组,研究组口服度洛西汀联合阿立哌唑治疗,对照组单用度洛西汀治疗,观察8周。采用汉密顿抑郁量表评定临床疗效,副反应量表评定不良反应。结果治疗8周末研究组显效率59.1%、有效率77.3%,对照组分别为31.1%、42.2%,研究组显效率、有效率均显著高于对照组(χ2=7.04、11.35,P<0.01)。两组不良反应较轻微,发生率比较差异无显著性(P>0.05)。结论度洛西汀联合阿立哌唑治疗难治性抑郁症起效快,疗效显著,安全性高,显著优于单用度洛西汀治疗。

  4. Aripiprazole-induced hyperprolactinemia in a young female with delusional disorder

    OpenAIRE

    Sam Padamadan Joseph

    2016-01-01

    Hyperprolactinemia is a common adverse effect of antipsychotic medication. Switching over to aripiprazole or adjunctive aripiprazole has been advocated for optimal management of antipsychotic-induced hyperprolactinemia. Adjunctive treatment with aripiprazole has been shown to normalize prolactin levels without affecting already achieved improvements in psychotic symptoms. However, here, we present the case of a 36 year old female with delusional disorder who developed symptomatic hyperprolact...

  5. Aripiprazole-induced Hyperprolactinemia in a Young Female with Delusional Disorder.

    Science.gov (United States)

    Joseph, Sam Padamadan

    2016-01-01

    Hyperprolactinemia is a common adverse effect of antipsychotic medication. Switching over to aripiprazole or adjunctive aripiprazole has been advocated for optimal management of antipsychotic-induced hyperprolactinemia. Adjunctive treatment with aripiprazole has been shown to normalize prolactin levels without affecting already achieved improvements in psychotic symptoms. However, here, we present the case of a 36 year old female with delusional disorder who developed symptomatic hyperprolactinemia while on aripiprazole treatment. Dopamine acts as a tonic inhibitor of prolactin secretion through the tubero-infundibular dopaminergic system. Aripiprazole being a partial agonist has a lower intrinsic activity at the D2 receptor than dopamine, allowing it to act as both, a functional agonist and antagonist, depending on the surrounding levels of dopamine. Hence, in the absence of a competing D2 antagonist and the presence of dopamine (the natural agonist), aripiprazole could act as a functional antagonist and thus elevate prolactin levels. PMID:27335526

  6. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1.

    Science.gov (United States)

    Preskorn, Sheldon; Flynn, Alexandra; Macaluso, Matthew

    2015-09-01

    This series of columns has 2 main goals: (1) to explain the use of class warnings by the US Food and Drug Administration and (2) to increase clinicians' awareness of movement disorders that may occur in patients being treated with antipsychotic medications and why it is appropriate and good practice to refrain from immediately assuming the diagnosis is tardive dyskinesia/dystonia (TD). This first column in the series will focus on the second goal, which will then serve as a case example for the first goal. Clinicians should refrain from jumping to a diagnosis of TD because a host of other causes need to be ruled out first before inferring iatrogenic causation. The causal relationship between chronic treatment with dopamine antagonists and TD is based on pharmacoepidemiology (ie, the prevalence of such movement disorders is higher in individuals receiving chronic treatment with such agents than in a control group). There is nothing pathognomonic about movement disorders, nor is there any test that can currently prove a drug caused a movement disorder in a specific individual. Another goal of this series is to describe the types of research that would be needed to establish whether a specific agent has a meaningful risk of causing TD. In this first column of the series, we present the case of a patient who developed orofacial dyskinesia while being treated with aripiprazole. In this case, the movement disorder was prematurely called TD, which led to a malpractice lawsuit. This case highlights a number of key questions clinicians are likely to encounter in day-to-day practice. We then review data concerning the historical background, incidence, prevalence, and risk factors for 2 movement disorders, TD and spontaneous dyskinesia. Subsequent columns in this series will review: (1) unique aspects of the psychopharmacology of aripiprazole, (2) the limited and inconsistent data in the literature concerning the causal relationship between aripiprazole and TD, (3) the use of

  7. Role of aripiprazole in treatment-resistant schizophrenia

    Directory of Open Access Journals (Sweden)

    Mossaheb N

    2012-05-01

    Full Text Available Nilufar Mossaheb,1 Rainer M Kaufmann21Department of Child and Adolescent Psychiatry, 2Department of Psychiatry and Psychotherapy, Medical University, Vienna, AustriaAbstract: About one third of patients with schizophrenia respond unsatisfactorily to antipsychotic treatment and are termed “treatment-resistant”. Clozapine is still the gold standard in these cases. However, 40%–70% of patients do not improve sufficiently on clozapine either. In the search for more efficacious strategies for treatment-resistant schizophrenia, drugs with different pharmacological profiles seem to raise new hopes, but are they valid? The aim of this review was to evaluate the evidence for aripiprazole as a potential strategy in monotherapy or combination therapy for patients with treatment-resistant schizophrenia. The evidence for aripiprazole monotherapy and for the combination of aripiprazole with psychotropics other than clozapine is scant, and no recommendation can be made on the basis of the currently available data. More effort has been made in describing combinations of aripiprazole and clozapine. Most of the open-label and case studies as well as case reports have shown positive effects of this combination on overall psychopathology and to some extent on negative symptoms. Several reports describe the possibility of dose reduction for clozapine in combination with aripiprazole, a strategy that might help so-called “treatment-intolerant” patients. The findings of four randomized controlled trials with respect to changes in psychopathology seem less conclusive. The most commonly found beneficial effects are better metabolic outcomes and indicators of the possibility of reducing the clozapine dose. However, other side effects, such as akathisia, are repeatedly reported. Further, none of the studies report longer-term outcomes. In the absence of alternatives, polypharmacy is a common strategy in clinical practice. Combining aripiprazole with clozapine in

  8. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.

    Directory of Open Access Journals (Sweden)

    Xianbin Li

    Full Text Available OBJECTIVE: To compare the safety and efficacy of adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia. METHODS: POPULATION: adult patients presenting with antipsychotic-induced hyperprolactinemia diagnosed by prolactin level with or without prolactin-related symptoms. INTERVENTIONS: adjunctive aripiprazole vs. adjunctive placebo. OUTCOME MEASURES: adverse events and efficacy of treatment. STUDIES: randomized controlled trials. RESULTS: Five randomized controlled trials with a total of 639 patients (326 adjunctive aripiprazole, 313 adjunctive placebo met the inclusion criteria. Adjunctive aripiprazole was associated with a 79.11% (125/158 prolactin level normalization rate. Meta-analysis of insomnia, headache, sedation, psychiatric disorder, extrapyramidal symptom, dry mouth, and fatigue showed no significant differences in the adjunctive aripiprazole treatment group compared with the placebo group (risk difference (Mantel-Haenszel, random or fixed -0.05 to 0.04 (95% confidence interval -0.13 to 0.16; I(2 =0% to 68%, P=0.20 to 0.70. However, sedation, insomnia, and headache were more frequent when the adjunctive aripiprazole dose was higher than 15 mg/day. Meta-analysis of the prolactin level normalization indicated adjunctive aripiprazole was superior to placebo (risk difference (Mantel-Haenszel, random 0.76 (95% confidence interval 0.67 to 0.85; I(2 =43%, P<0.00001. The subgroup analysis confirmed that the subjects who received adjunctive aripiprazole 5 mg/day showed a degree of prolactin normalization similar to that of all participants. No significant differences between groups in discontinuation and improvements of psychiatric symptoms. CONCLUSION: Adjunctive aripiprazole is both safe and effective as a reasonable choice treatment for patients with antipsychotic-induced hyperprolactinemia. The appropriate dose of adjunctive aripiprazole may be 5 mg/day.

  9. Aripiprazole alone or in combination for acute mania

    OpenAIRE

    Brown, Rachel; Taylor, Matthew; Geddes, John

    2013-01-01

    BackgroundBipolar disorder is a mental disorder characterised by episodes of elevated or irritable mood (manic or hypomanic episodes) and episodes of low mood and loss of energy (depressive episodes). Drug treatment is the first-line treatment for acute mania with the initial aim of rapid control of agitation, aggression and dangerous behaviour. Aripiprazole, an atypical antipsychotic, is used in the treatment of mania both as monotherapy and combined with other medicines. The British Associa...

  10. Cognitive-enhancing effects of aripiprazole: a case report

    Directory of Open Access Journals (Sweden)

    Galderisi Silvana

    2008-10-01

    Full Text Available Abstract Patients with schizophrenia often present mild to severe cognitive deficits which contribute to their social disability. Second-generation antipsychotics have shown only mild to moderate beneficial effects on cognition. The present case report suggests cognitive enhancing effects of aripiprazole, a dopamine partial agonist, shown to increase dopamine release in prefrontal cortex in animal studies. The patient was in his first-episode of schizophrenia, and had no previous exposure to first-generation antipsychotics. Before schizophrenia onset his cognitive functioning was poor and he could not attend regular courses to reach his high school degree; he started but was not able to attend the University courses for several years. After schizophrenia onset, he was treated, in sequence, with olanzapine, amisulpride and aripiprazole. During treatment with the first two second-generation antipsychotics, positive symptoms markedly improved while cognitive functioning remained poor. During treatment with aripiprazole, clinical remission was obtained and the patient was able to attend university courses and pass several examinations. Social functioning was markedly improved. Aripiprazole demonstrated cognitive enhancing effects in this patient. These effects were long-lasting and paralleled by a positive impact on social functioning.

  11. Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole

    Directory of Open Access Journals (Sweden)

    Izchak Kohen

    2010-03-01

    Full Text Available Izchak Kohen1, Paula E Lester2, Sum Lam31Division of Geriatric Psychiatry, Zucker-Hillside Hospital, Glen Oaks, NY, USA; 2Division of Geriatric Medicine, Winthrop University Hospital, Mineola, NY, USA; 3Division of Pharmacy and Geriatrics, St. John’s University College of Pharmacy and Allied Health Professions, Queens, NY, USAAbstract: Delusions, hallucinations and other psychotic symptoms can accompany a number of conditions in late life. As such, elderly patients are commonly prescribed antipsychotic medications for the treatment of psychosis in both acute and chronic conditions. Those conditions include schizophrenia, bipolar disorder, depression and dementia. Elderly patients are at an increased risk of adverse events from antipsychotic medications because of age-related pharmacodynamic and pharmacokinetic changes as well as polypharmacy. Drug selection should be individualized to the patient’s previous history of antipsychotic use, current medical conditions, potential drug interactions, and potential side effects of the antipsychotic. Specifically, metabolic side effects should be closely monitored in this population. This paper provides a review of aripiprazole, a newer second generation antipsychotic agent, for its use in a variety of psychiatric disorders in the elderly including schizophrenia, bipolar disorder, dementia, Parkinson’s disease and depression. We will review the pharmacokinetics and pharmacodynamics of aripiprazole as well as dosing, diagnostic indications, efficacy studies, and tolerability including its metabolic profile. We will also detail patient focused perspectives including quality of life, patient satisfaction and adherence.Keywords: aripiprazole, antipsychotics, elderly, adverse drug reaction

  12. Aripiprazole: a review of its use in the management of schizophrenia in adults.

    Science.gov (United States)

    Croxtall, Jamie D

    2012-02-01

    Oral aripiprazole (Abilify®) is an atypical antipsychotic agent that is approved worldwide for use in adult patients with schizophrenia. It is a quinolinone derivative that has a unique receptor binding profile as it exhibits both partial agonist activity at dopamine D(2) receptors and serotonin 5-HT(1A) receptors and antagonist activity at 5-HT(2A) receptors. In several well designed, randomized, clinical trials of 4-6 weeks duration, aripiprazole provided symptomatic control for patients with acute, relapsing schizophrenia or schizoaffective disorder. Furthermore, following 26 weeks' treatment, the time to relapse was significantly longer for patients with chronic, stabilized schizophrenia receiving aripiprazole compared with those receiving placebo. Using a variety of efficacy outcomes, aripiprazole showed a mixed response when evaluated against other antipsychotic agents in randomized clinical trials. Longer-term data showed that improvements in remission rates and response rates favoured aripiprazole over haloperidol, although, the time to failure to maintain a response was not significantly different between the treatment arms. On the other hand, improvements in positive and negative symptom scores mostly favoured olanzapine over aripiprazole, although, the time to all-cause treatment discontinuation was not significantly different between the two treatments. Several open-label, switching trials showed that aripiprazole provided continued control of symptoms in patients with schizophrenia or schizoaffective disorder. Using a variety of efficacy outcomes or quality-of-life scores, longer-term treatment generally favoured patients switched to receive aripiprazole compared with standard-of-care oral antipsychotics. Aripiprazole was generally well tolerated in patients with schizophrenia. In particular, its use seems to be associated with a lower incidence of extrapyramidal symptoms than haloperidol and fewer weight-gain issues than olanzapine. Aripiprazole also

  13. Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia

    Directory of Open Access Journals (Sweden)

    Ranjbar F

    2015-03-01

    and 110. The median time to recovery based on normalization of prolactin was 84 days. Psychotic symptoms were present in 26 subjects at baseline, but in only two by the end of the study. Conclusion: The results of this study confirm the effects of aripiprazole in reducing risperidone-induced hyperprolactinemia and its sequelae. Aripiprazole also led to significant improvements in psychotic symptoms when compared with those present prior to treatment with aripiprazole. Keywords: hyperprolactinemia, aripiprazole, risperidone, psychotic disorder

  14. Effect of aripiprazole on mismatch negativity (MMN in schizophrenia.

    Directory of Open Access Journals (Sweden)

    Zhenhe Zhou

    Full Text Available BACKGROUND: Cognitive deficits are considered core symptoms of the schizophrenia. Cognitive function has been found to be a better predictor of functional outcome than symptom levels. Changed mismatch negativity (MMN reflects abnormalities of early auditory processing in schizophrenia. Up to now, no studies for the effects of aripiprazole on MMN in schizophrenia have been reported. METHODOLOGY/PRINCIPAL FINDINGS: Subjects included 26 patients with schizophrenia, and 26 controls. Psychopathology was rated in patients with the Positive and Negative Syndrome Scale (PANSS at baseline, after 4- and 8-week treatments with aripiprazole. Auditory stimuli for ERP consisted of 100 millisecond/1000 Hz standards, intermixed with 100 millisecond/1500 Hz frequency deviants and 250 millisecond/1000 Hz duration deviants. EEG was recorded at Fz. BESA 5.1.8 was used to perform data analysis. MMN waveforms were obtained by subtracting waveforms elicited by standards from waveforms elicited by frequency- or duration-deviant stimuli. Aripiprazole decreased all PANSS. Patients showed smaller mean amplitudes of frequency and duration MMN at baseline than did controls. A repeated measure ANOVA with sessions (i.e., baseline, 4- and 8-week treatments and MMN type (frequency vs. duration as within-subject factors revealed no significant MMN type or MMN type × session main effect for MMN amplitudes. Session main effect was significant. LSD tests demonstrated significant differences between MMN amplitudes at 8 weeks and those at both baseline and 4 weeks. There was significant negative correlation between changes in amplitudes of frequency and duration MMN and changes in PANSS total scores at baseline and follow-up periods. CONCLUSIONS: Aripiprazole improved the amplitudes of MMN. MMN offers objective evidence that treatment with the aripiprazole may ameliorate preattentive deficits in schizophrenia.

  15. Aripiprazole Augmentation in Treatment of Resistant Obsessive Compulsive Disorder

    Directory of Open Access Journals (Sweden)

    Karim Abdel Aziz

    2016-02-01

    Full Text Available Background: Aripiprazole is a novel antipsychotic medication that has been tried in the treatment of several psychiatric disorders. In an open clinical study, we evaluated the safety and efficacy of aripiprazole in patients with obsessive compulsive disorder resistant to normal regimen of treatment. Method: A total of nine hundred and sixty one patients were admitted over three year period of time (January 2012- December 2014 to the psychiatric department of Al Ain hospital, United Arab Emirates. All patients whose been fulfilled DSM-IV diagnosis of obsessive compulsive disorder (OCD (36 patients screened for further assessment. Patients with a diagnosis of schizophrenia (22 patients and one patient with eating disorder were excluded. Thirteen patients were contacted to be involved in the study. Participants were unstable although they were adherent to their medications (SSRIs when seen in the outpatient clinic two weeks after their discharge. One patient refused to participate in the study. A final number of 12 agreed to participate in the study. twelve patients aged 22 to 65 years who had DSM-IV diagnosis of OCD were treated with aripiprazole besides their normal treatment for a period of three months with daily doses ranging from ten to 20 mg daily. Results: a positive clinical response was noted in eight of the 12 patients within three months of study recruitment according to the Clinical Global Impression-Improvement scale. Aripiprazole was well tolerated by most of the patients. The most commonly reported side effect was headache. Conclusion: our findings suggest that aripiprazole may be an effective adjuvant and safe treatment for resistant OCD.

  16. Clinical efficacy and safety of lithium carbonate combined with aripiprazole in treatment of bipolar depression%碳酸锂联合阿立哌唑治疗双相障碍抑郁发作的疗效和安全性

    Institute of Scientific and Technical Information of China (English)

    粟幼嵩; 陈俊; 李则挚; 王勇; 黄佳; 方贻儒; 王祖承

    2011-01-01

    目的 探讨碳酸锂联合阿立哌唑治疗双相障碍抑郁发作的疗效和安全性.方法 81例双相障碍抑郁发作患者随机分为联合用药组(n=42)和锂盐组(n=39),分别给予碳酸锂联合阿立哌唑治疗或单用碳酸锂治疗,持续8周.在基线期及治疗第1、2、4、8周末,采用17项汉密顿抑郁量表(HAMD-17)和Young躁狂评定量表(YMRS)评定疗效,计算治疗有效率,采用治疗时出现的症状量表(TESS)评定不良反应.结果 基线期两组HAMD-17评分差异无统计学意义(P>0.05),治疗第1、2、4周末联合用药组HAMD-17评分显著低于锂盐组(P<0.05或P<0.01);治疗第8周末联合用药组HAMD-17评分低于锂盐组,但差异无统计学意义(P>0.05).两组基线期及治疗各阶段的YMRS评分均<7.两组治疗有效率和不良反应发生率比较差异均无统计学意义(P>0.05).结论 与单用碳酸锂比较,碳酸锂联合阿立哌唑治疗双相障碍抑郁发作起效快,疗效相似,不良反应无明显增加.%Objective To investigate the clinical efficacy and safety of lithium carbonate combined with aripiprazole in treatment of bipolar depression. Methods Eighty-one patients with bipolar depression were randomly divided into lithium carbonate combined with aripiprazole group (re = 42) or lithium carbonate group ( n = 39), and were treated with lithium carbonate combined with aripiprazole and lithium carbonate for 8 weeks respectively. At the baseline and the end of fthe irst, second, fourth and eighth week of treatment, Hamilton Depression Scale-17 ( HAMD-17) and Young Mania Rating Scale (YMRS) were employed to evaluate the clinical efficacy, the effective rates were calculated, and Treatment Emergent Symptom Scale (TESS) was adopted to assess the side effects. Results There was no significant difference in HAMD-17 score between two group at the baseline (P>0.05), while HAMD-17 scores at the end of first, second and fourth week of treatment in lithium

  17. 阿立哌唑治疗精神分裂症老年患者临床疗效观察%OBSERVATION ON THE CLINIC EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF THE ELDERLY PATIENTS WITH SCHIZOPHRENIA

    Institute of Scientific and Technical Information of China (English)

    阿怀红

    2011-01-01

    [目的] 研究阿立哌唑治疗精神分裂症老年患者的临床疗效和不良反应,为临床提供依据.[方法] 选择符合CCMD-3精神分裂症诊断标准、简明精神疾病评定量表(BPRS)>35分、年龄≥65岁的病例共60例.随机分为阿立哌唑组与奋乃静组各30例.治疗前及治疗8周后分别用简明精神病评定量表(BPRS)及阳性和阴性综合征量表(PANSS)评定疗效,用副反应量表(TESS)评定不良反应.[结果] 阿立哌唑在治疗精神分裂症老年患者总疗效和对情感障碍、意志障碍的改善明显优于奋乃静.阿立哌唑在行为毒性、神经系和植物神经系的副作用明显低于奋乃静.阿立哌唑副反应轻且相对安全、依从性高.[结论] 阿立哌唑治疗精神分裂症老年患者效果确切、安全性强、依从性高,能全面提高患者生活质量.%[Objective] To study the efficacy and side effect of aripiprazole in the treatment of the elderly patients with schizophrenia, and to provide the basis for the clinical. [Methodsl According to CCMD-3, 65 patients with BPRS score over 35 and aged above 60 years old were selected and randomly divided into two groups: 30 patients had heen given aripiprazole for 8 weeks, and 30 patients had been given perphenazine for 8 weeks, then all patients were assessed by BPRS, PANSS and TESS. [ Results) Both aripiprazole and perphenazine had same effect on Psychiatric symptams. Aripiprazole were much better than perphenazine in these respects: anxiety, depression and exceasive activity. Aripiprazole has less side effecta than perphenazine. Aripiprazole was Side-Light and relatively safe and high compliance. [Conclusion] Aripiprazole is an effective trealment of the elderly patients with schizophrenia, strong security and , high compliance, we can improve the overall quality of life of patients.

  18. Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole

    Directory of Open Access Journals (Sweden)

    Ilse C A Bakker

    2016-06-01

    Full Text Available In this report, we describe a female patient with both prolactinoma and psychotic disorder who was successfully treated with aripiprazole, a partial dopamine 2 receptor agonist. During the follow-up of more than 10 years, her psychotic symptoms improved considerably, prolactin levels normalised and the size of the prolactinoma decreased. This observation may be of clinical relevance in similar patients who often are difficult to treat with the regular dopaminergic drugs.

  19. Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole

    OpenAIRE

    Bakker, Ilse C A; Schubart, Chris D.; Zelissen, Pierre M J

    2016-01-01

    Summary In this report, we describe a female patient with both prolactinoma and psychotic disorder who was successfully treated with aripiprazole, a partial dopamine 2 receptor agonist. During the follow-up of more than 10 years, her psychotic symptoms improved considerably, prolactin levels normalised and the size of the prolactinoma decreased. This observation may be of clinical relevance in similar patients who often are difficult to treat with the regular dopaminergic drugs. Learning poin...

  20. The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review.

    Science.gov (United States)

    Muneer, Ather

    2016-01-01

    Bipolar disorder is characterized by exacerbations of opposite mood polarity, ranging from manic to major depressive episodes. In the current nosological system of the Diagnostic and Statistical Manual - 5(th) edition (DSM-5), it is conceptualized as a spectrum disorder consisting of bipolar disorder type I, bipolar disorder type II, cyclothymic disorder, and bipolar disorder not otherwise specified. Treatment of all phases of this disorder is primarily with mood stabilizers, but many patients either show resistance to the conventional mood stabilizing medications or are intolerant to their side-effects. In this setting, second-generation antipsychotics have gained prominence as many bipolar subjects who are otherwise treatment refractory show response to these agents. Aripiprazole is a novel antipsychotic initially approved for the treatment of schizophrenia but soon found to be effective in bipolar disorder. This drug is well studied, as randomized controlled trials have been conducted in various phases of bipolar disorders. Aripiprazole exhibits the pharmacodynamic properties of partial agonism, functional selectivity, and serotonin-dopamine activity modulation - the new exemplars in the treatment of major psychiatric disorders. It is the first among a new series of psychotropic medications, which now also include brexpiprazole and cariprazine. The current review summarizes the data from controlled trials regarding the efficacy and safety of aripiprazole in adult bipolar patients. On the basis of this evidence, aripiprazole is found to be efficacious in the treatment and prophylaxis of manic and mixed episodes but has no effectiveness in acute and recurrent bipolar depression. PMID:27190727

  1. Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice

    Institute of Scientific and Technical Information of China (English)

    Jaqueline Nascimento PICADA; Viviane Minuzzo PONTES; Patrícia PEREIRA; Bruna de Jesus Neto DOS SANTOS; Franciele CELSO; Jéssica Dias MONTEIRO; Kelly Morais DA ROSA; Leandro Rosa CAMACHO; Luciana Rodrigues VIEIRA; Taís Madelon FREITAS; Tatiana Grasiela DASILVA

    2011-01-01

    Aim:Aripiprazole is an antipsychotic agent to treat schizophrenia,which acts through dopamine D2 partial agonism,serotonin 5-HT1A partial agonism and 5-HT2A antagonism.This study was designed to evaluate the neurobehavioral effects and genotoxic/mutagenic activities of the agent,as well as its effects on lipoperoxidation.Methods:Open field and inhibitory avoidance tasks were used.Thirty min before performing the behavioral tasks,adult male CF-1 mice were administered aripiprazole (1,3 or 10 mg/kg,ip) once for the acute treatment,or the same doses for 5 d for the subchronic treatment.Genotoxic effects were assessed using comet assay in the blood and brain tissues.Mutagenic effects were evaluated using bone marrow micronucleus test.Lipoperoxidation was assessed with thiobarbituric acid reactive substances (TBARS).Results:Acute and subchronic treatments significantly decreased the number of crossing and rearing in the open field task.Acute treatment significantly increased the step-down latency for both the short- and long-term memory in the inhibitory avoidance task.Subchronic treatments with aripiprazole (3 and 10 mg/kg) caused significant DNA strain-break damage in peripheral blood but not in the brain.Mutagenic effect was not detected in the acute and subchronic treatments.Nor TBARS levels in the liver were affected.Conclusion:Aripiprazole improved memory,but could impair motor activities in mice.The drug increased DNA damage in blood,but did not show mutagenic effects,suggesting that it might affect long-term genomic stability.

  2. Improving depression care: barriers, solutions, and research needs.

    Science.gov (United States)

    Von Korff, M; Katon, W; Unützer, J; Wells, K; Wagner, E H

    2001-06-01

    Potential solutions for barriers to improved organization of care of depressive illness were identified. These included (1) aligning efforts to improve depression care with broader strategies for improving care of other chronic conditions; (2) increasing the availability of depression case management services in primary care; (3) developing registries and reminder systems to ensure active follow-up of depressed patients; (4) achieving agreement on how depression outcomes should be measured to provide outcomes-based performance standards; (5) providing greater support from mental health specialists for management of depressed patients by primary care providers; (6) campaigns to reduce the stigma associated with treatment of depressive illness; (7) increased dissemination of interventions that activate and empower patients managing a depressive illness; (8) redefining the lack of time of primary care providers for high-quality depression care as issues in organization of care and provider training; and (9) development of incentives (organizational or financial) for high-quality depression care. Research needs were identified according to what has been learned to date. Identified research needs included: studies of approaches to organization of case management, research in new populations (e.g., new diagnostic groups, rural populations, the disadvantaged, the elderly, and those with chronic medical illnesses), research on stepped care and relapse prevention strategies, evaluation of the societal benefits of improved depression care, and multisite trials and meta-analytic approaches that can provide adequate statistical power to assess societal benefits of improved care.

  3. Aripiprazole for acute mania in an elderly person

    Directory of Open Access Journals (Sweden)

    Balaji Bharadwaj

    2011-01-01

    Full Text Available New-onset bipolar disorder is rare in the elderly. Symptom profile is similar to that in young adults but the elderly are more likely to have neurological co-morbidities. There are no case reports of elderly mania being treated with aripiprazole, an atypical antipsychotic. A 78-year-old gentleman presented to us with symptoms suggestive of mania of 1 month′s duration. He had similar history 3 years ago and a family history of postpartum psychosis in his mother. There were no neurological signs on examination and work-up for an organic etiology was negative except for age-related cerebral atrophy. He improved with aripiprazole and tolerated the medications well. The use of psychotropic medications in the elderly is associated with side-effects of sedation, increased cardiovascular risk, and greater risk of extra-pyramidal side-effects. The use of partial dopaminergic antagonists like aripiprazole may be useful in the balancing of effects and side-effects.

  4. Study on the escitalopram combined with low dose of aripiprazole in the treatment of depression with somatic symptoms%艾司西酞普兰联合小剂量阿立哌唑治疗伴躯体症状抑郁症的研究

    Institute of Scientific and Technical Information of China (English)

    夏金校; 姚华华; 王一冰; 曹世林; 甘建光; 段迪; 吕柏军

    2011-01-01

    AIM: To explore the clinical efficacy of escitalopram combined with low dose of aripiprazole in the treatment of depression with somatic symptoms. METHODS: Eighty patients suffering from depression with somatic symptoms were randomly divided into study group (n = 41) and control group (n = 39), who received either escitalopram combined with low dose of aripiprazole or escitalopram only, respectively. The clinical efficacy and safety were evaluated with Hamilton Depression Rating Scale (HAMD), Self-rating Depression Scale (SDS), Clinical Global Impression (CGD , Treatment E-mergent Symptom Scale (TESS) and Dysfunctional Attitudes Scales (DAS) at the point of baseline and the 1st, 2nd, 4th and 8th weekend. Meanwhile, the medication compliance andsymptom recrudescence rate of two groups were also assessed in 3 months. RESULTS: Scores of HAMD, SDS and CGI decreased in both groups, but more significantly and quickly in study group. There was no difference between two groups in TESS. Patients in study group had better compliance, fewer symptom recrudescence rate and lower scores in DAS in 3 months, compared with control group. CONCLUSION: Escitalopram combined with low dose of aripiprazole works better in the treatment of depression with somatic symptoms than using escitalopram only.%目的:观察艾司西酞普兰联合小剂量阿立哌唑治疗伴躯体症状抑郁症的临床疗效.方法:将80例伴躯体症状抑郁症患者随机分为服用艾司西酞普兰联合小剂量阿立哌唑(简称观察组)41例和单用艾司西酞普兰(简称对照组)39例.从药物起效、症状改善时间,治疗1、2、4及8周末汉密尔顿抑郁量表(HAMD)、抑郁自评量表(SDS)、临床疗效总评量表(CGI)有不良反应量表(TESS)评定,3个月内服药依从性、症状复燃率及DAS评定.结果:治疗后两组HAMD、SDS、CGI分值较治疗前均有显著下降,观察组下降更明显,起效与症状改善上观察组均较对照组快,两组的TESS评分差

  5. Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania

    Directory of Open Access Journals (Sweden)

    Amir Akhavan Rezayat

    2014-01-01

    Full Text Available Background: Second-generation antipsychotics, approved for the treatment of mania, are associated with adverse effects such as weight gain and metabolic disorders. Aripiprazole, a recently introduced second-generation antipsychotic, are thought to account for its low propensity for weight gain, metabolic disturbances and sedation. The purpose of this study was to investigate the effect of risperidone versus aripiprazole in the treatment of acute mania. Materials and Methods: Fifty patients with acute episodes of mania were enrolled in this study, and they were randomly assigned into a risperidone group of 24 cases and an aripiprazole group of 26 cases. In group A, aripiprazole with a dose of 5-30 mg/day and in group B, risperidone with a dose of 2-8 mg/day was given to patients. The average dose of aripiprazole was 27 mg/day, and the average dose of risperidone was 6 mg/day. The effects of each drug for the treatment of acute mania were assessed on the 1 st day of admission and on days 2, 4, 6, 8 and at weeks 2, 4 and 6 after therapy using the young mania rating scale (YMRS and at the baseline and on weeks 3 and 6 after admission using the clinical global impression (CGI scale. Results: The mean age of the group of risperidone was 34 ± 8.6 years and in a group of aripiprazole it was 34 ± 9.1 years (P = 0.83. Comparison of YMRS scores over the period of 6 weeks revealed a statistically significant difference in both groups (P < 0.0001.There was also a statistically significant difference in YMRS scores between risperidone and aripiprazole at day 8 (P = 0.026 and weeks 2 (P = 0.035 and 4 (P = 0.042. There was also a statistically significant difference in CGI-Severity scale score at weeks 3 (P = 0.003 and 6 (P = 0.000 and in CGI-Improvement scale score at weeks 3 (P = 0.005 and 6 (P = 0.002. The most common side-effect observed in both groups was headache (0%15/4 in aripiprazole vs. %16/7 in risperidone Conclusion: Aripiprazole that is readily

  6. Change in Child Psychopathology with Improvement in Parental Depression

    Science.gov (United States)

    Gunlicks, Meredith L.; Weissman, Myrna M.

    2008-01-01

    The article identifies and evaluates the current research evidence of associations between improvement in parents' depression and their children's psychopathology. Findings indicate some evidence of associations between successful treatment of parents' depression and improvement in children's symptoms and functioning but further studies on these…

  7. 舍曲林联合阿立哌唑口腔崩解片治疗难治性抑郁症患者的临床效果%Clinical effects of Sertraline combined with Aripiprazole orally disintegrating tablets in treatment of treatment-resistant depression

    Institute of Scientific and Technical Information of China (English)

    王绍臣; 杨静娟; 敖瑞

    2015-01-01

    目的::观察舍曲林联合小剂量阿立哌唑口腔崩解片治疗难治性抑郁症患者的疗效。方法:将76难治性抑郁症患者随机分成治疗组40例、对照组36例。治疗组患者用舍曲林联合小剂量阿立哌唑口腔崩解片治疗,对照组患者单用舍曲林治疗,观察8周。分别于治疗前及治疗后第1、2、4、8周末采用HAMD(汉密尔顿抑郁量表)评定疗效,用TESS(副反应量表)观察不良反应。结果:经8周治疗后,两组患者经Ridit评分,差异有统计学意义(P<0.05)。 HAMD评分第1、2、4周末两组患者有显著性差异(P<0.01~0.05),两组患者的不良反应均较低。结论:舍曲林联合小剂量阿立哌唑口腔崩解片治疗难治性抑郁症患者的疗效肯定,不良反应轻微。%Objective:To observe clinical effects of Sertraline combined with small-dose Aripiprazole orally disintegrating tab-lets in treatment of treatment-resistant depression. Methods:76 patients with treatment-resistant depression were randomly assigned into research group (40 patients) and control group (36 patients). Research group received Sertraline combine with small-dose Aripi-prazole ODT for 8 weeks and control group accepted Sertraline alone for 8 weeks. The efficacy and adverse reactions before the treat-ment and at the end of 1st, 2nd, 4th and 8th week of treatment were measured by Hamilton depression scale (HAMD) and treatment emergent symptom scale ( TESS) . Results:There were significant differences of HAMD scores between the two groups at the end of 1st, 2nd, and 4th week of the treatment (P<0. 01~0. 05), and there were also statistical differences of Ridit scores between the two groups patients at the end of 8th week of treatment. The two groups both had fewer adverse reactions. Conclusions: Sertraline com-bined with small-dose Aripiprazole ODT has a certain efficacy in the treatment of treatment-resistant depression with mild adverse re-actions.

  8. Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial.

    Directory of Open Access Journals (Sweden)

    Jingyuan Zhao

    Full Text Available The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia.One hundred and thirteen patients who were receiving a stable dose of risperidone were randomly assigned to either adjunctive aripiprazole treatment (10 mg/day (aripiprazole group or no additional treatment (control group at a 1:1 ratio for 8 weeks. Schizophrenia symptoms were measured using the Positive and Negative Syndrome Scale (PANSS. Rating scales and safety assessments (RSESE, BARS, UKU were performed at baseline and at weeks 4 and 8. Serum levels of prolactin were determined at baseline and at weeks 2, 4, 6 and 8. Metabolic parameters were determined at baseline and again at weeks 4 and 8.One hundred and thirteen patients were enrolled in this study, and 107 patients completed the study (54 in the aripiprazole group, and 53 in the control group. PANSS-total scores in the aripiprazole group decreased significantly at week 4 (P = 0.003 and week 8 (P = 0.007 compared with the control group. PANSS-negative scores in the aripiprazole group also decreased significantly at week 4 (P = 0.005 and week 8 (P< 0.001 compared with the control group. Serum levels of prolactin in the aripiprazole group decreased significantly at week 2 (P< 0.001, week 4 (P< 0.001, week 6 (P< 0.001 and week 8 (P< 0.001 compared with the control group. There were no significant differences in changes of Fasting Plasma Glucose, Total cholesterol, Triglycerides and High Density Lipoprotein within each group at week 4 and 8 execpt low density lipoproteins. There was no significant difference in the incidence of adverse reactions between the two groups.Adjunctive aripiprazole treatment may be beneficial in reducing serum levels of prolactin and improving negative symptoms in schizophrenia patients with risperidone-induced hyperprolactinemia.chictr.org ChiCTR-IOR-15006278.

  9. Improving Depression Care Through an Online Learning Collaborative.

    Science.gov (United States)

    Starkey, Melissa; Wiest, Dawn; Qaseem, Amir

    2016-01-01

    Depression is a leading cause of disability worldwide, and many internists diagnose and treat depression. This study aimed to examine the impact of a practice improvement intervention on screening and managing patients with depression in primary care. This pre-post study design included a physician practice survey designed to capture what the physicians believed they were doing in practice, a chart audit tool to capture what physicians were actually doing in practice, and an intervention that included an evidence-based educational program, online toolkit, and practice improvement coaching conference calls that promoted group learning. Following completion of the intervention, participants increasingly used the Patient Health Questionnaire-9 to detect, diagnose, and gauge treatment success for depression and reported increased use of guidelines and team-based care. Although barriers to improving depression care exist, this study suggests that evidence-based quality improvement programs can positively affect practice. PMID:25351473

  10. Augmentation of Clozapine with Aripiprazole in Severe Psychotic Bipolar and Schizoaffective Disorders: A Pilot Study

    Science.gov (United States)

    Benedetti, Alessandra; Di Paolo, Antonello; Lastella, Marianna; Casamassima, Francesco; Candiracci, Chiara; Litta, Antonella; Ciofi, Laura; Danesi, Romano; Lattanzi, Lorenzo; Del Tacca, Mario; Cassano, Giovanni Battista

    2010-01-01

    Aim: To evaluate the efficacy and safety of the augmentation of clozapine with aripiprazole in patients with treatment-resistant schizoaffective and psychotic bipolar disorders in a retrospective manner. Pharmacodynamic and pharmacokinetic interactions between the two drugs were also investigated. Patients: Three men and 4 women (median age 36 and 40 years, respectively) who had mean scores at BPRS and CGI-Severity of 59.1±12.0 and 5.4±0.5, respectively, were treated with clozapine (mean dose 292.9±220.7 mg/day). Patients received an adjunctive treatment with aripiprazole (mean dose 6.8 ± 3.7 mg/day). Clozapine, norclozapine and aripiprazole plasma levels were measured by means of a high performance liquid chromatograpy with UV detection. Results: Total scores at BPRS decreased significantly (from 59.1±12.0 to 51.1±15.6, p=0.007) after aripirazole augmentation. In particular, the factors “thought disorder” (from 10.4±4.4 to 9.0±4.5, p=.047) and “anergia” (from 10.0±2.7 to 8.0±2.4, p=.018) significantly improved. Concomitant administration of aripiprazole and clozapine did not result in an increase in side effects over the period of treatment. Dose-normalized plasma levels of both clozapine and norclozapine and the clozapine/norclozapine metabolic ratio in all patients did not vary as well. Conclusion: The augmentation of clozapine with aripirazole was safe and effective in severe psychotic schizoaffective and bipolar disorders which failed to respond to atypical antipsychotics. A possible pharmacokinetic interaction between clozapine and aripiprazole does not account for the improved clinical benefit obtained after aripiprazole augmentation. PMID:20648219

  11. Orthognathic surgery improves quality of life and depression, but not anxiety, and patients with higher preoperative depression scores improve less.

    Science.gov (United States)

    Brunault, P; Battini, J; Potard, C; Jonas, C; Zagala-Bouquillon, B; Chabut, A; Mercier, J-M; Bedhet, N; Réveillère, C; Goga, D; Courtois, R

    2016-01-01

    This study assessed quality of life (QoL), depression, and anxiety before and after orthognathic surgery and identified risk factors for poorer postoperative outcome. This multicentre prospective study included 140 patients from five French medical centres. We assessed patients before surgery (T1), 3 months after surgery (T2), and 12 months after surgery (T3). We assessed the severity of the orofacial deformity, physical, psychological, social, and environmental QoL (WHOQOL-BREF), and depression and anxiety (GHQ-28). Risk factors for poorer outcome were identified using linear mixed models. Between baseline and 12 months, there was significant improvement in psychological and social QoL and in depression (although below the norms reported in the general population), but not in anxiety. Physical QoL was poorer in patients who were younger, who had a mild orofacial deformity, and who were depressed. Psychological QoL was poorer in younger patients and in depressed patients. Social QoL was poorer in patients who were single, who had a mild orofacial deformity, and who were depressed. Although orthognathic surgery provides a moderate improvement in psychological and social QoL, the systematic screening and treatment of depression could further improve QoL after surgery because it is a major predictor of poor QoL in this population.

  12. Two Cases of Hypersexuality Probably Associated with Aripiprazole

    OpenAIRE

    Cheon, EunJin; Koo, Bon-Hoon; Seo, Sang Soo; Lee, Jun-Yeob

    2013-01-01

    Sexual dysfunction is a common side effect in patients treated with antipsychotics but significant differences exist across different compounds. We report hypersexuality symptoms in two female patients with schizophrenia who were receiving treatment with aripiprazole. The patients experienced more frequent sexual desire and greater sexual preoccupation after taking aripiprazole. We discuss the potential neuro-chemical mechanisms for this and argue that aripiprazole's unique pharmacological pr...

  13. Depression Care Management: Can Employers Purchase Improved Outcomes?

    Directory of Open Access Journals (Sweden)

    Kathryn Rost

    2011-01-01

    Full Text Available Fourteen vendors are currently selling depression care management products to US employers after randomized trials demonstrate improved work outcomes. The research team interviewed 10 (71.4% of these vendors to compare their products to four key components of interventions demonstrated to improve work outcomes. Five of 10 depression products incorporate all four key components, three of which are sold by health maintenance organizations (HMOs; however, HMOs did not deliver these components at the recommended intensity and/or duration. Only one product delivered by a disease management company delivered all four components of care at the recommended intensity and duration. This “voltage drop,” which we anticipate will increase with product implementation, suggests that every delivery system should carefully evaluate the design of its depression product before implementation for its capacity to deliver evidence-based care, repeating these evaluations as new evidence emerges.

  14. Training primary care physicians improves the management of depression

    NARCIS (Netherlands)

    van Os, TWDP; Ormel, J; van den Brink, RHS; Jenner, JA; Van der Meer, K; Tiemens, BG; van der Doorn, W; Smit, A; van den Brink, W

    1999-01-01

    The purpose of this pretest-posttest study was to evaluate effects of a training program designed to improve primary care physicians' (PCPs) ability to recognize mental health problems (MHP) and Co diagnose and manage depression according to clinical guidelines. The primary care settings were in the

  15. Innovative ICT solutions to improve treatment outcomes for depression: the ICT4Depression project.

    Science.gov (United States)

    Warmerdam, Lisanne; Riper, Heleen; Klein, Michel; van den Ven, Pepijn; Rocha, Artur; Ricardo Henriques, Mario; Tousset, Eric; Silva, Hugo; Andersson, Gerhard; Cuijpers, Pim

    2012-01-01

    Depression is expected to be the disorder with the highest disease burden in high-income countries by the year 2030. ICT4Depression (ICT4D) is a European FP7 project, which aims to contribute to the alleviation of this burden by making use of depression treatment and ICT innovations. In this project we developed an ICT-based system for use in primary care that aims to improve access as well as actual care delivery for depressed adults. Innovative technologies within the ICT4D system include 1) flexible self-help treatments for depression, 2) automatic assessment of the patient using mobile phone and web-based communication 3) wearable biomedical sensor devices for monitoring activities and electrophysiological indicators, 4) computational methods for reasoning about the state of a patient and the risk of relapse (reasoning engine) and 5) a flexible system architecture for monitoring and supporting people using continuous observations and feedback via mobile phone and the web. The general objective of the ICT4D project is to test the feasibility and acceptability of the ICT4D system within a pilot study in the Netherlands and in Sweden during 2012 and 2013.

  16. Low-dose aripiprazole for refractory burning mouth syndrome.

    Science.gov (United States)

    Umezaki, Yojiro; Takenoshita, Miho; Toyofuku, Akira

    2016-01-01

    We report a case of refractory burning mouth syndrome (BMS) ameliorated with low dose of aripiprazole. The patient was a 66-year-old female who had suffered from chronic burning pain in her tongue for 13 months. No abnormality associated with the burning sensation was detected in the laboratory tests and the oral findings. Considering the clinical feature and the history together, we diagnosed the burning sensation as BMS. The BMS pain was decreased by aripiprazole (powder) 1.0 mg/d, though no other antidepressants had satisfying pain relief. It could be supposed that the efficacy of aripiprazole is caused by dopamine stabilization in this case, and BMS might have a subtype that is reactive to aripiprazole. Further studies are needed to confirm the efficacy of aripiprazole for BMS. PMID:27279742

  17. Quality Improvement in Nursing Homes: Identifying Depressed Residents is Critical to Improving Quality of Life.

    Science.gov (United States)

    Crogan, Neval L; Evans, Bronwynne C

    2008-05-01

    The prevalence of depression in nursing home residents is three to five times higher than in older adults from the community.1 Depression is thought to be related to the gloomy institutionalized environment and an assortment of losses, including those associated with function, independence, social roles, friends and relatives, and past leisure activities.2 Despite the public's increased awareness of depression, it remains underrecognized and undertreated by professionals who care for older residents in nursing homes.3 It seems intuitive that depression must be recognized before it can be treated, yet our national long-term care system continues to utilize an unreliable scale from the Minimum Data Set as its foundation for assessment. Warnings of the scale's inadequacy have been sounded repeatedly almost since its conception4,5 and its potential role in lack of recognition and treatment of depression by nursing home staff, nurse practitioners, and physicians is a troubling one.The purpose of this article is to (1) report the prevalence of depression in a sub-sample of residents from a National Institutes of Health study whose depression was not detected by the MDS and, consequently, was previously untreated, (2) compare their nutritional and functional status with residents whose depressive states were previously detected by the MDS and treated, and (3) recommend quality improvement strategies for identification and treatment of depression in nursing home residents.

  18. Effective treatment of depression improves post-myocardial infarction survival

    Institute of Scientific and Technical Information of China (English)

    Soudabeh; Khojasteh; Banankhah; Erika; Friedmann; Sue; Thomas

    2015-01-01

    effective treatment of depression reduced mortality in depressed post-MI patients.It is important to monitor the effectiveness of depression treatment and change treatments if necessary to reduce depression and improve cardiac outcomes in depressed post-MI patients.

  19. Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial

    Science.gov (United States)

    Zhao, Jingyuan; Song, Xueqin; Ai, Xiaoqing; Gu, Xiaojing; Huang, Guangbiao; Li, Xue; Pang, Lijuan; Ding, Minli; Ding, Shuang; Lv, Luxian

    2015-01-01

    Objective The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia. Methods One hundred and thirteen patients who were receiving a stable dose of risperidone were randomly assigned to either adjunctive aripiprazole treatment (10 mg/day) (aripiprazole group) or no additional treatment (control group) at a 1:1 ratio for 8 weeks. Schizophrenia symptoms were measured using the Positive and Negative Syndrome Scale (PANSS). Rating scales and safety assessments (RSESE, BARS, UKU) were performed at baseline and at weeks 4 and 8. Serum levels of prolactin were determined at baseline and at weeks 2, 4, 6 and 8. Metabolic parameters were determined at baseline and again at weeks 4 and 8. Results One hundred and thirteen patients were enrolled in this study, and 107 patients completed the study (54 in the aripiprazole group, and 53 in the control group). PANSS-total scores in the aripiprazole group decreased significantly at week 4 (P = 0.003) and week 8 (P = 0.007) compared with the control group. PANSS-negative scores in the aripiprazole group also decreased significantly at week 4 (P = 0.005) and week 8 (P< 0.001) compared with the control group. Serum levels of prolactin in the aripiprazole group decreased significantly at week 2 (P< 0.001), week 4 (P< 0.001), week 6 (P< 0.001) and week 8 (P< 0.001) compared with the control group. There were no significant differences in changes of Fasting Plasma Glucose, Total cholesterol, Triglycerides and High Density Lipoprotein within each group at week 4 and 8 execpt low density lipoproteins. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusions Adjunctive aripiprazole treatment may be beneficial in reducing serum levels of prolactin and improving negative symptoms in schizophrenia patients with risperidone-induced hyperprolactinemia. Trial Registration chictr.org Chi

  20. Behandling af Tourettes syndrom med aripiprazol

    DEFF Research Database (Denmark)

    Stenstrøm, Anne Dorte; Sindø, Ingrid

    2008-01-01

    Tourette's syndrome (TS) is a motoric disorder characterised by multiple motor and vocal tics. The treatment for patients with moderate to severe TS includes antipsychotic medication. A case report is described in which a 20 year-old male had taken antipsychotic medication since the age of five......, due to TS. The initial treatment consisted of pimozide and risperidone, both of which had an unsatisfactorily efficacy on tics and side effects in the form of weight gain and sedation. The patient is now treated with aripiprazole and there is a marked reduction of tics and no side effects...

  1. Dilemma of prescribing aripiprazole under the Taiwan health insurance program: a descriptive study

    Directory of Open Access Journals (Sweden)

    Hsu YC

    2015-01-01

    Full Text Available Yi-Chien Hsu,1,2 Yu-Ching Chou,3 Hsin-An Chang,1,2,4 Yu-Chen Kao,1,2,5 San-Yuan Huang,1,2 Nian-Sheng Tzeng1,2,4 1Department of Psychiatry, Tri-Service General Hospital, Taipei, Taiwan; 2School of Medicine, 3School of Public Health, 4Student Counseling Center, National Defense Medical Center, Taipei, Taiwan; 5Department of Psychiatry, Tri-Service General Hospital, Song-Shan Branch, Taipei, Taiwan Objectives: Refractory major depressive disorder (MDD is a serious problem leading to a heavy economic burden. Antipsychotic augmentation treatment with aripiprazole and quetiapine is approved for MDD patients and can achieve a high remission rate. This study aimed to examine how psychiatrists in Taiwan choose medications and how that choice is influenced by health insurance payments and administrative policy.Design: Descriptive study.Outcome measures: Eight questions about the choice of treatment strategy and atypical antipsychotics, and the reason to choose aripiprazole.Intervention: We designed an augmentation strategy questionnaire for psychiatrists whose patients had a poor response to antidepressants, and handed it out during the annual meeting of the Taiwanese Society of Psychiatry in October 2012. It included eight questions addressing the choice of treatment strategy and atypical antipsychotics, and the reason whether or not to choose aripiprazole as the augmentation antipsychotic.Results: Choosing antipsychotic augmentation therapy or switching to other antidepressant strategies for MDD patients with an inadequate response to antidepressants was common with a similar probability (76.1% vs 76.4%. The most frequently used antipsychotics were aripiprazole and quetiapine, however a substantial number of psychiatrists chose olanzapine, risperidone, and sulpiride. The major reason for not choosing aripiprazole was cost (52.1%, followed by insurance official policy audit and deletion in the claims review system (30.1%.Conclusion: The prescribing

  2. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone.

    Science.gov (United States)

    Qiao, Ying; Yang, Fuzhong; Li, Chunbo; Guo, Qian; Wen, Hui; Zhu, Suoyu; Ouyang, Qiong; Shen, Weidi; Sheng, Jianhua

    2016-03-30

    This study investigated the effects of a low-dose aripiprazole adjunctive treatment for risperidone- or paliperidone-induced hyperprolactinemia in Han Chinese women with schizophrenia. After 4 weeks of risperidone or paliperidone treatment, 60 out of 66 patients improved significantly and experienced hyperprolactinemia. They were randomly assigned to the treatment group (aripiprazole adjunctive treatment) (n=30) or control group (non-adjunctive treatment) (n=30). The dosage of risperidone and paliperidone were maintained; and aripiprazole was maintained at 5mg/day during the 8-week study period. The prolactin levels at the end of the 8th week were significantly lower in the treatment group than in the control group. The estradiol level correlated negatively with serum prolactin level both in the treatment group and the control group at the end of the 8th week and the 4th week respectively. The Positive and Negative Syndrome Scale score improved significantly during the 8-week study period in both groups. The incidence of treatment-emergent adverse event was similar in two groups. Low-dose aripiprazole adjunctive treatment is effective in relieving risperidone- and paliperidone-induced hyperprolactinemia in female schizophrenic patients without increasing adverse event. PMID:26921057

  3. Depression remitted after subarachnoid haemorrhage

    DEFF Research Database (Denmark)

    Lauritsen, Lise; Vinberg, Maj

    2015-01-01

    A 65-year-old man was seen in a specialized ambulatory for mood disorders because of treatment-resistant depression. He was treated throughout a period of three years with selective serotonin reuptake inhibitor, dual action, lithium, nortriptyline, reboxetine, aripiprazole, benzodiazepines...

  4. Low-dose aripiprazole for refractory burning mouth syndrome

    Directory of Open Access Journals (Sweden)

    Umezaki Y

    2016-05-01

    Full Text Available Yojiro Umezaki,1 Miho Takenoshita,2 Akira Toyofuku2 1Psychosomatic Dentistry Clinic, Dental Hospital, 2Psychosomatic Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan Abstract: We report a case of refractory burning mouth syndrome (BMS ameliorated with low dose of aripiprazole. The patient was a 66-year-old female who had suffered from chronic burning pain in her tongue for 13 months. No abnormality associated with the burning sensation was detected in the laboratory tests and the oral findings. Considering the clinical feature and the history together, we diagnosed the burning sensation as BMS. The BMS pain was decreased by aripiprazole (powder 1.0 mg/d, though no other antidepressants had satisfying pain relief. It could be supposed that the efficacy of aripiprazole is caused by dopamine stabilization in this case, and BMS might have a subtype that is reactive to aripiprazole. Further studies are needed to confirm the efficacy of aripiprazole for BMS. Keywords: burning mouth syndrome, low-dose aripiprazole, chronic pain

  5. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR study (NCT00237913

    Directory of Open Access Journals (Sweden)

    Pans Miranda

    2008-12-01

    Full Text Available Abstract Background The aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (SOC, which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone (The Schizophrenia Trial of Aripiprazole [STAR] study [NCT00237913]. Method This open-label, 26-week, multi-centre, randomised study compared aripiprazole to SOC (olanzapine, quetiapine or risperidone in patients with schizophrenia (DSM-IV-TR criteria. The primary effectiveness variable was the mean total score of the Investigator Assessment Questionnaire (IAQ at Week 26. The outcome research variables included the Arizona Sexual Experience scale (ASEX. This along with the data collected on serum prolactin levels at week 4, 8, 12, 18 and 26 will be the focus of this paper. Results A total of 555 patients were randomised to receive aripiprazole (n = 284 or SOC (n = 271. Both treatment groups experienced improvements in sexual function from baseline ASEX assessments. However at 8 weeks the aripiprazole treatment group reported significantly greater improvement compared with the SOC group (p = 0.007; OC. Although baseline mean serum prolactin levels were similar in the two treatment groups (43.4 mg/dL in the aripiprazole group and 42.3 mg/dL in the SOC group, p = NS at Week 26 OC, mean decreases in serum prolactin were 34.2 mg/dL in the aripiprazole group, compared with 13.3 mg/dL in the SOC group (p Conclusion The study findings suggest that aripiprazole has the potential to reduce sexual dysfunction, which in turn might improve patient compliance.

  6. SPE-UPLC-MS/MS method for sensitive and rapid determination of aripiprazole in human plasma to support a bioequivalence study.

    Science.gov (United States)

    Patel, Daxesh P; Sharma, Primal; Sanyal, Mallika; Shrivastav, Pranav S

    2013-04-15

    An improved and rugged UPLC-MS/MS method has been developed and validated for sensitive and rapid determination of aripiprazole in human plasma using aripiprazole-d8 as the internal standard (IS). The analyte and IS were extracted from 100 μL of human plasma by solid-phase extraction using Phenomenex Strata-X (30 mg, 1 cc) cartridges. Chromatography was achieved on an Acquity UPLC BEH C18 (50 mm × 2.1 mm, 1.7 μm) analytical column using methanol: 10mM ammonium formate (85:15, v/v) as the mobile phase with isocratic elution. Quantitation was done using multiple reaction monitoring in the positive ionization mode. The linearity of the method was established in the concentration range 0.05-80 ng/mL. The mean extraction recovery was greater than 96% across QC levels, while intra- and inter batch accuracy and precision (% CV) values ranged from 97.4 to 101.9% and from 1.20 to 3.72% respectively. The relative matrix effect in eight different lots of plasma samples, expressed as % CV for the calculated slopes of calibration curves was 1.08%. The stability of aripiprazole was studied under different storage conditions. The validated method was used to support a bioequivalence study of 10mg aripiprazole formulation in 36 healthy Indian subjects. PMID:23510852

  7. [Hypersexuality associated with aripiprazole: a new case and review of the literature].

    Science.gov (United States)

    Vrignaud, Laura; Aouille, Jerémie; Mallaret, Michel; Durrieu, Geneviève; Jonville-Béra, Annie-Pierre

    2014-01-01

    We report the case of a patient with hypersexuality while he was treated with aripiprazole since 6 months. Clinical manifestations were an increased libido, unusual frequent masturbation and sexual instincts. All have resolved upon discontinuation of aripiprazole, and recurred after it was restarted. The partial dopaminergic agonist effect of aripiprazole could probably explain the occurrence of this compulsive behaviour. PMID:25293487

  8. Diabetes education improves depressive state in newly diagnosed patients with type 2 diabetes

    OpenAIRE

    Chen, Bin; Zhang, Xiyao; XU, XIUPING; Lv, Xiaofeng; Yao, Lu; Huang, Xu; Guo, Xueying; Liu, Baozhu; Li, Qiang; Cui, Can

    2013-01-01

    Objectives: The prevalence of depression is relatively high in individuals with diabetes. However, screening and monitoring of depressive state in patients with diabetes is still neglected in developing countries and the treatment of diabetes-related depression is rarely performed in these countries. In this study, our aim was to study the role of diabetes education in the improvement of depressive state in newly diagnosed patients with type 2 diabetes. Methods: The Dutch version of the cente...

  9. Depression

    DEFF Research Database (Denmark)

    Kessing, Lars Veddel; Bukh, Jens Drachmann

    2014-01-01

    The prevalence of depression is not clearly established, but estimated to 3-4% in a Danish questionnaire study. Lifetime's prevalences of 12-17% are reported in other community samples. In the current diagnostic system depression is defined categorically and operationally. It has been argued......, that these diagnostic criteria represent an oversimplification, which has blurred the concept of depression. We suggest a greater emphasis on the depressed mood as the core symptom of depression, which may increase the specificity of the diagnosis. Furthermore, basic principles for the treatment of depression...

  10. Depression

    DEFF Research Database (Denmark)

    Kessing, Lars Veddel; Bukh, Jens Otto Drachmann

    2014-01-01

    The prevalence of depression is not clearly established, but estimated to 3-4% in a Danish questionnaire study. Lifetime's prevalences of 12-17% are reported in other community samples. In the current diagnostic system depression is defined categorically and operationally. It has been argued, that...... these diagnostic criteria represent an oversimplification, which has blurred the concept of depression. We suggest a greater emphasis on the depressed mood as the core symptom of depression, which may increase the specificity of the diagnosis. Furthermore, basic principles for the treatment of...... depression are presented....

  11. A Depression Training Session With Consumer Educators to Reduce Stigmatizing Views and Improve Pharmacists’ Depression Care Attitudes and Practices

    Science.gov (United States)

    Smits, Tim; Laekeman, Gert; Foulon, Veerle

    2013-01-01

    Objective. To measure the impact of a depression training day for pharmacists that included a 75-minute session with a consumer educator. Design. The training day included interactive lectures on depression; the effects and side effects of and indications for the use of antidepressants; adherence issues; non-drug treatment options for depression; and basic skills in communication. Pharmacists also participated in a session with a consumer educator and in counseling exercises that included role playing. Assessment. The study used a randomized, clustered, comparative design to measure pharmacists' stigma, attitudes, and current practice related to the provision of pharmaceutical care to people with depression. Mean scores for depression-care practice after the training session were significantly higher in the intervention group than in the control group. Analysis of the changes between baseline and postintervention measures in both the control and intervention groups confirmed a significant difference in the change in both social distance and practice but no significant difference in the change in attitude between the 2 groups of pharmacists. Conclusion. A continuing-education depression training day for pharmacists that involve consumer educators may improve the care delivered in the community pharmacy to people with depression. PMID:23966723

  12. Depression

    OpenAIRE

    Grace Sherry L; Gucciardi Enza; Stewart Donna E

    2004-01-01

    Abstract Health Issue Depression causes significant distress or impairment in physical, social, occupational and other key areas of functioning. Women are approximately twice as likely as men to experience depression. Psychosocial factors likely mediate the risks for depression incurred by biological influences. Key Findings Data from the 1999 National Population Health Survey show that depression is more common among Canadian women, with an annual self-reported incidence of 5.7% compared wit...

  13. Depression

    OpenAIRE

    Stewart, Donna E.; Gucciardi, Enza; Grace, Sherry L.

    2004-01-01

    Health Issue Depression causes significant distress or impairment in physical, social, occupational and other key areas of functioning. Women are approximately twice as likely as men to experience depression. Psychosocial factors likely mediate the risks for depression incurred by biological influences. Key Findings Data from the 1999 National Population Health Survey show that depression is more common among Canadian women, with an annual self-reported incidence of 5.7% compared with 2.9% in...

  14. The Teen Depression Awareness Project: Building an Evidence Base for Improving Teen Depression Care. Research Highlights

    Science.gov (United States)

    Adamson, David M.

    2010-01-01

    Depression's effects on adolescent functioning and family burden are not well understood; there is also limited understanding of teens' and parents' attitudes and knowledge about depression, how these and other factors influence readiness for treatment, and the barriers to care that teens and their parents encounter. To address these knowledge…

  15. Depression

    DEFF Research Database (Denmark)

    Cizza, G; Ravn, Pernille; Chrousos, G P;

    2001-01-01

    Existing studies of the relationship between depression and osteoporosis have been heterogeneous in their design and use of diagnostic instruments for depression, which might have contributed to the different results on the comorbidity of these two conditions. Nevertheless, these studies reveal...... a strong association between depression and osteoporosis. Endocrine factors such as depression-induced hypersecretion of corticotropin-releasing hormone and hypercortisolism, hypogonadism, growth hormone deficiency and increased concentration of circulating interleukin 6, might play a crucial role...... in the bone loss observed in subjects suffering from major depression....

  16. Interventions to improve return to work in depressed people

    NARCIS (Netherlands)

    Nieuwenhuijsen, Karen; Faber, Babs; Verbeek, Jos H.; Neumeyer-Gromen, Angela; Hees, Hiske L.; Verhoeven, Arco C.; van der Feltz-Cornelis, Christina M.; Bultmann, Ute

    2014-01-01

    Background Work disability such as sickness absence is common in people with depression. Objectives To evaluate the effectiveness of interventions aimed at reducing work disability in employees with depressive disorders. Search methods We searched CENTRAL (The Cochrane Library), MEDLINE, EMBASE, CIN

  17. Interventions to improve occupational health in depressed people

    NARCIS (Netherlands)

    Nieuwenhuijsen, K.; Bultmann, U.; Neumeyer-Gromen, A.; Verhoeven, A.C.; Verbeek, J.H.; van der Feltz-Cornelis, C.M.

    2008-01-01

    BACKGROUND: Work disability such as sickness absence is common in people with depression. OBJECTIVES: To evaluate the effectiveness of interventions aimed at reducing work disability in depressed workers. SEARCH STRATEGY: We searched the CCDANCTR-Studies and CCDANCTR-References on 2/8/2006, Cochrane

  18. Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: An open trial.

    OpenAIRE

    Scantamburlo, Gabrielle; Hansenne, Michel; Geenen, Vincent; Legros, Jean-Jacques; Ansseau, Marc

    2015-01-01

    The aim of this open trial was to assess the antidepressant/anxiolytic effects of oxytocin used as an adjunct to antidepressant in treatment-resistant depression. Fourteen patients, who have not responded to 40mg of escitalopram, received intranasal synthetic oxytocin during 4 weeks, in association with antidepressant. This is the first open trial study suggesting OT in association with escitalopram significantly reduced scores on Hamilton Depression Rating Scale. Peer reviewed

  19. Salivary and serum biomarkers for the study of side effects of aripiprazole coprescribed with mirtazapine in rats.

    Science.gov (United States)

    Bogdan, Maria; Silosi, Isabela; Surlin, Petra; Tica, Andrei Adrian; Tica, Oana Sorina; Balseanu, Tudor-Adrian; Rauten, Anne-Marie; Camen, Adrian

    2015-01-01

    The aim of this study was to investigate whether the co-administration of aripiprazole and mirtazapine could determine weight gain and lipid metabolism disorders in Wistar rats, compared to the same side effects produced by mirtazapine alone, and the risk of hepatotoxicity due to the combination of the two substances. Tumor necrosis factor alpha (TNF-α), liver fatty acid binding protein (L-FABP/FABP1) and repulsive guidance molecule C/hemojuvelin (RGM-C/HJV) levels were determined in serum and in saliva. Also, serum levels for total cholesterol (TC), low and high-density lipoprotein (LDL, HDL), triglycerides (TG), aspartate aminotransferase (ASAT) and alanine amino transferase (ALAT) were assessed. We found positive and statistically significant correlations between serum and salivary levels of TNF-α, L-FABP/FABP1 and RGM-C/HJV. Mirtazapine determined significantly differences of TNF-α and L-FABP serum levels; final body weight; TC and LDL levels, leading to higher concentrations than its association with aripiprazole. Although not statistically significant, mirtazapine group experienced higher values for salivary levels of TNF-α, TG and ASAT, and lower values for HDL, compared to aripiprazole + mirtazapine group. The results suggest that aripiprazole might improve some of the disturbances caused by mirtazapine, and that the two drugs combination cause no additional alterations in liver function. Also, the findings indicate that TNF-α, L-FABP/FABP1 and RGM-C/HJV levels can be helpful as biomarkers for metabolic disturbances and impaired function of hepatocytes, and that their salivary determination can replace serum determination. PMID:26221370

  20. Salivary and serum biomarkers for the study of side effects of aripiprazole coprescribed with mirtazapine in rats.

    Science.gov (United States)

    Bogdan, Maria; Silosi, Isabela; Surlin, Petra; Tica, Andrei Adrian; Tica, Oana Sorina; Balseanu, Tudor-Adrian; Rauten, Anne-Marie; Camen, Adrian

    2015-01-01

    The aim of this study was to investigate whether the co-administration of aripiprazole and mirtazapine could determine weight gain and lipid metabolism disorders in Wistar rats, compared to the same side effects produced by mirtazapine alone, and the risk of hepatotoxicity due to the combination of the two substances. Tumor necrosis factor alpha (TNF-α), liver fatty acid binding protein (L-FABP/FABP1) and repulsive guidance molecule C/hemojuvelin (RGM-C/HJV) levels were determined in serum and in saliva. Also, serum levels for total cholesterol (TC), low and high-density lipoprotein (LDL, HDL), triglycerides (TG), aspartate aminotransferase (ASAT) and alanine amino transferase (ALAT) were assessed. We found positive and statistically significant correlations between serum and salivary levels of TNF-α, L-FABP/FABP1 and RGM-C/HJV. Mirtazapine determined significantly differences of TNF-α and L-FABP serum levels; final body weight; TC and LDL levels, leading to higher concentrations than its association with aripiprazole. Although not statistically significant, mirtazapine group experienced higher values for salivary levels of TNF-α, TG and ASAT, and lower values for HDL, compared to aripiprazole + mirtazapine group. The results suggest that aripiprazole might improve some of the disturbances caused by mirtazapine, and that the two drugs combination cause no additional alterations in liver function. Also, the findings indicate that TNF-α, L-FABP/FABP1 and RGM-C/HJV levels can be helpful as biomarkers for metabolic disturbances and impaired function of hepatocytes, and that their salivary determination can replace serum determination.

  1. Switching to Aripiprazole as a Strategy for Weight Reduction: A Meta-Analysis in Patients Suffering from Schizophrenia

    Directory of Open Access Journals (Sweden)

    Yoram Barak

    2011-01-01

    Full Text Available Weight gain is one of the major drawbacks associated with the pharmacological treatment of schizophrenia. Existing strategies for the prevention and treatment of obesity amongst these patients are disappointing. Switching the current antipsychotic to another that may favorably affect weight is not yet fully established in the psychiatric literature. This meta-analysis focused on switching to aripiprazole as it has a pharmacological and clinical profile that may result in an improved weight control. Nine publications from seven countries worldwide were analyzed. These encompassed 784 schizophrenia and schizoaffective patients, 473 (60% men and 311 (40% women, mean age 39.4±7.0 years. The major significant finding was a mean weight reduction by −2.55±1.5 kgs following the switch to aripiprazole (<.001. Switching to an antipsychotic with a lower propensity to induce weight gain needs be explored as a strategy. Our analysis suggests aripiprazole as a candidate for such a treatment strategy.

  2. Depression

    DEFF Research Database (Denmark)

    Johansen, Jon O. J.

    2013-01-01

    Nyhederne er fulde af historier om depression. Overskrifter som: ’Danskerne propper sig med lykkepiller’ eller ‘depression er stadigvæk tabu’ går tit igen i dagspressen. Men hvor er nuancerne, og hvorfor gider vi læse de samme historier igen og igen? Måske er det fordi, vores egne forestillinger er...

  3. Depression.

    Science.gov (United States)

    Strock, Margaret

    Approximately ten percent of the population suffers from a depressive illness each year. Although the economic cost is high, the cost in human suffering is immeasurable. To help educate the population about this disorder, this paper presents a definition of depression and its common manifestations. The symptoms that people often experience are…

  4. Short term synaptic depression improves information transfer in perceptual multistability

    Directory of Open Access Journals (Sweden)

    Zachary P Kilpatrick

    2013-07-01

    Full Text Available Competitive neural networks are often used to model the dynamics of perceptual bistability. Switching between percepts can occur through fluctuations and/or a slow adaptive process. Here, we analyze switching statistics in competitive networks with short term synaptic depression and noise. We start by analyzing a ring model that yields spatially structured solutions and complement this with a study of a space-free network whose populations are coupled with mutual inhibition. Dominance times arising from depression driven switching can be approximated using a separation of timescales in the ring and space-free model. For purely noise-driven switching, we derive approximate energy functions to justify how dominance times are exponentially related to input strength. We also show that a combination of depression and noise generates realistic distributions of dominance times. Unimodal functions of dominance times are more easily told apart by sampling, so switches induced by synaptic depression induced provide more information about stimuli than noise-driven switching. Finally, we analyze a competitive network model of perceptual tristability, showing depression generates a history-dependence in dominance switching.

  5. Neural correlates of delusional infestation responding to aripiprazole monotherapy: a case report

    Directory of Open Access Journals (Sweden)

    Ponson L

    2015-02-01

    Full Text Available Laura Ponson,1,2 Frédéric Andersson,1 Wissam El-Hage1,2 1Université François-Rabelais de Tours, Inserm, Imagerie et Cerveau UMR U930, Tours, France, 2CHRU de Tours, Clinique Psychiatrique Universitaire, Tours, France Background: The pathophysiology and appropriate pharmacological interventions for delusional infestation remain unknown.Case presentation: Here, we report a case of primary delusional infestation successfully treated with aripiprazole. We performed functional magnetic resonance imaging (fMRI to investigate brain structures and functional modifications. Before antipsychotic treatment, pre- versus post-treatment fMRI images revealed a marked increase in brain activation in the supplementary motor area (SMA.Conclusion: Our results highlight the efficacy and safety of aripiprazole in the treatment of delusional infestation and the possible role of SMA dysfunction in delusional infestation. Indeed, our results suggest that psychiatric improvement of delusional infestation is associated with normalization of brain activity, particularly in the SMA. Keywords: supplementary motor area, antipsychotics, fMRI

  6. Depressants

    Science.gov (United States)

    ... treatment of insomnia that share many of the properties of benzodiazepines. Other CNS depressants include meprobamate, methaqualone ( ... they are prescribed for to put you to sleep, relieve anxiety and muscle spasms, and prevent seizures. ...

  7. Depressants

    Science.gov (United States)

    ... Other long-term effects include: impaired sexual function insomnia and other sleep problems breathing problems convulsions (similar to seizures) depression and other mental health issues continue Other Possible Problems Taking too much ...

  8. A controlled study between Aripiprazole combined with low-Dose of Clozapine and single Aripiprazole in the Treatment of Female Chronic Schizophrenia%阿立哌唑合用小剂量氯氮平与阿立哌唑单用治疗女性慢性精神分裂症对照研究

    Institute of Scientific and Technical Information of China (English)

    陆德青; 肖刚

    2014-01-01

    Objective To investigate the clinical efficacy and adverse reaction of aripiprazole combined with low- dose of clozapine in the treatment of female patients with chronic schizophrenia.Methods The Study Group 20 cases were treated by aripiprazole combined with low-dose of clozapine treatment,20 cases in the control group only treated with aripiprazole,analyzed the assessment efficacy with the Brief Psychiatric Rating Scale(BPRS)and Scale for the Assessment of Negative Symptoms(SANS),applied the Treatment Emergent Symptom Scale(TESS)to analyze their adverse reactions.Results There was no significant difference between the BPRS scores of the two groups before treatment.After treatment,it showed Significant diference in depression and anxiety and thought disorder(P<0.05), in the activity and total scores,it showed a very significant difference(P<0.01);The same group before and after treatment,the difference is very significant(P<0.01).SANS scores of the two groups had no sign- ificant difference before treatment,After treatment,in lack of interest/social lack had significant differences(P<0.05); The same group before and after treatment,the difference is very significant(P<0.01).TESS statistics showed that two groups’Side reaction occurred with the same frequency.Conclusion Regardless of aripiprazole combined with smal dose of clozapine or single use of aripiprazole in female patients with chronic schizophrenia had a definite effect,aripiprazole combined with smal dose of clozapine has advantages in improvement activities,improve interest/social and so on ,and the adverse reactions were not increased.%目的:探讨阿立哌唑合用小剂量氯氮平与阿立哌唑单用治疗女性慢性精神分裂症患者的临床疗效和不良反应。方法研究组20例应用阿立哌唑合用小剂量氯氮平治疗,对照组20例仅应用阿立哌唑单独治疗,应用简明精神病评定量表(BPRS)和阴性症状量表(SANS)评定疗效,应用副反应

  9. The prescribing pattern of a new antipsychotic: A descriptive study of aripiprazole for psychiatric in-patients

    DEFF Research Database (Denmark)

    Johansson, M.; Manniche, C.; Andersen, Stig Ejdrup

    2008-01-01

    (range 0-8) psychoactive drugs parallel with aripiprazole. This study demonstrates reality in psychopharmacology and quote aripiprazole as example. In day-to-day practice, aripiprazole is used as part of highly individualized regimens comprising polypharmacy and excessive dosing. Although theoretically......In June 2004, aripiprazole was marketed as a second-generation antipsychotic with an entire new mechanism of action. The objective of this descriptive study is to examine the day-to-day prescriptions of aripiprazole to an unselected population of psychiatric in-patients. From 1 February to 1 May...... 2006, present and former in-patients treated with aripiprazole were identified. Prescriptions of aripiprazole and psychoactive comedication were collected retrospectively from the patient records. Seventy-one patients, mainly schizophrenic, received aripiprazole 2.5 to 55 mg/day for median 350 days...

  10. Assessing organizational readiness for depression care quality improvement: relative commitment and implementation capability

    OpenAIRE

    Rubenstein, Lisa V; Danz, Marjorie S; Crain, A. Lauren; Glasgow, Russell E.; Whitebird, Robin R.; Solberg, Leif I.

    2014-01-01

    Background Depression is a major cause of morbidity and cost in primary care patient populations. Successful depression improvement models, however, are complex. Based on organizational readiness theory, a practice’s commitment to change and its capability to carry out the change are both important predictors of initiating improvement. We empirically explored the links between relative commitment (i.e., the intention to move forward within the following year) and implementation capability. Me...

  11. Improving Confidence for Self Care in Patients with Depression and Chronic Illnesses

    OpenAIRE

    Ludman, Evette J; Peterson, Do; Katon, Wayne J; Lin, Elizabeth H. B.; Von Korff, Michael; Ciechanowski, Paul; Young, Bessie; Gensichen, Jochen

    2013-01-01

    The aim of this study was to examine whether patients who received a multi-condition collaborative care intervention for chronic illnesses and depression had greater improvement in self-care knowledge and efficacy, and whether greater knowledge and self-efficacy is positively associated with improved target outcomes. A randomized controlled trial with 214 patients with comorbid depression and poorly controlled diabetes and/or coronary heart disease tested a 12-month team-based intervention th...

  12. Depression improvement and parenting in low-income mothers in home visiting.

    Science.gov (United States)

    Ammerman, Robert T; Altaye, Mekibib; Putnam, Frank W; Teeters, Angelique R; Zou, Yuanshu; Van Ginkel, Judith B

    2015-06-01

    Research on older children and high-resource families demonstrates that maternal improvement in depression often leads to parallel changes in parenting and child adjustment. It is unclear if this association extends to younger children and low-income mothers. This study examined if In-Home Cognitive Behavioral Therapy (IH-CBT), a treatment for depressed mothers participating in home visiting programs, contributes to improvements in parenting and child adjustment. Ninety-three depressed mothers in home visiting between 2 and 10 months postpartum were randomly assigned to IH-CBT (n = 47) plus home visiting or standard home visiting (SHV; n = 46). Mothers were identified via screening and subsequent diagnosis of major depressive disorder (MDD). Measures of depression, parenting stress, nurturing parenting, and child adjustment were administered at pre-treatment, post-treatment, and 3 months follow-up. Results indicated that there were no differences between IH-CBT and controls on parenting and child adjustment. Low levels of depression were associated with decreased parenting stress and increased nurturing parenting. Improvement in depression was related to changes in parenting in low-income mothers participating in home visiting programs. IH-CBT was not independently associated with these improvements, although to the extent that treatment facilitated improvement; there were corresponding benefits to parenting. Child adjustment was not associated with maternal depression, a finding possibly attributed to the benefits of concurrent home visiting or measurement limitations. Future research should focus on longer-term follow-up, implications of relapse, and child adjustment in later years.

  13. Depression improvement and parenting in low-income mothers in home visiting.

    Science.gov (United States)

    Ammerman, Robert T; Altaye, Mekibib; Putnam, Frank W; Teeters, Angelique R; Zou, Yuanshu; Van Ginkel, Judith B

    2015-06-01

    Research on older children and high-resource families demonstrates that maternal improvement in depression often leads to parallel changes in parenting and child adjustment. It is unclear if this association extends to younger children and low-income mothers. This study examined if In-Home Cognitive Behavioral Therapy (IH-CBT), a treatment for depressed mothers participating in home visiting programs, contributes to improvements in parenting and child adjustment. Ninety-three depressed mothers in home visiting between 2 and 10 months postpartum were randomly assigned to IH-CBT (n = 47) plus home visiting or standard home visiting (SHV; n = 46). Mothers were identified via screening and subsequent diagnosis of major depressive disorder (MDD). Measures of depression, parenting stress, nurturing parenting, and child adjustment were administered at pre-treatment, post-treatment, and 3 months follow-up. Results indicated that there were no differences between IH-CBT and controls on parenting and child adjustment. Low levels of depression were associated with decreased parenting stress and increased nurturing parenting. Improvement in depression was related to changes in parenting in low-income mothers participating in home visiting programs. IH-CBT was not independently associated with these improvements, although to the extent that treatment facilitated improvement; there were corresponding benefits to parenting. Child adjustment was not associated with maternal depression, a finding possibly attributed to the benefits of concurrent home visiting or measurement limitations. Future research should focus on longer-term follow-up, implications of relapse, and child adjustment in later years. PMID:25369906

  14. Aripiprazole-associated tic in a schizophrenia patient

    Directory of Open Access Journals (Sweden)

    Guo X

    2015-03-01

    Full Text Available Xieli Guo,1,2,* Dali Lu,3,* Yugang Jiang1 1Department of Neurosurgery, Second Xiangya Hospital of Central South University, Changsha, Hunan, People’s Republic of China; 2Department of Neurosurgery, Jinjiang Hospital of Quanzhou Medical College, Jinjiang, Fujian, People’s Republic of China; 3Department of Psychiatry, Xiamen Xianyue Hospital, Xiamen, Fujian, People’s Republic of China *These authors contributed equally to this work Abstract: Tic disorder, characterized by the presence of both motor and vocal tics is common in adolescents and adults. Antipsychotics including typical antipsychotics and atypical antipsychotics are generally recognized by experts as the most effective pharmacological treatment for tics. However, previous studies suggest that tic-like symptoms might manifest during treatment with atypical antipsychotics such as clo­zapine, quetiapine, but not aripiprazole. We present the first case, to our knowledge, of an adult schizophrenia patient who developed tics during treatment with aripiprazole. Keywords: aripiprazole, antipsychotics, tic, schizophrenia, side effect

  15. Depression.

    Science.gov (United States)

    Tallo, Donato

    2014-04-15

    Reading the CPD article was beneficial to my professional nursing practice and development. I gained a greater understanding of how depression is likely to exacerbate the effects of a physical illness or complicate the treatment of other health conditions. PMID:24712633

  16. Depression

    Science.gov (United States)

    ... to get better. Not a Normal Part of Aging Click for more information Depression is a common problem among older adults, but it is NOT a ... Z | videos A-Z | training | about us | contact us | site map National Institute on Aging | U.S. National Library of Medicine | National Institutes of ...

  17. Improvement of Glycemic Control in Insulin-Dependent Diabetics with Depression by Concomitant Treatment with Antidepressants.

    Science.gov (United States)

    Radojkovic, Jana; Sikanic, Natasa; Bukumiric, Zoran; Tadic, Marijana; Kostic, Nada; Babic, Rade

    2016-01-01

    BACKGROUND It is still disputable whether negative effects of comorbid depression in diabetics can be diminished by successful treatment of depression. The primary aim of this study was to assess whether addition of antidepressants to existing insulin treatment would further improve glycemic control in these patients. A secondary objective was to assess whether such treatment impairs their lipid and inflammatory status. MATERIAL AND METHODS Total of 192 patients with poorly controlled diabetes (defined as HbA1c ≥8%) in the absence of any uncontrolled medical condition entered the 6-month run-in phase with optimization of diabetic therapy. Depression status was screened at the end of this phase by BDI-II depression testing. Patients with BDI-II ≥14 and psychiatric confirmation of depression (58 patients) entered the 6-month interventional phase with SSRI class antidepressants. RESULTS Fifty patients completed the study. During the run-in phase, HbA1c dropped from 10.0±1.8% to 8.5±1.2% (pdepression scale and improvement in glycemic control was observed (R²=0.139, p=0.008). Lipid profile and inflammatory status did not change significantly during the interventional phase. CONCLUSIONS Patients with poorly controlled diabetes and comorbid depression might benefit from screening and treatment of depression with SSRI antidepressants by achieving an incremental effect on glycoregulation. This therapy did not have any adverse effects on lipid profile or inflammatory status. PMID:27329213

  18. Everolimus improves memory and learning while worsening depressive- and anxiety-like behavior in an animal model of depression.

    Science.gov (United States)

    Russo, Emilio; Leo, Antonio; Crupi, Rosalia; Aiello, Rossana; Lippiello, Pellegrino; Spiga, Rosangela; Chimirri, Serafina; Citraro, Rita; Cuzzocrea, Salvatore; Constanti, Andrew; De Sarro, Giovambattista

    2016-07-01

    Everolimus (EVR) is an orally-administered rapamycin analog that selectively inhibits the mammalian target of rapamycin (mTOR) kinase (mainly mTORC1 and likely mTORC2) and the related signaling pathway. mTOR is a serine/threonine protein kinase regulating multiple important cellular functions; dysfunction of mTOR signaling has also been implicated in the pathophysiology of several neurological, neurodegenerative, developmental and cognitive disorders. EVR is widely used as an anti-neoplastic therapy and more recently in children with tuberous sclerosis complex (TSC). However, no clear correlation exists between EVR use and development of central side effects e.g. depression, anxiety or cognitive impairment. We studied the effects of a 3 weeks administration of EVR in mice chronically treated with betamethasone 21-phosphate disodium (BTM) as a model of depression and cognitive decline. EVR treatment had detrimental effects on depressive- and anxiety-like behavior while improving cognitive performance in both control (untreated) and BTM-treated mice. Such effects were accompanied by an increased hippocampal neurogenesis and synaptogenesis. Our results therefore might support the proposed pathological role of mTOR dysregulation in depressive disorders and confirm some previous data on the positive effects of mTOR inhibition in cognitive decline. We also show that EVR, possibly through mTOR inhibition, may be linked to the development of anxiety. The increased hippocampal neurogenesis by EVR might explain its ability to improve cognitive function or protect from cognitive decline. Our findings suggest some caution in the use of EVR, particularly in the developing brain; patients should be carefully monitored for their psychiatric/neurological profiles in any clinical situation where an mTOR inhibitor and in particular EVR is used e.g. cancer treatment, TSC or immunosuppression. PMID:27019134

  19. Physician attitude toward depression care interventions: Implications for implementation of quality improvement initiatives

    OpenAIRE

    Chanin Johann C; Chou Ann F; Henke Rachel; Zides Amanda B; Scholle Sarah

    2008-01-01

    Abstract Background Few individuals with depression treated in the primary care setting receive care consistent with clinical treatment guidelines. Interventions based on the chronic care model (CCM) have been promoted to address barriers and improve the quality of care. A current understanding of barriers to depression care and an awareness of whether physicians believe interventions effectively address those barriers is needed to enhance the success of future implementation. Methods We cond...

  20. The cardiac safety of aripiprazole treatment in patients at high risk for torsade

    DEFF Research Database (Denmark)

    Polcwiartek, Christoffer; Sneider, Benjamin; Graff, Claus;

    2015-01-01

    reviewed and cardiac safety data were extracted. Continuous and dichotomous QTc data were used in the meta-analysis. RESULTS: Preclinical studies suggested that aripiprazole has limited affinity for the delayed rectifier potassium current. TdP was reported in two case reports and SCD was reported in one...... case report and one case series. No clinical studies assessing aripiprazole's cardiac safety in patients at high risk for torsade were found. No thorough QT (TQT) study with aripiprazole was found. The meta-analysis revealed that the mean ΔQTc interval was decreased with aripiprazole and QTc...... factors. OBJECTIVES: Aripiprazole's cardiac safety has not been assessed in patients at high risk for torsade, where QTc prolongation risk is highly increased. METHODS: MEDLINE, Embase, and The Cochrane Library were searched for preclinical, clinical, and epidemiological studies. Eligible studies were...

  1. The Stress Gym: An Online Intervention to Improve Stress and Depressive Symptoms in Adults.

    Science.gov (United States)

    Hinkle, Julie F

    2015-01-01

    Finding methods to facilitate efficient assimilation of relevant health care information is important for quality outcomes, including promoting maximal wellness and optimal patient outcomes in vulnerable populations. The Internet is a promising information resource that can be used to reach those suffering from depression, but evidence of its efficacy in this population is lacking. This study was designed to examine The Stress Gym intervention, a web-enhanced behavioral self-management program (WEB-SM) consisting of nine modules focused on the management of stress and depression. The effect of the Stress Gym intervention on depressive symptoms, stress, and attention was examined, from pre- to post-intervention, in participants with stress and in participants who were experiencing both stress and depressive symptoms. A statistically significant decrease in depressive symptoms and stress was observed and there was a statistically significant increase in attention after the Stress Gym intervention, on average, for all participants. This study supports the efficacy of Stress Gym as a tool to reduce depressive symptoms, stress, and attentional difficulties. There were significant improvements in participants overall and for participants when they were segregated into two groups, those with stress only and those with depressive symptoms and stress. With many patients choosing to explore health concerns online, it is important to have evidence-based programs available online that can help them manage their symptoms.

  2. The Coronary Health Improvement Projects Impact on Lowering Eating, Sleep, Stress, and Depressive Disorders

    Science.gov (United States)

    Merrill, Ray M.; Aldana, Stephen G.; Greenlaw, Roger L.; Diehl, Hans A.

    2008-01-01

    Background: The Coronary Health Improvement Project (CHIP) is designed to lower cardiovascular risk factors among a group of generally healthy individuals through health education. Purpose: This study will evaluate the efficacy of the CHIP intervention at improving eating, sleep, stress, and depressive disorders. Methods: A health education…

  3. Depression remitterede efter subaraknoidal hæmoragi

    DEFF Research Database (Denmark)

    Lauritsen, Lise; Vinberg, Maj

    2015-01-01

    A 65-year-old man was seen in a specialized ambulatory for mood disorders because of treatment-resistant depression. He was treated throughout a period of three years with selective serotonin reuptake inhibitor, dual action, lithium, nortriptyline, reboxetine, aripiprazole, benzodiazepines...

  4. A Practice Improvement Education Program Using a Mentored Approach to Improve Nursing Facility Depression Care-Preliminary Data.

    Science.gov (United States)

    Chodosh, Joshua; Price, Rachel M; Cadogan, Mary P; Damron-Rodriguez, JoAnn; Osterweil, Dan; Czerwinski, Alfredo; Tan, Zaldy S; Merkin, Sharon S; Gans, Daphna; Frank, Janet C

    2015-11-01

    Depression is common in nursing facility residents. Depression data obtained using the Minimum Data Set (MDS) 3.0 offer opportunities for improving diagnostic accuracy and care quality. How best to integrate MDS 3.0 and other data into quality improvement (QI) activity is untested. The objective was to increase nursing home (NH) capability in using QI processes and to improve depression assessment and management through focused mentorship and team building. This was a 6-month intervention with five components: facilitated collection of MDS 3.0 nine-item Patient Health Questionnaire (PHQ-9) and medication data for diagnostic interpretation; education and modeling on QI approaches, team building, and nonpharmacological depression care; mentored team meetings; educational webinars; and technical assistance. PHQ-9 and medication data were collected at baseline and 6 and 9 months. Progress was measured using team participation measures, attitude and care process self-appraisal, mentor assessments, and resident depression outcomes. Five NHs established interprofessional teams that included nursing (44.1%), social work (20.6%), physicians (8.8%), and other disciplines (26.5%). Members participated in 61% of eight offered educational meetings (three onsite mentored team meetings and five webinars). Competency self-ratings improved on four depression care measures (P = .05 to change while medication use declined, from 37.2% of residents at baseline to 31.0% at 9 months (P < .001). This structured mentoring program improved care processes, achieved medication reductions, and was well received. Application to other NH-prevalent syndromes is possible. PMID:26503548

  5. Reduction in delta activity predicted improved negative affect in Major Depressive Disorder.

    Science.gov (United States)

    Cheng, Philip; Goldschmied, Jennifer; Casement, Melynda; Kim, Hyang Sook; Hoffmann, Robert; Armitage, Roseanne; Deldin, Patricia

    2015-08-30

    While prior research has demonstrated a paradoxical antidepressant effect of slow-wave disruption (SWD), the specific dimensions of depression affected is still unclear. The current study aimed to extend this research by utilizing a dimensional approach in examining the antidepressant effects of SWD. Of particular interest is the affective dimension, as negative affect in depression is arguably the most salient characteristic of depression. This sample included 16 individuals with depression (10 female) recruited from the community. Participants slept in the lab for three nights (adaptation, baseline night, and SWD) with polysomnography, and completed measures of negative affect and depression severity the following morning. Results show that reduction in delta power was linearly associated with improved negative affect. Comparison of individual change scores revealed that half of the individuals showed improved negative affect, which is comparable to the reported 40-60% antidepressant response rate to sleep deprivation. Results suggest that vulnerability in the sleep homeostatic system may be a contributing individual differences factor in response to slow-wave disruption in depression. PMID:26123231

  6. Improving confidence for self care in patients with depression and chronic illnesses.

    Science.gov (United States)

    Ludman, Evette J; Peterson, Do; Katon, Wayne J; Lin, Elizabeth H B; Von Korff, Michael; Ciechanowski, Paul; Young, Bessie; Gensichen, Jochen

    2013-01-01

    The aim of this study was to examine whether patients who received a multicondition collaborative care intervention for chronic illnesses and depression had greater improvement in self-care knowledge and efficacy, and whether greater knowledge and self-efficacy was positively associated with improved target outcomes. A randomized controlled trial with 214 patients with comorbid depression and poorly controlled diabetes and/or coronary heart disease tested a 12-month team-based intervention that combined self-management support and collaborative care management. At 6 and 12 month outcomes the intervention group showed significant improvements over the usual care group in confidence in ability to follow through with medical regimens important to managing their conditions and to maintain lifestyle changes even during times of stress. Improvements in self care-efficacy were significantly related to improvements in depression, and early improvements in confidence to maintain lifestyle changes even during times of stress explained part of the observed subsequent improvements in depression. PMID:23398269

  7. Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors

    Directory of Open Access Journals (Sweden)

    Mike Briley

    2010-09-01

    Full Text Available Mike Briley, Chantal MoretNeuroBiz Consulting and Communication, Castres, FranceAbstract: Depression is a disabling condition resulting in significant impairment in social functioning, involving the patient’s family, friends, work colleagues, and society at large. Although both psychologic and pharmacologic treatments generally improve many depressive symptoms, they do not always result in significant improvement in social functioning. The importance of recovery of social functioning in depressed patients is now widely appreciated, and studies are beginning to include it in evaluations of therapeutic efficacy. Among the various social adjustment evaluation rating scales, the Social Adaptation Self-Evaluation Scale, a social motivation and behavior scale, has been found to be simple to use and sensitive to change. Using this scale, the selective norepinephrine reuptake inhibitor, reboxetine, has been shown to be significantly more effective in improving social functioning than the selective serotonin reuptake inhibitor, fluoxetine. These findings are consistent with the notion that improvement in social adaptation involves functions depending primarily on noradrenergic neurotransmission. This hypothesis suggests that the serotonin and norepinephrine reuptake inhibitors, venlafaxine, duloxetine, and milnacipran, could be particularly helpful in improving social functioning. Preliminary studies with the serotonin and norepinephrine reuptake inhibitors suggest that they significantly improve social functioning. Comparative studies with selective serotonin reuptake inhibitors on the effects on social functioning should be encouraged.Keywords: Social Adaptation Self-Evaluation Scale, social functioning, depression, serotonin and norepinephrine reuptake inhibitors, noradrenergic neurotransmission

  8. Cognitive behavioral therapy in combination with systemic family therapy improves mild to moderate postpartum depression

    Directory of Open Access Journals (Sweden)

    Yongmei Hou

    2014-03-01

    Full Text Available Objective: To explore the effect of cognitive behavioral therapy (CBT in combination with systemic family therapy (SFT on mild to moderate postpartum depression and sleep quality. Methods: 249 primiparous women with mild to moderate postpartum depression were recruited and randomly assigned to a control group (n=128, which received conventional postpartum care, or to a psychological intervention group (n=121, which received conventional postpartum care combined with psychological intervention. The Edinburgh Postnatal Depression Scale (EPDS and Pittsburgh Sleep Quality Index (PSQI were employed to evaluate depression and sleep quality, respectively. Results: 104 patients in the intervention group and 109 in the control group completed the study. After intervention, the EPDS score, PSQI score, sleep quality score, sleep latency score, sleep duration score, habitual sleep efficiency score, sleep disturbance score, and daytime dysfunction score were significantly lower in the intervention group than in the control group. The EPDS and PSQI scores of each group at different time points after intervention were markedly decreased compared with those before intervention, and the reduction in the intervention group was more evident than that in the control group. Conclusion: CBT in combination with SFT can improve depression and sleep quality in patients with mild to moderate postpartum depression.

  9. Effects of aripiprazole on caffeine-induced hyperlocomotion and neural activation in the striatum.

    Science.gov (United States)

    Batista, Luara A; Viana, Thércia G; Silveira, Vívian T; Aguiar, Daniele C; Moreira, Fabrício A

    2016-01-01

    Aripiprazole is an antipsychotic that acts as a partial agonist at dopamine D2 receptors. In addition to its antipsychotic activity, this compound blocks the effects of some psychostimulant drugs. It has not been verified, however, if aripiprazole interferes with the effects of caffeine. Hence, this study tested the hypothesis that aripiprazole prevents caffeine-induced hyperlocomotion and investigated the effects of these drugs on neural activity in the striatum. Male Swiss mice received injections of vehicle or antipsychotic drugs followed by vehicle or caffeine. Locomotion was analyzed in a circular arena and c-Fos protein expression was quantified in the dorsolateral, dorsomedial, and ventrolateral striatum, and in the core and shell regions of nucleus accumbens. Aripiprazole (0.1, 1, and 10 mg/kg) prevented caffeine (10 mg/kg)-induced hyperlocomotion at doses that do not change basal locomotion. Haloperidol (0.01, 0.03, and 0.1 mg/kg) also decreased caffeine-induced hyperlocomotion at all doses, although at the two higher doses, this compound reduced basal locomotion. Immunohistochemistry analysis showed that aripiprazole increases c-Fos protein expression in all regions studied, whereas caffeine did not alter c-Fos protein expression. Combined treatment of aripiprazole and caffeine resulted in a decrease in the number of c-Fos positive cells as compared to the group receiving aripiprazole alone. In conclusion, aripiprazole prevents caffeine-induced hyperlocomotion and increases neural activation in the striatum. This latter effect is reduced by subsequent administration of caffeine. These results advance our understanding on the pharmacological profile of aripiprazole.

  10. Improved Sleep in Military Personnel is Associated with Changes in the Expression of Inflammatory Genes and Improvement in Depression Symptoms

    Directory of Open Access Journals (Sweden)

    Whitney S. Livingston

    2015-04-01

    Full Text Available Study Objectives: Sleep disturbances are common in military personnel and are associated with increased risk for psychiatric morbidity, including posttraumatic stress disorder and depression, as well as inflammation. Improved sleep quality is linked to reductions in inflammatory bio-markers; however, the underlying mechanisms remain elusive. Methods: In this study we examine whole genome expression changes related to improved sleep in 68 military personnel diagnosed with insomnia. Subjects were classified into the following groups and then compared: improved sleep (n=46, or non-improved sleep (n=22 following three months of standard of care treatment for insomnia. Within subject differential expression was determined from microarray data using the Partek Genomics Suite analysis program and the interactive pathway analysis was used to determine key regulators of observed expression changes. Changes in symptoms of depression and posttraumatic stress disorder were also compared. Results: At baseline both groups were similar in demographics, clinical characteristics, and gene-expression profiles. The microarray data revealed that 217 coding genes were differentially expressed at the follow-up-period compared to baseline in the participants with improved sleep. Expression of inflammatory cytokines were reduced including IL-1β, IL-6, IL-8 and IL-13, with fold changes ranging from -3.19 to -2.1, and there were increases in the expression of inflammatory regulatory genes including toll-like receptors 1, 4, 7, and 8 in the improved sleep group. Interactive pathway analysis revealed 6 gene networks, including ubiquitin which was a major regulator in these gene-expression changes. The improved sleep group also had a significant reduction in the severity of depressive symptoms.Conclusions: Interventions that restore sleep likely reduce the expression of inflammatory genes, which relate to ubiquitin genes and relate to reductions in depressive symptoms.

  11. Respiratory sinus arrhythmia reactivity to a sad film predicts depression symptom improvement and symptomatic trajectory.

    Science.gov (United States)

    Panaite, Vanessa; Hindash, Alexandra Cowden; Bylsma, Lauren M; Small, Brent J; Salomon, Kristen; Rottenberg, Jonathan

    2016-01-01

    Respiratory sinus arrhythmia (RSA) reactivity, an index of cardiac vagal tone, has been linked to self-regulation and the severity and course of depression (Rottenberg, 2007). Although initial data supports the proposition that RSA withdrawal during a sad film is a specific predictor of depression course (Fraguas, 2007; Rottenberg, 2005), the robustness and specificity of this finding are unclear. To provide a stronger test, RSA reactivity to three emotion films (happy, sad, fear) and to a more robust stressor, a speech task, were examined in currently depressed individuals (n=37), who were assessed for their degree of symptomatic improvement over 30weeks. Robust RSA reactivity to the sad film uniquely predicted overall symptom improvement over 30weeks. RSA reactivity to both sad and stressful stimuli predicted the speed and maintenance of symptomatic improvement. The current analyses provide the most robust support to date that RSA withdrawal to sad stimuli (but not stressful) has specificity in predicting the overall symptomatic improvement. In contrast, RSA reactivity to negative stimuli (both sad and stressful) predicted the trajectory of depression course. Patients' engagement with sad stimuli may be an important sign to attend to in therapeutic settings. PMID:26681648

  12. Training primary-care physicians to recognize, diagnose and manage depression: does it improve patient outcomes?

    NARCIS (Netherlands)

    Tiemens, B.G.; Ormel, J.; Jenner, J.A; Van Der Meer, K.; van Os, T.W.D.P.; van den Brink, R.H.S.; Smit, A.; Van den Brink, W.

    1999-01-01

    Background, We developed a comprehensive, 20-hour training programme for primary-care physicians, that sought to improve their ability to detect, diagnose and manage depression. We evaluated the effects of physician training on patient outcomes, using a pre-post design. Methods. In the pre-training

  13. Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole

    DEFF Research Database (Denmark)

    Jakobsen, Klaus Damgaard; Bruhn, Christina Hedegaard; Pagsberg, Anne-Katrine;

    2016-01-01

    insomnia, Parkinsonism, behavioral changes psychoses, and weight gain, whereas the adverse effects in the PS group was predominantly anxiety, convulsions, and neuroleptic malignant syndrome. Although aripiprazole is considered safe and well tolerated in children and adolescents, severe adverse events...... as neuroleptic malignant syndrome, extreme insomnia, and suicidal behavior has been reported to health authorities. Clinicians should pay attention to these possible hazards when prescribing aripiprazole to this vulnerable group of patients....

  14. Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania

    OpenAIRE

    Amir Akhavan Rezayat; Paria Hebrani; Fatemeh Behdani; Mohamad Salaran; Majid Nabizadeh Marvast

    2014-01-01

    Background: Second-generation antipsychotics, approved for the treatment of mania, are associated with adverse effects such as weight gain and metabolic disorders. Aripiprazole, a recently introduced second-generation antipsychotic, are thought to account for its low propensity for weight gain, metabolic disturbances and sedation. The purpose of this study was to investigate the effect of risperidone versus aripiprazole in the treatment of acute mania. Materials and Methods: Fifty patients wi...

  15. Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial

    OpenAIRE

    Jingyuan Zhao; Xueqin Song; Xiaoqing Ai; Xiaojing Gu; Guangbiao Huang; Xue Li; Lijuan Pang; Minli Ding; Shuang Ding; Luxian Lv

    2015-01-01

    Objective The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia. Methods One hundred and thirteen patients who were receiving a stable dose of risperidone were randomly assigned to either adjunctive aripiprazole treatment (10 mg/day) (aripiprazole group) or no additional treatment (control group) at a 1:1 ratio for 8 weeks. Schizophrenia symptoms were measured using the Positive an...

  16. A Chinese Chan-Based Mind-Body Intervention Improves Sleep on Patients with Depression: A Randomized Controlled Trial

    OpenAIRE

    Chan, Agnes S.; Wong, Queenie Y.; Sophia L. Sze; Kwong, Patrick P. K.; Yvonne M. Y. Han; Mei-chun Cheung

    2012-01-01

    Sleep disturbance is a common problem associated with depression, and cognitive-behavioral therapy (CBT) is a more common behavioral intervention for sleep problems. The present study compares the effect of a newly developed Chinese Chan-based intervention, namely Dejian mind-body intervention (DMBI), with the CBT on improving sleep problems of patients with depression. Seventy-five participants diagnosed with major depressive disorder were randomly assigned to receive 10 weekly sessions of C...

  17. Act In case of Depression: The evaluation of a care program to improve the detection and treatment of depression in nursing homes. Study Protocol

    Directory of Open Access Journals (Sweden)

    Vernooij-Dassen Myrra JFJ

    2011-05-01

    Full Text Available Abstract Background The aim of this study is evaluating the (cost- effectiveness of a multidisciplinary, evidence based care program to improve the management of depression in nursing home residents of somatic and dementia special care units. The care program is an evidence based standardization of the management of depression, including standardized use of measurement instruments and diagnostical methods, and protocolized psychosocial, psychological and pharmacological treatment. Methods/Design In a 19-month longitudinal controlled study using a stepped wedge design, 14 somatic and 14 dementia special care units will implement the care program. All residents who give informed consent on the participating units will be included. Primary outcomes are the frequency of depression on the units and quality of life of residents on the units. The effect of the care program will be estimated using multilevel regression analysis. Secondary outcomes include accuracy of depression-detection in usual care, prevalence of depression-diagnosis in the intervention group, and response to treatment of depressed residents. An economic evaluation from a health care perspective will also be carried out. Discussion The care program is expected to be effective in reducing the frequency of depression and in increasing the quality of life of residents. The study will further provide insight in the cost-effectiveness of the care program. Trial registration Netherlands Trial Register (NTR: NTR1477

  18. Information technology tools to improve treatment of patients with depression: focus on guidelines implementation.

    Science.gov (United States)

    Meglic, Matic; Ivanovski, Matic; Marusic, Andrej

    2008-06-01

    Information technology has the potential to improve and support the treatment of depression. Use of clinical guidelines can improve outcome of treatment, but implementation of guidelines is a demanding process and the resulting user compliance is often poor. Electronic health records, clinical decision support systems and other information technology tools seem at first glance to be a preferable way to implement clinical guidelines since they require user's active and problem oriented participation. This article reviews attempts made so far at use of information tools for implementation of clinical guidelines for depression treatment and discusses their effects. It turns out that there are few existing solutions, ambiguous effects and that usage is often limited. In future the factors determining development of successful electronic tools for clinical guidelines implementation will need to be further specified. Further research projects are underway in Slovenia to investigate these issues.

  19. Community Partners in Care: Leveraging Community Diversity to Improve Depression Care for Underserved Populations

    OpenAIRE

    Khodyakov, Dmitry; Mendel, Peter; Dixon, Elizabeth; Jones, Andrea; Masongsong, Zoe; Wells, Kenneth

    2009-01-01

    Research suggests that the quality and outcomes of depression treatment for adults can be substantially improved through “collaborative care” programs. However, there is a lack of resources required to implement such programs in vulnerable communities. Our paper examines the planning phase of the Community Partners in Care (CPIC) initiative, which addresses this problem through a unique approach in which academic institutions partner directly with a wide range of community-based and service o...

  20. The improved Clinical Global Impression Scale (iCGI: development and validation in depression

    Directory of Open Access Journals (Sweden)

    Kadouri Alane

    2007-02-01

    Full Text Available Abstract Background The Clinical Global Impression scale (CGI is frequently used in medical care and clinical research because of its face validity and practicability. This study proposes to improve the reliability of the Clinical Global Impression (CGI scale in depressive disorders by the use of a semi-standardized interview, a new response format, and a Delphi procedure. Methods Thirty patients hospitalised for a major depressive episode were filmed at T1 (first week in hospital and at T2 (2 weeks later during a 5' specific interview. The Hamilton Depressive Rating Scale and the Symptom Check List were also rated. Eleven psychiatrists rated these videos using either the usual CGI response format or an improved response format, with or without a Delphi procedure. Results The new response format slightly improved (but not significantly the interrater agreement, the Delphi procedure did not. The best results were obtained when ratings by 4 independent raters were averaged. In this situation, intraclass correlation coefficients were about 0.9. Conclusion The Clinical Global Impression is a useful approach in psychiatry since it apprehends patients in their entirety. This study shows that it is possible to quantify such impressions with a high level of interrater agreement.

  1. 阿立哌唑合并康复训练改善精神分裂症患者生活质量的临床研究%Clinical Study of Aripiprazole Combined with Rehabilitation Training to Improve the Quality of Life in Patients with Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    程闯; 张新风

    2013-01-01

    Objective:To explore the effect of aripiprazole combined with rehabilitation training in patients with schizophrenia quality of life of the spirit.Method:Met the Chinese classification and diagnostic criteria of mental disorders Third Edition(CCMD-3)criteria for the diagnosis of 90 patients with schizophrenia were randomly divided into two groups,aripiprazole and clozapine in the treatment of,a total of 8 weeks,two groups were psychiatric rehabilitation training. The positive and negative symptoms scale before and after treatment(PANSS)was introduced in June to assess the efficacy,the side effects scale(TESS)assessment of adverse reactions,the WHO quality of life scale(WHOQOL-100)assessment of quality of life.Result:Aripiprazole group and clozapine group markedly effective rate were 73.3%and 75.6%,with no significant difference between two groups(P>0.05);4,8 weeks after treatment,two groups of PANSS scale scores were decreased than that before treatment(P0.05);治疗后4、8周,两组PANSS量表各项因子分均较治疗前下降(P<0.05),但治疗后8周阿立哌唑组阴性症状及一般精神病理分较氯氮平组差异有统计学意义(P<0.05);阿立哌唑组不良反应发生率显著低于氯氮平组(P<0.05);治疗6个月后两组在(WHOQOL-100)量表各领域均较治疗前有统计学意义(P<0.05),但阿立哌唑组在生理领域、心理领域、社会关系领域、精神支柱、生活质量方面较氯氮平组差异有统计学意义(P<0.05)。结论:阿立哌唑治疗精神分裂症疗效与氯氮平相仿,不良反应少,合并精神康复治疗可显著改善精神分裂症患者的生活质量。

  2. Acute exercise improves cognition in the depressed elderly: the effect of dual-tasks

    Directory of Open Access Journals (Sweden)

    Paulo Eduardo Vasques

    2011-01-01

    Full Text Available OBJECTIVE: The goal of this study was to assess the acute effect of physical exercise on the cognitive function of depressed elderly patients in a dual-task experiment. INTRODUCTION: Physical exercise has a positive effect on the brain and may even act as a treatment for major depressive disorder. However, the effects of acute cardiovascular exercise on cognitive function during and after one session of aerobic training in elderly depressive patients are not known. METHODS: Ten elderly subjects diagnosed with major depressive disorder performed neuropsychological tests during and after a moderate physical exercise session (65-75%HRmax. A Digit Span Test (Forward and Backward and a Stroop Color-Word Test were used to assess cognitive function. The elderly participants walked on an electric treadmill for 30 minutes and underwent the same cognitive testing before, during, immediately after, and 15 minutes after the exercise session. In the control session, the same cognitive testing was conducted, but without exercise training. RESULTS: The results of the Digit Span Test did not change between the control and the exercise sessions. The results of the Stroop Color-Word Test improved after physical exercise, indicating a positive effect of exercise on cognition. CONCLUSIONS: These data suggest that the cognitive functions of depressed elderly persons, especially attention and inhibitory control, are not impaired during and after an acute session of physical exercise. In contrast, the effect of dual-tasks showed beneficial results for these subjects, mainly after exercise. The dual-task may be a safe and useful tool for assessing cognitive function.

  3. Perinatal depression

    OpenAIRE

    Alhusen, Jeanne L.; Alvarez, Carmen

    2016-01-01

    Abstract: Perinatal depression is a common condition with significant adverse maternal, fetal, neonatal, and early childhood outcomes. The perinatal period is an opportune time to screen, diagnose, and treat depression. Improved recognition of perinatal depression, particularly among low-income women, can lead to improved perinatal health outcomes.

  4. Act In case of Depression: the evaluation of a care program to improve the detection and treatment of depression in nursing homes. Study Protocol

    NARCIS (Netherlands)

    Gerritsen, D.L.; Smalbrugge, M.; Teerenstra, S.; Leontjevas, R.; Adang, E.M.M.; Vernooij-Dassen, M.J.F.J.; Derksen, E.; Koopmans, R.T.C.M.

    2011-01-01

    BACKGROUND: The aim of this study is evaluating the (cost-) effectiveness of a multidisciplinary, evidence based care program to improve the management of depression in nursing home residents of somatic and dementia special care units. The care program is an evidence based standardization of the man

  5. [Application of HPLC-UV method for aripiprazole determination in serum].

    Science.gov (United States)

    Synowiec, Anna; Gomółka, Ewa; Zyss, Tomasz; Zieba, Andrzej; Florek, Ewa; Piekoszewski, Wojciech

    2012-01-01

    Aripiprazole is a new drug applied in schizophrenia treatment. There are not strict indications for aripiprazole therapeutic drug monitoring. Despite, serum aripiprazole measuring would help control the drug doses effectiveness. The drug monitoring can eliminate overdosing, adverse effects and let control proper drug ingestion. The aim of the paper was to develop a simple method for aripiprazole determination in serum for therapeutic drug monitoring. High performance liquid chromatography with spectrophotometric detection (HPLC-UV) was used. Resolution was performed on LC-8 column; moving phase was solution 0,025M trimethylammonium buffer: acetonitrile (62:38). Isocratic flow was 1,2 ml/min; internal standard (IS) was promazine; monitored wavelength was lambda=214 nm. The validation parameters were: limits of linearity (LOL) 100-800 ng/ml, limit of detection (LOD) 10 ng/ml, limit of quantity (LOQ) 100 ng/ml. Coefficient of variation (CV) describing accuracy and precision didn't cross 10%. The method was useful for therapeutic drug monitoring in serum of patients treated with aripiprazole. PMID:23421079

  6. Health outcomes in acromegaly: depression and anxiety are promising targets for improving reduced quality of life

    Directory of Open Access Journals (Sweden)

    Victor Jacobus Geraedts

    2015-01-01

    Full Text Available IINTRODUCTION. Remission criteria of acromegaly are based on biochemical variables, i.e. normalization of increased hormone levels. However, the established reduction in Quality of Life (QoL is suggested to be independent of biochemical control. The aim of this study was to test which aspects predict Qol best in acromegaly. METHODS/Design. This is a prospective cohort study in 80 acromegalic patients, with a cross-sectional and longitudinal part. The main outcome measure was health-related quality of life (QoL, measured by a generic and a disease-specific questionnaire (the SF-36 and AcroQol. Main predictors were age, gender, biochemical control, disease characteristics, treatment modalities and psychopathology. RESULTS. Our cohort of 80 acromegalics had a mean age 54.7 ± 12.3 years with an average disease duration of 10.8 ± 10.0 years. Ratio macro-/microadenoma was 54/26. In adjusted mixed method models, we found that psychopathology significantly predicts QoL in acromegaly (in models including the variables age, gender, disease duration, tumor size, basal hormone levels, relevant treatment modalities and relevant comorbidities, with a higher degree of psychopathology indicating a lower QoL (depression vs. AcroQoL: B=-1.175, p<0.001, depression vs. SF36: B=-1.648, p<0.001, anxiety vs. AcroQoL: B=-0.399, p<0.001, anxiety vs. SF36: B=-0.661, p<0.001. The explained variances demonstrate superiority of psychopathology over biochemical control and other variables in predicting QoL in our models. DISCUSSION. Superiority of psychopathology over biochemical control calls for a more extensive approach regarding diagnosing depression and anxiety in pituitary adenomas to improve QoL. Depressive symptoms and anxiety are modifiable factors that might provide valuable targets for possible future treatment interventions.

  7. Improving Health Outcomes for Patients with Depression: A Population Health Imperative. Report on an Expert Panel Meeting.

    Science.gov (United States)

    Clarke, Janice L; Skoufalos, Alexis; Medalia, Alice; Fendrick, A Mark

    2016-09-01

    Improving Health Outcomes for Patients with Depression: A Population Health Imperative. Report on an Expert Panel Meeting Janice L. Clarke, RN, Alexis Skoufalos, EdD, Alice Medalia, PhD, and A. Mark Fendrick, MD Editorial: A Call to Action : David B. Nash, MD, MBA   S-2 OVERVIEW: Depression and the Population Health Imperative    S-3 Promoting Awareness of the Issues and Opportunities for Improvement    S-5 Cognitive Dysfunction in Affective Disorders    S-5 Critical Role of Employers in Improving Health Outcomes for Employees with Depression    S-6 Closing the Behavioral Health Professional and Process Gaps    S-6 Achieving the Triple Aim for Patients with Depressive Disorders    S-6 Improving the Experience of Care for Patients with Depression    S-6 Improving Quality of Care and Health Outcomes for Patients with Depression    S-7 Changing the Cost of Care Discussion from How Much to How Well    S-8 Panel Insights and Recommendations    S-9 Conclusion    S-10. PMID:27636743

  8. Reward circuit DBS improves Parkinson's gait along with severe depression and OCD.

    Science.gov (United States)

    Williams, Nolan R; Hopkins, Thomas R; Short, E Baron; Sahlem, Gregory L; Snipes, Jonathan; Revuelta, Gonzalo J; George, Mark S; Takacs, Istvan

    2016-01-01

    A 59-year-old Caucasian man with a past history of Parkinson's disease (PD) status post-bilateral subthalamic nucleus (STN) deep brain stimulation (DBS), who also had treatment-resistant (TR) obsessive-compulsive disorder (OCD), and treatment-resistant depression (TRD), presented for further evaluation and management of his TR OCD. After an unsuccessful attempt to treat his OCD by reprogramming his existing STN DBS, he was offered bilateral ventral capsule/ventral striatum (VC/VS) DBS surgery. In addition to the expected improvement in OCD symptoms, he experienced significant improvement in both PD-related apathy and depression along with resolution of suicidal ideation. Furthermore, the patient's festinating gait dramatically improved. This case demonstrates that DBS of both the STN and VC/VS appears to have an initial signal of safety and tolerability. This is the first instance where both the STN and the VC/VS DBS targets have been implanted in an individual and the first case where a patient with PD has received additional DBS in mood-regulatory circuitry. PMID:26644268

  9. Assessment of an enhanced program for depression management in primary care: a cluster randomized controlled trial. The INDI project (Interventions for Depression Improvement

    Directory of Open Access Journals (Sweden)

    Hernández Josep M

    2007-09-01

    Full Text Available Abstract Background Most depressed patients are attended at primary care. However, there are significant shortcomings in the diagnosis, management and outcomes of these patients. The aim of this study is to determine whether the implementation of a structured programme for managing depression will provide better health outcomes than usual management. Methods/Design Design: A cluster-randomized controlled trial involving two groups, one of which is the control group consisting of patients who are treated for depression in the usual way and the other is the intervention group consisting of patients on a structured programme for treating depression. Setting: 20 primary care centres in the province of Tarragona (Spain Sample: 400 patients over 18 years of age who have experienced an episode of major depression (DSM-IV and who need to initiate antidepressant treatment Intervention: A multi-component programme with clinical, educational and organisational procedures that includes training for the health care provider and evidence-based clinical guidelines. It also includes primary care nurses working as care-managers who provide educational and emotional support for the patients and who are responsible for active and systematic clinical monitoring. The programme aims to improve the primary care/specialized level interface. Measurements: The patients will be monitored by telephone interviews. The interviewer will not know which group the patient belongs to (blind trial. These interviews will be given at 0, 3, 6 and 12 months. Main variables: Severity of the depressive symptoms, response rate and remission rate. Analysis: Outcomes will be analyzed on an intent-to-treat basis and the unit of analysis will be the individual patient. This analysis will take into account the effect of study design on potential lack of independence between observations within the same cluster. Discussion The effectiveness of caring for depression in primary care can be

  10. Improving Treatment of Depression Among Latinos With Diabetes Using Project Dulce and IMPACT

    OpenAIRE

    Gilmer, Todd P.; Walker, Chris; Johnson, Elizabeth D.; Philis-Tsimikas, Athena; Unützer, Jürgen

    2008-01-01

    OBJECTIVE—To assess the feasibility and cost of integrating diabetes and depression care management in three community clinics serving a low-income and predominately Spanish-speaking Latino population. RESEARCH DESIGN AND METHODS—We screened diabetes patients for depression, and for those with depressive symptoms, we provided depression care management. We assessed changes in depressive symptoms using the Patient Health Questionnaire-9 (PHQ-9), diabetes self-care activities (nutrition, exerci...

  11. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review

    DEFF Research Database (Denmark)

    Ennis, Zandra Nymand; Damkier, Per

    2015-01-01

    To review available data on first-trimester exposure to olanzapine, quetiapine, risperidone and aripiprazole and risk of congenital malformations. We performed a systematic literature search in accordance with PRISMA guidelines identifying studies containing original data on first....../22 (5.1%) and 100/5 (5.0%), respectively. Relative risk estimates and 95% confidence intervals were 1.0 (0.7-1.4) (olanzapine), 1.0 (0.6-1.7) (quetiapine), 1.5 (0.9-2.2) (risperidone) and 1.4 (0.5-3.1) (aripiprazole). First-trimester exposure to olanzapine is not associated with an increased risk...... of congenital malformation. Data for quetiapine and risperidone do not suggest a substantially increased risk, while the risk estimate for aripiprazole remains imprecise owing to a low amount of data....

  12. Aripiprazole in the acute and maintenance phase of bipolar I disorder

    Directory of Open Access Journals (Sweden)

    Zupancic M

    2012-01-01

    Full Text Available Melanie Zupancic1, Misty L Gonzalez2,31Southern Illinois University School of Medicine, 2Division of Medicine Psychiatry, Southern Illinois University School of Medicine, 3Southern Illinois University Edwardsville School of Pharmacy, Southern Illinois University Edwardsville, Springfield, IL, USAAbstract: Bipolar affective disorder is a disabling illness with substantial morbidity and many management challenges. Traditional mood stabilizers such as lithium, valproate, and carbamazepine are often inadequate in controlling symptoms both during the acute and maintenance phase of treatment. Aripiprazole is a second-generation antipsychotic with a unique mechanism of action. Evidence suggests that it is effective in acute manic and mixed states. There are limited data to suggest its efficacy as a maintenance agent. Future studies will be needed to better define the role of aripiprazole relative to other traditional pharmacologic agents.Keywords: aripiprazole, bipolar disorder, acute treatment, maintenance treatment

  13. Aripiprazole as augmentation therapy in bipolar patients with current minor or subsyndromal mood symptoms

    OpenAIRE

    Schweitzer, Isaac; Sarris, Jerome; Tuckwell, Virginia; Maguire, Kay; Smith, Deidre; Ng, Chee

    2013-01-01

    Background This study aims to evaluate the effectiveness of aripiprazole augmentation of maintenance treatment for bipolar disorder in patients with minor or subsyndromal mood episodes while on a stable dose of a mood stabiliser and/or antidepressant. Methods All subjects had a diagnosis of bipolar I or II disorder (Diagnostic and Statistical Manual of Mental Disorders-4th Edition, Text Revision). Open-label aripiprazole was given over 8 weeks initially. The starting dose was 5 to 15 mg/day w...

  14. Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.

    Science.gov (United States)

    Csomor, Philipp A; Preller, Katrin H; Geyer, Mark A; Studerus, Erich; Huber, Theodor; Vollenweider, Franz X

    2014-09-01

    Despite advances in the treatment of schizophrenia spectrum disorders with atypical antipsychotics (AAPs), there is still need for compounds with improved efficacy/side-effect ratios. Evidence from challenge studies suggests that the assessment of gating functions in humans and rodents with naturally low-gating levels might be a useful model to screen for novel compounds with antipsychotic properties. To further evaluate and extend this translational approach, three AAPs were examined. Compounds without antipsychotic properties served as negative control treatments. In a placebo-controlled, within-subject design, healthy males received either single doses of aripiprazole and risperidone (n=28), amisulpride and lorazepam (n=30), or modafinil and valproate (n=30), and placebo. Prepulse inhibiton (PPI) and P50 suppression were assessed. Clinically associated symptoms were evaluated using the SCL-90-R. Aripiprazole, risperidone, and amisulpride increased P50 suppression in low P50 gaters. Lorazepam, modafinil, and valproate did not influence P50 suppression in low gaters. Furthermore, low P50 gaters scored significantly higher on the SCL-90-R than high P50 gaters. Aripiprazole increased PPI in low PPI gaters, whereas modafinil and lorazepam attenuated PPI in both groups. Risperidone, amisulpride, and valproate did not influence PPI. P50 suppression in low gaters appears to be an antipsychotic-sensitive neurophysiologic marker. This conclusion is supported by the association of low P50 suppression and higher clinically associated scores. Furthermore, PPI might be sensitive for atypical mechanisms of antipsychotic medication. The translational model investigating differential effects of AAPs on gating in healthy subjects with naturally low gating can be beneficial for phase II/III development plans by providing additional information for critical decision making.

  15. Nutrition and Depression: Implications for Improving Mental Health Among Childbearing-Aged Women

    OpenAIRE

    Bodnar, Lisa M.; Wisner, Katherine L.

    2005-01-01

    Adequate nutrition is needed for countless aspects of brain functioning. Poor diet quality, ubiquitous in the United States, may be a modifiable risk factor for depression. The objective was to review and synthesize the current knowledge of the role of nutrition in depression, and address implications for childbearing-aged women. Poor omega-3 fatty acid status increases the risk of depression. Fish oil and folic acid supplements each have been used to treat depression successfully. Folate def...

  16. Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice

    DEFF Research Database (Denmark)

    Sørensen, Gunnar; Sager, Thomas N; Petersen, Jørgen H;

    2008-01-01

    RATIONALE: The novel antipsychotic aripiprazole in use for treatment of schizophrenia is a partial agonist at dopamine D(2) receptors with actions at a variety of other receptors as well. Cocaine is believed to exert an important part of its rewarding effect by increasing extracellular levels...

  17. Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole.

    Science.gov (United States)

    Jakobsen, Klaus Damgaard; Bruhn, Christina Hedegaard; Pagsberg, Anne-Katrine; Fink-Jensen, Anders; Nielsen, Jimmi

    2016-10-01

    Aripiprazole is a partial dopamine agonist with only minor neurological and psychiatric adverse effects, making it a potential first-line drug for the treatment of psychiatric disorders. However, the evidence of its use in children and adolescents is rather sparse. The aim of this case study is to discuss adverse drug reaction (ADR) reports concerning aripiprazole-associated neurological and psychiatric events in children and adolescents. The ADR report database at Danish Medicines Agency was searched for all ADRs involving children and adolescents (disorders (PS group) and nonpsychotic disorders (non-PS group). The PS group consisted of 5 patients with schizophrenia and psychoses, not otherwise specified; and the non-PS group consisted of fourteen cases including autism spectrum disorders, attention deficit and hyperactivity disorder, obsessive-compulsive disorder, and Tourette syndrome. The main reported adverse effects in the non-PS group were chronic insomnia, Parkinsonism, behavioral changes psychoses, and weight gain, whereas the adverse effects in the PS group was predominantly anxiety, convulsions, and neuroleptic malignant syndrome. Although aripiprazole is considered safe and well tolerated in children and adolescents, severe adverse events as neuroleptic malignant syndrome, extreme insomnia, and suicidal behavior has been reported to health authorities. Clinicians should pay attention to these possible hazards when prescribing aripiprazole to this vulnerable group of patients. PMID:27504593

  18. Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents

    Directory of Open Access Journals (Sweden)

    Kirino E

    2014-11-01

    Full Text Available Eiji Kirino1–3 1Department of Psychiatry, Juntendo University School of Medicine, 2Department of Psychiatry, Juntendo University Shizuoka Hospital, 3Juntendo Institute of Mental Health, Shizuoka, Japan Abstract: Bipolar disorder is a pernicious illness. Compared with the later-onset form, early onset bipolar disorder is associated with worse psychosocial outcomes, and is characterized by rapid cycling and increased risks of substance abuse and suicide attempts. Controlling mood episodes and preventing relapse in this group of pediatric patients requires careful treatment. Here, we review the effectiveness of aripiprazole for bipolar disorder in children and adolescents, with discussion of this drug's unique pharmacological profile and various clinical study outcomes. Aripiprazole acts as a serotonin 5-HT2A receptor antagonist, as well as a partial agonist of the serotonin 5-HT1A and dopamine D2 receptors. It can be safely used in children and adolescents, as it is highly tolerated and shows lower rates of the side effects typically observed with other antipsychotic drugs, including sedation, weight gain, hyperprolactinemia, and extrapyramidal syndrome. The presently reviewed randomized controlled trials (RCTs and non-RCTs generally reported aripiprazole to be effective and well-tolerated in children and adolescents with bipolar disorder. However, due to the limited number of RCTs, the present conclusions must be evaluated cautiously. Furthermore, aripiprazole cannot yet be considered a preferred treatment for children and adolescents with bipolar disorder, as there is not yet evidence that aripiprazole shows greater efficacy compared to other second-generation antipsychotics. Additional data are needed from future head-to-head comparison studies. Keywords: child, mania, mixed state

  19. Aripiprazole and Risperidone for Treatment of Methamphetamine-Associated Psychosis in Chinese Patients.

    Science.gov (United States)

    Wang, Gang; Zhang, Yao; Zhang, Sheng; Chen, Huijing; Xu, Zaifeng; Schottenfeld, Richard S; Hao, Wei; Chawarski, Marek Cezary

    2016-03-01

    We evaluated tolerability and efficacy of aripiprazole and risperidone for treatment of methamphetamine (METH) associated psychotic symptoms in China. Patients with acute METH-associated psychotic symptoms (N=42) and with Positive and Negative Syndrome Scale (PANSS) total score between 60 and 120 were randomized to aripiprazole (initial dose 5-10mg per day followed by flexible doses 5-15 mg per day) or risperidone (initial dose 2-4 mg per day followed by flexible doses 4-6 mg per day) from day 3 to 25 of inpatient hospital stay. Outcome measures included PANSS and Clinical Global Impressions-Severity of Illness scale (CGI-S), METH craving Visual Analogue Scale (VAS), Simpson Angus Scale (SAS), Barnes Assessments Akathasia Rating Scale (BARS), and self-reported adverse effects evaluated during treatment. Retention was evaluated using Kaplan-Meier survival analysis and the MIXED models procedure was used to compare the groups on measures of psychotic and extra-pyramidal symptoms. Patients in both aripiprazole and risperidone groups showed statistically significant reductions in psychotic symptomatology from baseline during treatment (p<0.001) with no statistically significant differences between the treatment groups (p=0.73 and p=0.15, respectively). Risperidone-treated patients reported significantly greater METH craving reductions (p<0.001). Overall, 71% of patients completed the entire study, but the aripiprazole group had a significantly lower retention than the risperidone group (p=0.007), primarily due to medication related adverse effects. Aripiprazole-treated patients also had significantly more akathisia (p=0.03) and agitation (p=0.02) than risperidone-treated patients. Patients in both groups who tolerated their medications and completed the entire study achieved comparable reductions of psychotic symptoms. PMID:26733277

  20. Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation.

    Science.gov (United States)

    Weinberger, Jeremy F; Raison, Charles L; Rye, David B; Montague, Amy R; Woolwine, Bobbi J; Felger, Jennifer C; Haroon, Ebrahim; Miller, Andrew H

    2015-07-01

    Blockade of the inflammatory cytokine tumor necrosis factor (TNF) in depressed patients with increased inflammation has been associated with decreased depressive symptoms. Nevertheless, the impact of TNF blockade on sleep in depressed patients has not been examined. Accordingly, sleep parameters were measured using polysomnography in 36 patients with treatment resistant major depression at baseline and 2weeks after 3 infusions (week 8) of either the TNF antagonist infliximab (n=19) or placebo (n=17). Markers of inflammation including c-reactive protein (CRP) and TNF and its soluble receptors were also assessed along with depression measured by the 17-item Hamilton Depression Rating Scale. No differences in sleep parameters were found as a function of infliximab treatment over time. Nevertheless, wake after sleep onset (WASO), the spontaneous arousal index and sleep period time significantly decreased, and sleep efficiency significantly increased, from baseline to week 8 in infliximab-treated patients with high (CRP>5mg/L) (n=9) versus low inflammation (CRP⩽5mg/L) (n=10), controlling for changes in scores of depression. Stage 2 sleep also significantly decreased in infliximab-treated patients with high versus low inflammation. Decreases in soluble TNF receptor 1 (sTNFR1) significantly correlated with decreases in WASO and increases in sleep efficiency in infliximab-treated subjects with high inflammation. Placebo-treated subjects exhibited no sleep changes as a function of inflammation, and no correlations between inflammatory markers and sleep parameters in placebo-treated patients were found. These data suggest that inhibition of inflammation may be a viable strategy to improve sleep alterations in patients with depression and other disorders associated with increased inflammation.

  1. Acute exercise improves cognition in the depressed elderly: the effect of dual-tasks

    OpenAIRE

    Paulo Eduardo Vasques; Helena Moraes; Heitor Silveira; Andrea Camaz Deslandes; Jerson Laks

    2011-01-01

    OBJECTIVE: The goal of this study was to assess the acute effect of physical exercise on the cognitive function of depressed elderly patients in a dual-task experiment. INTRODUCTION: Physical exercise has a positive effect on the brain and may even act as a treatment for major depressive disorder. However, the effects of acute cardiovascular exercise on cognitive function during and after one session of aerobic training in elderly depressive patients are not known. METHODS: Ten elderly subjec...

  2. Anxiety and depression in association with morbid obesity: changes with improved physical health after duodenal switch

    OpenAIRE

    Sletteskog Nils; Bergsholm Per; Aasprang Anny; Andersen John; Våge Villy; Natvig Gerd

    2010-01-01

    Background Patients with morbid obesity have an increased risk for anxiety and depression. The "duodenal switch" is perhaps the most effective obesity surgery procedure for inducing weight loss. However, to our knowledge, data on symptoms of anxiety and depression after the duodenal switch are lacking. Furthermore, it has been hypothesized that self-reported physical health is the major predictor of symptoms of depression in patients with morbid obesity. We therefore investigated the symptom...

  3. Low-dose aripiprazole resolved complex hallucinations in the left visual field after right occipital infarction (Charles Bonnet syndrome).

    Science.gov (United States)

    Chen, Cheng-Che; Liu, Hsing-Cheng

    2011-06-01

    We reported a patient who suffered from complex visual hallucinations with left homonymous hemianopsia. Brain imaging showed an acute haemorrhage infarct at the right occipital lobe. Charles Bonnet syndrome (CBS) was suspected and aripiprazole was prescribed at 5 mg daily. After 3 weeks, the symptoms of hallucinations and anxiety were relieved. Although some CBS patients might be self-limited without discomfort, low-dose aripiprazole can be considered as a safe medication for significantly anxious patients with CBS.

  4. A Videotape-Based Training Method for Improving the Detection of Depression in Residents of Long-Term Care Facilities

    Science.gov (United States)

    Wood, Stacey; Cummings, Jeffrey L.; Schnelle, Betha; Stephens, Mary

    2002-01-01

    Purpose: This article reviews the effectiveness of a new training program for improving nursing staffs' detection of depression within long-term care facilities. The course was designed to increase recognition of the Minimal Data Set (MDS) Mood Trigger items, to be brief, and to rely on images rather than didactics. Design and Methods: This study…

  5. No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol

    Directory of Open Access Journals (Sweden)

    Ingeborg eBolstad

    2015-05-01

    Full Text Available Background: Aripiprazole is an atypical antipsychotic drug that is characterized by partial dopamine D2 receptor agonism. Its pharmacodynamic profile is proposed to be beneficial in the treatment of cognitive impairment, which is prevalent in psychotic disorders. This study compared brain activation characteristics produced by aripiprazole with that of haloperidol, a typical D2 receptor antagonist, during a task targeting executive functioning.Methods: Healthy participants received an acute oral dose of haloperidol, aripiprazole or placebo before performing an executive functioning task while blood-oxygen-level-dependent (BOLD functional magnetic resonance imaging (fMRI was carried out. Results: There was a tendency towards reduced performance in the aripiprazole group compared to the two other groups. The image analysis yielded a strong task-related BOLD-fMRI response within each group. An uncorrected between-group analysis showed that aripiprazole challenge resulted in stronger activation in the frontal and temporal gyri and the putamen compared with haloperidol challenge, but after correcting for multiple testing there was no significant group difference. Conclusion: No significant group differences between aripiprazole and haloperidol in frontal cortical activation were obtained when corrected for multiple comparisons.This study is registered in ClinicalTrials.gov (identifier: 2009-016222-14; https://clinicaltrials.gov/.

  6. Major depression

    Science.gov (United States)

    Depression - major; Depression - clinical; Clinical depression; Unipolar depression; Major depressive disorder ... providers do not know the exact causes of depression. It is believed that chemical changes in the ...

  7. Major depression

    Science.gov (United States)

    Depression - major; Depression - clinical; Clinical depression; Unipolar depression; Major depressive disorder ... Doctors do not know the exact causes of depression. It is believed that chemical changes in the ...

  8. Nutrition and depression: implications for improving mental health among childbearing-aged women.

    Science.gov (United States)

    Bodnar, Lisa M; Wisner, Katherine L

    2005-11-01

    Adequate nutrition is needed for countless aspects of brain functioning. Poor diet quality, ubiquitous in the United States, may be a modifiable risk factor for depression. The objective was to review and synthesize the current knowledge of the role of nutrition in depression, and address implications for childbearing-aged women. Poor omega-3 fatty acid status increases the risk of depression. Fish oil and folic acid supplements each have been used to treat depression successfully. Folate deficiency reduces the response to antidepressants. Deficiencies of folate, vitamin B12, iron, zinc, and selenium tend to be more common among depressed than nondepressed persons. Dietary antioxidants have not been studied rigorously in relation to depression. Childbearing-aged women are particularly vulnerable to the adverse effects of poor nutrition on mood because pregnancy and lactation are major nutritional stressors to the body. The depletion of nutrient reserves throughout pregnancy and a lack of recovery postpartum may increase a woman's risk of depression. Prospective research studies are needed to clarify the role of nutrition in the pathophysiology of depression among childbearing-aged women. Greater attention to nutritional factors in mental health is warranted given that nutrition interventions can be inexpensive, safe, easy to administer, and generally acceptable to patients. PMID:16040007

  9. Does Adding Medication to Psychotherapy for Depression Improve or Worsen Outcome?

    Science.gov (United States)

    Karon, Bertram P.

    2007-01-01

    That two-thirds of depressed adults are resistant to medication has led to the addition of psychotherapy to treatment, but is medication necessary? Results are at least as good with psychotherapy alone, and the relapse rate is less. Handling of suicidal danger, sleep disorders, and common depressing issues in college students are discussed along…

  10. Is self-disclosure in couples coping with cancer associated with improvement in depressive symptoms?

    NARCIS (Netherlands)

    Hagedoorn, Mariet; Puterman, Eli; Sanderman, Robbert; Wiggers, Theo; Baas, Peter C.; van Haastert, Michiel; DeLongis, Anita; van, Haastert M.

    2011-01-01

    Objective: This study examined associations between the degree of self-disclosure and changes in depressive symptoms in couples coping with colorectal cancer. Method: Sixty-four newly diagnosed patients and their partners completed a measure of depressive symptoms (Center of Epidemiologic Studies De

  11. A Chinese Chan-Based Mind-Body Intervention Improves Sleep on Patients with Depression: A Randomized Controlled Trial

    Directory of Open Access Journals (Sweden)

    Agnes S. Chan

    2012-01-01

    Full Text Available Sleep disturbance is a common problem associated with depression, and cognitive-behavioral therapy (CBT is a more common behavioral intervention for sleep problems. The present study compares the effect of a newly developed Chinese Chan-based intervention, namely Dejian mind-body intervention (DMBI, with the CBT on improving sleep problems of patients with depression. Seventy-five participants diagnosed with major depressive disorder were randomly assigned to receive 10 weekly sessions of CBT or DMBI, or placed on a waitlist. Measurements included ratings by psychiatrists who were blinded to the experimental design, and a standardized questionnaire on sleep quantity and quality was obtained before and after the 10-week intervention. Results indicated that both the CBT and DMBI groups demonstrated significantly reduced sleep onset latency and wake time after sleep onset (effect size range = 0.46–1.0, P≤0.05 as compared to nonsignificant changes in the waitlist group (P>0.1. Furthermore, the DMBI group, but not the CBT or waitlist groups, demonstrated significantly reduced psychiatrist ratings on overall sleep problems (effect size = 1.0, P=0.00 and improved total sleep time (effect size = 0.8, P=0.05 after treatment. The present findings suggest that a Chinese Chan-based mind-body intervention has positive effects on improving sleep in individuals with depression.

  12. Implementation outcomes of evidence-based quality improvement for depression in VA community based outpatient clinics

    Directory of Open Access Journals (Sweden)

    Fortney John

    2012-04-01

    Full Text Available Abstract Background Collaborative-care management is an evidence-based practice for improving depression outcomes in primary care. The Department of Veterans Affairs (VA has mandated the implementation of collaborative-care management in its satellite clinics, known as Community Based Outpatient Clinics (CBOCs. However, the organizational characteristics of CBOCs present added challenges to implementation. The objective of this study was to evaluate the effectiveness of evidence-based quality improvement (EBQI as a strategy to facilitate the adoption of collaborative-care management in CBOCs. Methods This nonrandomized, small-scale, multisite evaluation of EBQI was conducted at three VA Medical Centers and 11 of their affiliated CBOCs. The Plan phase of the EBQI process involved the localized tailoring of the collaborative-care management program to each CBOC. Researchers ensured that the adaptations were evidence based. Clinical and administrative staff were responsible for adapting the collaborative-care management program for local needs, priorities, preferences and resources. Plan-Do-Study-Act cycles were used to refine the program over time. The evaluation was based on the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance Framework and used data from multiple sources: administrative records, web-based decision-support systems, surveys, and key-informant interviews. Results Adoption: 69.0% (58/84 of primary care providers referred patients to the program. Reach: 9.0% (298/3,296 of primary care patients diagnosed with depression who were not already receiving specialty care were enrolled in the program. Fidelity: During baseline care manager encounters, education/activation was provided to 100% (298/298 of patients, barriers were assessed and addressed for 100% (298/298 of patients, and depression severity was monitored for 100% (298/298 of patients. Less than half (42.5%, 681/1603 of follow-up encounters during the acute

  13. Directions for Effectiveness Research to Improve Health Services for Late-Life Depression in the United States.

    Science.gov (United States)

    Hoeft, Theresa J; Hinton, Ladson; Liu, Jessica; Unützer, Jürgen

    2016-01-01

    Considerable progress has been made in the treatment of late-life depression over the past 20 years, yet considerable gaps in care remain. Gaps in care are particularly pronounced for older men, certain racial and ethnic minority groups, and those with comorbid medical or mental disorders. We reviewed the peer-reviewed literature and conducted interviews with experts in late-life depression to identify promising directions for effectiveness research to address these gaps in care. We searched the PubMed, PsychInfo, and CINHAL databases between January 1, 1998, through August 31, 2013, using terms related to late-life depression and any of the following: epidemiology, services organization, economics of care, underserved groups including health disparities, impact on caregivers, and interventions. The results of this selective review supplemented by more current recommendations from national experts highlight three priority research areas to improve health services for late-life depression: focusing on the unique needs of the patient through patient-centered care and culturally sensitive care, involving caregivers outside the traditional clinical care team, and involving alternate settings of care. We build on these results to offer five recommendations for future effectiveness research that hold considerable potential to advance intervention and health services development for late-life depression.

  14. The Practice Improvement in Education (PIE) Project: Patient Outcome Related to Education on Depression in Nursing Homes

    Science.gov (United States)

    Wen, Aida; Bell, Christina; Parkins, Sebrina; Shishido, Jan; Masaki, Kamal

    2015-01-01

    Background Depression is an important factor related to agitation and other behaviors in nursing home residents. As the next step in our Geriatric Education Center (GEC) Practice Improvement in Education (PIE) project on depression in nursing homes, we focused on non-pharmacologic behavioral management and psychoactive medication reduction. Methods This quality improvement (QI) pilot included training on effective interdisciplinary management approaches for depressive symptoms and challenging behaviors, and implementing an adapted ABC (antecedents, behaviors, consequences) log and behavioral activation. We targeted two nursing home floors and included data on residents present both before and after the QI, in June 2013 and July 2014. We examined changes in depressive symptom scores (Patient Health Questionnaire, or PHQ-9, scale 0-27, higher=worse) and antipsychotic/antidepressant medication use with paired T-tests and Fisher's exact tests. Results Of the 66 nursing home residents in this QI pilot, 70% were female, 60.6% were > 89 years old (range = 48–108, mean = 88.8), 83% were Asian and 51% had severe cognitive impairment. Mean PHQ-9 scores decreased significantly from 3.74 to 2.38 (P = .017). Of the 13/66 (19.7%) residents on antipsychotic medications, 10/13 (76.9%) had dose reductions and 4/13 (30.8%) had medications completely discontinued (P < .0001 for change pre/post). Of the 34 (51.5%) residents on antidepressant medication, 15/34 (42.9%) had dose reductions and 3/34 (8.8%) had medications completely discontinued (P < .0001 for change pre/post). Conclusion Mean depression scores and antipsychotic and antidepressant medication use decreased significantly in this GEC PIE QI project to manage depression and behaviors non-pharmacologically in nursing home residents.

  15. Improving the cost-effectiveness of a healthcare system for depressive disorders by implementing telemedicine: a health economic modeling study

    Science.gov (United States)

    Lokkerbol, Joran; Adema, Dirk; Cuijpers, Pim; Reynolds, Charles F.; Schulz, Richard; Weehuizen, Rifka; Smit, Filip

    2014-01-01

    Objective Depressive disorders are important causes of disease burden and are associated with substantial economic costs. Therefore, it is important to design a health care system that can effectively manage depression at sustainable costs. This paper computes the benefit-to-costs ratio of the current Dutch health care system for depression, and investigates whether offering more online preventive interventions improves the cost-effectiveness overall. Methods A health economic (Markov) model was used to synthesize clinical and economic evidence and to compute population-level costs and effects of interventions. The model compares a base-case scenario without preventive telemedicine and alternative scenarios with preventive telemedicine. The central outcome is the benefit-to-cost ratio, also known as return-on-investment (ROI). Results In terms of ROI, a health care system with preventive telemedicine for depressive disorders offers better value for money than a health care system without internet-based prevention. Overall, the ROI increases from €1.45 ($1.72) in the base-case scenario to €1.76 ($2.09) in the alternative scenario where preventive telemedicine is offered. In a scenario where the costs of offering preventive telemedicine are balanced by cutting back on the expenditure for curative interventions, ROI increases to €1.77 ($2.10), while keeping the health care budget constant. Conclusion In order for a health care system for depressive disorders to remain economically sustainable, its cost-benefit ratio needs to be improved. Offering preventive telemedicine at a large scale is likely to introduce such an improvement. PMID:23759290

  16. Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report

    Directory of Open Access Journals (Sweden)

    Vinciguerra Valentina

    2008-12-01

    Full Text Available Abstract Background Obsessive-compulsive disorder is associated with a relevant impairment in social and interpersonal functioning and severe disability. This seems to be particularly true for the poor insight subtype, characterised by a lack of consciousness of illness and, consequently, compliance with treatment. Poor responsiveness to serotonergic drugs in poor insight obsessive-compulsive patients may also require an augmentation therapy with atypical antipsychotics. Methods We reviewed a case in which a patient with a long history of poor insight obsessive-compulsive disorder was treated with a high dosage of serotonin reuptake inhibitors. Results The treatment resulted in a poor outcome. This patient was therefore augmentated with aripiprazole. Conclusion Doctors should consider aripiprazole as a possible augmentation strategy for serotonergic poor responder obsessive-compulsive patients, but further research on these subjects is needed.

  17. The impact a first episode of major depression has on marital dissatisfaction: Is remission associated with improvement in dissatisfaction?

    Directory of Open Access Journals (Sweden)

    Jaime Moyá

    2010-03-01

    Full Text Available Background and Objectives: Prior research suggests that marital dissatisfaction is associated with Major Depression (MD. The purpose of this study was to investigate whether remission from a first episode of MD is associated with improvement in marital dissatisfaction and whether the degree of marital dissatisfaction at the time of diagnosis has an influence on the outcome of MD. Methods: The Hamilton Rating Scale for Depression, the Dyadic Adjustment Scale and the Areas of Change Questionnaire were administered to 59 married couples in which one member fulfilled DSM-IV criteria for a first Episode of MD, but her husband (or his wife did not suffer any mental disorder, and to 53 control couples at 6 outpatient clinics, at baseline and after a 6-months follow-up. Results: The level of marital dissatisfaction in couples with a persistent depressed participant decreased in comparison to couples without a depressed subject (p < 0.05 CI: -10.6 and -0.2, but there were no significant differences between couples in which the depressed spouse recovered from MD and comparison couples. Regardless of MD´s severity, high levels of satisfaction were associated with a higher probability to recover. Limitations: The follow-up period was short and we assessed the level of marital dissatisfaction using self-report measures. Conclusion: This study shows that MD has an influence on Marital Satisfaction even at a very early stage of the Depressive Disorder. What is more, changes in any of the two factors (MD or marital dissatisfaction influenced the other factor´s course; thus an effective intervention on MD may have a positive impact on marital dissatisfaction as well.

  18. Towards an improvement of the differentiation of depressive disorders. A multidimensional approach

    OpenAIRE

    Winter, Remco Frank Peter de

    2009-01-01

    Background: It is assumed that the endogenous subtype of depression is a form of depression with various biological abnormalities and a genetic predisposition. The clinical picture rarely shows prior stress and/or an abnormal personality. According to the DSM-IV, this subtype is reproduced as the melancholic subtype, but this subtype has insufficient external validity. This is mainly due to the specific operational method used in the categorical DSM system. Question: Reformulating the melanch...

  19. Verbessert sich das Gedächtnis euthymer bipolarer Patienten durch die Behandlung mit Aripiprazol?

    OpenAIRE

    Bellmann, Katharina

    2016-01-01

    BACKGROUND: Medical treatment in bipolar disorder has been more focused on dealing with the acute phase of the illness and preventing future relapse rather than treating cognitive dysfunctions. Cognitive impairment in bipolar patients is related to the central vulnerability of the dopaminergic and serotonergic system. Aripiprazole as a partial agonist at D2/D3- and 5HT1A- receptors includes activity in the dopaminergic and serotonergic systems. Previous studies on animals and schizophrenic pa...

  20. Normalization of Risperidone-Induced Hyperprolactinemia with the Addition of Aripiprazole

    OpenAIRE

    Shores, Larry E.

    2005-01-01

    The objective of this study was to monitor metabolic changes, including hyperprolactinemia, in adolescents medicated with atypical antipsychotics, especially when polypharmacy is involved. This study specifically followed risperidone-induced hyperprolactinemia in adolescents (14 male patients and 2 female patients) after aripiprazole was added to begin transitioning to another atypical antipsychotic. No other changes were made in the medication regimen. Risperidone was continued at the previo...

  1. Improving Health Outcomes for Patients with Depression: A Population Health Imperative. Report on an Expert Panel Meeting

    Science.gov (United States)

    Skoufalos, Alexis; Medalia, Alice; Fendrick, A. Mark

    2016-01-01

    Improving Health Outcomes for Patients with Depression: A Population Health Imperative. Report on an Expert Panel Meeting Janice L. Clarke, RN, Alexis Skoufalos, EdD, Alice Medalia, PhD, and A. Mark Fendrick, MD Editorial: A Call to Action: David B. Nash, MD, MBA   S-2 Overview: Depression and the Population Health Imperative   S-3 Promoting Awareness of the Issues and Opportunities for Improvement   S-5 Cognitive Dysfunction in Affective Disorders   S-5 Critical Role of Employers in Improving Health Outcomes for Employees with Depression   S-6 Closing the Behavioral Health Professional and Process Gaps   S-6 Achieving the Triple Aim for Patients with Depressive Disorders   S-6 Improving the Experience of Care for Patients with Depression   S-6 Improving Quality of Care and Health Outcomes for Patients with Depression   S-7 Changing the Cost of Care Discussion from How Much to How Well   S-8 Panel Insights and Recommendations   S-9 Conclusion   S-10 PMID:27636743

  2. Effects of amisulpride and aripiprazole on progressive-ratio schedule performance: comparison with clozapine and haloperidol.

    Science.gov (United States)

    den Boon, F S; Body, S; Hampson, C L; Bradshaw, C M; Szabadi, E; de Bruin, N

    2012-09-01

    Clozapine and some other atypical antipsychotics (e.g. quetiapine, olanzapine) have been found to exert a characteristic profile of action on operant behaviour maintained by progressive-ratio schedules, as revealed by Killeen's Mathematical Principles of Reinforcement model of schedule-controlled behaviour. These drugs increase the value of a parameter that expresses the 'incentive value' of the reinforcer (a) and a parameter that is inversely related to the organism's 'motor capacity' (δ). This experiment examined the effects of two further atypical antipsychotics, aripiprazole and amisulpride, on progressive-ratio schedule performance in rats; the effects of clozapine and a conventional antipsychotic, haloperidol, were also examined. In agreement with previous findings, clozapine (4, 8 mg kg⁻¹) increased a and δ, whereas haloperidol (0.05, 0.1 mg kg⁻¹) reduced a and increased δ. Aripiprazole (3,30 mg kg⁻¹) increased δ but did not affect a. Amisulpride (5, 50 mg kg⁻¹) had a delayed and protracted effect: δ was increased 3-6 hours after treatment; a was increased 1.5 hours, and reduced 12-24 hours after treatment. Interpretation based on Killeen's model suggests that aripiprazole does not share clozapine's ability to enhance reinforcer value. Amisulpride produced a short-lived enhancement, followed by a long-lasting reduction, of reinforcer value. Both drugs impaired motor performance.

  3. Successful treatment of catatonic syndrome in bipolar I disorder adding aripiprazole to ECT: A case report

    Directory of Open Access Journals (Sweden)

    Diego Hidalgo, MD

    2012-09-01

    Full Text Available Background and Objectives: Catatonic syndrome is a condition presenting in multiple ways, sharing many of them with the neuroleptic malignant syndrome and other diseases. This diagnostic challenge is the main cause of keep treating catatonic syndromes without neuroleptics. Methods: Review of the literature and a case report. Results: We present the case of a 19 years old bipolar I patient with a severe catatonic syndrome, with a torpid clinical evolution, partial response to benzodiazepines and ECT, which successfully resolved with intramuscular aripiprazole. We found through a systematic review (PubMed 2005-2010 that there are few but significant case reports of catatonic syndromes treated with new second generation antipsychotics for different reasons with good outcomes as ours. The pharmacological profile of aripiprazole and the low incidence of NMS reported make it a suitable option in treating this syndrome. Conclusions: We think that this case report could contribute to add more evidence for aripiprazole to be considered a good third-line option in the treatment of catatonic syndrome. However, this would require randomized controlled trials to confirm its effectiveness and safety.

  4. Use of antipsychotics in the treatment of depressive disorders

    Institute of Scientific and Technical Information of China (English)

    Ping WANG; Tianmei SI

    2013-01-01

    There is a long history of using antipsychotic medications in the treatment of depressive disorders. Atypical antipsychotics, which have fewer side effects than traditional antipsychotics, have been used as monotherapy or adjunctively with antidepressants to treat depressive disorders with or without psychotic symptoms. The antidepressant effect of atypical antipsychotics involves regulation of monoamine, glutamate, gamma-aminobutyric acid (GABA), cortisol, and neurotrophic factors. To date, the United States Food and Drug Administration (USFDA) has approved aripiprazole and quetiapine slow-release tablets as adjunctive treatment for depressive disorders, and the combination of olanzapine and fluoxetine for the treatment of treatment-resistant depression. When using atypical antipsychotics in the treatment of depressed patients, clinicians need to monitor patients for the emergence of adverse effects including extrapyramidal symptoms (EPS), weight gain, and hyperglycemia.

  5. Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission.

    Science.gov (United States)

    Kurhe, Yeshwant; Mahesh, Radhakrishnan

    2015-09-01

    In our earlier study we reported the antidepressant activity of ondansetron in obese mice. The present study investigates the effect of ondansetron on depression and anxiety associated with obesity in experimental mice with biochemical evidences. Male Swiss albino mice were fed with high fat diet (HFD) for 14weeks to induce obesity. Then the subsequent treatment with ondansetron (0.5 and 1mg/kg, p.o.), classical antidepressant escitalopram (ESC) (10mg/kg, p.o.) and vehicle (distilled water 10ml/kg, p.o.) was given once daily for 28days. Behavioral assay for depression including sucrose preference test, forced swim test (FST) and anxiety such as light dark test (LDT) and hole board test (HBT) were performed in obese mice. Furthermore, in biochemical estimations oral glucose tolerance test (OGTT), plasma leptin, insulin, corticosterone, brain oxidative stress marker malonaldehyde (MDA), antioxidant reduced glutathione (GSH) and serotonin assays were performed. Results indicated that HFD fed obese mice showed severe depressive and anxiety-like behaviors. Chronic treatment with ondansetron inhibited the co-morbid depression and anxiety in obese mice by increasing sucrose consumption in sucrose preference test and reducing the immobility time in FST, increasing time and transitions of light chamber in LDT, improving head dip and crossing scores in HBT compared to HFD control mice. Ondansetron in obese mice inhibited glucose sensitivity in OGTT, improved plasma leptin and insulin sensitivity, reversed hypothalamic pituitary adrenal (HPA) axis hyperactivity by reducing the corticosterone concentration, restored brain pro-oxidant/anti-oxidant balance by inhibiting MDA and elevating GSH concentrations and facilitated serotonergic neurotransmission. In conclusion, ondansetron reversed the co-morbid depression and anxiety associated with obesity in experimental mice by attenuating the behavioral and biochemical abnormalities. PMID:26188166

  6. Brain activation predicts treatment improvement in patients with major depressive disorder.

    LENUS (Irish Health Repository)

    Samson, Andrea C

    2012-02-01

    Major depressive disorder (MDD) is associated with alterations in brain function that might be useful for therapy evaluation. The current study aimed to identify predictors for therapy improvement and to track functional brain changes during therapy. Twenty-one drug-free patients with MDD underwent functional MRI twice during performance of an emotional perception task: once before and once after 4 weeks of antidepressant treatment (mirtazapine or venlafaxine). Twelve healthy controls were investigated once with the same methods. A significant difference between groups was a relative greater activation of the right dorsolateral prefrontal cortex (dlPFC) in the patients vs. controls. Before treatment, patients responding better to pharmacological treatment showed greater activation in the dorsomedial PFC (dmPFC), posterior cingulate cortex (pCC) and superior frontal gyrus (SFG) when viewing of negative emotional pictures was compared with the resting condition. Activations in the caudate nucleus and insula contrasted for emotional compared to neutral stimuli were also associated with successful treatment. Responders had also significantly higher levels of activation, compared to non-responders, in a range of other brain regions. Brain activation related to treatment success might be related to altered self-referential processes and a differential response to external emotional stimuli, suggesting differences in the processing of emotionally salient stimuli between those who are likely to respond to pharmacological treatment and those who will not. The present investigation suggests the pCC, dmPFC, SFG, caudate nucleus and insula may have a key role as a biological marker for treatment response and predictor for therapeutic success.

  7. IL-1β and BDNF are associated with improvement in hypersomnia but not insomnia following exercise in major depressive disorder

    OpenAIRE

    Rethorst, C D; Greer, T L; Toups, M S P; Bernstein, I; Carmody, T. J.; Trivedi, M H

    2015-01-01

    Given the role of sleep in the development and treatment of major depressive disorder (MDD), it is becoming increasingly clear that elucidation of the biological mechanisms underlying sleep disturbances in MDD is crucial to improve treatment outcomes. Sleep disturbances are varied and can present as insomnia and/or hypersomnia. Though research has examined the biological underpinnings of insomnia in MDD, little is known about the role of biomarkers in hypersomnia associated with MDD. This pap...

  8. Difficulties in post-stroke gait improvement caused by post-stroke depression

    Institute of Scientific and Technical Information of China (English)

    Stanislaw Kijowski

    2014-01-01

    Background Depression is a common problem impeding post-stroke rehabilitation.Up to 70% of patients show depression symptoms during the first twelve months after stroke onset.However,the depression and its effect on functional recovery can be difficult to diagnose.The purpose of this study was to use gait analysis as a tool to compare the recovery after stroke in patients with and without depression and to assess the impact of the initiation time of rehabilitation after stroke onset.Methods One hundred and forty five consecutive patients after first ever stroke admitted for designed rehabilitation program within 2 to 31 months after stroke onset participated.All patients received 4 weeks treatment program included comprehensive rehabilitation consisted of multipurpose activities 5 days a week.These included individual and group exercises,physiotherapy,occupational therapy and gait training.Gait analysis with Kistler force plates was employed to assess gait pattern symmetry before and after the treatment.Gait symmetry was evaluated based on seven gait parameters.Regaining of gait pattern symmetry was assumed as a measure of rehabilitation outcome.Results After rehabilitation program gait symmetry w()ined in patients without depression.Gait asymmetry remained unchanged in patients diagnosed with depression.No major differences in outcome from rehabilitation were noted in regards to the initiation time of rehabilitation after the stroke onset.Conclusions Depression limits gait recovery after stroke.The time of initiation of rehabilitation after stroke onset does not limit the motor recovery after rehabilitation program.

  9. Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness

    DEFF Research Database (Denmark)

    Penner, Iris-Katharina; Sivertsdotter, Eva Catharina; Celius, Elisabeth G;

    2015-01-01

    BACKGROUND: Fatigue is a frequent symptom in multiple sclerosis (MS) and often interrelated with depression and sleep disorders making symptomatic treatment decisions difficult. In the single-arm, observational phase IV TYNERGY study, relapsing-remitting MS patients showed a clinically meaningful...

  10. Increased Mesohippocampal Dopaminergic Activity and Improved Depression-Like Behaviors in Maternally Separated Rats Following Repeated Fasting/Refeeding Cycles

    Directory of Open Access Journals (Sweden)

    Jeong Won Jahng

    2012-01-01

    Full Text Available We have previously reported that rats that experienced 3 h of daily maternal separation during the first 2 weeks of birth (MS showed binge-like eating behaviors with increased activity of the hypothalamic-pituitary-adrenal axis when they were subjected to fasting/refeeding cycles repeatedly. In this study, we have examined the psychoemotional behaviors of MS rats on the fasting/refeeding cycles, together with their brain dopamine levels. Fasting/refeeding cycles normalized the ambulatory activity of MS rats, which was decreased by MS experience. Depression-like behaviors, but not anxiety, by MS experience were improved after fasting/refeeding cycles. Fasting/refeeding cycles did not significantly affect the behavioral scores of nonhandled (NH control rats. Fasting/refeeding cycles increased dopamine levels not only in the hippocampus but also in the midbrain dopaminergic neurons in MS rats, but not in NH controls. Results demonstrate that fasting/refeeding cycles increase the mesohippocampal dopaminergic activity and improve depression-like behaviors in rats that experienced MS. Together with our previous paper, it is suggested that increased dopamine neurotransmission in the hippocampus may be implicated in the underlying mechanisms by which the fasting/refeeding cycles induce binge-like eating and improve depression-like behaviors in MS rats.

  11. Improving physical quality of life with group physical activity in the adjunctive treatment of major depressive disorder

    Directory of Open Access Journals (Sweden)

    Mannu Francesca

    2008-01-01

    Full Text Available Abstract Background The aim of the study was to compare the change in quality of life over 32 weeks in depressed women assuming antidepressant drug with (experimental group or without (control group physical exercise from a study which results on objective dimension of outcome were already published. Methods Trial with randomized naturalistic control. Patients selected from the clinical activity registries of a Psychiatric University Unit. Inclusion criteria: female, between 40 and 60 years, diagnosis of Major Depressive Disorders (MMD, DSM-IV TR resistant to ongoing treatment. Exclusion criteria: diagnosis of psychotic disorders; any contraindications to physical activity. 30 patients (71.4% of the eligible participated to the study. Cases: 10 randomized patients undergoing pharmacological treatment plus physical activity. Controls: 20 patients undergoing only pharmacological therapy. Quality of life was measured by means of WHOQOL-Bref. Results The patients that made physical activity had their WHOQOL-Bref physical score improved from T0 to T8, the differences was statistically significant. In the control group WHOQOL-Bref physical remains the same and, consequentially, the difference between T0 and T8 do not reach any statistical significance. The perceived quality of life in the other domains did not change during the treatment in both groups. Thus no other differences were found between and within groups. Discussion and Conclusion The data presented in the previous paper found that physical activity seems a good adjunctive treatment in the long term management of patients with MDD. These new data indicated that physical activity may also improve the perceived physical quality of life. The dimensions related with social functioning, environment and psychical well being seem do not improved, unexpectedly, during the trial. Two objective dimension not strictly related to the depressive symptoms improved: social functioning and Clinical Global

  12. Combination of omega-3 Fatty acids, lithium, and aripiprazole reduces oxidative stress in brain of mice with mania.

    Science.gov (United States)

    Arunagiri, Pandiyan; Rajeshwaran, Krishnamoorthy; Shanthakumar, Janakiraman; Tamilselvan, Thangavel; Balamurugan, Elumalai

    2014-09-01

    Manic episode in bipolar disorder (BD) was evaluated in the present study with supplementation of omega-3 fatty acids in combination with aripiprazole and lithium on methylphenidate (MPD)-induced manic mice model. Administration of MPD 5 mg/kg bw intraperitoneally (i.p.) caused increase in oxidative stress in mice brain. To retract this effect, supplementation of omega-3 fatty acids 1.5 ml/kg (p.o.), aripiprazole 1.5 mg/kg bw (i.p.), and lithium 50 mg/kg bw (p.o) were given to mice. Omega-3 fatty acids alone and in combination with aripiprazole- and lithium-treated groups significantly reduced the levels of superoxide dismutase (SOD), catalase (CAT), and lipid peroxidation products (thiobarbituric acid reactive substances) in the brain. MPD treatment significantly decreased the reduced glutathione (GSH) level and glutathione peroxidase (GPx) activity, and they were restored by supplementation of omega-3 fatty acids with aripiprazole and lithium. There is no remarkable difference in the effect of creatine kinase (CK) activity between MPD-induced manic model and the treatment groups. Therefore, our results demonstrate that oxidative stress imbalance and mild insignificant CK alterations induced by administration of MPD can be restored back to normal physiological levels through omega-3 fatty acids combined with lithium and aripiprazole that attributes to effective prevention against mania in adult male Swiss albino mice.

  13. The impact of comorbid depression on recovery from personality disorders and improvements in psychosocial functioning: results from a randomized controlled trial.

    Science.gov (United States)

    Renner, Fritz; Bamelis, Lotte L M; Huibers, Marcus J H; Speckens, Anne; Arntz, Arnoud

    2014-12-01

    Depressive disorders often co-occur with personality disorders. The extent to which depressive disorders influence treatment outcome in personality disorders remains unclear. The aim of this study was to determine the impact of co-morbid depression on recovery from personality disorders and improvements in psychosocial functioning. This study drew data from a randomized-controlled trial in which patients (N = 320) with cluster-c (92%), paranoid, histrionic and/or narcissistic personality disorders received schema-therapy, treatment-as-usual, or clarification-oriented psychotherapy. Recovery from personality disorders at three-year follow-up and improvements in psychosocial functioning over a course of three years was predicted by the diagnostic status of depressive disorders at baseline using mixed model regression analyses. Based on the number of axis-I and axis-II disorders, personality disorder severity and global symptomatic distress and functioning a baseline severity index was computed and included in subsequent analyses to test the specificity of baseline depression in predicting outcomes. Patients with co-occurring depression reported higher baseline severity compared to patients without co-occurring depression. Depression at baseline was associated with lower recovery rates at three-year follow-up (p = 0.01) but this effect disappeared after controlling for baseline severity. Patients with depression at baseline reported higher psychosocial impairments throughout treatment (p personality disorders but this effect disappears when general severity is taken into account. Patients with primarily cluster-c personality disorders and co-occurring depression might benefit from additional depression treatment in terms of improved psychosocial functioning.

  14. Strategies to improve anxiety and depression in patients with COPD: a mental health perspective

    Directory of Open Access Journals (Sweden)

    Tselebis A

    2016-02-01

    Full Text Available Athanasios Tselebis,1 Argyro Pachi,1 Ioannis Ilias,2 Epaminondas Kosmas,3 Dionisios Bratis,1 Georgios Moussas,1 Nikolaos Tzanakis4,5 1Psychiatric Department, “Sotiria” General Hospital of Chest Disease, Athens, Greece; 2Endocrinology Department, “Elena Venizelou” Hospital, Athens, Greece; 3Pulmonary Department, “Metropolitan” General Hospital, Athens, Greece; 4Department of Thoracic Medicine, 5Social Medicine, Laboratory of Epidemiology, University of Crete Medical School, Heraklion, Greece Abstract: Chronic obstructive pulmonary disease (COPD is a chronic inflammatory lung disease characterized by progressive and only partially reversible symptoms. Worldwide, the incidence of COPD presents a disturbing continuous increase. Anxiety and depression are remarkably common in COPD patients, but the evidence about optimal approaches for managing psychological comorbidities in COPD remains unclear and largely speculative. Pharmacological treatment based on selective serotonin reuptake inhibitors has almost replaced tricyclic antidepressants. The main psychological intervention is cognitive behavioral therapy. Of particular interest are pulmonary rehabilitation programs, which can reduce anxiety and depressive symptoms in these patients. Although the literature on treating anxiety and depression in patients with COPD is limited, we believe that it points to the implementation of personalized strategies to address their psychopathological comorbidities. Keywords: COPD, anxiety, depression, pharmacological treatment, psychotherapy

  15. Depression among Alumni of Foster Care: Decreasing Rates through Improvement of Experiences in Care

    Science.gov (United States)

    White, Catherine Roller; O'Brien, Kirk; Pecora, Peter J.; English, Diana; Williams, Jason R.; Phillips, Chereese M.

    2009-01-01

    The Northwest Foster Care Alumni Study examined the relation between experiences in foster care and depression among young adults who spent at least a year in foster care as adolescents. Results indicate that preparation for leaving foster care, nurturing supports from the foster family, school stability, access to tutoring, access to therapeutic…

  16. Comparison between the AA/EPA ratio in depressed and non depressed elderly females: omega-3 fatty acid supplementation correlates with improved symptoms but does not change immunological parameters

    Directory of Open Access Journals (Sweden)

    Rizzo Angela

    2012-10-01

    Full Text Available Abstract Background Depression is one of the most frequently missed diagnoses in elderly people, with obvious negative effects on quality of life. Various studies have shown that long chain omega-3 polyunsaturated fatty acids (n-3 PUFA may be useful in its management. Our objective was to evaluate whether a supplement containing n-3 PUFA improves depressive symptoms in depressed elderly patients, and whether the blood fatty acid pattern is correlated with these changes. Methods The severity of depressive symptoms according to the Geriatric Depression Scale (GDS, blood fatty acid composition and erythrocyte phospholipids were analyzed in 46 depressed females aged 66-95y, diagnosed with depression according to DSMIV, within the context of a randomized, double-blind, placebo-controlled trial. 22 depressed females were included in the intervention group (2.5 g/day of n-3 PUFA for 8 weeks, and 24 in the placebo group. We also measured immunological parameters (CD2, CD3, CD4, CD8, CD16, CD19 and cytokines (IL-5, IL-15. Results The mean GDS score and AA/EPA ratio, in whole blood and RBC membrane phospholipids, were significantly lower after 2 months supplementation with n-3 PUFA. A significant correlation between the amelioration of GDS and the AA/EPA ratio with some immunological parameters, such as CD2, CD19, CD4, CD16 and the ratio CD4/CD8, was also found. Nevertheless, omega-3 supplementation did not significantly improve the studied immunological functions. Conclusions n-3 PUFA supplementation ameliorates symptoms in elderly depression. The n-3 PUFA status may be monitored by means of the determination of whole blood AA/EPA ratio.

  17. Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN.

    Directory of Open Access Journals (Sweden)

    Linda P M M Wijlaars

    Full Text Available BACKGROUND: In 2003, the Committee on Safety of Medicines (CSM advised against treatment with selective serotonin reuptake inhibitors (SSRIs other than fluoxetine in children, due to a possible increased risk of suicidal behaviour. This study examined the effects of this safety warning on general practitioners' depression diagnosing and prescription behaviour in children. METHODS AND FINDINGS: We identified a cohort of 1,502,753 children (6 m in The Health Improvement Network (THIN UK primary care database. Trends in incidence of depression diagnoses, symptoms and antidepressant prescribing were examined 1995-2009, accounting for deprivation, age and gender. We used segmented regression analysis to assess changes in prescription rates. Overall, 45,723 (3% children had ≥ 1 depression-related entry in their clinical records. SSRIs were prescribed to 16,925 (1% of children. SSRI prescription rates decreased from 3.2 (95%CI:3.0,3.3 per 1,000 person-years at risk (PYAR in 2002 to 1.7 (95%CI:1.7,1.8 per 1,000 PYAR in 2005, but have since risen to 2.7 (95%CI:2.6,2.8 per 1,000 PYAR in 2009. Prescription rates for CSM-contraindicated SSRIs citalopram, sertraline and especially paroxetine dropped dramatically after 2002, while rates for fluoxetine and amitriptyline remained stable. After 2005 rates for all antidepressants, except paroxetine and imipramine, started to rise again. Rates for depression diagnoses dropped from 3.0 (95%CI:2.8,3.1 per 1,000 PYAR in 2002 to 2.0 (95%CI:1.9,2.1 per 1,000 PYAR in 2005 and have been stable since. Recording of symptoms saw a steady increase from 1.0 (95%CI:0.8,1.2 per 1,000 PYAR in 1995 to 4.7 (95%CI:4.5,4.8 per 1,000 PYAR in 2009. CONCLUSIONS: The rates of depression diagnoses and SSRI prescriptions showed a significant drop around the time of the CSM advice, which was not present in the recording of symptoms. This could indicate caution on the part of GPs in making depression diagnoses and prescribing

  18. Improving treatment of depression in the elderly: two innovations in statistical design of clinical trials.

    Science.gov (United States)

    Lavori, Philip W

    2005-08-01

    Depression in the elderly patient may present special challenges for the design of clinical treatment trials due to a complex antidepressant treatment history, individual contraindications to certain medications, medical comorbidity, as well as concurrent medications for other medical conditions. The chronic, relapsing, and remitting nature of depression calls for a dynamic, adaptive treatment strategy, matching treatment changes to patient responses. To market a drug successfully in a cost-conscious environment, it also may be necessary to define the unique contribution that a new drug makes to the treatment of patients, in addition to proving that it is efficacious (by comparison to placebo). These issues, although not unique to the elderly, take on greater importance and weight as patient populations age. This article describes 2 innovations in clinical trials design that may help deal with these issues.

  19. A pilot study of folic acid supplementation for improving homocysteine levels, cognitive and depressive status in eating disorders

    Directory of Open Access Journals (Sweden)

    Viviana Loria-Kohen

    2013-06-01

    Full Text Available Background & aims: Several authors have reported low folate intake in patients with eating disorders (ED. This vitamin plays an essential role in synthesis reactions for neurotransmitters and structural elements of neurons, and therefore its deficiency has been associated with the presence of different disorders linked to mental function. The aim of this study was to determine the effect of folic acid supplementation on homocysteine levels and the cognitive and depressive status of a group of patients with eating disorders with low folate intake. Subjects/methods: The study was designed as a randomised, prospective clinical trial, which included 24 participants assigned to two treatment groups for six months: supplemented group (SG (10 mg/day of folic acid [ACFOL®] and a placebo group (PG. Both groups maintained their medical, dietary and psychological treatment. At baseline and end of the intervention, anthropometric, dietary and biochemical parameters (plasma homocysteine [Hcy], serum and red blood cell folate were recorded. Cognitive and depressive status questionnaires were administered (Stroop Test, Trail Making Test and Beck Depression Inventory. Results: Twenty-two patients completed the study (SG: 12, PG: 10, mean age: 24.2 ± 8.8 years, BMI 18, ± 3.5 kg/m². The SG significantly increased their serum and red blood cell folate levels and lowered Hcy levels (9.4 ± 2.4 µmol/l vs. 7.5 ± 1.7 µmol/l, P < 0.01. The SG also significantly improved most of their test scores for cognitive and depressive status. The PG showed no significant changes in any of the evaluated variables. Conclusions: The results show that folic acid supplementation may be used as another tool within the comprehensive and multidisciplinary treatment applied to patients with ED.

  20. Clinical Usefulness of Aripiprazole and Lamotrigine in Schizoaffective Presentation of Tuberous Sclerosis

    Science.gov (United States)

    Lee, Seung-Yup; Min, Jung-Ah; Lee, In Goo; Kim, Jung Jin

    2016-01-01

    Tuberous sclerosis is not as rare as once thought and has high psychiatric comorbidities. However, bipolar or psychotic features associated with tuberous sclerosis have been rarely reported. This report first presents a tuberous sclerosis patient, resembling a schizoaffective disorder of bipolar type. A patient with known tuberous sclerosis displayed mood fluctuation and psychotic features. Her symptoms did not remit along with several psychiatric medications. After hospitalization, the patient responded well with lamotrigine and aripiprazole without exacerbation. As demonstrated in this case, tuberous sclerosis may also encompass bipolar affective or psychotic features. We would like to point out the necessity to consider bipolarity in evaluating and treating tuberous sclerosis. PMID:27489387

  1. Implementing collaborative care for depression treatment in primary care: A cluster randomized evaluation of a quality improvement practice redesign

    Directory of Open Access Journals (Sweden)

    Lee Martin

    2011-10-01

    Full Text Available Abstract Background Meta-analyses show collaborative care models (CCMs with nurse care management are effective for improving primary care for depression. This study aimed to develop CCM approaches that could be sustained and spread within Veterans Affairs (VA. Evidence-based quality improvement (EBQI uses QI approaches within a research/clinical partnership to redesign care. The study used EBQI methods for CCM redesign, tested the effectiveness of the locally adapted model as implemented, and assessed the contextual factors shaping intervention effectiveness. Methods The study intervention is EBQI as applied to CCM implementation. The study uses a cluster randomized design as a formative evaluation tool to test and improve the effectiveness of the redesign process, with seven intervention and three non-intervention VA primary care practices in five different states. The primary study outcome is patient antidepressant use. The context evaluation is descriptive and uses subgroup analysis. The primary context evaluation measure is naturalistic primary care clinician (PCC predilection to adopt CCM. For the randomized evaluation, trained telephone research interviewers enrolled consecutive primary care patients with major depression in the evaluation, referred enrolled patients in intervention practices to the implemented CCM, and re-surveyed at seven months. Results Interviewers enrolled 288 CCM site and 258 non-CCM site patients. Enrolled intervention site patients were more likely to receive appropriate antidepressant care (66% versus 43%, p = 0.01, but showed no significant difference in symptom improvement compared to usual care. In terms of context, only 40% of enrolled patients received complete care management per protocol. PCC predilection to adopt CCM had substantial effects on patient participation, with patients belonging to early adopter clinicians completing adequate care manager follow-up significantly more often than patients of

  2. Clinical efficacy comparison of escitalopram treatment combined with aripiprazole on obsessive compulsive disorder%艾司西酞普兰联合阿立哌唑治疗强迫症患者的疗效观察

    Institute of Scientific and Technical Information of China (English)

    姜涛

    2011-01-01

    Objective; To investigate the effectiveness and safety of escitalopram with or without aripi-prazole in the treatment of obsessive-compulsive disorder. Method;60 patients with obsessive compulsive disorder were randomly assigned to receive escitalopram with or without aripiprazole. Effectiveness and adverse effect were assessed by Yale-Brown obsessive compulsive scale (Y-BOCS) and treatment emergent symptom scale ( TESS) , respectively. Results; Patients both received escitalopram and escitalopram with aripiprazole showed significant improvement by Y-BOCS scores after treatment,while the combination group showed a better outcome. There was no significant difference in TESS evaluation between the two groups. Conclusion; Escitalopram could effectively treat obsessive-compulsive disorder, while escitalopram combined with aripiprazole is more effective.%目的:探讨艾司西酞普兰与阿立哌唑联合治疗强迫症的疗效及不良反应.方法:对60例强迫症患者随机分为单用艾司西酞普兰组(单用组)及艾司西酞普兰与阿立哌唑联合用药组(合用组)治疗强迫症患者各30例进行开放、随机、对照研究,通过耶鲁布朗强迫量表(Y-BOCS)评定疗效,治疗中出现的症状量表(TESS)评定不良反应. 结果:艾司西酞普兰治疗后显著改善强迫症状,艾司西酞普兰联合阿立哌唑也能显著改善强迫症状,后者改善效果更好;两组不良反应轻微.结论:艾司西酞普兰联合阿立哌唑较单用艾司西酞普兰的抗强迫效果更好.

  3. A randomized,controlled study of lithium carbonate monotheraPy or combined ariPiPrazole theraPy in Patients with biPolar disorder tyPe I manic ePisode%碳酸锂单用与合并阿立哌唑治疗双相障碍I型躁狂发作患者的随机对照研究

    Institute of Scientific and Technical Information of China (English)

    宋振华; 粟幼嵩; 王勇; 黄佳; 季曹珺; 吴彦; 王祖承

    2014-01-01

    目的:探讨碳酸锂单用及合并阿立哌唑治疗双相障碍 I 型躁狂发作患者的疗效和安全性。方法:86例门诊双相障碍 I 型躁狂发作患者被随机分为联合组(碳酸锂+阿立哌唑治疗)和单药组(碳酸锂单药治疗),疗程8周。分别在治疗前、治疗2、4、8周进行杨氏躁狂量表(YMRS)和汉密顿抑郁量表(HAMD)-17项评定,采用治疗中出现的症状量表( TESS)评定不良反应。结果:治疗前两组YMRS 评分差异无统计学意义;治疗2、4、8周后联合组 YMRS 减分值明显高于对照组(P ﹤0.05或 P ﹤0.01);治疗前后两组 HAMD 均﹤7分;两组 TESS 评分差异无统计学意义。结论:碳酸锂联合阿立哌唑治疗双相障碍 I 型躁狂发作较单用碳酸锂起效快,症状改善更明显,且未见不良反应明显增加。%To investigate the clinical efficacy and safety of lithium carbonate monotherapy or combined aripiprazole therapy in patients with bipolar disorder type I manic episode. Method:Eighty-six out-patients with bipolar disorder type I manic episode were randomly divided into combining therapy group( trea-ted with lithium carbonate + aripiprazole)and monotherapy guoup(treated with lithium carbonate only),the course was 8 weeks. The patients were assessed by Young′s manic scale(YMRS)and Hamilton depression scale items(HAMD)-17 before treatment and 2,4,8 weeks after treatment. The adverse reaction was evaluated by treatment emergent symptoms scale(TESS). Results:Before treatment,the score of YMRS between the two groups was not significantly different. At 2,4,8 weeks after treatment the subtraction scores of YMRS in the combining therapy group were more obvious than the monotherapy guoup(P ﹤ 0. 05 or P ﹤ 0. 01). The scores of HAMD at each time point in the both groups were ﹤ 7. The score of TESS between the two groups was not signifi-cantly different. Conclusion:Compared lithium carbonate monotherapy

  4. A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents with Irritability Associated with Autistic Disorder

    Science.gov (United States)

    Marcus, Ronald N.; Owen, Randall; Kamen, Lisa; Manos, George; McQuade, Robert D.; Carson, William H.; Aman, Michael G.

    2009-01-01

    Objective: To evaluate the short-term efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Method: Two hundred eighteen children and adolescents (aged 6-17 years) with a diagnosis of autistic disorder, and with behaviors such as tantrums, aggression, self-injurious behavior, or a…

  5. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials

    OpenAIRE

    Sambunaris, Angelo; Gommoll, Carl; Chen, ChangZheng; Greenberg, William M

    2014-01-01

    Major depressive disorder (MDD) is characterized by increased rates of impaired function and disability. During antidepressant treatment, functional improvement often lags behind symptomatic resolution, and residual impairment is associated with an increased risk for relapse. When evaluating MDD treatments, it is important to assess not only depressive symptoms but also functional outcomes. In this post-hoc analysis, data from five studies were pooled to examine the effect of levomilnacipran ...

  6. Comparison of the Efficacy of Cognitive Behavior Therapy and Mindfulness-based Therapy in Improving Cognitive Emotion Regulation in Major Depressive Disorder

    OpenAIRE

    H Bagherinia; Yamini, M.; L javadielmi; T nooradi

    2015-01-01

    Background & aim: Major depression disorder is one of the common mental disorders that the way of cognitive emotional regulation influences in development or reducing symptoms of this disorder. Since cognitive emotional regulation plays an important role in coping with life problems, this disorder causes emotional disturbances such as major depression. The aim of this study was to compare the efficacy of cognitive behavior therapy and mindfulness-based therapy to improve cognitive emotion reg...

  7. Improving the Management of Late-Life Depression in Primary Care: Barriers and Facilitators

    Directory of Open Access Journals (Sweden)

    Tamara Sussman

    2011-01-01

    Full Text Available The objectives of this study were to elicit Canadian health professionals' views on the barriers to identifying and treating late-life depression in primary care settings and on the solutions felt to be most important and feasible to implement. A consensus development process was used to generate, rank, and discuss solutions. Twenty-three health professionals participated in the consensus process. Results were analysed using quantitative and qualitative methods. Participants generated 12 solutions. One solution, developing mechanisms to increase family physicians' awareness of resources, was highly ranked for importance and feasibility by most participants. Another solution, providing family physicians with direct mental health support, was highly ranked as important but not as feasible by most participants. Deliberations emphasized the importance of case specific, as needed support based on the principles of shared care. The results suggest that practitioners highly value collaborative care but question the feasibility of implementing these principles in current Canadian primary care contexts.

  8. Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats

    DEFF Research Database (Denmark)

    Thomsen, Morgane; Fink-Jensen, Anders; Woldbye, David;

    2008-01-01

    the hypothesis that aripiprazole, both as acute and as chronic treatment, would preferentially decrease cocaine self-administration while sparing behavior maintained by a natural reinforcer, resulting in a shift in the allocation of behavior from cocaine-taking towards the alternative reinforcer. MATERIALS...... performance in the choice procedure was assessed daily. RESULTS: An intermediate dose of aripiprazole decreased cocaine self-administration and shifted the cocaine choice curve to the right as an acute treatment. However, as a chronic treatment, aripiprazole failed to decrease cocaine self-administration...... or cocaine choice, despite a dose-dependent decrease in overall response rates and food-maintained behavior. CONCLUSIONS: Our results confirm and extend earlier findings and indicate that acute administration of aripiprazole can decrease cocaine self-administration. However, based on the present data...

  9. Depression - resources

    Science.gov (United States)

    Resources - depression ... Depression is a medical condition. If you think you may be depressed, see a health care provider. ... following organizations are good sources of information on depression : American Psychological Association -- www.apa.org/topics/depress/ ...

  10. Research on Exercise Training Improves the Aging Depression Mechanism%运动改善老年抑郁的研究现状

    Institute of Scientific and Technical Information of China (English)

    高晓芳; 王维

    2014-01-01

    老年抑郁是老年群体中患病率相当高的一种精神障碍,抑郁带给人类社会的危害性及其严重。因此,老年抑郁症治疗的研究受到国内外研究者们的广泛关注。研究对运动改善老年抑郁样行为及其内在机制进行综述。%Depression is a mental disorder in a high prevalence rate of depression in the elderly population,to human society and its harmfulness is serious. Therefore, study on the treatment of geriatric depression is widely concerned by domestic and foreign researchers. It reviews that how improve the depression behavior by exercise and internal mechanism.

  11. Sleep deprivation in depression

    Directory of Open Access Journals (Sweden)

    Doongaji D

    1979-01-01

    Full Text Available Ten patients diagnosed as suffering from depressive illness were treated with 2 consecutive nights of sleep deprivation. Sleep deprivation was effective in both types of depression viz. endoge-nous and reactive. The improvement was greater and seemed to last longer in endogenous depression as compared to reactive depression at the time of evaluation, 7 days after completion of sleep deprivation. Depressed mood, suicidal tendencies and retard-ation seemed to show the greatest improvement while insight and gastro-intestinal and somatic symptoms, improved the least.

  12. Improvement in Depressive Symptoms Is Associated with Reduced Oxidative Damage and Inflammatory Response in Type 2 Diabetic Patients with Subsyndromal Depression: The Results of a Randomized Controlled Trial Comparing Psychoeducation, Physical Exercise, and Enhanced Treatment as Usual

    Directory of Open Access Journals (Sweden)

    Marijana Vučić Lovrenčić

    2015-01-01

    Full Text Available Aims. To examine one-year changes in oxidative damage and inflammation level in type 2 diabetic patients undergoing behavioral treatment for subsyndromal depression. Materials and Methods. A randomized controlled comparison of psychoeducation (A, physical exercise (B, and enhanced treatment as usual (C was performed in 209 eligible subjects in a tertiary diabetes care setting. Depressive symptoms (primary outcome and selected biomarkers of oxidative damage and inflammation (secondary outcomes were assessed at baseline and six- and twelve-month follow-up. Results. Out of the 74, 67, and 68 patients randomised into groups A, B, and C, respectively, 201 completed the interventions, and 179 were analysed. Participants in all three groups equally improved in depressive symptoms from baseline to one-year follow-up (repeated measures ANOVA; F=12.51, p<0.0001, η2=0.07. Urinary 8-oxo-deoxyguanosine (u-8-oxodG decreased (F=10.66, p<0.0001, η2=0.06, as did sialic acid and leukocytes (F=84.57, η2=0.32 and F=12.61, η2=0.07, resp.; p<0.0001, while uric acid increased (F=12.53, p<0.0001, η2=0.07 in all subjects during one year. Improvement of depressive symptoms at 6 months significantly predicted one-year reduction in u-8-oxodG (β=0.15, p=0.044. Conclusion. Simple behavioral interventions are capable not only of alleviating depressive symptoms, but also of reducing the intensity of damaging oxidative/inflammatory processes in type 2 diabetic patients with subsyndromal depression. This trial is registered with ISRCTN05673017.

  13. The HDAC inhibitor SAHA improves depressive-like behavior of CRTC1-deficient mice: possible relevance for treatment-resistant depression

    KAUST Repository

    Meylan, Elsa M.

    2016-03-09

    Major depression is a highly complex disabling psychiatric disorder affecting millions of people worldwide. Despite the availability of several classes of antidepressants, a substantial percentage of patients are unresponsive to these medications. A better understanding of the neurobiology of depression and the mechanisms underlying antidepressant response is thus critically needed. We previously reported that mice lacking CREB-regulated transcription coactivator 1 (CRTC1) exhibit a depressive-like phenotype and a blunted antidepressant response to the selective serotonin reuptake inhibitor fluoxetine. In this study, we similarly show that Crtc1‒/‒ mice are resistant to the antidepressant effect of chronic desipramine in a behavioral despair paradigm. Supporting the blunted response to this tricyclic antidepressant, we found that desipramine does not significantly increase the expression of Bdnf and Nr4a1-3 in the hippocampus and prefrontal cortex of Crtc1‒/‒ mice. Epigenetic regulation of neuroplasticity gene expression has been associated with depression and antidepressant response, and histone deacetylase (HDAC) inhibitors have been shown to have antidepressant-like properties. Here, we show that unlike conventional antidepressants, chronic systemic administration of the HDAC inhibitor SAHA partially rescues the depressive-like behavior of Crtc1‒/‒ mice. This behavioral effect is accompanied by an increased expression of Bdnf, but not Nr4a1-3, in the prefrontal cortex of these mice, suggesting that this epigenetic intervention restores the expression of a subset of genes by acting downstream of CRTC1. These findings suggest that CRTC1 alterations may be associated with treatment-resistant depression, and support the interesting possibility that targeting HDACs may be a useful therapeutic strategy in antidepressant development.

  14. No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial.

    Science.gov (United States)

    Park, Chul-Hyun; Park, Tae-Won; Yang, Jong-Chul; Lee, Keon-Hak; Huang, Guang-Biao; Tong, Zhao; Park, Myung-Sook; Chung, Young-Chul

    2012-03-01

    Noncompliance and poor outcome in patients with schizophrenia are closely related to the negative symptoms secondary to antipsychotics. No controlled study has evaluated whether amisulpride and aripiprazole induce negative symptoms. The aim of this study was to assess the effects of single doses of amisulpride, aripiprazole, haloperidol, and risperidone in healthy volunteers. Seventy-eight young volunteers took part in this double-blind, randomized, placebo-controlled, parallel study of four antipsychotics: 400 mg amisulpride, 10 mg aripiprazole, 3 mg haloperidol, and 2 mg risperidone. Assessments of negative symptoms were done 4 h after administration using both subjective rating scales (Neuroleptic Induced Deficit Syndrome Scale and Subjective Deficit Syndrome Scale) and an objective rating scale (Scale for the Assessment of Negative Symptoms). Risperidone only produced significant increases on the avolition score of the Neuroleptic Induced Deficit Syndrome Scale and blunted affect and alogia scores of the Scale for the Assessment of Negative Symptoms compared with placebo. The effect on blunted affect persisted after controlling for mental sedation. Amisulpride, aripiprazole, and haloperidol did not induce negative symptoms. Aripiprazole and risperidone induced mild extrapyramidal symptoms. The most common adverse events were somnolence and cognitive slowing. These data indicate that a single risperidone dose induces negative symptoms in normal volunteers, whereas amisulpride, aripiprazole, and haloperidol do not. These characteristics of antipsychotics should be considered when choosing optimal drugs for patients with psychosis.

  15. Role of aripiprazole in treatment-resistant schizophrenia

    OpenAIRE

    Mossaheb N; Kaufmann RM

    2012-01-01

    Nilufar Mossaheb,1 Rainer M Kaufmann21Department of Child and Adolescent Psychiatry, 2Department of Psychiatry and Psychotherapy, Medical University, Vienna, AustriaAbstract: About one third of patients with schizophrenia respond unsatisfactorily to antipsychotic treatment and are termed “treatment-resistant”. Clozapine is still the gold standard in these cases. However, 40%–70% of patients do not improve sufficiently on clozapine either. In the search for more e...

  16. Heart disease and depression

    Science.gov (United States)

    Heart disease and depression often go hand-in-hand. You are are more likely to feel sad or depressed after a heart attack ... heart disease. The good news is that treating depression may help improve both your mental and physical ...

  17. Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders

    Directory of Open Access Journals (Sweden)

    Cox JH

    2016-06-01

    Full Text Available Joanna H Cox,1 Stefano Seri,2,3 Andrea E Cavanna,2,4,5 1Heart of England NHS Foundation Trust, 2School of Life and Health Sciences, Aston Brain Centre, Aston University, 3Children’s Epilepsy Surgery Programme, The Birmingham Children’s Hospital NHS Foundation Trust, 4Department of Neuropsychiatry, Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, 5Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology and UCL, London, UK Abstract: Tourette syndrome is a childhood-onset chronic tic disorder characterized by multiple motor and vocal tics and often accompanied by specific behavioral symptoms ranging from obsessionality to impulsivity. A considerable proportion of patients report significant impairment in health-related quality of life caused by the severity of their tics and behavioral symptoms and require medical intervention. The most commonly used medications are antidopaminergic agents, which have been consistently shown to be effective for tic control, but are also associated with poor tolerability because of their adverse effects. The newer antipsychotic medication aripiprazole is characterized by a unique mechanism of action (D2 partial agonism, and over the last decade has increasingly been used for the treatment of tics. We conducted a systematic literature review to assess the available evidence on the efficacy and safety of aripiprazole in pediatric patients with Tourette syndrome and other chronic tic disorders (age range: 4–18 years. Our search identified two randomized controlled trials (involving 60 and 61 participants and ten open-label studies (involving between six and 81 participants. The majority of these studies used two validated clinician-rated instruments (Yale Global Tic Severity Scale and Clinical Global Impression scale as primary outcome measures. The combined results from randomized controlled trials and open-label studies showed that aripiprazole is an

  18. Depression - overview

    Science.gov (United States)

    Blues; Gloom; Sadness; Melancholy ... depression . The main types of depression include: Major depression . It occurs when feelings of sadness, loss, anger, or frustration interfere with daily life ...

  19. 阿立哌唑与喹硫平治疗精神分裂症的疗效与安全性%Efficacy and safety of aripiprazole and quetiapine in treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    刘永桥; 杜波; 宓为峰; 王晓志; 施莹; 李玲芝; 马文斌; 金超; 杨勇峰; 张鸿燕

    2014-01-01

    Objective To evaluate the efficacy and safety of quetiapine and aripiprazole on patients with schizophrenia.Methods The random-ized, open, multi-center trial recruited 168 patients with schizophrenia , who received a 8-week treatment of aripiprazole (n=79, 10-30 mg· d -1 ) or quetiapine ( n=89 , 400-800 mg · d -1 ).The psychotic syn-dromes were rated with the positive and negative syndrome scale ( PAN-SS)at the baseline, the end of the fourth week and the eighth week.The disease severity was evaluated by the Clinical global impression -severity scale ( CGI-S ) and the Clinical global impression -improvement scale ( CGI-I).The safety was evaluated based on the incidences of adverse events and the comparison of laboratory or electrocardiography examina-tions prior and post the treatment.Results The response rates of aripi-prazole and quetiapine were 71.4%and 72.9%.There was no statistical difference ( P>0.05 ).The incidence rates of adverse events related to aripiprazole and quetiapine were 54.05% and 41.77%.The incidence rate of extrapyramidal symptoms ( EPS ) of the two groups were 36.7%and 4.6%( P<0.001 ).Conclusion Aripiprazole and quetiapine both show similar efficacy in the treatment of schizophrenia.The incidence rates of adverse events are similar but with different profiles.%目的:评价阿立哌唑与喹硫平治疗精神分裂症的疗效和安全性。方法用随机、开放、多中心的研究方法。入选精神分裂症患者168例,随机分入阿立哌唑组79例,剂量10~30 mg· d-1;喹硫平组89例,剂量400~800 mg· d-1,疗程均8周。在基线,4,8周末,用阳性症状与阴性症状量表(PANSS)评价精神病性症状,以临床总体印象量表-严重程度(CGI-S)、疗效总评(CGI-I)评价疾病严重程度;以不良事件、实验室检查、心电图检查等评价安全性。结果阿立哌唑组与喹硫平组有效率分别为71.4%和72.9%,2组差异无统计学意义( P>0.05)。

  20. E fficacy of Aripiprazole and Risperidone on Memory Function in Patients with Schizophrenia%阿立哌唑和利培酮对首发精神分裂症患者记忆功能的影响

    Institute of Scientific and Technical Information of China (English)

    胡茂荣; 姜淑珍; 占海燕; 胡斌; 鲍成; 余斌; 周朝雄; 吴慧玲

    2013-01-01

    Objective To explore the efficacy of aripiprazole and risperidone on memory function in patients with schizophrenia. Methods 112 first-episode patients with schizophrenia were random-ized to aripiprazole group(n=56) and risperidone group(n=56). All subjects were assessed with the Wechsler Memory Scale-ⅢSpatial Span Task(WMS-Ⅲ SST), the Hopkins Verbal Learning Test-Re-vised (HVLT-R) and The Brief Visuospatial Memory Test-Revised (BVMT-R).Results Both groups showed no statistical significance in WMS-Ⅲ SST, HVLT-R and BVMT-R scores in the baseline (P>0.05).The performances after 12 weeks of treatment in the both groups was higher than those in the baseline in all tests(P0.05).Aripiprazole group was increased significantly compared with before treatment after treatment WMS-Ⅲ SST score (P<0.05), and after treatment there was a statistical significance between the two groups (P<0.05).Conclusion Memory impairments in the patients with first-episode schizophrenia was im-proved by aripiprazole and risperidone, and effect of aripiprazole on certain memory functions was better than those of risperidone.%目的:探讨阿立哌唑和利培酮对首发精神分裂症患者记忆功能的影响。方法112例首发精神分裂症患者随机分成阿立哌唑组和利培酮组,每组56例。在治疗前和治疗12周末采用韦氏记忆量表-第三版的空间广度测验(WMS-Ⅲ SST)、霍普金斯词汇学习测验-修订版(HVLT-R)、简单视觉空间记忆测验-修订版(BVMT-R)分别对工作记忆、言语记忆和视觉记忆领域进行评定。结果在治疗前,两组的WMS-Ⅲ SST HVLT-R 和BVMT-R得分比较均无统计学意义(P>0.05)。在治疗12周后,两组的HVLT-R 和BVMT-R得分较治疗前比较均有统计学意义(P<0.05)而治疗后两组间比较无统计学意义(P>0.05);阿立哌唑组在治疗后的WMS-Ⅲ SST得分较治疗前显著增加(P<0.05),且治疗后两组间比较有统计学意义(P<0.05

  1. Comparison of the Efficacy of Cognitive Behavior Therapy and Mindfulness-based Therapy in Improving Cognitive Emotion Regulation in Major Depressive Disorder

    Directory of Open Access Journals (Sweden)

    H Bagherinia

    2015-06-01

    Conclusion: The cognitive behavioral and based on mindfulness treatment were effective in cognitive emotional regulation improvement, since treatment of based on mindfulness puts emphasis on current feelings and avoidance of self-judgment, and can also be more effective than cognitive behavioral method in using adaptive strategies of cognitive emotional regulation by patients with major depression

  2. Enhancement of encapsulation efficiency of nanoemulsion-containing aripiprazole for the treatment of schizophrenia using mixture experimental design

    Directory of Open Access Journals (Sweden)

    Fard Masoumi HR

    2015-10-01

    Full Text Available Hamid Reza Fard Masoumi, Mahiran Basri, Wan Sarah Samiun, Zahra Izadiyan, Chaw Jiang Lim Nanodelivery Group, Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia Abstract: Aripiprazole is considered as a third-generation antipsychotic drug with excellent therapeutic efficacy in controlling schizophrenia symptoms and was the first atypical anti­psychotic agent to be approved by the US Food and Drug Administration. Formulation of nanoemulsion-containing aripiprazole was carried out using high shear and high pressure homo­genizers. Mixture experimental design was selected to optimize the composition of nanoemulsion. A very small droplet size of emulsion can provide an effective encapsulation for delivery system in the body. The effects of palm kernel oil ester (3–6 wt%, lecithin (2–3 wt%, Tween 80 (0.5–1 wt%, glycerol (1.5–3 wt%, and water (87–93 wt% on the droplet size of aripiprazole nanoemulsions were investigated. The mathematical model showed that the optimum formulation for preparation of aripiprazole nanoemulsion having the desirable criteria was 3.00% of palm kernel oil ester, 2.00% of lecithin, 1.00% of Tween 80, 2.25% of glycerol, and 91.75% of water. Under optimum formulation, the corresponding predicted response value for droplet size was 64.24 nm, which showed an excellent agreement with the actual value (62.23 nm with residual standard error <3.2%. Keywords: schizoaffective disorder, antipsychotic drug, bipolar I disorder, D-optimal mixture design, optimization formulation

  3. Improving Self-Help E-Therapy for Depression and Anxiety Among Sexual Minorities: An Analysis of Focus Groups With Lesbians and Gay Men

    OpenAIRE

    Rozbroj, Tomas; Lyons, Anthony; Pitts, Marian; Mitchell, Anne; Christensen, Helen

    2015-01-01

    Background E-therapies for depression and anxiety rarely account for lesbian and gay users. This is despite lesbians and gay men being at heightened risk of mood disorders and likely to benefit from having access to tailored self-help resources. Objective We sought to determine how e-therapies for depression and anxiety could be improved to address the therapeutic needs of lesbians and gay men. Methods We conducted eight focus groups with lesbians and gay men aged 18 years and older. Focus gr...

  4. Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.

    Science.gov (United States)

    Aggarwal, Arpit; Gopalakrishna, Ganesh; Lauriello, John

    2016-01-01

    Antipsychotics have long been the mainstay for the treatment of schizophrenia and other psychotic disorders. Long-acting injectables (LAI) of antipsychotics-provided once every two weeks to once every three months-promise to reduce the incidence of nonadherence. ARISTADA(™) (aripiprazole lauroxil; ALLAI) extended-release injectable suspension was approved by the U.S. Food and Drug Administration in October 2015 for the treatment of schizophrenia, and is the newest entrant in the LAI market. ALLAI is available as a single-use, pre-filled syringe, can be started in three different dosages, and also has the option of every six-week dosing. Treatment with oral aripiprazole is recommended for the first twenty-one days after the first ALLAI injection, which is a potential disadvantage. Adverse effects include sensitivity to extrapyramidal symptoms, especially akathisia, which is well documented in other aripiprazole preparations. There is no available data comparing ALLAI to other antipsychotics, and more head-to-head trials comparing different LAI formulations are needed. Based on the available data, ALLAI is an effective and safe option for treatment of schizophrenia. Further studies and post-marketing data will provide better understanding of this formulation. PMID:27074333

  5. Early reduction in painful physical symptoms is associated with improvements in long-term depression outcomes in patients treated with duloxetine

    Directory of Open Access Journals (Sweden)

    Quail Deborah

    2011-09-01

    Full Text Available Abstract Background To investigate the association of the change of painful physical symptoms (PPS after 4 weeks, with the 6-month treatment outcomes of depressive symptoms in patients treated with duloxetine in clinical practice. Methods Multicenter, prospective, 6-month, non-interventional study in adult outpatients with a depressive episode and starting treatment with duloxetine. Depression severity was assessed by the clinician (Inventory for Depressive Symptomatology [IDS-C] and patient (Kurz-Skala Stimmung/Aktivierung [KUSTA]. Somatic symptoms and PPS were assessed using the patient-rated Somatic Symptom Inventory (SSI and visual analog scales (VAS for pain items. Association of change in PPS with outcomes of depressive symptoms was analyzed based on mean KUSTA scores (mean of items mood, activity, tension/relaxation, sleep and achievement of a 50% reduction in the total IDS-C score after 6 months using linear and logistic regression models, respectively. Results Of the 4,517 patients enrolled (mean age: 52.2 years, 71.8% female, 3,320 patients (73.5% completed the study. 80% of the patients had moderate to severe overall pain (VAS > 30 mm at baseline. A 50% VAS overall pain reduction after 4 weeks was associated with a 13.32 points higher mean KUSTA score after 6 months, and a 50% pain reduction after 2 weeks with a 6.33 points improvement. No unexpected safety signals were detected in this naturalistic study. Conclusion Pain reduction after 2 and 4 weeks can be used to estimate outcomes of long-term treatment with duloxetine. PPS associated with depression have a potential role in predicting remission of depressive symptoms in clinical practice.

  6. Development of a Curriculum for Long-Term Care Nurses to Improve Recognition of Depression in Dementia

    Science.gov (United States)

    Williams, Christine L.; Molinari, Victor; Bond, Jennifer; Smith, Michael; Hyer, Kathryn; Malphurs, Julie

    2006-01-01

    There is increasing recognition of the severe consequences of depression in long-term care residents with dementia. Most health care providers are unprepared to recognize and to manage the complexity of depression in dementia. Targeted educational initiatives in nursing homes are needed to address this growing problem. This paper describes the…

  7. Improvement in quality of life in depressed patients following verum acupuncture or electroacupuncture plus paroxetine A randomized controlled study of 157 cases

    Institute of Scientific and Technical Information of China (English)

    Shenghui Ma; Zhangjin Zhang; Shanshan Qu; Yong Huang; Junqi Chen; Renyong Lin; Chongqi Wang; Ganlong Li; Canghuan Zhao; Shenchang Guo

    2012-01-01

    Depressed patients with scores of 17 or more on the 17 items of the Hamilton Depression Rating Scale were treated with the antidepressant drug paroxetine. They also underwent verum acupuncture or electroacupuncture at Baihui (GV20) and Yintang (GV29). The World Health Organization Quality of Life Scale Brief Version showed a significant increase in the total scores of patients who underwent verum acupuncture and electroacupuncture for 6 weeks compared with those who were given paroxetine only; significantly increased physical domain and social relationship scores in verum acupuncture patients compared with paroxetine only; and significantly elevated psychological domain scores with electroacupuncture compared with paroxetine only. These results indicate that both verum acupuncture and electroacupuncture can improve quality of life in depressed patients undergoing paroxetine treatment.

  8. The Role of Religious Psychotherapy with Independent Ruqyah in Reducing Depression and Improved Spiritual Quality of Life of Cancer Patients at Hospital of Hasanuddin University Makassar 2016

    Directory of Open Access Journals (Sweden)

    M. Fais Satrianegara

    2016-05-01

    Full Text Available This study aims to reveal the spiritual quality of life in cancer patients who receive spiritual support to the intervention of religious psychotherapy approaches as well as the efforts made to achieve a better life quality. The research method using pre-experimental one group pre and post test design with 10 respondent who were taken by purposive sampling technique. This study measured which measure depression score by using the instrument of BDI (Beck Depression Inventory and FACIT Sp.12 (The Functional Assessment of Chronic Illness Therapy Spiritual before and after the independent ruqyah and implement devotions sunnah in cancer patient who undergoing radiotherapy treatment in Hospital of Hasanuddin University, Makassar. Analysis of the data was analyzed using t-test. The results showed that there is a significant difference between levels of depression before and after the intervention (P <0.005. Cancer patients undergoing radiotherapy treatment and apply a independently ruqyah therapy consistently for 30 days can reduce levels of depression and improve the spiritual quality of life is better than before. The use of independent ruqyah can be considered as a palliative nursing interventions in the hospital for depression and in the framework of efforts in achieving the life quality of cancer patients.

  9. Role of betaine in improving the antidepressant effect of S-adenosyl-methionine in patients with mild-to-moderate depression

    Science.gov (United States)

    Di Pierro, Francesco; Orsi, Rossana; Settembre, Roberto

    2015-01-01

    Background S-adenosyl-methionine (SAMe) is a common add-on treatment used to counteract depressive symptoms in subjects with mild-to-moderate depression, who are low responders to other antidepressant drugs. However, there is some concern about the possible impact of SAMe therapy on homocysteine levels. Betaine is known both to counteract high level of homocysteine in plasma and to increase liquor and plasma levels of SAMe, thus potentiating its effect. Aim To evaluate the role played by betaine, administered along with SAMe, in potentiating the antidepressive role played by SAMe administered as such. Methods The study enrolled 46 subjects with a diagnosis of mild-to-moderate depression according to the Beck Depression Inventory Scale II. All the subjects had a suboptimal control of their symptoms. After randomization, they were treated with adjunctive treatment with either Samyr® (enteric-coated SAMe) or DDM Metile® (enteric-coated SAMe plus betaine) for 90 days. Results Both treatments acted similarly in improving symptoms such as anxiety, psychomotor agitation, feelings of helplessness and worthlessness, physical efficiency, and somatization, but treatment with DDM Metile® determined better statistically significant results following a 90-day therapy. Tolerability and compliance were overlapping in both the treatments. Conclusion The association of SAMe plus betaine seemed to demonstrate more effectiveness than SAMe alone when administered as an add-on therapy to subjects, affected by mild-to-moderate depression, who were low responders to conventional antidepressants. PMID:25653537

  10. Aripiprazole Injection

    Science.gov (United States)

    ... mixed with water (Abilify Maintena) and as a suspension (liquid) (Aristada) to be injected into a muscle ... decisions, and react quickly. Do not drive a car or operate machinery until you know how this ...

  11. Qigong Exercise Alleviates Fatigue, Anxiety, and Depressive Symptoms, Improves Sleep Quality, and Shortens Sleep Latency in Persons with Chronic Fatigue Syndrome-Like Illness

    Directory of Open Access Journals (Sweden)

    Jessie S. M. Chan

    2014-01-01

    Full Text Available Objectives. To evaluate the effectiveness of Baduanjin Qigong exercise on sleep, fatigue, anxiety, and depressive symptoms in chronic fatigue syndrome- (CFS- like illness and to determine the dose-response relationship. Methods. One hundred fifty participants with CFS-like illness (mean age = 39.0, SD = 7.9 were randomly assigned to Qigong and waitlist. Sixteen 1.5-hour Qigong lessons were arranged over 9 consecutive weeks. Pittsburgh Sleep Quality Index (PSQI, Chalder Fatigue Scale (ChFS, and Hospital Anxiety and Depression Scale (HADS were assessed at baseline, immediate posttreatment, and 3-month posttreatment. The amount of Qigong self-practice was assessed by self-report. Results. Repeated measures analyses of covariance showed a marginally nonsignificant (P= 0.064 group by time interaction in the PSQI total score, but it was significant for the “subjective sleep quality” and “sleep latency” items, favoring Qigong exercise. Improvement in “subjective sleep quality” was maintained at 3-month posttreatment. Significant group by time interaction was also detected for the ChFS and HADS anxiety and depression scores. The number of Qigong lessons attended and the amount of Qigong self-practice were significantly associated with sleep, fatigue, anxiety, and depressive symptom improvement. Conclusion. Baduanjin Qigong was an efficacious and acceptable treatment for sleep disturbance in CFS-like illness. This trial is registered with Hong Kong Clinical Trial Register: HKCTR-1380.

  12. Effectiveness of a Combined Dance and Relaxation Intervention on Reducing Anxiety and Depression and Improving Quality of Life among the Cognitively Impaired Elderly

    Directory of Open Access Journals (Sweden)

    Dina Adam

    2016-02-01

    Full Text Available Objectives: Cognitive impairment is a common problem among the elderly and is believed to be a precursor to dementia. This study aimed to explore the effectiveness of a combined dance and relaxation intervention as compared to relaxation alone in reducing anxiety and depression levels and improving quality of life (QOL and cognitive function among the cognitively impaired elderly. Methods: This quasi-experimental study was conducted between May and December 2013 in Peninsular Malaysia. Subjects from four government residential homes for older adults aged ≥60 years with mild to moderate cognitive function as assessed by the Mini-Mental State Examination were included in the study. Subjects were divided into an intervention group and a control group; the former participated in a combined poco-poco dance and relaxation intervention whilst the latter participated in relaxation exercises only. Both groups participated in two sessions per week for six weeks. Anxiety and depression were self-assessed using the Hospital Anxiety and Depression Scale and QOL was self-assessed using the Quality of Life in Alzheimer’s Disease questionnaire. Results: A total of 84 elderly subjects were included in the study; 44 were in the intervention group and 40 were in the control group. When compared to control subjects, those in the intervention group showed significantly decreased anxiety (P <0.001 and depression (P <0.001 levels as well as improved QOL (P <0.001 and cognitive impairment (P <0.001. Conclusion: Dance as a form of participationbased physical exercise was found to reduce anxiety and depression levels and improve QOL and cognitive function among the studied sample of cognitively impaired elderly subjects in Malaysia.

  13. Indicated school-based intervention to improve depressive symptoms among at risk Chilean adolescents: a randomized controlled trial

    OpenAIRE

    Gaete, Jorge; Martinez, Vania; Fritsch, Rosemarie; Rojas, Graciela; Montgomery, Alan A.; Araya, Ricardo

    2016-01-01

    Background Depression is a disabling condition affecting people of all ages, but generally starting during adolescence. Schools seem to be an excellent setting where preventive interventions may be delivered. This study aimed to test the effectiveness of an indicated school-based intervention to reduce depressive symptoms among at-risk adolescents from low-income families. Methods A two-arm, parallel, randomized controlled trial was conducted in 11 secondary schools in vulnerable socioeconomi...

  14. Establishing key components of yoga interventions for reducing depression and anxiety, and improving well-being: a Delphi method study

    OpenAIRE

    de Manincor, Michael; Bensoussan, Alan; Smith, Caroline; Fahey, Paul; Bourchier, Suzanne

    2015-01-01

    Background Previous research suggests benefits of yoga in reducing depression and anxiety. However, common concerns in reviews of the research include lack of detail, rationale and consistency of approach of interventions used. Issues related to heterogeneity include amount, types and delivery of yoga interventions. This study aims to document consensus-based recommendations for consistency of yoga interventions for reducing depression and anxiety. Methods The Delphi method was used to establ...

  15. Innovation in health economic modelling of service improvements for longer-term depression: demonstration in a local health community

    OpenAIRE

    Tosh, J.; Kearns, B; Brennan, A.(School of Physics, University of Melbourne, Victoria, Australia); Parry, G; Ricketts, T.; Saxon, D; Kilgarriff-Foster, A.; Thake, A; Chambers, E.; Hutten, R.

    2013-01-01

    Background The purpose of the analysis was to develop a health economic model to estimate the costs and health benefits of alternative National Health Service (NHS) service configurations for people with longer-term depression. Method Modelling methods were used to develop a conceptual and health economic model of the current configuration of services in Sheffield, England for people with longer-term depression. Data and assumptions were synthesised to estimate cost per Quality Ad...

  16. Improving responses to depression and related disorders: evaluation of a innovative, general, mental health care workers training program

    Directory of Open Access Journals (Sweden)

    Graham Annette L

    2010-09-01

    Full Text Available Abstract Background Australian General Practitioners have been beneficiaries of extensive training in mental health care delivery over the last few years but less so other workers who support those with mental illness. Training is needed as it is widely recognised that the most effective interventions to prevent and treat mental disorders are often not readily available. The Mental Health Aptitudes into Practice (MAP training package is a broad, innovative, interdisciplinary, general mental health training aimed at improving responses to individuals with depression and related disorders. The modular structure of this training program meant that such training could be targeted at those with varied backgrounds. Two hundred and seventy one days of free MAP training was delivered across Victoria in 2004/2005. The evaluation reported here assessed whether changes occurred in the trainees' confidence, mental health literacy, attitudes towards effective treatments, mental health knowledge and skills and community mental health ideology following training. Methods These elements were assessed using pen and paper tests prior, immediately following, 6 months after and then 12 months after the training. Trainees' confidence, mental health literacy and social distance were measured using scales that have been used in evaluations of Mental Health First Aid Training. Community mental health ideology was measured using a sub-scale of the Community Attitudes to the Mentally Ill (CAMI scale. The trainees' knowledge and skills were accessed using instrumentation specifically designed for this evaluation. Results Following training, participants had more confidence in their ability to work with those who have mental health issues and less desire for social distance from them. Participants' knowledge and skills in relation to the treatment of mental disorders increased. These changes were observed immediately after training. The limited existing evidence suggests

  17. Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature.

    Directory of Open Access Journals (Sweden)

    Alexander C Tsai

    2011-05-01

    Full Text Available BACKGROUND: Aripiprazole, a second-generation antipsychotic medication, has been increasingly used in the maintenance treatment of bipolar disorder and received approval from the U.S. Food and Drug Administration for this indication in 2005. Given its widespread use, we sought to critically review the evidence supporting the use of aripiprazole in the maintenance treatment of bipolar disorder and examine how that evidence has been disseminated in the scientific literature. METHODS AND FINDINGS: We systematically searched multiple databases to identify double-blind, randomized controlled trials of aripiprazole for the maintenance treatment of bipolar disorder while excluding other types of studies, such as open-label, acute, and adjunctive studies. We then used a citation search to identify articles that cited these trials and rated the quality of their citations. Our evidence search protocol identified only two publications, both describing the results of a single trial conducted by Keck et al., which met criteria for inclusion in this review. We describe four issues that limit the interpretation of that trial as supporting the use of aripiprazole for bipolar maintenance: (1 insufficient duration to demonstrate maintenance efficacy; (2 limited generalizability due to its enriched sample; (3 possible conflation of iatrogenic adverse effects of abrupt medication discontinuation with beneficial effects of treatment; and (4 a low overall completion rate. Our citation search protocol yielded 80 publications that cited the Keck et al. trial in discussing the use of aripiprazole for bipolar maintenance. Of these, only 24 (30% mentioned adverse events reported and four (5% mentioned study limitations. CONCLUSIONS: A single trial by Keck et al. represents the entirety of the literature on the use of aripiprazole for the maintenance treatment of bipolar disorder. Although careful review identifies four critical limitations to the trial's interpretation

  18. A collaborative approach to identifying effective incentives for mental health clinicians to improve depression care in a large managed behavioral healthcare organization

    OpenAIRE

    Meredith, Lisa S; Branstrom, Robert B.; Fikes, Ruth; Azocar, Francisca; Ettner, Susan L.

    2011-01-01

    This descriptive study used stakeholder input to prioritize evidence-based strategies for improving depression care and to select incentives for mental health clinicians to adopt those strategies, and to conduct a feasibility test of an incentive-based program in a managed behavioral healthcare organization (MBHO). In two rounds of interviews and a stakeholder meeting, MBHO administrators and clinicians selected increasing combination treatment (antidepressant plus psychotherapy) rates as the...

  19. 5-(4-hydroxy-3-dimethoxybenzylidene)-rhodanine (RD-1)-improved mitochondrial function prevents anxiety- and depressive-like states induced by chronic corticosterone injections in mice.

    Science.gov (United States)

    Yang, Nan; Ren, Zhili; Zheng, Ji; Feng, Lu; Li, Dongmei; Gao, Kai; Zhang, Lianfeng; Liu, Yanyong; Zuo, Pingping

    2016-06-01

    Most current pharmacologic antidepressant treatments target monoaminergic systems confronts some problems such as low rate of remission and high risk for relapse indicating new therapeutic strategy is urgently need. Evidences showed that impairments in mitochondrial function were associated with the pathogenesis of mood disorders and improvement in its function may be a novel therapeutic choice. In the present study, effects of 5-(4-hydroxy-3-dimethoxybenzylidene)-2-thioxo-4-thiazolidinone (RD-1) were investigated in mice model of depression/anxiety induced by corticosterone (20 mg/kg) subcutaneously repeated injections in 5-week male BALB/c mice. Our results showed that five weeks of corticosterone administration induced anxiety/depressive-like behavioral changes, including decreased central activities in open field test, increased the immobility time in forced swimming test and the latency in the novelty-suppressed feeding test, as well as reduced bodyweight. Results showed that oral administration with RD-1 at the doses of 25, 50, and 100 mg/kg for five weeks significantly improved the anxiety/depressive-like behavioral changes induced by corticosterone. In glucose metabolism analysis by photon emission computed tomography/-computed tomography (PET/CT) imaging, corticosterone significantly deactivated the prefrontal cortex (PFC), temporal lobe and hippocampus. RD-1 treatment obviously improved the energy metabolism in the involved brain regions. In primary cultured hippocampal neuron, corticosterone reduced speed of anterograde transport, yet speed of retrograde transport was increased. Furthermore, RD-1 enhanced the mitochondrial anterograde transport to supply energy for the neurotransmitter release. In conclusion, RD-1 prevents anxiety/depressive-like behavior of mice induced by corticosterone repeated injections with novel mechanism of improvement in the mitochondrial function. PMID:26926430

  20. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.

    Science.gov (United States)

    Sambunaris, Angelo; Gommoll, Carl; Chen, Changzheng; Greenberg, William M

    2014-07-01

    Major depressive disorder (MDD) is characterized by increased rates of impaired function and disability. During antidepressant treatment, functional improvement often lags behind symptomatic resolution, and residual impairment is associated with an increased risk for relapse. When evaluating MDD treatments, it is important to assess not only depressive symptoms but also functional outcomes. In this post-hoc analysis, data from five studies were pooled to examine the effect of levomilnacipran extended-release (ER) versus placebo on functional impairment as measured using the Sheehan Disability Scale. The mean change in the Sheehan Disability Scale total score was significantly greater for levomilnacipran ER versus placebo in the overall pooled population, for both sexes, and across all ages. Statistically significantly higher rates of functional response, functional remission, combined (functional and symptomatic) response, and combined remission were achieved with levomilnacipran ER compared with placebo in the pooled population, as well as in the male, female, younger, and middle-aged population subgroups. The levomilnacipran ER group also showed significantly improved functional outcomes versus placebo regardless of baseline depression severity. Similarly, functional impairment was significantly improved and higher functional and combined response and remission rates were achieved with levomilnacipran ER compared with placebo regardless of the baseline level of functional impairment. PMID:24667487

  1. Sub-chronic dietary tryptophan depletion--an animal model of depression with improved face and good construct validity.

    Science.gov (United States)

    Franklin, M; Bermudez, I; Murck, H; Singewald, N; Gaburro, S

    2012-02-01

    Sub-chronic tryptophan depletion (SCTD) is proposed as an animal model for depression. Aims were to test the hypothesis and optimise the time of SCTD-induced depression-related behaviour and associated biochemical changes. Sprague Dawley rats were treated with a low tryptophan (TRP) containing diet for 0, 7 or 14 days. Peripheral and central neurochemical markers were measured. SCTD-induced depression-related behaviour was assessed by the forced swim test (FST). Model sensitivity to antidepressants was tested by concomitant treatment with paroxetine. SCTD-induced significant reductions in weight gain and measures of peripheral and central TRP. Corticosterone, aldosterone and kynurenine (K), increased whilst kynurenic acid (KA), an NMDA antagonist decreased. 5-HT(2) receptor binding Bmax was enhanced but was reversed by paroxetine. Corticosterone and aldosterone were significantly negatively-correlated to weight gain. SCTD increased floating time and reduced swimming time in the FST but were reversed by paroxetine. Aldosterone was increased at 7 and 14 days, whereas other changes maximised at 14 days. Aldosterone may be an early marker or causal link for depression development. Increased corticosterone and brain tissue 5-HT-receptor density may be correlates of depressive behaviour. Consequential increases in NMDA signalling through increased K/KA ratios suggest the model may be useful for testing novel antidepressants. PMID:22074993

  2. Caregiver Depression

    Science.gov (United States)

    ... will not sell or share your name. Caregiver Depression Tweet Bookmark this page | Email | Print Many caregivers ... depression See your doctor Treatment Coping Symptoms of depression Caregiving is hard — and can lead to feelings ...

  3. Depression (PDQ)

    Science.gov (United States)

    ... others. Family members also have a risk of depression. Anxiety and depression are also common in family members ... cancer . A small number of children may have: Depression . Anxiety . Trouble sleeping. Problems getting along with family or ...

  4. Effects of an Internet-based cognitive behavioral therapy (iCBT program in Manga format on improving subthreshold depressive symptoms among healthy workers: a randomized controlled trial.

    Directory of Open Access Journals (Sweden)

    Kotaro Imamura

    Full Text Available OBJECTIVE: The purpose of this study was to develop a new Internet-based computerized cognitive behavior therapy (iCBT program in Manga format, the Japanese cartoon, for workers and to examine the effects of the iCBT program on improving subthreshold depression using a randomized controlled trial (RCT design among workers employed in private companies in Japan. METHOD: All workers in a company (n = 290 and all workers in three departments (n = 1,500 at the headquarters of another large company were recruited by an invitation e-mail. Participants who fulfilled the inclusion criteria were randomly allocated to intervention or control groups (N = 381 for each group. A six-week, six-lesson iCBT program using Manga (Japanese comic story was developed. The program included several CBT skills: self-monitoring, cognitive restructuring, assertiveness, problem solving, and relaxation. The intervention group studied the iCBT program at a frequency of one lesson per week. Depression (Beck Depression Inventory II; BDI-II was assessed as a primary outcome at baseline, and three- and six-month follow-ups for both intervention and control groups were performed. RESULTS: The iCBT program showed a significant intervention effect on BDI-II (t = -1.99, p<0.05 with small effect sizes (Cohen's d: -0.16, 95% Confidence Interval: -0.32 to 0.00, at six-month follow-up. CONCLUSIONS: The present study first demonstrated that a computerized cognitive behavior therapy delivered via the Internet was effective in improving depression in the general working population. It seems critical to improve program involvement of participants in order to enhance the effect size of an iCBT program. TRIAL REGISTRATION: UMIN Clinical Trials Registry UMIN000006210.

  5. Salivary and serum biomarkers for the study of side effects of aripiprazole coprescribed with mirtazapine in rats

    OpenAIRE

    Bogdan, Maria; SILOSI, Isabela; SURLIN, PETRA; Tica, Andrei Adrian; Tica, Oana Sorina; Balseanu, Tudor-Adrian; Rauten, Anne-Marie; Camen, Adrian

    2015-01-01

    The aim of this study was to investigate whether the co-administration of aripiprazole and mirtazapine could determine weight gain and lipid metabolism disorders in Wistar rats, compared to the same side effects produced by mirtazapine alone, and the risk of hepatotoxicity due to the combination of the two substances. Tumor necrosis factor alpha (TNF-α), liver fatty acid binding protein (L-FABP/FABP1) and repulsive guidance molecule C/hemojuvelin (RGM-C/HJV) levels were determined in serum an...

  6. Efficacy and safety of aripiprazole in treating negative symptoms of schizophrenia%阿立哌唑与利培酮治疗精神分裂症阴性症状的疗效和安全性观察

    Institute of Scientific and Technical Information of China (English)

    贾天成

    2014-01-01

    incidence of adverse effect in experimental group was less than that in the control group(P <0.05).Conclusion Both aripiprazole and risperidone can improve the negative symptoms of schizophrenia with the similar efficacy;however,aripi-prazole is adept in treating the symptoms of affection and cognition,compared with the advantage of risperidone in treating the symptoms of af-fection and behavior.Aripiprazole is generally safer than risperidone.

  7. PRISM (Program of Resources, Information and Support for Mothers: a community-randomised trial to reduce depression and improve women's physical health six months after birth [ISRCTN03464021

    Directory of Open Access Journals (Sweden)

    Mitchell Creina

    2006-02-01

    Full Text Available Abstract Background In the year after birth one in six women has a depressive illness, 94% experience at least one major health problem (e.g. back pain, perineal pain, mastitis, urinary or faecal incontinence, 26% experience sexual problems and almost 20% have relationship problems with partners. Women with depression report less practical and emotional support from partners, less social support, more negative life events, and poorer physical health and see factors contributing to depression as lack of support, isolation, exhaustion and physical health problems. Fewer than one in three seek help in primary care despite frequent health care contacts. Methods Primary care and community-based strategies embedded in existing services were implemented in a cluster-randomised trial involving 16 rural and metropolitan communities, pair-matched, within the State of Victoria, Australia. Intervention areas were also provided with a community development officer for two years. The primary aim was to reduce the relative risk of depression by 20% in mothers six months after birth and to improve their physical health. Primary outcomes were obtained by postal questionnaires. The analysis was by intention-to-treat, unmatched, adjusting for the correlated nature of the data. Results 6,248 of 10,144 women (61.6% in the intervention arm and 5057/ 8,411 (60.1% in the comparison arm responded at six months, and there was no imbalance in major covariates between the two arms. Women's mental health scores were not significantly different in the intervention arm and the comparison arm (MCS mean score 45.98 and 46.30, mean EPDS score 6.91 and 6.82, EPDS ≥ 13 ('probable depression' 15.7% vs. 14.9%, Odds ratioadj 1.06 (95%CI 0.91–1.24. Women's physical health scores were not significantly different in intervention and comparison arms (PCS mean scores 52.86 and 52.88. Conclusion The combined community and primary care interventions were not effective in reducing

  8. Improvement of Bondability by Depressing the Inhomogeneous Distribution of Nanoparticles in a Sintering Bonding Process with Silver Nanoparticles

    Science.gov (United States)

    Yan, Jianfeng; Zou, Guisheng; Wu, Aiping; Ren, Jialie; Hu, Anming; Zhou, Y. Norman

    2012-07-01

    Low-temperature bonding by sintering of Ag nanoparticles (NPs) is a promising lead-free bonding technique used in the electronic packaging industry. In this work, we prepare Ag nanoparticle (NP) paste using both an aqueous method and a polyol method. Sintering bonding trials were then conducted using different forms of Ag NPs. The results showed that use of the aqueous-based Ag NP paste led to inhomogeneous distribution of NPs, known as the "coffee-ring effect." This led to low strength of fabricated joints. We investigated the influence of the coffee-ring effect and ways to depress it by changing the bonding material composition. Our results show that, when using polyol-based Ag NP paste as the bonding material, the coffee-ring effect was successfully depressed due to increased Marangoni flow. The corresponding shear strength of joints was increased significantly to 50 MPa at bonding temperature of 250°C.

  9. 围产期认知干预在改善产后抑郁中的应用%Application of perinatal cognitive intervention in postpartum depression improvement

    Institute of Scientific and Technical Information of China (English)

    李馨; 谭惠兴; 林小凤; 胡敏

    2016-01-01

    Objective:To discuss on clinical application effects of perinatal cognitive intervention in postpartum depression improvement. Methods:Selected 100 pregnant women who would deliver in our hospital,and randomly divided them into observation group and control group. The control group women re-ceived conventional nursing,while observation group women received perinatal cognitive intervention. Compared postpartum depression conditions between both groups. Results:The occurrence rate of postpartum depression in observation group was lower than that in control group(P ﹤ 0. 05). Conclusion:Peri-natal cognitive intervention for pregnant women can effectively reduce occurrence rate of postpartum depression and plays a positive role in helping lying -in women to recuperate,so it is worth clinical popularization and application.%目的:探讨围产期认知干预在改善产后抑郁中的临床应用效果。方法:选择在我院住院分娩的孕产妇100例,将其随机等分为观察组和对照组,对照组予以常规护理,观察组行围产期认知干预。比较两组产妇产后抑郁发生情况。结果:观察组产妇产后抑郁发生率低于对照组(P ﹤0.05)。结论:针对孕产妇实施围产期认知干预,可以有效降低其产后抑郁发生率,对产妇恢复健康具有积极意义,值得临床推广应用。

  10. Screening for Depression

    Science.gov (United States)

    ... improve the lives of people who have mood disorders. The Power of Peers DBSA envisions wellness for people who live with depression and bipolar disorder. Because DBSA was created for and is led ...

  11. Pharmacological treatment of depression in women with breast cancer

    DEFF Research Database (Denmark)

    Toftegård Andersen, Lærke; Voigt Hansen, Melissa; Rosenberg, Jacob;

    2013-01-01

    escitalopram and the norepinephrine reuptake inhibitor, reboxetine, significantly improved depression and QOL compared with baseline values. In conclusion, depression is a clinical problem in patients with breast cancer. Pharmacological treatment with antidepressants may improve depression and QOL. However...

  12. Effects of an Internet-Based Cognitive Behavioral Therapy (iCBT) Program in Manga Format on Improving Subthreshold Depressive Symptoms among Healthy Workers: A Randomized Controlled Trial

    OpenAIRE

    Imamura, Kotaro; Kawakami, Norito; Furukawa, Toshi A; Matsuyama, Yutaka; Shimazu, Akihito; Umanodan, Rino; Kawakami, Sonoko; Kasai, Kiyoto

    2014-01-01

    Objective The purpose of this study was to develop a new Internet-based computerized cognitive behavior therapy (iCBT) program in Manga format, the Japanese cartoon, for workers and to examine the effects of the iCBT program on improving subthreshold depression using a randomized controlled trial (RCT) design among workers employed in private companies in Japan. Method All workers in a company (n = 290) and all workers in three departments (n = 1,500) at the headquarters of another large comp...

  13. Atypical Depression

    Directory of Open Access Journals (Sweden)

    Erhan Ertekin

    2013-09-01

    Full Text Available Atypical depression is defined as a specifier of major depressive disorder. Columbia criteria for atypical depression are commonly used to make a diagnosis. Female sex, onset at early age, chronic course, and higher rate of comorbidity (especially anxiety disorder and bipolar disorder is noteworthy in atypical depression. Although, the atypical depression seems to support the familial genetic transition, there is not any specific study supporting these data. In the treatment of atypical depression, monoamine oxidase inhibitors are reported to be more effective than tricyclic antidepressants. In recent studies, selective serotonin reuptake inhibitors have also proven to be efficient.

  14. Hippocampal neurogenesis and dendritic plasticity support running-improved spatial learning and depression-like behaviour in stressed rats.

    Directory of Open Access Journals (Sweden)

    Suk-Yu Yau

    Full Text Available Exercise promotes hippocampal neurogenesis and dendritic plasticity while stress shows the opposite effects, suggesting a possible mechanism for exercise to counteract stress. Changes in hippocampal neurogenesis and dendritic modification occur simultaneously in rats with stress or exercise; however, it is unclear whether neurogenesis or dendritic remodeling has a greater impact on mediating the effect of exercise on stress since they have been separately examined. Here we examined hippocampal cell proliferation in runners treated with different doses (low: 30 mg/kg; moderate: 40 mg/kg; high: 50 mg/kg of corticosterone (CORT for 14 days. Water maze task and forced swim tests were applied to assess hippocampal-dependent learning and depression-like behaviour respectively the day after the treatment. Repeated CORT treatment resulted in a graded increase in depression-like behaviour and impaired spatial learning that is associated with decreased hippocampal cell proliferation and BDNF levels. Running reversed these effects in rats treated with low or moderate, but not high doses of CORT. Using 40 mg/kg CORT-treated rats, we further studied the role of neurogenesis and dendritic remodeling in mediating the effects of exercise on stress. Co-labelling with BrdU (thymidine analog /doublecortin (immature neuronal marker showed that running increased neuronal differentiation in vehicle- and CORT-treated rats. Running also increased dendritic length and spine density in CA3 pyramidal neurons in 40 mg/kg CORT-treated rats. Ablation of neurogenesis with Ara-c infusion diminished the effect of running on restoring spatial learning and decreasing depression-like behaviour in 40 mg/kg CORT-treated animals in spite of dendritic and spine enhancement. but not normal runners with enhanced dendritic length. The results indicate that both restored hippocampal neurogenesis and dendritic remodelling within the hippocampus are essential for running to counteract

  15. Agmatine, by Improving Neuroplasticity Markers and Inducing Nrf2, Prevents Corticosterone-Induced Depressive-Like Behavior in Mice.

    Science.gov (United States)

    Freitas, Andiara E; Egea, Javier; Buendia, Izaskun; Gómez-Rangel, Vanessa; Parada, Esther; Navarro, Elisa; Casas, Ana Isabel; Wojnicz, Aneta; Ortiz, José Avendaño; Cuadrado, Antonio; Ruiz-Nuño, Ana; Rodrigues, Ana Lúcia S; Lopez, Manuela G

    2016-07-01

    Agmatine, an endogenous neuromodulator, is a potential candidate to constitute an adjuvant/monotherapy for the management of depression. A recent study by our group demonstrated that agmatine induces Nrf2 and protects against corticosterone effects in a hippocampal neuronal cell line. The present study is an extension of this previous study by assessing the antidepressant-like effect of agmatine in an animal model of depression induced by corticosterone in mice. Swiss mice were treated simultaneously with agmatine or imipramine at a dose of 0.1 mg/kg/day (p.o.) and corticosterone for 21 days and the daily administrations of experimental drugs were given immediately prior to corticosterone (20 mg/kg/day, p.o.) administrations. Wild-type C57BL/6 mice (Nrf2 (+/+)) and Nrf2 KO (Nrf2 (-/-)) were treated during 21 days with agmatine (0.1 mg/kg/day, p.o.) or vehicle. Twenty-four hours after the last treatments, the behavioral tests and biochemical assays were performed. Agmatine treatment for 21 days was able to abolish the corticosterone-induced depressive-like behavior and the alterations in the immunocontent of mature BDNF and synaptotagmin I, and in the serotonin and glutamate levels. Agmatine also abolished the corticosterone-induced changes in the morphology of astrocytes and microglia in CA1 region of hippocampus. In addition, agmatine treatment in control mice increased noradrenaline, serotonin, and dopamine levels, CREB phosphorylation, mature BDNF and synaptotagmin I immunocontents, and reduced pro-BDNF immunocontent in the hippocampus. Agmatine's ability to produce an antidepressant-like effect was abolished in Nrf2 (-/-) mice. The present results reinforce the participation of Nrf2 in the antidepressant-like effect produced by agmatine and expand literature data concerning its mechanisms of action. PMID:25966970

  16. Hippocampal Neurogenesis and Dendritic Plasticity Support Running-Improved Spatial Learning and Depression-Like Behaviour in Stressed Rats

    Science.gov (United States)

    Tong, Jian-Bin; Wong, Richard; Ching, Yick-Pang; Qiu, Guang; Tang, Siu-Wa; Lee, Tatia M. C.; So, Kwok-Fai

    2011-01-01

    Exercise promotes hippocampal neurogenesis and dendritic plasticity while stress shows the opposite effects, suggesting a possible mechanism for exercise to counteract stress. Changes in hippocampal neurogenesis and dendritic modification occur simultaneously in rats with stress or exercise; however, it is unclear whether neurogenesis or dendritic remodeling has a greater impact on mediating the effect of exercise on stress since they have been separately examined. Here we examined hippocampal cell proliferation in runners treated with different doses (low: 30 mg/kg; moderate: 40 mg/kg; high: 50 mg/kg) of corticosterone (CORT) for 14 days. Water maze task and forced swim tests were applied to assess hippocampal-dependent learning and depression-like behaviour respectively the day after the treatment. Repeated CORT treatment resulted in a graded increase in depression-like behaviour and impaired spatial learning that is associated with decreased hippocampal cell proliferation and BDNF levels. Running reversed these effects in rats treated with low or moderate, but not high doses of CORT. Using 40 mg/kg CORT-treated rats, we further studied the role of neurogenesis and dendritic remodeling in mediating the effects of exercise on stress. Co-labelling with BrdU (thymidine analog) /doublecortin (immature neuronal marker) showed that running increased neuronal differentiation in vehicle- and CORT-treated rats. Running also increased dendritic length and spine density in CA3 pyramidal neurons in 40 mg/kg CORT-treated rats. Ablation of neurogenesis with Ara-c infusion diminished the effect of running on restoring spatial learning and decreasing depression-like behaviour in 40 mg/kg CORT-treated animals in spite of dendritic and spine enhancement. but not normal runners with enhanced dendritic length. The results indicate that both restored hippocampal neurogenesis and dendritic remodelling within the hippocampus are essential for running to counteract stress. PMID:21935393

  17. Tualang honey improves memory performance and decreases depressive-like behavior in rats exposed to loud noise stress

    Directory of Open Access Journals (Sweden)

    Khairunnuur Fairuz Azman

    2015-01-01

    Full Text Available Recent evidence has exhibited dietary influence on the manifestation of different types of behavior induced by stressor tasks. The present study examined the effects of Tualang honey supplement administered with the goal of preventing or attenuating the occurrence of stress-related behaviors in male rats subjected to noise stress. Forty-eight adult male rats were randomly divided into the following four groups: i nonstressed with vehicle, ii nonstressed with Tualang honey, iii stressed with vehicle, and iv stressed with honey. The supplement was given once daily via oral gavage at 0.2 g/kg body weight. Two types of behavioral tests were performed, namely, the novel object recognition test to evaluate working memory and the forced swimming test to evaluate depressive-like behavior. Data were analyzed by a two-way analysis of variance (ANOVA using IBM SPSS 18.0. It was observed that the rats subjected to noise stress expressed higher levels of depressive-like behavior and lower memory functions compared to the unexposed control rats. In addition, our results indicated that the supplementation regimen successfully counteracted the effects of noise stress. The forced swimming test indicated that climbing and swimming times were significantly increased and immobility times significantly decreased in honey-supplemented rats, thereby demonstrating an antidepressant-like effect. Furthermore, cognitive function was shown to be intensely affected by noise stress, but the effects were counteracted by the honey supplement. These findings suggest that subchronic exposure to noise stress induces depressive-like behavior and reduces cognitive functions, and that these effects can be attenuated by Tualang honey supplementation. This warrants further studies to examine the role of Tulang honey in mediating such effects.

  18. Does Interpersonal Psychotherapy improve clinical care for adolescents with depression attending a rural child and adolescent mental health service? Study protocol for a cluster randomised feasibility trial

    Directory of Open Access Journals (Sweden)

    Villanueva Elmer V

    2007-10-01

    Full Text Available Abstract Background Depression amongst adolescents is a costly societal problem. Little research documents the effectiveness of public mental health services in mapping this problem. Further, it is not clear whether usual care in such services can be improved via clinician training in a relevant evidence based intervention. One such intervention, found to be effective and easily learned amongst novice clinicians, is Interpersonal Psychotherapy (IPT. The study described in the current paper has two main objectives. First, it aims to investigate the impact on clinical care of implementing Interpersonal Psychotherapy for Adolescents for the treatment of adolescent depression within a rural mental health service compared with Treatment as Usual (TAU. The second objective is to record the process and challenges (i.e. feasibility, acceptability, sustainability associated with implementing and evaluating an evidence-based intervention within a community service. This paper outlines the study rationale and design for this community based research trial. Methods/design The study involves a cluster randomisation trial to be conducted within a Child and Adolescent Mental Health Service in rural Australia. All clinicians in the service will be invited to participate. Participating clinicians will be randomised via block design at each of four sites to (a training and delivery of IPT, or (b TAU. The primary measure of impact on care will be a clinically significant change in depressive symptomatology, with secondary outcomes involving treatment satisfaction and changes in other symptomatology. Participating adolescents with significant depressive symptomatology, aged 12 to 18 years, will complete assessment measures at Weeks 0, 12 and 24 of treatment. They will also complete a depression inventory once a month during that period. This study aims to recruit 60 adolescent participants and their parent/guardian/s. A power analysis is not indicated as an intra

  19. Depression following acute coronary syndrome

    DEFF Research Database (Denmark)

    Joergensen, Terese Sara Hoej; Maartensson, Solvej; Ibfelt, Else Helene;

    2016-01-01

    PURPOSE: Depression is common following acute coronary syndrome, and thus, it is important to provide knowledge to improve prevention and detection of depression in this patient group. The objectives of this study were to examine: (1) whether indicators of stressors and coping resources were risk...... factors for developing depression early and later after an acute coronary syndrome and (2) whether prior depression modified these associations. METHODS: The study was a register-based cohort study, which includes 87,118 patients with a first time diagnosis of acute coronary syndrome during the period...... 2001-2009 in Denmark. Cox regression models were used to analyse hazard ratios (HRs) for depression. RESULTS: 1.5 and 9.5 % develop early (≤30 days) and later (31 days-2 years) depression after the acute coronary syndrome. Among all patients with depression, 69.2 % had first onset depression, while 30...

  20. Postpartum Depression

    Science.gov (United States)

    ... do not need treatment. The symptoms of postpartum depression last longer and are more severe. You may ... treatment right away, often in the hospital. Postpartum depression can begin anytime within the first year after ...

  1. Depression - overview

    Science.gov (United States)

    Depression may be described as feeling sad, blue, unhappy, miserable, or down in the dumps. Most of ... one time or another for short periods. Clinical depression is a mood disorder in which feelings of ...

  2. Measuring psychotic depression

    DEFF Research Database (Denmark)

    Østergaard, S D; Meyers, B S; Flint, A J;

    2014-01-01

    OBJECTIVE: Psychotic depression (PD) is a highly debilitating condition, which needs intensive monitoring. However, there is no established rating scale for evaluating the severity of PD. The aim of this analysis was to assess the psychometric properties of established depression rating scales...... and a number of new composite rating scales, covering both depressive and psychotic symptoms, in relation to PD. METHOD: The psychometric properties of the rating scales were evaluated based on data from the Study of Pharmacotherapy of Psychotic Depression. RESULTS: A rating scale consisting of the 6-item......'s correlation coefficient between change in HAMD-BPRS11 and Clinical Global Impression - Improvement (CGI-I) scores = -0.74--0.78) and unidimensionality (Loevinger's coefficient of homogeneity = 0.41) in the evaluation of PD. The HAM-D6 fulfilled the same criteria, whereas the full 17-item Hamilton Depression...

  3. Nutritional aspects of depression.

    Science.gov (United States)

    Lang, Undine E; Beglinger, Christoph; Schweinfurth, Nina; Walter, Marc; Borgwardt, Stefan

    2015-01-01

    Several nutrition, food and dietary compounds have been suggested to be involved in the onset and maintenance of depressive disorders and in the severity of depressive symptoms. Nutritional compounds might modulate depression associated biomarkers and parallel the development of depression, obesity and diabetes. In this context, recent studies revealed new mediators of both energy homeostasis and mood changes (i.e. IGF-1, NPY, BDNF, ghrelin, leptin, CCK, GLP-1, AGE, glucose metabolism and microbiota) acting in gut brain circuits. In this context several healthy foods such as olive oil, fish, fruits, vegetables, nuts, legumes, poultry, dairy and unprocessed meat have been inversely associated with depression risk and even have been postulated to improve depressive symptoms. In contrast, unhealthy western dietary patterns including the consumption of sweetened beverage, refined food, fried food, processed meat, refined grain, and high fat diary, biscuits, snacking and pastries have been shown to be associated with an increased risk of depression in longitudinal studies. However, it is always difficult to conclude a real prospective causal relationship from these mostly retrospective studies as depressed individuals might also change their eating habits secondarily to their depression. Additionally specific selected nutritional compounds, e.g. calcium, chromium, folate, PUFAs, vitamin D, B12, zinc, magnesium and D-serine have been postulated to be used as ad-on strategies in antidepressant treatment. In this context, dietary and lifestyle interventions may be a desirable, effective, pragmatical and non-stigmatizing prevention and treatment strategy for depression. At last, several medications (pioglitazone, metformin, exenatide, atorvastatin, gram-negative antibiotics), which have traditionally been used to treat metabolic disorders showed a certain potential to treat depression in first randomized controlled clinical trials.

  4. Nutritional Aspects of Depression

    Directory of Open Access Journals (Sweden)

    Undine E. Lang

    2015-09-01

    Full Text Available Several nutrition, food and dietary compounds have been suggested to be involved in the onset and maintenance of depressive disorders and in the severity of depressive symptoms. Nutritional compounds might modulate depression associated biomarkers and parallel the development of depression, obesity and diabetes. In this context, recent studies revealed new mediators of both energy homeostasis and mood changes (i.e. IGF-1, NPY, BDNF, ghrelin, leptin, CCK, GLP-1, AGE, glucose metabolism and microbiota acting in gut brain circuits. In this context several healthy foods such as olive oil, fish, fruits, vegetables, nuts, legumes, poultry, dairy and unprocessed meat have been inversely associated with depression risk and even have been postulated to improve depressive symptoms. In contrast, unhealthy western dietary patterns including the consumption of sweetened beverage, refined food, fried food, processed meat, refined grain, and high fat diary, biscuits, snacking and pastries have been shown to be associated with an increased risk of depression in longitudinal studies. However, it is always difficult to conclude a real prospective causal relationship from these mostly retrospective studies as depressed individuals might also change their eating habits secondarily to their depression. Additionally specific selected nutritional compounds, e.g. calcium, chromium, folate, PUFAs, vitamin D, B12, zinc, magnesium and D-serine have been postulated to be used as ad-on strategies in antidepressant treatment. In this context, dietary and lifestyle interventions may be a desirable, effective, pragmatical and non-stigmatizing prevention and treatment strategy for depression. At last, several medications (pioglitazone, metformin, exenatide, atorvastatin, gram-negative antibiotics, which have traditionally been used to treat metabolic disorders showed a certain potential to treat depression in first randomized controlled clinical trials.

  5. Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials

    Directory of Open Access Journals (Sweden)

    Oya K

    2015-09-01

    Full Text Available Kazuto Oya, Taro Kishi, Nakao Iwata Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan Objective: We conducted a systematic review and meta-analysis of the efficacy of aripiprazole once monthly (AOM for schizophrenia.Methods: Randomized controlled trials (RCTs on AOM, published until June 25, 2015, were retrieved from PubMed, Cochrane, and PsycINFO databases. Relative risk (RR, standardized mean difference (SMD, 95% confidence intervals (95% CIs, and numbers needed to treat/harm (NNT/NNH were calculated.Results: We identified four relevant RCTs (total n=1,860, two placebo-controlled trials, one noninferiority trial comparing AOM to oral aripiprazole (OA, and one including therapeutic doses of AOM and OA, as well as an AOM dose below therapeutic threshold (control arm. AOM was superior to placebo for decreasing Positive and Negative Syndrome Scale (PANSS total scores (SMD =-0.65, 95% CI =-0.90 to -0.41, n=1,126. However, PANSS total scores did not differ significantly between pooled AOM and OA groups. The pooled AOM group showed significantly lower incidence of all-cause discontinuation (RR =0.54, 95% CI =0.41–0.71, n=1,139, NNH =4 and inefficacy (RR =0.28, 95% CI =0.21–0.38, n=1,139, NNH =5 than placebo, but was not superior to placebo regarding discontinuation due to adverse events (AEs or death. The AOM group exhibited a lower incidence of all-cause discontinuation than OA (RR =0.78, 95% CI =0.64–0.95, n=986, NNH =14, but there were no intergroup differences in discontinuation due to inefficacy, AEs, or death. There were no significant differences in extrapyramidal symptoms scale scores between AOM and placebo or between AOM and OA. AOM resulted in higher weight gain than placebo (SMD =0.41, 95% CI =0.18–0.64, n=734 but lower than OA (SMD =-0.16, 95% CI =-0.29 to -0.02, n=847.Conclusion: AOM has antipsychotic efficacy and low risk of discontinuation due to AEs. Keywords: schizophrenia

  6. Chronic exercise improves repeated restraint stress-induced anxiety and depression through 5HT1A receptor and cAMP signaling in hippocampus

    OpenAIRE

    Kim, Mun Hee; Leem, Yea Hyun

    2014-01-01

    [Purpose] Mood disorders such as anxiety and depression are prevalent psychiatric illness, but the role of 5HT1A in the anti-depressive effects of exercise has been rarely known yet. We investigated whether long-term exercise affected a depressive-like behavior and a hippocampal 5HT1A receptor-mediated cAMP/PKA/CREB signaling in depression mice model. [Methods] To induce depressive behaviors, mice were subjected to 14 consecutive days of restraint stress (2 hours/day). Depression-like behavio...

  7. Shifts Toward Morningness During Behavioral Sleep Interventions Are Associated With Improvements in Depression, Positive Affect, and Sleep Quality.

    Science.gov (United States)

    Hasler, Brant P; Buysse, Daniel J; Germain, Anne

    2016-01-01

    Morningness-eveningness (M-E) is typically considered to be a trait-like construct. However, M-E could plausibly shift in concert with changes in circadian or homeostatic processes. We examined M-E changes across three studies employing behavioral or pharmacological sleep treatments. Baseline and posttreatment M-E scores were strongly correlated across all three samples. M-E showed small but systematic changes toward morningness in sleep-disturbed military veterans receiving behavioral interventions. No systematic M-E changes were observed in the two pharmacological studies (sleep-disturbed military veterans and adults with primary insomnia, respectively). In the behavioral study, M-E changes correlated with changes in depression, positive affect, and sleep quality. M-E changes also correlated with changes in positive affect in the adult insomnia group. M-E appears to exhibit state-like aspects in addition to trait-like aspects. PMID:26549156

  8. Behandlingsresistent depression kan behandles

    DEFF Research Database (Denmark)

    Vinberg, Maj; Levinsen, Mette Frandsen; Kessing, Lars Vedel

    2011-01-01

    Depression is considered resistant when two treatment attempts with antidepressants from different classes fail to produce significant clinical improvement. In cases of treatment-resistant depression, it is recommended to reevaluate the diagnosis, clarify comorbidity, substance abuse and lack...... of compliance. Regarding treatment, evidence is sparse, but switching to a different antidepressant, and combination or augmentation with another agent, admission and treatment with ECT are the options. The choice of treatment must be based on the characteristics of the depression, the severity of treatment...

  9. Placebo for depression: we need to improve the quality of scientific information but also reject too simplistic approaches or ideological nihilism.

    Science.gov (United States)

    Cipriani, Andrea; Geddes, John R

    2014-01-01

    The placebo response plays a major role in psychiatry, particularly in depression. A new network meta-analysis investigates whether the effects of placebo vary in studies comparing fluoxetine and venlafaxine, two widely prescribed antidepressants. Even though data from this article indicate that the effects of placebos do not differ, publication bias cannot be ruled out. The authors use their finding to criticise the paradigm of evidence-based medicine, questioning whether there is anything certain in psychiatry and, more precisely, in the field of antidepressant treatment for major depression. This study stimulates the debate about validity of scientific knowledge in medicine and highlights the importance of considering things from a different perspective. However, the authors' view should be considered with caution. As clinicians, we make decisions every day, integrating individual clinical expertise and patients' preferences and values with the best, up-to-date research data. The quality of scientific information must be improved, but we still think that valid conclusions to help clinical practice can be drawn from a critical and cautious use of the best available, if flawed, evidence. PMID:24962638

  10. Desipramine improves depression-like behavior and working memory by up-regulating p-CREB in Alzheimer's disease associated mice.

    Science.gov (United States)

    Wang, Dan-Dan; Li, Jia; Yu, Li-Peng; Wu, Mei-Na; Sun, Li-Na; Qi, Jin-Shun

    2016-06-01

    Aggregation of amyloid [Formula: see text] protein (A[Formula: see text] and progressive loss of memory are the main characteristics of Alzheimer's disease (AD). It is noteworthy that approximately 40% of AD patients have depressive symptom. The close correlation between cognitive deficits and mental depression suggests a possibility that antidepression treatment might be beneficial to cognitive improvement in AD. The present study, by using tail-suspension test (TST), forced swimming, alternative electro-stimulus Y maze test and immunohistochemistry, examined the neuroprotective effects of desipramine, a newer generation tricyclic antidepressants (TCA), and investigated its possible molecular mechanism. The results showed that: (1) intra-hippocampal injection of A[Formula: see text] induced depression-like behavior and associative learning deficits in mice, with an increased mean immobility time in tail-suspension and forced swimming test and an increased mean error times in Y maze test; (2) after treatment with desipramine (10[Formula: see text]mg/kg, i.p.), the average immobility time significantly decreased, from [Formula: see text][Formula: see text]s in A[Formula: see text] group to [Formula: see text][Formula: see text]s in A[Formula: see text] plus desipramine group ([Formula: see text]) in TST and from [Formula: see text][Formula: see text]s to [Formula: see text][Formula: see text]s ([Formula: see text] or 9, [Formula: see text]) in forced swimming test, respectively;the mean error times of mice in Y maze test also significantly decreased, from [Formula: see text] in A[Formula: see text] group to [Formula: see text] in A[Formula: see text] plus desipramine group ([Formula: see text], [Formula: see text]); (3) desipramine administration significantly prevented against A[Formula: see text]-induced down-regulation of phosphorylated cAMP response element binding protein (p-CREB) in the hippocampus. These results indicate that A[Formula: see text] could

  11. 首发精神分裂症患者使用阿立哌唑后血清IL-2、IL-4水平变化的探讨%Explore the level changes of IL-2,IL-4 in the first-episode schizophrenia after the treatment of arip-iprazole

    Institute of Scientific and Technical Information of China (English)

    刘倩倩; 李亚飞; 朱祥路; 蒋天玉

    2014-01-01

    Objective To explore the differences of serum IL-2 ,IL-4 in the first-episode schizo-phrenia and healthy controls were explored ,and to compare the changes of symptoms before and after aripiprazole treatment and the changes of serum IL-2 ,IL-4 .Methods Serum of IL-2 ,IL-4 was exam-ined with Flow Cytometry in 35 healthy volunteers and 35 first episode patients .The symptoms of pa-tients were evaluated with Positive and Negative Syndrome Scale .Results There were no statistical sig-nificantly differents in the serum of IL-2 ,IL-4 in the first-episode schizophrenia than normal .controls (P>0 .05) .The serum levels of IL-4 was lower in patients with first-episode schizophrenia after aripi-prazole treatment (P<0 .01) .IL-2 and IL-4 levels were increased in positive symptoms of schizophre-nia patients before aripiprazole treatment (positive symptoms) than normal controls (P<0 .05) .IL-2 and IL-4 levels were different in positive symptoms of schizophrenia patients before and after aripi-prazole treatment (P<0 .05) .Conclusion The patients with schizophrenia have immune dysfunction ;Aripiprazole of antipsychotics have lowered the level of IL-2 ,IL-4 and positive symptoms also im-proved .Conclusion.%目的:探讨首发精神分裂症患者血清细胞因子IL-2、IL-4与正常人的差异,比较分析首发精神分裂症患者经过阿立哌唑治疗前后症状改变及细胞因子IL-2、IL-4的变化。方法选择35例首发精神分裂症患者作为研究组,35例健康志愿者作为对照组,通过流式细胞学技术测定血清标本中IL-2、IL-4的水平,用PANSS量表评定精神症状。结果(1)首发精神分裂症患者IL-2、IL-4水平与正常对照组相比,差异无统计学意义(P>0.05)。(2)首发精神分裂症患者阿立哌唑治疗后较治疗前IL-4水平降低,差异有统计学意义(P<0.01)。(3)首发精神分裂症阳性症状患者血清IL-2、IL-4水平在治疗前均高于对照组(P<0.05

  12. Tailored lighting intervention improves measures of sleep, depression, and agitation in persons with Alzheimer’s disease and related dementia living in long-term care facilities

    Directory of Open Access Journals (Sweden)

    Figueiro MG

    2014-09-01

    Full Text Available Mariana G Figueiro,1 Barbara A Plitnick,1 Anna Lok,1 Geoffrey E Jones,1 Patricia Higgins,2,3 Thomas R Hornick,3,4 Mark S Rea1 1Lighting Research Center, Rensselaer Polytechnic Institute, Troy, NY, USA; 2School of Nursing, 3School of Medicine, Case Western Reserve University, 4Geriatric Research Education and Clinical Center, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH, USABackground: Light therapy has shown great promise as a nonpharmacological method to improve symptoms associated with Alzheimer’s disease and related dementias (ADRD, with preliminary studies demonstrating that appropriately timed light exposure can improve nighttime sleep efficiency, reduce nocturnal wandering, and alleviate evening agitation. Since the human circadian system is maximally sensitive to short-wavelength (blue light, lower, more targeted lighting interventions for therapeutic purposes, can be used. Methods: The present study investigated the effectiveness of a tailored lighting intervention for individuals with ADRD living in nursing homes. Low-level “bluish-white” lighting designed to deliver high circadian stimulation during the daytime was installed in 14 nursing home resident rooms for a period of 4 weeks. Light–dark and rest–activity patterns were collected using a Daysimeter. Sleep time and sleep efficiency measures were obtained using the rest–activity data. Measures of sleep quality, depression, and agitation were collected using standardized questionnaires, at baseline, at the end of the 4-week lighting intervention, and 4 weeks after the lighting intervention was removed. Results: The lighting intervention significantly (P<0.05 decreased global sleep scores from the Pittsburgh Sleep Quality Index, and increased total sleep time and sleep efficiency. The lighting intervention also increased phasor magnitude, a measure of the 24-hour resonance between light–dark and rest–activity patterns, suggesting an increase

  13. The impact of comorbid depression on recovery from personality disorders and improvements in psychosocial functioning: Results from a randomized controlled trial

    NARCIS (Netherlands)

    Renner, F.; Bamelis, L.L.; Huibers, M.J.; Speckens, A.; Arntz, A.

    2014-01-01

    Depressive disorders often co-occur with personality disorders. The extent to which depressive disorders influence treatment outcome in personality disorders remains unclear. The aim of this study was to determine the impact of co-morbid depression on recovery from personality disorders and improvem

  14. Anxiety and depression factors mining based on improved BUS algorithm%基于改进BUS算法的焦虑抑郁障碍因素挖掘

    Institute of Scientific and Technical Information of China (English)

    刘峰斌; 袁志勇; 肖玲; 王惠玲; 王高华

    2015-01-01

    For early prevention and diagnosis of patients with anxiety and depression, this paper applies association rule mining and summarization methods to medical records to discover sets of risk factors associated with anxiety and depression. Separate use of frequent itemsets mining algorithm would produce too many frequent itemsets and association rules, causing its practicability greatly reduced. It preprocesses the medical records. Then it uses the FP-growth algorithm to find frequent itemsets in the data after pretreatment. At last, it uses the latest improvement Bottom-Up Summarization(BUS)algorithm to summarize the discovered frequent itemsets. At the same time, it compares the association rules obtained at last with the association rules uncompressed and the association rules obtained by the original BUS algorithm and Top-K. Experi-mental results show that the rules obtained by improved BUS algorithm have moderate number, less redundant information and the people covered by these rules are at high risk of anxiety or depression.%针对焦虑抑郁患者的早期预防和诊断需求,将关联规则挖掘和压缩方法应用于焦虑抑郁障碍因素的研究,在病人数据中挖掘出与焦虑抑郁障碍相关性较高的因素集合。单独使用频繁项集挖掘算法会产生过多的频繁项集和关联规则,导致其实用性大为降低。对收集的病人数据进行预处理,采用FP-growth算法,挖掘出预处理后数据中的频繁项集,采用最新改进Bottom-Up Summarization(BUS)算法,对挖掘出的频繁项集进行压缩。同时将最后得到的关联规则与未压缩得到的关联规则、原始BUS算法及Top-K算法压缩后得到的关联规则进行对比。实验结果表明,使用改进BUS算法得到的规则数量适中、信息冗余较少而且覆盖的人群具有更高的患病风险。

  15. Effect of aripiprazole combined with clozapine on quality of life in patients with schizophrenia%阿立哌唑合并氯氮平对精神分裂症患者生活质量的影响

    Institute of Scientific and Technical Information of China (English)

    王小红; 周云云; 兰润林; 侯凌峰; 董继雪; 武建斌

    2013-01-01

    Objective:To investigate the effect of aripiprazole combined with clozapine on quality of life in patients with schizophrenia.Method:According to the therapeutic schedule,78 recurrent patients with schizophrenics who were clinical recovery or remarkable progress by the acute treatment were divided into the study group (38 cases) and control group (40 cases).The maintenance treatment was aripiprazole combined with lower dose clozapine in study group and single clozapine in control group.The quality of life was evaluated by scale of general quality of life (GQOL1-74) in the two groups before and after 6,12 months of maintenance treatment,respectively.The results were compared.Results:After 6 and 12 months of maintenance treatment,the scores of GQOL1-74 in in the two groups were significantly increased than before maintenance treatment,and the improvement of score in the study group was more obvious (P <0.01 or P <0.001).The scores of physical function dimension,social function dimension,self-esteem score in psychological functions dimensions in the study group were significantly higher than those in the control group (P < 0.05 or P < 0.01).Conclusion:The quality of life is better in patients with schizophrenia who had the maintenance treatment with aripiprazole combined lower dose clozapine than those with purely clozapine.%目的:探讨阿立哌唑合并氯氮平对精神分裂症患者生活质量的影响. 方法:将78例经急性期治疗达临床痊愈及显著进步的复发性精神分裂症患者按治疗方案分为研究组(38例)和对照组(40例),分别给予阿立哌唑合并低剂量氯氮平及氯氮平单药维持治疗.分别在维持治疗前、6及12个月时采用生活质量综合评定问卷(GQOLl-74)对两组患者生活质量进行评定和比较. 结果:维持治疗6及12个月时,两组GQOLl-74总分较维持治疗前显著提高,且研究组更显著(P<0.01或P<0.001);研究组的躯体功能、社会功能维度评分以及

  16. Clinical Observation on Fluvoxamine and Aripiprazole as Adjunctive Therapy in the Treatment of Obsessive-compulsive Disorders%阿立哌唑辅助氟伏沙明治疗强迫障碍的临床观察

    Institute of Scientific and Technical Information of China (English)

    魏宏强; 康瑞; 李爱玲; 赵秀娟

    2013-01-01

    Objective:To explore the efficacy and safety of fluvoxamine and aripiprazole as adjunctive therapy in the treatment of obsessive-compulsive disorders patients.Method:Total 54 obsessive-compulsive disorders patients were randomly divided into two groups:Fluvoxamine(250-300 mg/d)auxiliaried by aripiprazole(2.5-10 mg/d)group(study group)and fluvoxamine(250-300 mg/d)group(contral group),27 for each. Each group had a 8-week treatment.The efficacy were assessed and analyzed by Yale-Brown Obsessive Compulsive Scale(Y-BOCS) at baseline and at week 2,4,6 and 8. The side effects were assessed by Treatment Emergent Syptom Scale(TESS)during the treatment. Result:Study group and contral group had 1,2 case being off respectively. The obsession and compulsion scores of study group had all statistical difference at baseline and week 2,4 ,6,8 each other(P0.05). At week 4,in both groups,the compulsion scores had statistical difference(P0.05). Conclusion:Fluvoxamine and aripiprazole as adjunctive therapy can effectively continue to improve the compulsive symptoms in the treatment of obsessive-compulsive disorders patients,the rate of side effects is similar to that of simple fluvoxamine therapy.%  目的:探讨阿立哌唑辅助氟伏沙明治疗强迫障碍的临床疗效及安全性.方法:将54例强迫障碍患者随机分为两组(各27例):阿立哌唑(2.5~10 mg/d)辅助氟伏沙明(250~300 mg/d)组(研究组)、氟伏沙明(250~300 mg/d)组(对照组),治疗观察期均为8周.两组患者于基线及治疗2、4、6、8周末分别评定Yale-Brown强迫量表(Y-BOCS),并采用副反应量表(TESS)评定治疗期间的不良反应.结果:研究组、对照组分别脱落1例、2例.研究组的强迫思维和强迫行为评分在基线及2、4、6、8周末时点间比较差异均有统计学意义(P0.05);4周末时,两组间的强迫行为评分比较差异有统计学意义(P0.05).结论:阿立哌唑辅助氟伏沙明可有效、持续地改善强迫障

  17. Diurnal variation of depressive symptoms

    OpenAIRE

    Wirz-Justice, Anna

    2008-01-01

    Diurnal variation of depressive symptoms appears to be part of the core of depression. Yet longitudinal investigation of an individual's pattern regularity, relation to clinical state, and clinical improvement reveals little homogeneity. Morning lows, afternoon slump, evening worsening - all can occur during a single depressive episode. Mood variability, or the propensity to produce mood swings, appears to be the characteristic that most predicts capacity to respond to treatment. Laboratory s...

  18. 阿立哌唑合并氯氮平对难治性精神分裂症疗效和认知功能影响的研究%A self-controlled study of aripiprazole combined with clozapine on efficacy and cognitive function in patients with treatment-resistant schizophrenia

    Institute of Scientific and Technical Information of China (English)

    司桂梅; 王爱波; 秦爱玲

    2012-01-01

    Objective To explore the effects of aripiprazole combined with clozapine on efficacy and cognitive function for patients with treatment-resistant schizophrenia. Methods A total of 45 treatment-resistant schizophrenic patients treated with clozapine were combined with aripiprazole (10-30mg/d) for 12 weeks,at the same time clozapine was lowered to maintenance does within 2 weeks. The efficacy and side effects were assessed with Positive and Negative Symptom Scale (PANSS) and Treatment Emergent Symptoms Scale (TESS) ,the cognitive function were measured with Wisconsion Card Sorting Test (WCST) and Continuous Performance Test (CPT) at baseline and at the 12th weekend of the treatment. Results At the end of the treatment, scores of PANSS and TESS decreased significantly, and each parameters of cognitive function was significantly improved when compared with those at baseline. Conclusion Aripiprazole combined with clozapine can effectively improve the negative symptoms and cognitive functions in patients with treatment-resistant schizophrenia with few side effects.%目的 探讨阿立哌唑合并氯氮平对难治性精神分裂症疗效及认知功能的影响.方法 对45例原服用氯氮平治疗的难治性精神分裂症患者合并阿立哌唑( 10~30) mg/d治疗12周,同时2周内将氯氮平减量至维持剂量后不再变化,并于合并治疗前及治疗后12周末用阳性与阴性症状量表( PA NSS)、副反应量表(TESS)评定疗效和副反应,以威斯康星卡片(WCST)和连续作业测验(CPT)评定患者的认知功能.结果 合并阿立哌唑治疗后12周末PANSS总分和TESS评分较合并前有明显差异(P<0.01,P<0.05),各项认知功能指标均有不同程度改善.结论 阿立哌唑合并氯氮平对难治性精神分裂症阴性症状及认知功能的改善明显,副反应减少.

  19. Adjunctive Triple Chronotherapy (Combined Total Sleep Deprivation, Sleep Phase Advance, and Bright Light Therapy) Rapidly Improves Mood and Suicidality in Suicidal Depressed Inpatients: An Open Label Pilot Study

    OpenAIRE

    Sahlem, Gregory L.; Kalivas, Benjamin; Fox, James B.; Lamb, Kayla; Roper, Amanda; Williams, Emily N.; Williams, Nolan R.; Korte, Jeffrey E.; Zuschlag, Zachary D.; El Sabbagh, Salim; Guille, Constance; Barth, Kelly S.; Uhde, Thomas W.; George, Mark S.; Short, E. Baron

    2014-01-01

    Previous studies have demonstrated that combined total sleep deprivation (Wake therapy), sleep phase advance, and bright light therapy (Triple Chronotherapy) produce a rapid and sustained antidepressant effect in acutely depressed individuals. To date no studies have explored the impact of the intervention on unipolar depressed individuals with acute concurrent suicidality. Participants were suicidal inpatients (N=10, Mean age=44±16.4SD, 6F) with unipolar depression. In addition to standard o...

  20. A preliminary analysis of association between plasma microRNA expression alteration and symptomatology improvement in Major Depressive Disorder (MDD patients before and after antidepressant treatment

    Directory of Open Access Journals (Sweden)

    Zhang Qiao-li

    2014-12-01

    Full Text Available Background and Objectives: Currently, there is a serious need to find practical biomarker(s for Major Depressive Disorder (MDD therapeutic target(s. This study aimed to investigate the association between microRNA (miRNA, miR expression level in Peripheral Blood Mononuclear Cells (PBMCs and symptomatology improvement in MDD patients before and after six-week antidepressant treatment. Methods: By using an Affymetrix array that covers 723 human miRNAs, 26 miRNAs were identified with significantly altered expression in PBMCs in MDD patients, of which 10 miRNAs were selected for quantitative real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR study. Twenty out of all the 81 MDD patients were selected for miRNA expression levels testing and symptomatology assessments before and after six-week treatment. Results: Compared with the control group, the expression levels of miR-26b, miR-4743, miR-4498, miR-4485 and miR-1972 of the MDD group were significantly higher (P < 0.05; the changes of expression levels of miR-4743, miR-4498, miR-4485 and miR-1972 were positively related to retardation improvement (P < 0.05, and the change of expression level of miR-26b negatively to the improvement of day and night change (P < 0.05; regression analysis result demonstrated that the alteration of miR-4485 expression accounted for 28.8% of retardation improvement (P < 0.05. Conclusions: These five miRNAs (miR-4743, miR-4498, miR-4485, miR-1972 and miR-26b may serve as biomarker for MDD diagnosis and therapeutic targets for MDD treatment.

  1. Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole

    Directory of Open Access Journals (Sweden)

    Peters-Strickland T

    2016-10-01

    Full Text Available Timothy Peters-Strickland,1 Linda Pestreich,1 Ainslie Hatch,2 Shashank Rohatagi,1 Ross A Baker,1 John P Docherty,2 Lada Markovtsova,1 Praveen Raja,3 Peter J Weiden,4 David P Walling5 1Otsuka Pharmaceutical Development & Commercialization, Inc., 2ODH, Inc., Princeton, NJ, 3Proteus Digital Health, Inc., Redwood City, CA, 4Department of Psychiatry, University of Illinois, Chicago, IL, 5CNS Network, LLC, Long Beach, CA, USA Objective: Digital medicine system (DMS is a novel drug–device combination that objectively measures and reports medication ingestion. The DMS consists of medication embedded with an ingestible sensor (digital medicine, a wearable sensor, and software applications. This study evaluated usability of the DMS in adults with schizophrenia rated by both patients and their health care providers (HCPs during 8-week treatment with prescribed doses of digital aripiprazole.Methods: Six US sites enrolled outpatients into this Phase IIa, open-label study (NCT02219009. The study comprised a screening phase, a training phase (three weekly site visits, and a 5-week independent phase. Patients and HCPs independently rated usability of and satisfaction with the DMS.Results: Sixty-seven patients were enrolled, and 49 (73.1% patients completed the study. The mean age (SD of the patients was 46.6 years (9.7 years; the majority of them were male (74.6%, black (76.1%, and rated mildly ill on the Clinical Global Impression – Severity scale (70.1%. By the end of week 8 or early termination, 82.1% (55/67 of patients had replaced the wearable sensor independently or with minimal assistance, based on HCP rating. The patients used the wearable sensor for a mean (SD of 70.7% (24.7% and a median of 77.8% of their time in the trial. The patients contacted a call center most frequently at week 1. At the last visit, 78% (47/60 of patients were somewhat satisfied/satisfied/extremely satisfied with the DMS.Conclusion: A high proportion of patients with

  2. Nonsomatic treatment of depression.

    Science.gov (United States)

    Sherrill, Joel T; Kovacs, Maria

    2002-07-01

    There is solid evidence that active and goal-oriented cognitive-behavioral or relationship-focused therapies are generally superior to more generic therapies or to no treatment for clinically diagnosed and for undiagnosed but symptomatic youths. Between 50% to 87% of diagnosed youths who received a targeted treatment had recovered from their depressive episodes, in comparison to 21% to 75% of those who received some other generic therapy and 5% to 48% of wait-listed youths. The cognitive behavioral and relationship-oriented interventions that were tested tended to be even more successful in reducing depressive symptoms in school-based samples, possibly because the participants in the school-based studies may have been less disturbed than the clinically diagnosed cases. Although the targeted treatments generally yielded better results than the comparison conditions, the targeted interventions seem to be similarly successful in ameliorating depression. Determining which psychosocial therapy works best for a given depressed youngster remains problematic. As noted in recent reviews [30,46,47], little attention has been devoted to which interventions, or parts of an intervention, are likely to be effective with children with various characteristics. This issue acquires added importance because in some diagnosed samples half or more of the treated participants were still in a depressive episode at the end of the trial. Likewise, in intervention studies involving symptomatic, school-based youngsters, not all children improved, and gains were not uniform across domains of functioning (e.g., severity of depression, self-esteem, global functioning). Possibly, for some of the nonresponders, the participant's characteristics and relevant problems and the target interventions were mismatched. For example, a depressed youth with a long history of highly dysfunctional relationships may not respond optimally to a therapy focusing on negative cognitions; alternatively

  3. Postnatal depression.

    OpenAIRE

    Craig, Michael; Howard, Louise Michele

    1991-01-01

    The differentiation between postnatal depression and other types of depression is often unclear, but there are treatment issues in nursing mothers that do not apply in other situations. Overall, the prevalence of depression in postpartum women is the same as the prevalence in women generally, at about 12–13%.Suicide is a major cause of maternal mortality in resource-rich countries, but rates are lower in women postpartum than in women who have not had a baby.Most episodes resolve spontaneo...

  4. Minocycline Improves the Depressive Behaviors of Vascular Depression Mice and Influences the Neurotransmitters Content in Hippocampus via Restraining Neuroinlfammation%Minocycline对血管性抑郁小鼠抑郁行为及神经递质的作用

    Institute of Scientific and Technical Information of China (English)

    李海龙; 刘敏; 张海; 郑惠文; 周凯歌; 王云霞; 毕晓莹

    2014-01-01

    divided into experimental group (n=10), control group (n=10) and sham group (n=10). Minocycline (30 mg/kg, i.p.) and same dose of saline were administrated immediately after the surgery and subsequently the consecutive 6 days in experimental group and control group respectively. Mice in sham group were conducted the same surgery expect occluding carotid artery, then administered the same dose of saline as the control group. After the administration, tail suspension test and open-ifeld test were used to assess depression behaviors of mice on the post operation day (POD) 8 and 9 respectively, and Morris water maze was used to assess cognitive function on the POD 10. On POD 11, mice were deeply anesthetized and euthanized and transcardially perfused with phosphate buffered saline (PBS). Expressions of tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) in hippocampus were measured by enzyme-linked immunosorbent assay (ELISA) kit. Contents of 5-hydroxytryptamine (5-HT), norepinephrine (NE) and dopamine (DA) were measured by high performance liquid chromatography (HPLC). Results Among the three groups, the immobility time was signiifcantly different ([174.75±11.37]s vs [194.32±14.32]s vs [169.62±19.27]s, F=6.59, P=0.005), and the immobility time of experimental group and sham group was shorter than control group significantly. The times of exploring holes, prolonged time and distance of movement were signiifcantly different (F=6.17, P=0.008;F=11.55, P Conclusion Minocycline can restrain the expression of inflammatory cytokines in vascular depression mice, and inhibited inflammation may improve their depression behaviors, but no improvement found in the cognitive impairment. Among those relevant neurotransmitters, the content of DA changes most signiifcantly.

  5. 提高综合医院焦虑障碍与抑郁障碍的识别率%General Hospital to improve the recognition rate of anxiety disorders and depression disorder

    Institute of Scientific and Technical Information of China (English)

    苏文英; 陈芸; 赵新宇; 杨欣

    2014-01-01

    目的:通过对南充综合医院门诊病人的抑郁障碍和焦虑障碍的发生率及共病现象研究,提高焦虑障碍与抑郁障碍的识别率。方法:随机抽取1000例门诊患者进行焦虑自评量表(SAS)和抑郁自评量表(SDS)的问卷调查,通过数据统计分析,阳性筛查焦虑障碍和抑郁障碍的患病情况。结果:门诊中有8.56%的患者存在焦虑障碍,6.03%的患者存在抑郁障碍,2.96%的患者存在焦虑障碍与抑郁障碍共病现象。女性焦虑障碍患病率大于男性患病率,女性抑郁障碍患病率大于男性患病率。结论:综合医院提高焦虑障碍与抑郁障碍的识别率的过程中应注意性别的影响,加强综合门诊对焦虑障碍及抑郁障碍的识别率。%Through Nanchong depression and anxiety disorders in general hospitals and outpatient incidence of comorbidity research, improving the recognition rate of anxiety disorders and depression. Methods: 1000 cases were randomly selected outpatients Self-Rating Anxiety Scale (SAS) and Self-rating Depression Scale (SDS) questionnaire, through statistical analysis, positive screening for anxiety disorders and depressive disorders prevalence. Results: The patient had 8.56% of patients with anxiety disorders, 6.03% of patients with major depressive disorder, anxiety disorders and depressive disorders exist Comorbidity 2.96%of patients. Women prevalence of anxiety disorders than men prevalence of women than men prevalence of depressive disorder prevalence. Conclusion: General Hospital to improve the recognition rate of anxiety disorders and depressive disorders in the process should pay attention to the impact of gender, strengthen the comprehensive clinic for anxiety disorders and depression recognition rate.

  6. Postpartum Depression

    DEFF Research Database (Denmark)

    Smith-Nielsen, Johanne

    Background: In three academic articles, this PhD thesis investigates maternal postpartum depression (PPD) as a risk factor for the infant-mother attachment and infant development. Previous studies have been contradictory with respect to the question of whether PPD can have long term effects...... on offspring. This may be due to not differing between when PPD is only occurring in the postpartum period and when effects are also due to ongoing or recurrent depression. However, it may also be due to viewing maternal depression as a unitary construct, and not considering underlying maternal psychological...... difficulties which may moderate potential adverse effects. The present thesis investigates two potential maternal moderators of risk:. Comorbid personality disorder and adult attachment insecurity. Moreover, the question of early environmental effects of PPD versus effects of later or ongoing depression...

  7. Teen Depression

    Science.gov (United States)

    ... a real, treatable brain illness, or health problem. Depression can be caused by big transitions in life, stress, or changes in your body’s chemicals that affect your thoughts and moods. Even ...

  8. Postpartum depression

    Science.gov (United States)

    ... may be referred to a mental health specialist. Cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) are types of talk therapy that often help postpartum depression. Support groups may be helpful, but they should ...

  9. The detection and treatment of depression in the physically ill

    OpenAIRE

    Goldberg, David

    2010-01-01

    Depression and chronic physical illness are in reciprocal relationship with one another: not only do many chronic illnesses cause higher rates of depression, but depression has been shown to antedate some chronic physical illnesses. Depression associated with physical illness is less well detected than depression occurring on its own, and various ways of improving both the detection and treatment of depression accompanying physical illness are described. This paper is in fou...

  10. Improvement of quality of life, anxiety and depression after surgery in patients with stress urinary incontinence: Results of a longitudinal short-term follow-up

    Directory of Open Access Journals (Sweden)

    Giesinger Johannes M

    2008-09-01

    Full Text Available Abstract Objective The objective of this study was to compare the effect of incontinence surgery and pelvic floor training on quality of life (QOL, anxiety and depression in patients with stress urinary incontinence (SUI. Methods In a prospective longitudinal study, females with proven SUI were asked to complete a set of standardized questionnaires (sociodemographic data sheet, FACT-G, I-QOL, HADS before and eight weeks after treatment. The comparison groups consisted of a surgical treatment group and a conservative group that underwent supervised pelvic floor training for eight weeks. Results From the 67 female patients included in the study a number of 53 patients completed both assessment time points (mean age 57.4, mean years of SUI 7.6. The surgical treatment group consisted of 32 patients of which 21 patients received a modified Burch colposuspension and 11 patients a tension-free mid-urethral tape suspension. The 21 patients in the conservative group attended eight once-weekly supervised pelvic floor training sessions. After treatment the surgical intervention group showed a significantly higher improvement of QOL (FACT-G and I-QOL and anxiety (HADS than the pelvic floor training group. Conclusion For female patients with SUI surgery yielded a better outcome than pelvic floor training with regard to quality of life and anxiety.

  11. Xiao Yao San Improves Depressive-Like Behaviors in Rats with Chronic Immobilization Stress through Modulation of Locus Coeruleus-Norepinephrine System

    Directory of Open Access Journals (Sweden)

    Xiu-Fang Ding

    2014-01-01

    Full Text Available Most research focuses on the hypothalamic-pituitary-adrenal (HPA axis, hypothalamus-pituitary-thyroid (HPT axis, and hypothalamus-pituitary-gonadal (HPGA axis systems of abnormalities of emotions and behaviors induced by stress, while no studies of Chinese herbal medicine such as Xiao Yao San (XYS on the mechanisms of locus coeruleus-norepinephrine (LC-NE system have been reported. Therefore, experiments were carried out to observe mechanism of LC-NE system in response to chronic immobilization stress (CIS and explore the antidepressant effect of XYS. Rat model was established by CIS. LC morphology in rat was conducted. The serum norepinephrine (NE concentrations and NE biosynthesis such as tyrosine hydroxylase (TH, dopamine-β-hydroxylase (DBH, and corticotrophin-releasing-factor (CRF in LC were determined. Results showed that there were no discernible alterations in LC in rats. The serum NE concentrations, positive neurons, mean optical density (MOD, and protein levels of TH, DBH, and CRF in model group were significantly increased compared to the control group. But XYS-treated group displayed a significantly decreased in NE levels and expressions of TH, DBH, and CRF compared to the model group. In conclusion, CIS can activate LC-NE system to release NE and then result in a significant decrease in rats. XYS treatment can effectively improve depressive-like behaviors in rats through inhibition of LC-NE neurons activity.

  12. Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: A retrospective cohort study

    Directory of Open Access Journals (Sweden)

    Berger Ariel

    2012-08-01

    Full Text Available Abstract Background Schizophrenia and bipolar disorder are chronic debilitating disorders that are often treated with second-generation antipsychotic agents, such as aripiprazole, quetiapine, and ziprasidone. While patients who are hospitalized for schizophrenia and bipolar disorder often receive these agents at discharge, comparatively little information exists on subsequent patterns of pharmacotherapy. Methods Using a database linking hospital admission records to health insurance claims, we identified all patients hospitalized for schizophrenia (ICD-9-CM diagnosis code 295.XX or bipolar disorder (296.0, 296.1, 296.4-296.89 between January 1, 2001 and September 30, 2008 who received aripiprazole, quetiapine, or ziprasidone at discharge. Patients not continuously enrolled for 6 months before and after hospitalization (“pre-admission” and “follow-up”, respectively were excluded. We examined patterns of use of these agents during follow-up, including adherence with treatment (using medication possession ratios [MPRs] and cumulative medication gaps [CMGs] and therapy switching. Analyses were undertaken separately for patients with schizophrenia and bipolar disorder, respectively. Results We identified a total of 43 patients with schizophrenia, and 84 patients with bipolar disorder. During the 6-month period following hospitalization, patients with schizophrenia received an average of 101 therapy-days with the second-generation antipsychotic agent prescribed at discharge; for patients with bipolar disorder, the corresponding value was 68 therapy-days. Mean MPR at 6 months was 55.1% for schizophrenia patients, and 37.3% for those with bipolar disorder; approximately one-quarter of patients switched to another agent over this period. Conclusions Medication compliance is poor in patients with schizophrenia or bipolar disorder who initiate treatment with aripiprazole, quetiapine, or ziprasidone at hospital discharge.

  13. Optimal management of perimenopausal depression

    Directory of Open Access Journals (Sweden)

    Barbara L Parry

    2010-06-01

    Full Text Available Barbara L ParryDepartment of Psychiatry, University of California, San Diego, USAAbstract: Only recently has the perimenopause become recognized as a time when women are at risk for new onset and recurrence of major depression. Untreated depression at this time not only exacerbates the course of a depressive illness, but also puts women at increased risk for sleep disorders, cardiovascular disease, diabetes, and osteoporosis. Although antidepressant medication is the mainstay of treatment, adjunctive therapy, especially with estrogen replacement, may be indicated in refractory cases, and may speed the onset of antidepressant action. Many, but not all, studies, report that progesterone antagonizes the beneficial effects of estrogen. Although some antidepressants improve vasomotor symptoms, in general they are not as effective as estrogen alone for relieving these symptoms. Estrogen alone, however, does not generally result in remission of major depression in most (but not all studies, but may provide benefit to some women with less severe symptoms if administered in therapeutic ranges. The selective serotonin reuptake inhibitors (SSRIs in addition to estrogen are usually more beneficial in improving mood than SSRIs or estrogen treatment alone for major depression, whereas the selective norepinephrine and serotonin reuptake inhibitors do not require the addition of estrogen to exert their antidepressant effects in menopausal depression. In addition to attention to general health, hormonal status, and antidepressant treatment, the optimal management of perimenopausal depression also requires attention to the individual woman’s psychosocial and spiritual well being.Keywords: menopause, depression, management

  14. Older Adults and Depression

    Science.gov (United States)

    ... Older Adults and Depression Share Older Adults and Depression Download PDF Download ePub Download Mobi Order a ... If so, you may have depression. What is depression? Everyone feels down or sad sometimes, but these ...

  15. Caregiving and Depression

    Science.gov (United States)

    ... FCA - A A + A You are here Home Depression and Caregiving Order this publication Printer-friendly version ... a more serious depression over time. Symptoms of Depression People experience depression in different ways. Some may ...

  16. Postpartum Depression Facts

    Science.gov (United States)

    ... for herself or her family. What is postpartum depression? Postpartum depression is a mood disorder that can affect ... for themselves or for others. What causes postpartum depression? Postpartum depression does not have a single cause, but ...

  17. Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP

    Directory of Open Access Journals (Sweden)

    Haeberle Anne

    2012-09-01

    Full Text Available Abstract Background For the pharmacological treatment of bipolar depression several guidelines exist. It is largely unknown, to what extent the prescriptions in daily clinical routine correspond to these evidence based recommendations and which combinations of psychotropic drugs are frequently used. Methods The prescriptions of psychotropic drugs were investigated of all in-patients with bipolar depression (n = 2246; time period 1994–2009 from hospitals participating in the drug surveillance program AMSP. For the drug use in 2010, 221 cases were analysed additionally. Results From 1994 to 2009, 85% of all patients received more than one class of psychotropic substances: 74% received antidepressants in combination therapy, 55% antipsychotics, 48% anticonvulsants and 33% lithium. When given in combination, lithium is the most often prescribed substance for bipolar depression (33%, followed by valproic acid (23%, mirtazapine and venlafaxine (16% each, quetiapine (15%, lamotrigine (14% and olanzapine (13%. Both, lithium and valproic acid are often combined with selective serotonin reuptake inhibitors (SSRI, but also with mirtazapine und venlafaxine. Combinations of more than one antidepressant occur quite often, whereby combinations with bupropion, paroxetine, fluoxetine or fluvoxamine are very rare. In 2010, quetiapine (alone and combined was the most frequently prescribed drug (39%; aripiprazole was administered in 10%. Conclusion Combinations of antidepressants (SSRI, mirtazapine, venlafaxine with mood stabilizers (lithium, valproic acid, lamotrigine and / or atypical antipsychotics (quetiapine, olanzapine are common. Of most of those combinations the efficacy has not been studied. The use of aripiprazole and the concomitant use of two or three antidepressants contrast the guidelines.

  18. Potential long-term effects of a mind-body intervention for women with major depressive disorder: sustained mental health improvements with a pilot yoga intervention.

    Science.gov (United States)

    Kinser, Patricia Anne; Elswick, R K; Kornstein, Susan

    2014-12-01

    Despite pharmacologic and psychotherapeutic advances over the past decades, many individuals with major depressive disorder (MDD) experience recurrent depressive episodes and persistent depressive symptoms despite treatment with the usual care. Yoga is a mind-body therapeutic modality that has received attention in both the lay and research literature as a possible adjunctive therapy for depression. Although promising, recent findings about the positive mental health effects of yoga are limited because few studies have used standardized outcome measures and none of them have involved long-term follow-up beyond a few months after the intervention period. The goal of our research study was to evaluate the feasibility, acceptability, and effects of a yoga intervention for women with MDD using standardized outcome measures and a long follow-up period (1year after the intervention). The key finding is that previous yoga practice has long-term positive effects, as revealed in both qualitative reports of participants' experiences and in the quantitative data about depression and rumination scores over time. Although generalizability of the study findings is limited because of a very small sample size at the 1-year follow-up assessment, the trends in the data suggest that exposure to yoga may convey a sustained positive effect on depression, ruminations, stress, anxiety, and health-related quality of life. Whether an individual continues with yoga practice, simple exposure to a yoga intervention appears to provide sustained benefits to the individual. This is important because it is rare that any intervention, pharmacologic or non-pharmacologic, for depression conveys such sustained effects for individuals with MDD, particularly after the treatment is discontinued. PMID:25457687

  19. Getting out of Depression: Teens' Self-Help Interventions to Relieve Depressive Symptoms

    Science.gov (United States)

    Wisdom, Jennifer P.; Barker, Ellen C.

    2006-01-01

    Most depressed adolescents do not access medical care for symptoms, yet many improve without professional intervention. While several self-help interventions have empirical support, teens' non-directed efforts to reduce symptoms are not documented. We reviewed 14 depressed adolescents' reports of attempts to reduce depressive symptoms. Results…

  20. Therapeutic effects of aripiprazole and olanzapine on the patients with first-episode acute schizophrenia and their influence on plasma prolactin level%阿立哌唑与奥氮平对首发精神分裂症 急性期疗效及对催乳素的影响

    Institute of Scientific and Technical Information of China (English)

    吴小立; 王继辉; 钟智勇; 韩自力

    2011-01-01

    AIM:To study the efficacy on first-episode acute schizophrenia treated with aripiprazole and olanzapine and the effect on plasma prolactin level. METHODS: 65 inpatients with first-episode acute schizophrenia were divided into either olanzapine group [n = 42, M21, F21; age(23. 9±6. 6)year] or aripiprazole group[(n=23, M1l, F12; age (23. 7 ± 7. 2) year] for 4 week treatment. The plasma prolactin level, the Positive and Negative Syndrome Scale (PANSS) and clinical global impressionglobal improvement (CGI-I) were measured before and after 4 week treatment. RESULTS: The score of PANSS (59 ± 13) after therapy in olanzapine group was significantly lower than that before therapy (103+15) (P 0.05) in the CGI-I score between the two groups. The difference of negative symptoms and general psychopathological sub-scale scoreschanging from base to end between the two groups was statistically significant (P<0. 01). Compared with the prolactin baseline level (547 ±382) uIu/mL,the plasma prolactin level (418 ±362) ulu/mL in olanzapine group was significantly decreased after treatment, and there was no difference. Compared with the prolactin baseline level (351 ±299) ulu/mL, the plasma prolactin level (123 ±114) ulu/mL in aripiprazole group was significantly decreased after treatment, and there was significant difference ( P < 0.01). CONCLUSION: The therapeutic effects were similar in the aripiprazole and olanzapine group for first-episode acute schizophrenia. Olanzapine is better for the general psychopathological symptoms, and aripiprazole is better for the negative symptoms. Aripiprazole maybe decrease the plasma prolactin level of first-episode acute schizophrenia.%目的:研究奥氮平和阿立哌唑对首发精神分裂症患者急性期疗效及对血中催乳素(PRI)水平的影响.方法:65例首发精神分裂症患者分为奥氮平组42例[男21例,女21例;年龄(23.9±6.6)岁]和阿立哌唑组23例[男11例,女12例;年龄(23.7±7.2)岁].分别给予奥

  1. The research on the clinical effect of cognitive therapy in improving pregnancy depression%认知疗法在改善妊娠期抑郁症状的临床效果研究

    Institute of Scientific and Technical Information of China (English)

    向琴

    2012-01-01

    目的:探讨认知疗法对妊娠期女性抑郁症状的改善效果.方法:选取2009年3月~2010年3月在该院产科门诊建卡进行围产期产检的有抑郁症状的孕妇120例,作为研究对象,将所有孕妇随机分为观察组和对照组,对照组孕妇实施常规护理,观察组孕妇在常规护理的基础上予以认知疗法,比较两组孕妇经治疗后抑郁症状改善情况及后续分娩的剖宫产率、产程时间、疼痛发生率及疼痛级别、产后抑郁症发生率结果,综合评价认知疗法对妊娠期并发抑郁症孕妇的治疗效果.结果:两组孕妇经过治疗后,抑郁评分均较治疗前改善,但观察组孕妇的抑郁评分指数改善效果明显优于对照组孕妇.对照组患者分娩期的剖宫产率、产程时间、疼痛发生率及疼痛级别、产后抑郁症的发生率均明显高于观察组患者,P值均<0.05,均有统计学意义.结论:认知疗法对围产期妇女抑郁症状改善及提高分娩过程质量具有重要意义,值得临床推广应用.%Objective: To investigate the effect of cognitive therapy in improving pregnancy depression. Methods; 120 pregnant women with depressive symptoms from March 2009 to March 2010 in our hospital were selected as the research object. All pregnant women were randomly divided into control group and observation group. The pregnant women in the control group were taken routine care. The pregnant women in the observation group were taken cognitive therapy on the basis of routine care. The improving situation for depression and follow - up rate of cesarean section delivery, labor time, the incidence of pain and pain level, the results of the incidence of postpartum depression for pregnant women after treatment were compared. The effect of cognitive therapy in improving symptoms of depression during pregnancy was evaluated. Results; After treatment the scores of depression in the two groups were improved. But the improved effect in the

  2. Study on Psychological Nursing Improvement Cognitive Function of Depression Patients%心理护理改善抑郁症患者认知功能的对照研究

    Institute of Scientific and Technical Information of China (English)

    刘倩

    2014-01-01

    Objective:To evaluate the effect of psychological nursing in improving cognitive function in patients with depression.Method:Collected the clinical data of 80 patients with depression in our hospital,all the cases were randomly divided into two groups,the observation group(40 cases) was given oral fluoxetine,on the basis of the conventional nursing given psychological care.The control group(40 cases) just taken the foundation treatment and conventional nursing.The depression severity was assessed with Hamilton depression scale(HAMD),Wisconsin card sorting test(WCST) and the attachment test(TMT) before and after treatment.Result:HAMD grade,the WCST and TMT test times of all the cases after treatment were significant improved than before(P<0.05);After psychological nursing,the cognitive function of depression patients in observation group were significantly better than the control group(P<0.05).Conclusion:The psychological nursing can improve the cognitive function in depression,and conducive to the recovery.%目的:评价心理护理改善抑郁症患者认知功能的效果。方法:收集笔者所在医院临床心理科80例住院抑郁症患者临床资料,采用随机数字表法分为两组,观察组(40例)口服氟西汀,在常规护理基础上增加心理护理;对照组40例,仅给予基础治疗,采用常规护理。治疗前后分别进行汉密尔顿抑郁量表(HAMD)评定、威斯康星卡片分类测验(WCST)和连线测验(TMT)。结果:干预后两组HAMD评分、WCST测验、TMT测验得分较干预前均有所改善(P<0.05);观察组心理护理后对患者的认知功能改善作用显著优于对照组(P<0.05)。结论:心理护理对抑郁症患者认知功能的改善有积极作用,并有利于病情的康复。

  3. 31-Year-Old Female Shows Marked Improvement in Depression, Agitation, and Panic Attacks after Genetic Testing Was Used to Inform Treatment

    Directory of Open Access Journals (Sweden)

    Scott Lawrence

    2014-01-01

    Full Text Available This case describes a 31-year-old female Caucasian patient with complaints of ongoing depression, agitation, and severe panic attacks. The patient was untreated until a recent unsuccessful trial of citalopram followed by venlafaxine which produced a partial response. Genetic testing was performed to assist in treatment decisions and revealed the patient to be heterozygous for polymorphisms in 5HT2C, ANK3, and MTHFR and homozygous for a polymorphism in SLC6A4 and the low activity (Met/Met COMT allele. In response to genetic results and clinical presentation, venlafaxine was maintained and lamotrigine was added leading to remission of agitation and depression.

  4. Cognitive improvement after treatment of depressive symptoms in the acute phase of stroke Melhora cognitiva com tratamento antidepressivo na fase aguda do acidente vascular cerebral

    Directory of Open Access Journals (Sweden)

    Samuel Simis

    2006-06-01

    Full Text Available The outcome of antidepressant treatment for depressive symptoms and cognitive impairment at the acute phase of stroke is controversial. We investigated 93 patients, treating with citalopram 36 with severe depressive symptoms (HAM-D: Hamilton Depression Rating Scale >18, whilst 19 patients with mild depressive symptoms, and 38 non-depressed patients, remained untreated. At baseline (two weeks after stroke, patients with severe depressive symptoms had lower scores in total Dementia Rating Scale (DRS and in the attention and memory DRS subscales, than the non-depressed patients (pOs resultados do tratamento com antidepressivo para os sintomas depressivos e comprometimento cognitivo da fase aguda do acidente vascular cerebral não estão estabelecidos. Investigamos 93 pacientes, 36 com sintomas depressivos graves (HAM-D: Escala de Depressão de Hamilton >18 foram tratados com citalopram, enquanto 19 pacientes com sintomas depressivos leves e 38 não-deprimidos não foram tratados. Ao início do tratamento (duas semanas depois do icto, pacientes com sintomas depressivos graves tinham escores mais baixos na Escala de Avaliação de Demência (DRS total e nas subescalas de atenção e de memória da DRS do que os pacientes não-deprimidos (p<0,001. Ao fim de três meses de acompanhamento essas diferenças tinham desaparecido, mas pacientes que inicialmente tinham sintomas depressivos leves passaram a ter escores mais altos no HAM-D do que os não-deprimidos (p=0,015, e escores mais baixos nas subescalas de atenção e memória da DRS (p<0,01 do que os pacientes tratados com citalopram. O tratamento associou-se a melhora de humor, memória e atenção, e demonstra que é necessário um estudo controlado com placebo para o tratamento de sintomas depressivos leves.

  5. The Complex Role of Sleep in Adolescent Depression

    OpenAIRE

    Clarke, Greg; Harvey, Allison G.

    2012-01-01

    Psychological and pharmacological treatments for youth depression yield post-acute response and remission rates that are modest at best. Improving these outcomes is an important long-term goal. To that end, in this paper, the authors examine the possibility that a youth CBT insomnia intervention may be employed as an adjunct to traditional depression-focused treatment with the aim of improving depression outcomes. This “indirect route” to improving youth depression treatment outcomes is based...

  6. [Postpartum depression].

    Science.gov (United States)

    Guo, S F

    1993-09-01

    A retrospective study was carried out in Beijing, China, in 1992. Edinburgh postnatal depression scale was used to inquire the mothers at 6-12 month after delivery. A total of 550 women were investigated by mailing. 425 women replied. The positive rate of PPD in our study was 17.9%. Women who had had a history of mood disorder before pregnancy had a higher risk of PPD. Social and psychological factors such as lacking support from the women's relatives, the poor marital relationship and the bad living condition shown to be significantly associated with postnatal depression. PPD can seriously affected the physical and mental health and well-being of women, her child's early education causing delayed development and her family causing a great deal of suffering, personal distress and marital troubles even causing divorce and suicide. Thus it is important to identify the high risk women and give treatment as early as possible. PMID:8313745

  7. Aqueous Solubility of Piperazine and 2-Amino-2-methyl-1-propanol plus Their Mixtures Using an Improved Freezing-Point Depression Method

    DEFF Research Database (Denmark)

    Fosbøl, Philip Loldrup; Neerup, Randi; Waseem Arshad, Muhammad;

    2011-01-01

    In this work the solid–liquid equilibrium (SLE) and freezing-point depression (FPD) in the electrolytic binary aqueous systems piperazine (PZ, CAS No. 110-85-0) and aqueous 2-amino-2-methyl-1-propanol (AMP, CAS No. 124-68-5) were measured. The FPD and solubility were also determined in the ternar...

  8. Can a Targeted, Group-Based CBT Intervention Reduce Depression and Anxiety and Improve Self-Concept in Primary-Age Children?

    Science.gov (United States)

    O'Callaghan, Paul; Cunningham, Enda

    2015-01-01

    This pilot study examined the impact of a 10 session, group-based, early-intervention cognitive behavioural therapy (CBT) programme (Cool Connections) on anxiety, depression and self-concept in nine 8-11 year old pupils in Northern Ireland. The intervention was facilitated by a teacher, education welfare officer and two classroom assistants, with…

  9. Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-i Improves Comorbid Anxiety and Depression-A Meta-Analysis of Randomized Controlled Trials.

    Directory of Open Access Journals (Sweden)

    Yuan-Yuan Ye

    Full Text Available As the internet has become popularized in recent years, cognitive behavioral therapy for insomnia (CBT-i has shifted from a face-to-face approach to delivery via the internet (internet-based CBT-i, ICBT-i. Several studies have investigated the effects of ICBT-i on comorbid anxiety and depression; however, the results remain inconclusive. Thus, a meta-analysis was conducted to determine the effects of ICBT-i on anxiety and depression. Electronic databases, including PubMed, EMBASE, PsycINFO and the Cochrane Library (throughout May 28, 2015, were systematically searched for randomized controlled trials (RCTs of ICBT-i. Data were extracted from the qualified studies and pooled together. The standardized mean difference (SMD and 95% confidence interval (95% CI were calculated to assess the effects of ICBT-i on comorbid anxiety and depression. Nine records that included ten studies were ultimately qualified. The effect sizes (ESs were -0.35 [-0.46, -0.25] for anxiety and -0.36 [-0.47, -0.26] for depression, which were stable using a between-group or within-group comparison and suggest positive effects of ICBT-i on both comorbid disorders. Although positive results were identified in this meta-analysis, additional high-quality studies with larger sample sizes are needed in the future.

  10. 喹硫平利培酮阿立哌唑对精神分裂症患者认知功能的影响%The effect of quetiapine,risperidone and aripiprazole on cog-nitive function of schizophrenia patients

    Institute of Scientific and Technical Information of China (English)

    鞠康; 陈思路; 谢茹韵; 高炬; 孙祝平; 季卫东

    2015-01-01

    目的:探讨喹硫平、利培酮和阿立哌唑对精神分裂症患者临床疗效及认知功能的影响。方法将154例精神分裂症患者分为3组,分别口服喹硫平(65例)、利培酮(47例)和阿立哌唑(42例)治疗,观察24周。采用阳性与阴性症状量表评定临床疗效,重复性成套神经心理状态测验评定认知功能。结果治疗24周末3组阳性与阴性症状量表评分均有显著改善,但喹硫平组改善阳性症状显著优于利培酮组和阿立哌唑组(P<0.05);3组重复性成套神经心理状态测验的9个因子分比较差异有显著性( P<0.05或0.01),阿立哌唑组对8个因子分的改善优于其他2组。不同性别、文化程度患者的认知功能改善有显著性差异(P<0.05)。合并躯体疾病患者认知功能的改善显著差于单纯精神分裂症患者(P<0.05)。结论喹硫平、利培酮和阿立哌唑均能显著改善精神分裂症患者的各种精神症状及认知功能;合并躯体疾病的患者认知功能改善差于单纯精神分裂症患者,性别、文化程度是影响认知功能改变的重要因素。%Objective To explore the efficacy of quetiapine ,risperidone and aripiprazole in schizophrenia patients and their effects on cognitive functions .Methods A total of 154 schizophrenics were assigned to three groups taking orally quetiapine (n=65) ,risperidone (n=47) or aripiprazole (n=42) for 24 weeks . Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) and cognitive functions with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) .Results In the 24th week the PANSS scores of 3 groups improved more significantly ,so did that in quetiapine than risperi‐done and aripiprazole group (P<0 .05);there were significant differences in 9 factor scores of the RBANS among 3 groups (P<0 .05 or 0 .01) ,8 factor scores improved more significantly in

  11. Adjunctive triple chronotherapy (combined total sleep deprivation, sleep phase advance, and bright light therapy) rapidly improves mood and suicidality in suicidal depressed inpatients: an open label pilot study.

    Science.gov (United States)

    Sahlem, Gregory L; Kalivas, Benjamin; Fox, James B; Lamb, Kayla; Roper, Amanda; Williams, Emily N; Williams, Nolan R; Korte, Jeffrey E; Zuschlag, Zachary D; El Sabbagh, Salim; Guille, Constance; Barth, Kelly S; Uhde, Thomas W; George, Mark S; Short, E Baron

    2014-12-01

    Previous studies have demonstrated that combined total sleep deprivation (Wake therapy), sleep phase advance, and bright light therapy (Triple Chronotherapy) produce a rapid and sustained antidepressant effect in acutely depressed individuals. To date no studies have explored the impact of the intervention on unipolar depressed individuals with acute concurrent suicidality. Participants were suicidal inpatients (N = 10, Mean age = 44 ± 16.4 SD, 6F) with unipolar depression. In addition to standard of care, they received open label Triple Chronotherapy. Participants underwent one night of total sleep deprivation (33-36 h), followed by a three-night sleep phase advance along with four 30-min sessions of bright light therapy (10,000 lux) each morning. Primary outcome measures included the 17 item Hamilton depression scale (HAM17), and the Columbia Suicide Severity Rating Scale (CSSRS), which were recorded at baseline prior to total sleep deprivation, and at protocol completion on day five. Both HAM17, and CSSRS scores were greatly reduced at the conclusion of the protocol. HAM17 scores dropped from a mean of 24.7 ± 4.2 SD at baseline to a mean of 9.4 ± 7.3 SD on day five (p = .002) with six of the ten individuals meeting criteria for remission. CSSRS scores dropped from a mean of 19.5 ± 8.5 SD at baseline to a mean of 7.2 ± 5.5 SD on day five (p = .01). The results of this small pilot trial demonstrate that adjunctive Triple Chronotherapy is feasible and tolerable in acutely suicidal and depressed inpatients. Limitations include a small number of participants, an open label design, and the lack of a comparison group. Randomized controlled studies are needed. PMID:25231629

  12. Depression screening and patient outcomes in pregnancy or postpartum : A systematic review

    NARCIS (Netherlands)

    Thombs, Brett D.; Arthurs, Erin; Coronado-Montoya, Stephanie; Roseman, Michelle; Delisle, Vanessa C.; Leavens, Allison; Levis, Brooke; Azoulay, Laurent; Smith, Cheri; Ciofani, Luisa; Coyne, James C.; Feeley, Nancy; Gilbody, Simon; Schinazi, Joy; Stewart, Donna E.; Zelkowitz, Phyllis

    2014-01-01

    Objective: Clinical practice guidelines disagree on whether health care professionals should screen women for depression during pregnancy or postpartum. The objective of this systematic review was to determine whether depression screening improves depression outcomes among women during pregnancy or

  13. Rosa damascena oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: results from a double-blind, randomized, and placebo-controlled clinical trial

    Directory of Open Access Journals (Sweden)

    Farnia V

    2015-03-01

    Full Text Available Vahid Farnia,1 Mehdi Shirzadifar,2 Jalal Shakeri,1 Mansour Rezaei,3 Hafez Bajoghli,4,5 Edith Holsboer-Trachsler,6 Serge Brand6,7 1Substance Abuse Prevention Research Center, Psychiatry Department, Kermanshah University of Medical Sciences, Kermanshah, Iran; 2Student Research Center, Psychiatry Department, Kermanshah University of Medical Sciences, Kermanshah, Iran; 3Department of Statistics and Epidemiology, Kermanshah University of Medical Sciences, Kermanshah, Iran; 4Iranian National Center for Addiction Studies, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran; 5ASEAN Institute for Health Development, Mahidol University, Nakhon Pathom, Thailand; 6Psychiatric Clinics of the Center for Affective, Stress and Sleep Disorders, Psychiatric Hospital of the University of Basel, Basel, Switzerland; 7Sport Science Section, Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland Background: A substantial disadvantage of psychopharmacological treatment of major depressive disorder (MDD with selective serotonin-reuptake inhibitors (SSRIs is the impact on sexual dysfunction. The aim of the present study was to investigate whether the oil of Rosa damascena can have a positive influence on SSRI-induced sexual dysfunction (SSRI-I SD of male patients who are suffering from MDD and are being treated with SSRIs.Method: In a double-blind, randomized, and placebo-controlled clinical trial, a total of 60 male patients treated with an SSRI and suffering from MDD (mean age =32 years and SSRI-I SD were randomly assigned to take either verum (R. damascena oil or a placebo. Patients completed self-ratings of depression and sexual function at baseline, at 4 weeks later, and at the end of the study, 8 weeks after it started.Results: Over time, sexual dysfunction improved more in the verum group than in the control group. Improvements were observed in the verum group from week 4 to week

  14. Correlation research of delighted thinking on improving negative emotion of depression patients%愉悦思维对改善抑郁症患者负性情绪的相关性研究

    Institute of Scientific and Technical Information of China (English)

    杜荣荣; 刘文琴; 林彩霞; 潘志芳; 张景明

    2010-01-01

    Objective To investigate the effect of delighted thinking on improving negative emotion of depression patients. Methods 100 depression patients were randomly divided into the observation group and the control group with 50 in each according to admission sequence. Both groups was executed antidepressionant drugs treatment and routine psychiatric care simultaneously. The observation group was given delighted thinking training on the basis of above treatment. The emotional recovery of two groups was observed. Results There was significant difference on facial expression, communication and limbs language after executing delighted thinking training in the observation group. And there was significant difference on scores of Hamilton depression rating scale (HAMD) at discharge. Scores of Nurses' Observation Scale during early, middle and late stage of delighted thinking training greatly improved compared with those before training. Conclusions Delighted thinking contributes to throw off negative thinking pattern of self-denial, stimulate positive passion threshold, improve depressed mood and raise treatment effect for depression patients.%目的 探讨愉悦思维对改善抑郁症患者负性情绪的作用.方法 将100例抑郁症患者按入院先后顺序随机分为观察组和对照组各50例.2组患者同时实施抗抑郁药物治疗及精神科常规护理.观察组在此基础上进行愉悦思维训练.观察2组患者情绪的恢复情况.结果 观察组患者面部表情、语言交流、肢体语言在实施诱导愉悦思维后有显著改善;2组患者在出院时汉密尔顿抑郁量表评分比较差异显著.观察组患者在愉悦思维训练的早、中、晚期护士观察量表评分较训练前均有显著提高.结论 愉悦思维有助于患者摆脱自我否定的负性思维模式,刺激患者的正性情感阈值,改善抑郁心境,提高治疗效果.

  15. Psychosocial Interventions in Depressive Disorders

    Directory of Open Access Journals (Sweden)

    Ceyda Basogul

    2015-03-01

    Full Text Available In the last ten years, improvements in effective psychosocial interventions in the prevention and treatment of depression are remarkable. The World Health Organization stated that major depression affects children, adults and the elderly and is the leading cause of approximately 12% of all disabilities around the World. Medical expenses, loss of workforce, suicide risk, the risk of relapse or recurrence are taken into account, depression is an issue that needs to be handled with utmost care for health care workers especially psychiatric nurses. The purpose of this literature review is to examine psychosocial interventions and effectiveness of these interventions for depressive disorders shows a gradual increase in prevalence in worlwide. [Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry 2015; 7(1: 1-15

  16. Persistent depressive disorder

    Science.gov (United States)

    PDD; Chronic depression; Depression - chronic ... The exact cause of persistent depressive disorder (PDD) is unknown. It tends to run in families. PDD occurs more often in women. Most people with PDD will also ...

  17. Depression and Multiple Sclerosis

    Science.gov (United States)

    Depression - National Multiple Sclerosis Society Skip to navigation Skip to content Menu Navigation National Multiple Sclerosis Society ... Twitter Email Home Symptoms & Diagnosis MS Symptoms Depression Depression Share Smaller Text Larger Text Print In this ...

  18. Men and Depression

    Science.gov (United States)

    ... in crisis? For more information Share Men and Depression Download PDF Download ePub Order a free hardcopy ... If so, you may have depression. What is depression? Everyone feels sad or irritable sometimes, or has ...

  19. Depression in Women

    Science.gov (United States)

    ... or someone I know is in crisis? Share Depression in Women Download PDF Download ePub Order a ... If so, you may have depression. What is depression? Everyone sometimes feels sad, but these feelings usually ...

  20. The Role of Anger/Hostility in Treatment-Resistant Depression: A Secondary Analysis From the ADAPT-A Study.

    Science.gov (United States)

    Fisher, Lauren B; Fava, Maurizio; Doros, Gheorghe D; Alpert, Jonathan E; Henry, Michael; Huz, Ilana; Freeman, Marlene P

    2015-10-01

    Major depressive disorder is often accompanied by elevated levels of anger, hostility, and irritability, which may contribute to worse outcomes. The present study is a secondary analysis examining the role of anger/hostility in the treatment response to low-dose aripiprazole added to antidepressant therapy in 225 patients with major depressive disorder and inadequate response to antidepressant treatment. Repeated-measures model demonstrated no drug-placebo difference in treatment response across levels of anger/hostility. However, within-group analyses showed significantly lower placebo response rates in patients with high anger/hostility and a trend for lower drug response rates in patients with high anger/hostility. Pooled response rates across phases and treatments revealed a lower response rate among patients with high anger/hostility. Depressed patients with high anger/hostility demonstrate greater illness severity and lower depressive treatment response rates than patients with low anger/hostility, suggesting that patients with high anger/hostility may have poorer outcomes in response to adjunctive treatment.

  1. Various forms of depression

    OpenAIRE

    BENAZZI, FRANCO

    2006-01-01

    The current subtyping of depression is based on the Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision (DSM-IV-TR) categorical division of bipolar and depressive disorders. Current evidence, however, supports a dimensional approach to depression, as a continuum/spectrum of overlapping disorders, ranging from bipolar I depression to major depressive disorder. Types of depression which have recently been the focus of most research will be reviewed ; bipolar II depressi...

  2. Quetiapine versus aripiprazole in children and adolescents with psychosis - protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial

    DEFF Research Database (Denmark)

    Pagsberg, Anne Katrine; Jeppesen, Pia; Klauber, Dea Gowers;

    2014-01-01

    weeks after randomisation. The primary outcome is change in the positive symptom score of the Positive and Negative Syndrome Scale. The recruitment period is 2010-2014. DISCUSSION: Antipsychotics are currently the only available pharmacologic treatments for psychotic disorders. However, information......BACKGROUND: The evidence for choices between antipsychotics for children and adolescents with schizophrenia and other psychotic disorders is limited. The main objective of the Tolerability and Efficacy of Antipsychotics (TEA) trial is to compare the benefits and harms of quetiapine versus...... aripiprazole in children and adolescents with psychosis in order to inform rational, effective and safe treatment selections. METHODS/DESIGN: The TEA trial is a Danish investigator-initiated, independently funded, multi-centre, randomised, blinded clinical trial. Based on sample size estimation, 112 patients...

  3. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia

    Directory of Open Access Journals (Sweden)

    Piantato Ennio

    2009-05-01

    Full Text Available Abstract Background One third to two thirds of people with schizophrenia have persistent psychotic symptoms despite clozapine treatment. Under real-world circumstances, the need to provide effective therapeutic interventions to patients who do not have an optimal response to clozapine has been cited as the most common reason for simultaneously prescribing a second antipsychotic drug in combination treatment strategies. In a clinical area where the pressing need of providing therapeutic answers has progressively increased the occurrence of antipsychotic polypharmacy, despite the lack of robust evidence of its efficacy, we sought to implement a pre-planned protocol where two alternative therapeutic answers are systematically provided and evaluated within the context of a pragmatic, multicentre, independent randomised study. Methods/Design The principal clinical question to be answered by the present project is the relative efficacy and tolerability of combination treatment with clozapine plus aripiprazole compared with combination treatment with clozapine plus haloperidol in patients with an incomplete response to treatment with clozapine over an appropriate period of time. This project is a prospective, multicentre, randomized, parallel-group, superiority trial that follow patients over a period of 12 months. Withdrawal from allocated treatment within 3 months is the primary outcome. Discussion The implementation of the protocol presented here shows that it is possible to create a network of community psychiatric services that accept the idea of using their everyday clinical practice to produce randomised knowledge. The employed pragmatic attitude allowed to randomly allocate more than 100 individuals, which means that this study is the largest antipsychotic combination trial conducted so far in Western countries. We expect that the current project, by generating evidence on whether it is clinically useful to combine clozapine with aripiprazole

  4. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia

    Science.gov (United States)

    Nosè, Michela; Accordini, Simone; Artioli, Paola; Barale, Francesco; Barbui, Corrado; Beneduce, Rossella; Berardi, Domenico; Bertolazzi, Gerardo; Biancosino, Bruno; Bisogno, Alfredo; Bivi, Raffaella; Bogetto, Filippo; Boso, Marianna; Bozzani, Alberto; Bucolo, Piera; Casale, Marcello; Cascone, Liliana; Ciammella, Luisa; Cicolini, Alessia; Cipresso, Gabriele; Cipriani, Andrea; Colombo, Paola; Dal Santo, Barbara; De Francesco, Michele; Di Lorenzo, Giorgio; Di Munzio, Walter; Ducci, Giuseppe; Erlicher, Arcadio; Esposito, Eleonora; Ferrannini, Luigi; Ferrato, Farida; Ferro, Antonio; Fragomeno, Nicoletta; Parise, Vincenzo Fricchione; Frova, Maria; Gardellin, Francesco; Garzotto, Nicola; Giambartolomei, Andrea; Giupponi, Giancarlo; Grassi, Luigi; Grazian, Natalia; Grecu, Lorella; Guerrini, Gualtiero; Laddomada, Francesco; Lazzarin, Ermanna; Lintas, Camilla; Malchiodi, Francesca; Malvini, Lara; Marchiaro, Livio; Marsilio, Alessandra; Mauri, Massimo Carlo; Mautone, Antonio; Menchetti, Marco; Migliorini, Giuseppe; Mollica, Marco; Moretti, Daniele; Mulè, Serena; Nicholau, Stylianos; Nosè, Flavio; Occhionero, Guglielmo; Pacilli, Anna Maria; Pecchioli, Stefania; Percudani, Mauro; Piantato, Ennio; Piazza, Carlo; Pontarollo, Francesco; Pycha, Roger; Quartesan, Roberto; Rillosi, Luciana; Risso, Francesco; Rizzo, Raffella; Rocca, Paola; Roma, Stefania; Rossattini, Matteo; Rossi, Giuseppe; Rossi, Giovanni; Sala, Alessandra; Santilli, Claudio; Saraò, Giuseppe; Sarnicola, Antonio; Sartore, Francesca; Scarone, Silvio; Sciarma, Tiziana; Siracusano, Alberto; Strizzolo, Stefania; Tansella, Michele; Targa, Gino; Tasser, Annamarie; Tomasi, Rodolfo; Travaglini, Rossana; Veronese, Antonio; Ziero, Simona

    2009-01-01

    Background One third to two thirds of people with schizophrenia have persistent psychotic symptoms despite clozapine treatment. Under real-world circumstances, the need to provide effective therapeutic interventions to patients who do not have an optimal response to clozapine has been cited as the most common reason for simultaneously prescribing a second antipsychotic drug in combination treatment strategies. In a clinical area where the pressing need of providing therapeutic answers has progressively increased the occurrence of antipsychotic polypharmacy, despite the lack of robust evidence of its efficacy, we sought to implement a pre-planned protocol where two alternative therapeutic answers are systematically provided and evaluated within the context of a pragmatic, multicentre, independent randomised study. Methods/Design The principal clinical question to be answered by the present project is the relative efficacy and tolerability of combination treatment with clozapine plus aripiprazole compared with combination treatment with clozapine plus haloperidol in patients with an incomplete response to treatment with clozapine over an appropriate period of time. This project is a prospective, multicentre, randomized, parallel-group, superiority trial that follow patients over a period of 12 months. Withdrawal from allocated treatment within 3 months is the primary outcome. Discussion The implementation of the protocol presented here shows that it is possible to create a network of community psychiatric services that accept the idea of using their everyday clinical practice to produce randomised knowledge. The employed pragmatic attitude allowed to randomly allocate more than 100 individuals, which means that this study is the largest antipsychotic combination trial conducted so far in Western countries. We expect that the current project, by generating evidence on whether it is clinically useful to combine clozapine with aripiprazole rather than with haloperidol

  5. Study on Improvement of Empathy Nursing on Emotion of Depression Patients%共情护理对抑郁症患者情绪的改善研究

    Institute of Scientific and Technical Information of China (English)

    王凤梅

    2015-01-01

    目的:研究共情护理在抑郁症患者中的应用及对患者生活质量的改善效果。方法入选我院80例符合抑郁诊断标准的住院患者,随机分为两组,对照组和观察组各40例,对照组给予常规护理,观察组在常规护理基础上给予共情护理,比较两组患者护理前后的生活质量水平。结果根据抑郁自评量表,对照组与观察组护理前抑郁评分无统计学差异(P>0.05),对照组护理后抑郁评分低于护理前,但无统计学差异(P>0.05),观察组护理前后抑郁评分差异具有统计学意义(P<0.05)。观察组生活质量评分表得分均高于对照组(P<0.05)。结论共情护理模式应用于抑郁症患者的护理中,可以提高患者的生活质量,增强治疗效果。%Objective To study the application of empathy nursing in patients with depression and the effect of improving the life quality of patients. Methods Selected 80 cases in our hospital inpatients with depression diagnosis standard, the control group was given conventional nursing, the observation group on the basis of conventional care giving empathy nursing, life quality level were compared between the two groups before and after nursing. Results According to the self rating depression scale, the control group and the observation group care before the depression scores had no statistical difference (P>0.05), the control group after the depression score lower than the nursing care before, but the difference was not statistically signiifcant (P>0.05), observe the depression score between the groups before and after care was statistically signiifcant (P<0.05). The observation group quality of life score were higher than the control group (P<0.05). Conclusion Empathy nursing model applied in nursing care of patients with depression, can improve the patient's quality of life, enhance the therapeutic effect.

  6. 音乐疗法改善女性恶性肿瘤患者焦虑及抑郁心理的效果%Effects of Music Therapy in Improving Anxiety and Depression for Female Malignant Tumor Patients

    Institute of Scientific and Technical Information of China (English)

    李小妹; 周凯娜

    2011-01-01

    Objective To explore the effect of music therapy in improving anxiety and depression for patients with breast or cervical cancer. Methods Totally 240 patients with breast cancer or cervical cancer were recruited and randomly allocated to the intervention group(n = 120) and control group(n = 120). State-trait anxiety inventory(STAI) and self-rating depression scale(SDS) were used as data collection instruments. Based on the routine nursing care,patients of the intervention group accepted music therapy( music listening) , twice a day (one is in the early morning and the other is in the evening) ,30min per session from the first day before surgery to the third month after surgery; whereas the control group patients only received the routine nursing care. The scores of STAI and SDS were compared on the day before surgery, and the 30 d,60 d,90 d after surgery respectively. Results The scores of anxiety and depression at 30 d, 60 d,90 d after surgery showed a downward trend over time in both groups. The scores of anxiety and depression in the intervention group were significantly lower than those in the control group. Linear mixed model analysis of repeated measurements showed significant differences on anxiety and depression score at different intervals(P<0. 01) as well as an interaction effect between the two groups(P<0. 01). Conclusion Music therapy can improve the negative psychological state of anxiety and depression for patients with breast cancer or cervical cancer, and have satisfied measure time and group effects and long-term therapeutic effects.%目的 探讨音乐疗法改善乳腺癌及宫颈癌患者焦虑及抑郁心理的作用.方法 将240例乳腺癌及宫颈癌患者采用随机数字表法分为干预组和对照组各120例,干预组患者于术后第1天起在常规护理基础上接受音乐疗法(聆听法),每日2次(晨起和晚睡前),每次30 min,持续至术后3个月;对照组接受常规护理.比较两组患者术前1d和术后30、60

  7. Depression in Cancer Patients

    Directory of Open Access Journals (Sweden)

    Beyhan Bag

    2014-06-01

    Full Text Available It is not enough to consider treatment and care depression in the oncology that is the most common psychiatric illness in cancer patient affects of cancer treatment and the patient`s quality of life negatively, which is determined through researches in the field. With development of psycho-oncology it has been demonstrated to establish an important link between the cancer patient`s treatment as well as psycho-social support for the patient and psychiatric treatment and care for the if it is needed. With this connection between them it has been proposed to use of bio-psycho-social-model in cancer patient to improve their care. To achieve this goal, it is expected from medical personnel to realize patients psychosocial need und if he/she has a psychiatric disorders or syndromes. For the medical personnel that work in oncology services, it is inevitable to organize in order to raise the awareness of depression in the cancer patients. In the present study, it is focused on raising the awareness of depression in cancer patient for the medical personnel. [Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry 2014; 6(2.000: 186-198

  8. Depression and Internal Medicine

    Directory of Open Access Journals (Sweden)

    Domenico Panuccio

    2013-05-01

    Full Text Available BACKGROUND Depression is 2-4 times more frequent in medically ill patients than in the general population, it significantly undermines the quality of life and makes prognosis worse in terms of morbidity and mortality. Nevertheless the majority of cases are not recognized or appropriately treated. A growing body of evidence suggests that mood disorders and many medical illnesses are linked in a bidirectional way by several biological mechanisms. Autonomic function changes, hyperactivity of the hypothalamic-pituitary-adrenal axis, increases in plasma cortisol, elevated levels of proinflammatory cytokines, increased platelet activation and hypercoagulability, all of them occur in patients with depression and all of them are causal factors in development and progression of atherothrombotic lesions or they are implicated in the pathogenesis of neoplasm and other illness such as chronic pain, chronic obstructive pulmonary disease, rheumatoid arthritis and so on. CONCLUSIONS Although antidepressant use has not been shown to reduce mortality rates in patients with medical illness, it alleviates depression, improves the quality of life and reduces morbidity. Clinicians should be aware of this association and should make an effort in detecting and treating not only biological illness but also mood disorders.

  9. The effect of empathy nursing on improvement of depressive emotion and life function in depressive patients%共情护理对抑郁症患者抑郁情绪及生活功能的改善作用

    Institute of Scientific and Technical Information of China (English)

    马洪霞; 陈圣霞; 李遵清; 李织若

    2012-01-01

    Objective To explore the effect of empathy nursing on depressive emotion and life function in depressive patients and to improve treatment and nurse effect.Method Sixties depressive inpatients treated with antidepressive drugs were randomly assigned to receive general nursing and health education ( experimental group 31 ) and empathy nursing (control group 29).Hamilton Depression Scale (HAMD),Nurses'observation scale for inpatient evaluation (NOSIE) and the hospital nursing work satisfaction questionnaire were used before and after intervention to evaluate the clinical and nursing effects of two groups.Results After interventions,the total score of HAMD was ( 16.7 ± 3.2) in experimental group and (20.2 ± 3.6) in control group,with significant difference between two groups.The social ability factor of score of NOSIE was (9.78 ± 2.13 ) in experimental group and ( 13.32 ± 3.22) in control group,and the scores of 3 other factors of NOSIE in experimental group was obviously lower than that in control group.The score ( 121.37 ± 11.25 ) of nursing work satisfaction in experimental group was obviously higher than that( 113.26 ± 9.72) in control group ( t =2.98).Conclusions Empathy nursing can improve depressive emotion and life function of patients with depression,and improve nursing work satisfaction.%目的 探讨共情护理对抑郁症患者的抑郁情绪及生活功能的改善作用,为抑郁症患者的治疗及护理提供客观依据.方法 60例住院抑郁症患者分为研究组(31例)和对照组(29例),研究组实施共情护理,对照组实施普通护理,干预时间为4周,干预前后,采用汉密顿抑郁量表(HAMD)、住院患者护理观察量表(NOSIE)、医院护理工作满意度调查表评定两组临床及护理效果.结果 干预后,研究组和对照组HAMD总分分别为(16.7±3.2)分、(20.2±3.6)分,差异具有显著性.干预后,研究组和对照组NOS-IE中社会能力因子分分别为(9.78±2.13)分、(13.32±3.22)分,差异

  10. Not all partial dopamine D2 receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse

    Directory of Open Access Journals (Sweden)

    Athan Spiros

    2010-09-01

    Full Text Available Athan Spiros1, Robert Carr1, Hugo Geerts1,21In Silico Biosciences, Berwyn, PA, USA; 2School of Medicine, University of Pennsylvania, PA, USAAbstract: Species differences in physiology and unique active human metabolites contribute to the limited predictive value of preclinical rodent models for many central nervous system (CNS drugs. In order to explore possible drivers for this translational disconnect, we developed a computer model of a dopaminergic synapse that simulates the competition among three agents and their binding to pre- and postsynaptic receptors, based on the affinities for their targets and their actual concentrations. The model includes presynaptic autoreceptor effects on neurotransmitter release and modulation by presynaptic firing frequency and is calibrated with actual experimental data on free dopamine levels in the striatum of the rodent and the primate. Using this model, we simulated the postsynaptic dopamine D2 receptor activation levels of bifeprunox and aripiprazole, two relatively similar dopamine D2 receptor agonists. The results indicate a substantial difference in dose–response for the two compounds when applying primate calibration parameters as opposed to rodent calibration parameters. In addition, when introducing the major human and rodent metabolites of aripiprazole with their specific pharmacological activities, the model predicts that while bifeprunox would result in a higher postsynaptic D2 receptor antagonism in the rodent, aripiprazole would result in a higher D2 receptor antagonism in the primate model. Furthermore, only the highest dose of aripiprazole, but not bifeprunox, reaches postsynaptic functional D2 receptor antagonism similar to 4 mg haloperidol in the primate model. The model further identifies a limited optimal window of functionality for dopamine D2 receptor partial agonists. These results suggest that computer modeling of key CNS processes, using well-validated calibration paradigms, can

  11. The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms

    DEFF Research Database (Denmark)

    Voigt Hansen, Melissa; Danielsen, A K; Hageman, I;

    2014-01-01

    Circadian- and sleep disturbances may be central for understanding the pathophysiology and treatment of depression. The effect of melatonin on depression/depressive symptoms has been investigated previously. This systematic review assesses the current evidence of a therapeutic- and prophylactic...... effect of melatonin in adult patients against depression or depressive symptoms. A search was performed in The Cochrane Library, PubMed, EMBASE and PsycINFO for published trials on November 14th 2013. Inclusion criteria were English language, RCTs or crossover trials. Our outcome was measurement of...... meta-analyses. Melatonin doses varied from 0.5-6 mg daily and the length of follow-up varied from 2 weeks to 3.5 years. Three studies were done on patients without depression at inclusion, two studies in patients with depression and five studies included a mixture. Six studies showed an improvement in...

  12. Depression and Smoking

    Science.gov (United States)

    ... Someone Quit Stress & Mood Stress & Mood Smoking & Mood Stress Depression Anger Weight Management Weight Management Smoking and Weight ... Lifestyle Healthier Lifestyle Physical Fitness Food & Nutrition Sleep, Stress & Relaxation ... » Tools » Depression Basics » Depression and Smoking Depression and Smoking Why ...

  13. Current Issues in the Classification of Psychotic Major Depression

    Science.gov (United States)

    Keller, Jennifer; Schatzberg, Alan F.; Maj, Mario

    2007-01-01

    Depression is one of the most common mental disorders worldwide. There are a number of depression subtypes, and there has been much debate about how to most accurately capture and organize the features and subtypes of major depression. We review the current state of categorizing unipolar major depression with psychotic features (psychotic major depression, PMD), including clinical, biological, and treatment aspects of the disorder. We then propose some improvements to the current unipolar major depression categorization system. Finally, we identify important issues in need of further research to help elucidate the subtype of unipolar PMD. PMID:17548842

  14. Studying depression using imaging and machine learning methods.

    Science.gov (United States)

    Patel, Meenal J; Khalaf, Alexander; Aizenstein, Howard J

    2016-01-01

    Depression is a complex clinical entity that can pose challenges for clinicians regarding both accurate diagnosis and effective timely treatment. These challenges have prompted the development of multiple machine learning methods to help improve the management of this disease. These methods utilize anatomical and physiological data acquired from neuroimaging to create models that can identify depressed patients vs. non-depressed patients and predict treatment outcomes. This article (1) presents a background on depression, imaging, and machine learning methodologies; (2) reviews methodologies of past studies that have used imaging and machine learning to study depression; and (3) suggests directions for future depression-related studies.

  15. 阿立哌唑的药理作用及治疗精神分裂症的疗效观察%Observation of the Curative Effect of Pharmacological Effects and Treatment of Mental Aripiprazole Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    刘丽红

    2015-01-01

    目的:分析阿立哌唑的药理作用,探究其治疗精神分裂症疗效。方法将67例患者分为治疗组34例和对照组33例,分别经阿立哌唑、利培酮治疗。结果两组治疗效果、PANSS评分对比(P>0.05),治疗组不良反应低于对照组(P<0.05)。结论阿立哌唑可有效治疗精神分裂症。%Objective Pharmacological analysis of aripiprazole, explore the treatment effect of schizophrenia. Methods 67 patients were divided into treatment group 34 cases and control group 33 cases, respectively, by aripiprazole risperidone in the treatment of. Results The effect of PANSS treatment, scores of two groups were compared (P>0.05), adverse reaction in the treatment group than in the control group (P<0.05). Conclusion Aripiprazole is more effective in the treatment of schizophrenia.

  16. Interaction of aripiprazole combined with clozapine in treatment of schizophrenia%阿立哌唑与氯氮平联合治疗精神分裂症的交互作用

    Institute of Scientific and Technical Information of China (English)

    陈波; 黄华利; 李玲

    2014-01-01

    Objective To discuss the interaction of aripiprazole combined with clozapine in treatment of schizo-phrenia ,in order to make suitable dose of this combination therapy explicit .Methods A total of 97 cases of schizo-phrenia diagnosed in our hospital between Oct .,2011 and May ,2013 were divided into 4 groups(low dose of aripi-prazole combined with low dose of clozapine ,low dose of aripiprazole combined with high dose of clozapine ,high dose of aripiprazole combined with low dose of clozapine ,high dose of aripiprazole combined with high dose of clozapine ) . The results of efficacy and side effects were all recorded and analyzed .Results In treatment efficacy ,high dose of aripiprazole and clozapine was the best ,when compared with other 3 groups(P<0 .05) ,low dose of aripiprazole and clozapine was the worst (P<0 .05) .On the other hand ,the incidence of side effects was highest in group of high dose of aripiprazole and clozapine ,group of high dose of aripiprazole combined with low dose of clozapine and group of low dose of aripiprazole and clozapine were better than others in safety .Conclusion The efficacy and side effects of aripi-prazole and clozapine are dose dependent ,when using these two medicines to treat schizophrenia ,the doses should be suitable to make good efficacy and avoid side effects .If the side effects are obvious ,the dose of clozapine should be de-creased ,however ,the dose of aripiprazole can be decreased extenuatorily ;If the patients can tolerate the treatment ,the doses of these two medicine can be increased .%目的:探讨阿立哌唑与氯氮平联合治疗精神分裂症的交互作用,以明确两种药物联合治疗精神分裂症时的合适剂量。方法将2011年10月至2013年5月于重庆市黔江中心医院诊治为精神分裂症的97例患者随机分为4组(低剂量阿立哌唑+低剂量氯氮平组、低剂量阿立哌唑+高剂量氯氮平组、高剂量阿立哌唑+低剂量氯氮平组、高剂量阿立

  17. A control study of SVSRT plus aripiprazole in the treatment of manic episode of bipolar disorder%丙戊酸钠缓释片联合阿立哌唑治疗双相障碍躁狂发作对照研究

    Institute of Scientific and Technical Information of China (English)

    李菲; 谭柏坚; 郭彦杨

    2016-01-01

    plus aripiprazole in the treatment of manic episode of bipolar disorder has an evident effect and could effectively improve patients ’ quality of life and sleep quality .

  18. Depression in Cognitive Impairment

    Science.gov (United States)

    Pellegrino, Laurel D.; Lyketsos, Constantine G.; Marano, Christopher M.

    2014-01-01

    Depression and cognitive disorders, including dementia and mild cognitive impairment, are common in the elderly. Depression is also a common feature of cognitive impairment although the symptoms of depression in cognitive impairment differ from depression without cognitive impairment. Pre-morbid depression approximately doubles the risk of subsequent dementia. There are two predominant, though not mutually exclusive, constructs linking pre-morbid depression to subsequent cognitive impairment: Alzheimer’s pathology and the vascular depression hypothesis. When evaluating a patient with depression and cognitive impairment, it is important to obtain caregiver input and to evaluate for alternative etiologies for depressive symptoms such as delirium. We recommend a sequential approach to the treatment of depression in dementia patients: (1) a period of watchful waiting for milder symptoms, (2) psychosocial treatment program, (3) a medication trial for more severe symptoms or failure of psychosocial interventions, and (4) possible ECT for refractory symptoms. PMID:23933974

  19. Group prevention of depression and anxiety symptoms.

    Science.gov (United States)

    Seligman, Martin E P; Schulman, Peter; Tryon, Alyssa M

    2007-06-01

    To prevent depression and anxiety, we delivered a brief, classroom-based cognitive-behavioral workshop along with ongoing Web-based materials and e-mail coaching to college students at risk for depression. At risk was defined as having mild to moderate depressive symptoms on a self-report measure of depression. Two hundred forty students were randomized into either an eight-week workshop that met in groups of 10, once per week for 2 h or into an assessment-only control group. We plan to track participants for 3 years after the workshop and here we report the 6 month preventive effects on depression and anxiety. The workshop group had significantly fewer depressive symptoms and anxiety symptoms than the control group, but there was no significant difference between the conditions on depression or anxiety episodes at 6 month follow up. The workshop group had significantly better well being than the control group, and the workshop group had significantly greater improvement in optimistic explanatory style than the control group. Improved explanatory style was a significant mediator of the prevention effects from pre- to post-workshop for depressive and anxiety symptoms, as well as for improved well being. PMID:17074301

  20. Therapieresistente Depression

    Directory of Open Access Journals (Sweden)

    Holsboer-Trachsler E

    2006-01-01

    Full Text Available In der Behandlung einer Depression wird ein Nichtansprechen auf zwei adäquate Antidepressivatherapien während je 6–8 Wochen als Therapieresistenz bezeichnet. Da häufig zu geringe Dosierungen oder eine zu kurze Behandlungsdauer die Ursache für ein Nichtansprechen sind, sollte in einem ersten Schritt die medikamentöse Therapie hinsichtlich Dauer und Dosierung, eventuell unter Einbezug von Plasmaspiegelbestimmungen, überprüft und optimiert werden. Als pharmakologische Maßnahmen werden zunächst ein Wechsel des Antidepressivums und danach eine Kombination von verschiedenen Antidepressiva mit unterschiedlichem biochemischem Wirkungsansatz empfohlen. Zeigen beide nicht den gewünschten Erfolg, so sollte zusätzlich zur bestehenden Antidepressivabehandlung eine Augmentationstherapie, primär mit Lithium und/oder dem Schilddrüsenhormon T3, durchgeführt werden. Ein neuer, vielversprechender Behandlungsansatz ist eine Augmentationstherapie mit atypischen Neuroleptika. Als akut wirkende nichtpharmakologische Zusatzmaßnahme hat sich der partielle Schlafentzug bewährt. Weitere nichtpharmakologische Strategien umfassen Psychotherapie, Elektrokrampftherapie und Vagusnervstimulationsbehandlung.

  1. Tablet-Based Education to Reduce Depression-Related Stigma

    Science.gov (United States)

    Lu, Catherine; Winkelman, Megan; Wong, Shane Shucheng

    2016-01-01

    Objectives: This study investigated the efficacy of a tablet-based multimedia education application, the Project Not Alone Depression Module, in improving depression literacy and reducing depression stigma among a community-based mental health clinic population. Methods: A total of 93 participants completed either a tablet-based multimedia…

  2. The Behavioral Treatment of Depression in Elderly Outpatients.

    Science.gov (United States)

    Gallagher, Dolores

    The behavioral view that depression results from inadequate, ineffective and/or insufficient reinforcers was explored. Since the depressed person does not act in a manner open to positive reinforcement by others, he suffers ongoing and deepening depression. The task of the therapist is to improve behavior, especially social skills, so that the…

  3. Recombinant Human Erythropoietin for Treating Treatment-Resistant Depression

    DEFF Research Database (Denmark)

    Miskowiak, Kamilla W; Vinberg, Maj; Christensen, Ellen M;

    2014-01-01

    improves mood and memory in treatment-resistant depression. Forty treatment-resistant depressed unipolar patients with Hamilton Depression Rating Scale-17 (HDRS-17) score ≥ 17 were randomized to eight weekly EPO (Eprex; 40,000 IU) or saline infusions in a double-blind, placebo-controlled, parallel...

  4. Depression severity, diet quality, and physical activity in women with obesity and depression

    OpenAIRE

    Appelhans, Bradley M.; Whited, Matthew C.; Schneider, Kristin L.; Ma, Yunsheng; Oleski, Jessica L.; Merriam, Philip A.; Waring, Molly E.; Olendzki, Barbara C.; Mann, Devin M.; OCKENE, IRA S.; Pagoto, Sherry L.

    2012-01-01

    Major depressive disorder (MDD) is prevalent in clinical weight loss settings and predicts poor weight loss outcomes. It is unknown whether the severity of depressive symptoms among those with MDD is associated with diet quality or physical activity levels. This knowledge is important for improving weight loss treatment for these patients. It was hypothesized that more severe depression is associated with poorer diet quality and lower physical activity levels among individuals with obesity an...

  5. Well-Being and the Risk of Depression under Stress

    OpenAIRE

    Faren Grant; Constance Guille; Srijan Sen

    2013-01-01

    Improving our ability to accurately predict individual risk for depression would have profound public health benefits. While there has been growing interest in understanding the relation between measures of positive emotion, such as well-being, and depression, it is not clear whether low well-being is an independent predictor of short term depression risk. We assessed whether low well-being is a risk factor for depressive symptoms. Medical internship is a well-established period of stress whe...

  6. Coping with Unexpected Events: Depression and Trauma

    Science.gov (United States)

    ... improve the lives of people who have mood disorders. The Power of Peers DBSA envisions wellness for people who live with depression and bipolar disorder. Because DBSA was created for and is led ...

  7. Screening for Depression In Hospitalized Pediatric Patients

    Directory of Open Access Journals (Sweden)

    Mohammad-Reza ESMAEELI

    2013-12-01

    Full Text Available Abstract How to Cite This Article: Esmaeeli M, Erfani Sayar R, Saghebi A, Elmi Saghi, Rahmani Sh, Elmi S, Rabbani Javadi A. Screening for Depression in Hospitalized Pediatric Patients. Iran J Child Neurol. 2014 Winter; 8(1:47-51. Objective In chronically ill children who are hospitalized, many mood changes occur. For example, in children with cancer or renal failure, prolonged hospitalization and chemotherapy can lead to depression. With the improved survival of childhood malignancies, the effect of treatment on child’s psychosocial well-being becomes increasingly relevant. In this study, we examined the prevalence of depression in hospitalized children with chronic and acute conditions in Dr Sheikh Pediatrics Hospital in Mashhad. Materials & Methods After receiving the approval from the Ethics Committee of Mashhad University of Medical Sciences, we did this cross-sectional descriptive study, from April to June 2012 in Dr Sheikh Pediatric Hospital in Mashhad. Ninety children, aged between 8 to 16 years, were screened for depression. The sampling method was census. Children with a history of depressive or other mental disorders were excluded. Three groups of children (children with chronic renal disease, malignancy, and acute disease were evaluated for depression using standard Children Depression Inventory Questionnaire (CDI. Two specifically trained nurses with the supervision of a psychiatrist filled out the questionnaires at patients’ bedside. Depression scores were then analyzed by SPSS software. Results Of 90 children, 43(47.7% were male and 47(52.2% were female. The Children’s mean age was 11±2.3 years, and the mean length of hospitalization was 8±5.3 days. Depression was detected in various degrees in 63% of patients (N=57, and 36.6% of children (N=32 had no symptoms of depression. Severe depression was not seen in any of the patients with acute illness. More than half of patients with cancer and chronic kidney disease had

  8. 阿立哌唑与氯丙嗪治疗精神分裂症的安全性系统评价%Systematic review the safety of aripiprazole versus clorpromazine in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    杜彪; 李庆平; 母波; 刘福; 周春阳

    2012-01-01

    目的 评价阿立哌唑与氯丙嗪治疗精神分裂症的不良反应的差异.方法 检索国内阿立哌唑与氯丙嗪对照研究治疗精神分裂症的文献,用系统评价方法对10篇文献评估.结果 药物不良反应发生率2组差异有统计学意义(P<0.05).其中,发生头痛、失眠,阿立哌唑组明显比氯丙嗪组多(P<0.05);发生口干、震颤、静坐不能、肌强直、便秘、肝功能异常、心动过速、体重增加、直立性低血压、视物模糊、嗜睡、心电图异常、月经失调、溢乳不良反应,氯丙嗪组明显比阿立哌唑组多(P<0.05).结论 阿立哌唑组发生不良反应的总体风险低于氯丙嗪.%Objective To study the difference in adverse drug reaction ( ADR) between aripiprazole and clorpromazine in the treatment of schizophrenia. Methods A total of 10 paper about control study comparing aripiprazole with clorpromazine in treatment of schizophrenia retrieved were subjected to system evaluation. Results There was significant difference in ADR incidences between the two groups ( P < 0. 05 ). The incidences of ADR ( such as headache insomnia) in aripiprazole group were significantly higher than in clorpromazine group (P < 0. 05 ). The incidences of ADR ( such as dry mouth, tremor, akathisia, rigidity, constipation, abnormal, liver function, tachycardia, weight gain, orthostatic hypotension, blurred vision, drowsiness, menstruation disturbance syndrome) in clorpromazine group were significantly higher than in aripiprazole group ( P < 0. 05 ). Conclusion Aripiprazole has less overall risk of ADR than clorpromazine for the treatment of schizophrenia.

  9. 氨磺必利与阿立哌唑治疗首发精神分裂症对照研究%A Comparative Study of Amisulpride and Aripiprazole in the Treatment of First Episode Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    仇红杰

    2014-01-01

    目的:探讨氨磺必利与阿立哌唑治疗首发精神分裂症的临床疗效与安全性。方法:将75例首发精神分裂症患者按照随机数字表法分成两组,氨磺必利组37例,阿立哌唑组38例,治疗8周。采用阳性与阴性症状量表(PANSS)评定疗效,采用治疗中出现的症状量表(TESS)评定不良反应。结果:氨磺必利组的治疗总有效率为89.19%,阿立哌唑组为92.11%,两组比较差异无统计学意义(P>0.05)。治疗第4、6、8周PANSS总分及各因子评分两组比较差异均无统计学意义(P>0.05)。结论:氨磺必利与阿立哌唑治疗首发精神分裂症均有良好效果,不良反应均较少。%Objective:To investigate the efficacy and safety of Amisulpride and Aripiprazole in the treatment of first episode schizophrenia. Method:75 patients of first opisode schizoprenia were randomly divided into two groups(amisulpride 37,aripiprazole 38).Both of the amisulpride and aripiprazole were administered to two groups respectively for 8 weeks. Their symptoms were assessed with PANSS and their side effects were assessed with TESS before and after the treatment. Result:The total cure rates were 89.19%in amisulpride group and 92.11%in aripiprazole group,with no significant difference between the two groups(P>0.05). PANSS score and each factor score in treatment of 4,6,8 weeks between the two groups had no statistical significance(P>0.05). Conclusion:Both of the amisulpride and aripiprazole have notable curative effect with less side-effect in the treatment of first episode schizophrenia.

  10. Pharmacist interventions in depressed patients

    OpenAIRE

    Rubio Valera, Maria

    2012-01-01

    1) Objectives: - To systematically evaluate the effectiveness of pharmacist care compared with usual care (UC) on improving adherence to antidepressants in depressed outpatients. - To evaluate the effectiveness and cost‐effectiveness of a community pharmacist intervention (CPI) compared to UC in the improvement of adherence to antidepressants and patient wellbeing in a primary care population initiating treatment with antidepressants. 2) Methods: A systematic review and meta‐a...

  11. Depression among type 2 diabetic patients

    Directory of Open Access Journals (Sweden)

    Taghreed Mohamed El-Shafie ,Entesar Omar A. El-Saghier and Iman ,Kamal Ramadan

    2011-07-01

    Full Text Available Background & Objectives: Diabetes and depression are highly prevalent conditions and have significant impact on health outcomes. The combination of depression with type 2 diabetes is a public health problem. Therefore, we aimed to assess some socio-demographic characteristics of type 2 diabetes and to investigate the relationship between type 2 diabetes and depression among patients aged from 40 to 60 years old. Methods: 125 patients diagnosed with type 2 diabetes attending diabetes clinics in the Al-Zahraa hospital were invited to participate in this cross-sectional study. Patients were interviewed using structured questionnaires to gather data on socio-demographics, clinical, self care compliance, medication usage, and diabetes complications. The MADRS was administered as a screening tool for depression level evaluation. Binary logistic regression model was used to examine association between predictor variables and risk of depression among diagnosed type 2 diabetes at 95% C.I. and P < 0.05. Results: One hundred and twenty five participants completed the interview. More than half of participants were females (58.4% and the mean age was 48 (sd = 5.9, 47.2% hypertensive, and 59.2% on insulin. More than two third (74.4% of patients were depressed; (24.8% mild, 37.6% moderate and 12% severely depressed. Almost four out of five patients (88.8% had diabetes complications, Depression was strongly associated with neuropathy, age, retinopathy, sex and cardiac complications. However, the likelihood of depression was not associated with nephropathy, hypertension and sexual dysfunction. Conclusion: The current study demonstrates a strong correlation between depression and diabetes particularly complications. In particular, patients who are depressed tended to have poorer self-care, more severe physical symptoms and were less likely to adhere to prescribed care regimens. These findings raise the possibility that improving the mental health as part of a

  12. Depression, anxiety, hostility and hysterectomy.

    Science.gov (United States)

    Ewalds-Kvist, S Béatrice M; Hirvonen, Toivo; Kvist, Mårten; Lertola, Kaarlo; Niemelä, Pirkko

    2005-09-01

    Sixty-five women (aged 32 - 54 yrs) were assessed at 2 months before to 8 months after total abdominal hysterectomy on four separate occasions. Beck's Depression Inventory (BDI), Taylor's Manifest Anxiety Scale (TMAS), the Buss-Durkee Hostility Inventory (BDHI), Measurement of Masculinity-Femininity (MF), Likert scales and semantic differentials for psychological, somatic and sexual factors varied as assessment tools. High-dysphoric and low-dysphoric women were compared with regard to hysterectomy outcomes. Married nulliparae suffered from enhanced depression post-surgery. Pre-surgery anxiety, back pain and lack of dyspareunia contributed to post-surgery anxiety. Pre-surgery anxiety was related to life crises. Pre- and post-surgery hostility occurred in conjunction with poor sexual gratification. Post-hysterectomy health improved, but quality of sexual relationship was impaired. Partner support and knowledge counteracted hysterectomy aftermath. Post-hysterectomy symptoms constituted a continuum to pre-surgery signs of depression, anxiety or hostility.

  13. Diagnosis of depression among adolescents

    DEFF Research Database (Denmark)

    Haavet, Ole Rikard; Christensen, Kaj Aage Sparle; Sirpal, Manjit;

    2007-01-01

    BACKGROUND: The objective of the study is to improve general practitioners' diagnoses of adolescent depression. Major depression is ranked fourth in the worldwide disability impact. METHOD: Validation of 1) three key questions, 2) SCL-dep6, 3) SCL-10, 4) 9 other SCL questions and 5) WHO-5...... in a clinical study among adolescents. The Composite International Diagnostic Interview (CIDI) is to be used as the gold standard interview. The project is a GP multicenter study to be conducted in both Norway and Denmark. Inclusion criteria are age (14-16) and fluency in the Norwegian and Danish language....... A number of GPs will be recruited from both countries and at least 162 adolescents will be enrolled in the study from the patient lists of the GPs in each country, giving a total of at least 323 adolescent participants. DISCUSSION: The proportion of adolescents suffering from depressive disorders also...

  14. Dementia: Depression and Alzheimer's Disease

    Science.gov (United States)

    MENU Return to Web version Dementia | Depression and Alzheimer’s Disease What is depression? When doctors talk about depression, they mean the medical illness called major depression. Someone who has ...

  15. Recognizing teen depression

    Science.gov (United States)

    ... page: //medlineplus.gov/ency/patientinstructions/000648.htm Recognizing teen depression To use the sharing features on this ... teen's life. Be Aware of the Risk for Teen Depression Your teen is more at risk for ...

  16. Depression and cardiovascular disease.

    Science.gov (United States)

    Bradley, Steven M; Rumsfeld, John S

    2015-10-01

    There is a wealth of evidence linking depression to increased risk for cardiovascular disease (CVD) and worse outcomes among patients with known CVD. In addition, there are safe and effective treatments for depression. Despite this, depression remains under-recognized and undertreated in patients at risk for or living with CVD. In this review, we first summarize the evidence linking depression to increased risk of CVD and worse patient outcomes. We then review the mechanisms by which depression may contribute to cardiovascular risk and poor cardiovascular outcomes. We then summarize prior studies of depression treatment on cardiovascular outcomes. Finally, we offer guidance in the identification and management of depression among CVD populations. Given that 1 in 4 CVD patients has concurrent depression, application of these best-practices will assist providers in achieving optimal outcomes for their CVD patients. PMID:25850976

  17. Depression Disturbs Germany

    Institute of Scientific and Technical Information of China (English)

    2011-01-01

    The suicide of Robert Enke,the goalkeeper of the Germany national football team who had battled depression for years,stunned the country and cast depression into the national spotlight as a disturbing disease.

  18. Depression - stopping your medicines

    Science.gov (United States)

    ... prescription medicines you may take to help with depression, anxiety, or pain. Like any medicine, there are ... at risk for: Returning symptoms, such as severe depression Increased risk of suicide (for some people) Withdrawal ...

  19. Depression - stopping your medicines

    Science.gov (United States)

    ... this page: //medlineplus.gov/ency/patientinstructions/000570.htm Depression - stopping your medicines To use the sharing features ... prescription medicines you may take to help with depression, anxiety, or pain. Like any medicine, there are ...

  20. Depression and Pregnancy

    Science.gov (United States)

    ... best live chat Live Help Fact Sheets Share Depression and Pregnancy Thursday, 20 March 2014 In every ... risk. This sheet talks about whether exposure to depression may increase the risk for birth defects over ...

  1. Learning about depression

    Science.gov (United States)

    ... medlineplus.gov/ency/patientinstructions/000325.htm Learning about depression To use the sharing features on this page, ... trigger or reason. What Are the Signs of Depression? You may notice some or all of the ...

  2. Depression and Suicide Risk

    Science.gov (United States)

    Depression and Suicide Risk (2014) Definition: A mood disorder that causes a persistent feeling of sadness and ... i Prevalence: 1. Ranges of lifetime risk for depression: from 6.7% overall to 40% in men, ...

  3. Adjustments and Depression

    Medline Plus

    Full Text Available ... depression and adjustment to my SCI? How do I deal with depression and adjustment to my SCI? ☷ ▾ ... following an SCI? What are the secondary conditions? I have no health insurance, what are my options? ...

  4. Depression and College Students

    Science.gov (United States)

    ... other mental health issues? Reference Share Depression and College Students Download PDF Download ePub Order a free hardcopy Answers to college students’ frequently asked questions about depression Feeling moody, sad, ...

  5. Depression in Older Adults

    Science.gov (United States)

    ... Student - College Concerns Stressed or Depressed? Know the Difference Boost Your School Performance by Taking Care of You Top Ten Freshman Year Issues Alcohol, Substance Abuse and Depression Winter Break Survival Tips for College ...

  6. Depression in the Workplace

    Science.gov (United States)

    ... Balance 5 Myths About Mental Illness Support an Employee Workplace Bullying & Violence Signs of a Healthy Workplace Complementary Medicine ... depression can be successfully treated. With early recognition, intervention, and support, most employees can overcome clinical depression and pick up where ...

  7. Postpartum Depression Action Plan

    Science.gov (United States)

    MENU Return to Web version Postpartum Depression | Postpartum Depression Action Plan Patient __________________________ Physician/NP/PA __________________ Clinic ____________________________ Phone Number ____________________ Choose one area and add other areas as you begin to feel ...

  8. Adjustments and Depression

    Medline Plus

    Full Text Available ... to my SCI? How do I deal with depression and adjustment to my SCI? ☷ ▾ Page contents The ... the moment you are injured. Understanding adjustment and depression Adjustment to paralysis is a process of changing ...

  9. Frailty and Depression in Older Adults

    DEFF Research Database (Denmark)

    Brown, Patrick J; Roose, Steven P; Fieo, Robert;

    2014-01-01

    was observed for fatigue. CONCLUSION: The confluence of specific characteristics of frailty (fatigue and slow gait speed) and depressive illness is associated with an increased risk of death in older adults; this association is particularly strong in older depressed women. Future research should investigate......OBJECTIVE: To identify salient characteristics of frailty that increase risk of death in depressed elders. METHODS: Data were from the Nordic Research on Ageing Study from research sites in Denmark, Sweden, and Finland. Participants were 1,027 adults aged 75 years (436 men and 591 women). Time...... whether multimodal interventions targeting depressive illness, mobility deficits, and fatigue can decrease mortality and improve quality of life in older depressed individuals with characteristics of the syndrome of frailty....

  10. Mechanisms Underlying Neurocognitive Dysfunctions in Recurrent Major Depression

    Science.gov (United States)

    Gałecki, Piotr; Talarowska, Monika; Anderson, George; Berk, Michael; Maes, Michael

    2015-01-01

    Recent work shows that depression is intimately associated with changes in cognitive functioning, including memory, attention, verbal fluency, and other aspects of higher-order cognitive processing. Changes in cognitive functioning are more likely to occur when depressive episodes are recurrent and to abate to some degree during periods of remission. However, with accumulating frequency and duration of depressive episodes, cognitive deficits can become enduring, being evident even when mood improves. Such changes in cognitive functioning give depression links to mild cognitive impairment and thereby with neurodegenerative conditions, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, and multiple sclerosis. Depression may then be conceptualized on a dimension of depression – mild cognitive impairment – dementia. The biological underpinnings of depression have substantial overlaps with those of neurodegenerative conditions, including reduced neurogenesis, increased apoptosis, reactive oxygen species, tryptophan catabolites, autoimmunity, and immune-inflammatory processes, as well as decreased antioxidant defenses. These evolving changes over the course of depressive episodes drive the association of depression with neurodegenerative conditions. As such, the changes in cognitive functioning in depression have important consequences for the treatment of depression and in reconceptualizing the role of depression in wider neuroprogressive conditions. Here we review the data on changes in cognitive functioning in recurrent major depression and their association with other central conditions. PMID:26017336

  11. Depression in adolescence

    OpenAIRE

    Thapar, Anita; Collishaw, Stephan; Pine, Daniel S.; Thapar, Ajay K

    2012-01-01

    Unipolar depressive disorder in adolescence is common worldwide but often unrecognised. The incidence, notably in girls, rises sharply after puberty and, by the end of adolescence, the 1 year prevalence rate exceeds 4%. The burden is highest in low-income and middle-income countries. Depression is associated with sub stantial present and future morbidity, and heightens suicide risk. The strongest risk factors for depression in adolescents are a family history of depression and exposure to psy...

  12. Method of treating depression

    Science.gov (United States)

    Henn, Fritz

    2012-01-24

    Methods for treatment of depression-related mood disorders in mammals, particularly humans are disclosed. The methods of the invention include administration of compounds capable of enhancing glutamate transporter activity in the brain of mammals suffering from depression. ATP-sensitive K.sup.+ channel openers and .beta.-lactam antibiotics are used to enhance glutamate transport and to treat depression-related mood disorders and depressive symptoms.

  13. Management of Postpartum Depression

    OpenAIRE

    Guille, Constance; Newman, Roger; Fryml, Leah D.; Lifton, Clay K.; EPPERSON, C. NEILL

    2013-01-01

    Postpartum depression, now termed peripartum depression by the DSM-V, is one of the most common complications in the postpartum period and has potentially significant negative consequences for mothers and their families. This article highlights common clinical challenges in the treatment of peripartum depression and reviews the evidence for currently available treatment options. Psychotherapy is the first-line treatment options for women with mild-to-moderate peripartum depression. Antidepres...

  14. Measuring psychotic depression

    DEFF Research Database (Denmark)

    Østergaard, Søren Dinesen; Meyers, B S; Flint, A J;

    Psychotic depression (PD) is a highly debilitating condition, which needs intensive monitoring. However, there is no established rating scale for evaluating the severity of PD. The aim of this analysis was to assess the psychometric properties of established depression rating scales and a number...... of new composite rating scales, covering both depressive and psychotic symptoms, in relation to PD....

  15. Prevention of Depression.

    Science.gov (United States)

    Compas, Bruce E.; Connor, Jennifer; Wadsworth, Martha

    Substantial numbers of children and adolescents experience symptoms of sadness, dysphoria, and other characteristics associated with depression. The nature of depression in children and adolescents has presented challenges in identification and definition. This chapter reviews research on depression in children and adolescents. Three current…

  16. Understanding Depression (For Parents)

    Science.gov (United States)

    ... Story" 5 Things to Know About Zika & Pregnancy Depression KidsHealth > For Parents > Depression Print A A A ... to Help en español Comprender la depresión About Depression It's normal for kids to feel sad, down, ...

  17. What is depression?

    DEFF Research Database (Denmark)

    Sofie Davidsen, Annette; Fosgerau, Christina Fogtmann

    2014-01-01

    on the usefulness of the concept of depression and in their language and narrative styles when telling stories about depressed patients. The differences were captured in three polarities which expressed the range of experiences in the two groups. Psychiatrists considered the diagnosis of depression as a pragmatic...

  18. [Symptomatic and concurrent depressions].

    Science.gov (United States)

    Terra, J L

    1999-04-01

    The symptomatic and concurrent depressions description need to resort to comorbidity and symptomatic co-occurrence concepts. Patients with depressive symptoms or in a major depressive episode may also be suffering from another nonmood psychiatric disorders as alcoholism, anxiety or eating disorders. Many general medical conditions which are link with depression are illustrated with the examples of cancer, coronary artery disease, endocrinologic diseases, dementia, stroke and chronic fatigue syndrome. When depression and another psychiatric or medical conditions occur together, it is important to provide to the practitioner guidelines for the decision to treat one of the two disorders. This paper contains an example of decisional algorithm. PMID:10337217

  19. Interpersonal psychotherapy (IPT) in major depressive disorder.

    Science.gov (United States)

    Brakemeier, Eva-Lotta; Frase, Lukas

    2012-11-01

    In this article, we will introduce interpersonal psychotherapy as an effective short-term treatment strategy in major depression. In IPT, a reciprocal relationship between interpersonal problems and depressive symptoms is regarded as important in the onset and as a maintaining factor of depressive disorders. Therefore, interpersonal problems are the main therapeutic targets of this approach. Four interpersonal problem areas are defined, which include interpersonal role disputes, role transitions, complicated bereavement, and interpersonal deficits. Patients are helped to break the interactions between depressive symptoms and their individual interpersonal difficulties. The goals are to achieve a reduction in depressive symptoms and an improvement in interpersonal functioning through improved communication, expression of affect, and proactive engagement with the current interpersonal network. The efficacy of this focused and structured psychotherapy in the treatment of acute unipolar major depressive disorder is summarized. This article outlines the background of interpersonal psychotherapy, the process of therapy, efficacy, and the expansion of the evidence base to different subgroups of depressed patients. PMID:22955493

  20. Interpersonal psychotherapy (IPT) in major depressive disorder.

    Science.gov (United States)

    Brakemeier, Eva-Lotta; Frase, Lukas

    2012-11-01

    In this article, we will introduce interpersonal psychotherapy as an effective short-term treatment strategy in major depression. In IPT, a reciprocal relationship between interpersonal problems and depressive symptoms is regarded as important in the onset and as a maintaining factor of depressive disorders. Therefore, interpersonal problems are the main therapeutic targets of this approach. Four interpersonal problem areas are defined, which include interpersonal role disputes, role transitions, complicated bereavement, and interpersonal deficits. Patients are helped to break the interactions between depressive symptoms and their individual interpersonal difficulties. The goals are to achieve a reduction in depressive symptoms and an improvement in interpersonal functioning through improved communication, expression of affect, and proactive engagement with the current interpersonal network. The efficacy of this focused and structured psychotherapy in the treatment of acute unipolar major depressive disorder is summarized. This article outlines the background of interpersonal psychotherapy, the process of therapy, efficacy, and the expansion of the evidence base to different subgroups of depressed patients.

  1. 阿立哌唑与喹硫平治疗精神分裂症的疗效和安全性%Efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    王占敏; 宓为峰; 王晓志; 卢天兰; 付艺; 王雪芹; 郝晓楠; 李玲芝; 张鸿燕

    2012-01-01

    Objective To investigate the clinical efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia. Methods A randomized, controlled clinical trial was designed. One hundred and sixty - nine patients with schizophrenia were randomized into aripiprazole group (n = 79, 8 weeks, 10 -30 mg ? D-1) and quetiapine group (n = 90, 8 weeks, 400 - 750 mg ? D -1 ). The positive and negative syndrome scale (PANSS) and response rate were mainly used to evaluate efficacy. The safety was assessed by using the laboratory examination, vital signs and electrocardiogram ( ECG) at the baseline, week 4, 8. Results Compared with the baseline, total scores of PANSS in both groups decreased significantly at week 4 and week 8 ( P < 0. 01 ). At week 8 of treatment the mean reduction scores of PANSS and the clinical response rates were approximate, there were no significant differences between both groups. The incidence of adverse drug reactions related to the drugs 25. 3% (20/79) in aripiprazole and 17. 7% ( 16/90) in quetiapine treatment was approximate in both groups, with lower liability for heart rate in aripiprazole than in quetiapine treatment. The triglyceride(TG) and QRS interval in aripiprazole group showed more significant differences at week 8 than the baseline ( P < 0. 05 ). But the heart rate, body mass, body mass index ( BMI) , hemoglobin ( HGB ) , total cholesterol ( TC ) and low density lipoprotein ( LDL) in quetiapine group different significantly when compared with those at baseline (P < 0. 01). Conclusion Aripiprazole and quetiapine both have good efficacy in the treatment of schizophrenia. They have similar incidence of adverse drug reaction related to the drugs.%目的 评价阿立哌唑与喹硫平治疗精神分裂症的疗效及安全性.方法 169例符合DSM-Ⅳ(第4版)精神分裂症患者,阿立哌唑组79例,剂量10~30mg·d-1;喹硫平组90例,剂量400~ 750 mg·d-1,疗程均8周.治疗前,治疗第4,8周用阳性和阴性症状

  2. Simultaneously Determination of Sertraline and Aripiprazole in Human Plasma by HPLC with UV Detection%高效液相色谱法同时测定人血浆中舍曲林与阿立哌唑浓度

    Institute of Scientific and Technical Information of China (English)

    刘文宪; 陈清霞; 周桂成; 刘伟忠; 温预关; 王广发

    2011-01-01

    目的 建立同时测定人血浆中舍曲林、阿立哌唑浓度的反相高效液相色谱法.方法 以DiamonsilTM C18反相柱(150 mm×4.6 mm,5 μm)为色谱柱,流动相为0.03 mol·L-1醋酸铵-甲醇(18:82);流速:0.8 mL·min-1;柱温:40 ℃; 检测波长:220 nm.以乙酸乙酯-二氯甲烷(80:20)为提取剂.结果 舍曲林在20.0~640.0 ng·mL-1、阿立哌唑在25.0~1 000.0 ng·mL-1浓度范围内,峰面积与其浓度呈良好线性关系;舍曲林、阿立哌唑的低、中、高3种浓度相对平均回收率分别为101.30%,98.14%,97.92%和101.60%,97.75%,98.16%;提取回收率分别为70.56%,73.87%,76.45%和71.66%,74.12%,75.26%;日内、日间RSD均<10%,分析方法的检测限10.0 ng·mL-1.舍曲林线性方程:Y=92.251X+1.61,r=0.998 6(n=7);阿立哌唑线性方程:Y=85.489X+1.27,r=0.998 9(n=7).结论 该方法灵敏、准确、简单、快速,可用于临床血浆舍曲林与阿立哌唑浓度的监测和药动学研究.%Objective To establish a method for determining the concentration of sertraline and aripiprazole in human plasma by HPLC. Methods The C18 column( 150 mmx4. 6 mm,5 |xm )was used in the reversed HPLC system, the mobile phase consisted of 0.03 mol ■ L" ammonioum-methanol( 18 '. 82 ); the flow rate was 0. 8 mL ■ min ; the detection wavelength was at 220 nm. Ethyl acetate-dichloromethane( 80 '. 20 )were used as extracting solvent. Results The calibration curves were linear in the range of 20. 0-640. 0 ng ■ mL" for sertraline,25. 0-1 000. 0 ng ■ mL" for aripiprazole,respectively. The average recoveries of sertraline and aripiprazole at low,middle and high concentrations were 101. 30% ,98. 14% ,97. 92% and 101. 60% , 97.75% ,98. 16% .respectively; the extraction recovery were 70. 56% ,73. 87% ,76. 45% and 71. 66% ,74. 12% ,75. 26% , respectively. The intra-day and inter-day variations ( RSD ) were both less than 10% ( n = 5 ). The minimum detectable concentration of method was 10.0 ng ? mL"1. The calibration

  3. A clinical comparative study in first-onset schizophrenia patients treated with Aripiprazole and Quetiapine%阿立哌唑与喹硫平治疗首发精神分裂症的临床对照研究

    Institute of Scientific and Technical Information of China (English)

    刘娜

    2012-01-01

    Objective To study the clinical effects of Aripiprazole and Quetiapine in the treatment of first -onset schizophrenia. Methods 63 adult patients who were diagnosed as schizophreniain accordance with the CCMD-3 diagnosis standard were recruited in this study. All the cases were randomized into two groups and were treated with Aripiprazole and Quetiapine for 8 weeks. The positive and negative syndrome scale (PANSS) and treatment emergent side effect scale (TESS) were used to evaluate efficacy and adverse effects respectively. Results The significant efficacy rates of Aripiprazole was 93.55%, Quetiapine was 90.63%, there was no significant difference (P > 0.05). Before and after treatment between Aripiprazole group and Quetiapine group, the PANSS score had no significant difference (P > 0.05). The level of LEP and TG was elevated which were treated by Aripiprazole, the difference was statistically significant (P < 0.05). The level of LEP, PRL, BG and TG was elevated which were treated by Quetiapine, the difference was statistically significant (P < 0.05). Conclusion The curative effect of first-onset schizophrenia between Aripiprazole and Quetiapine is quite, but the adverse reactions are different, the former is better than the latter.%目的 探讨阿立哌唑与喹硫平治疗首发精神分裂症的临床疗效.方法 63例首发精神分裂症患者,符合CCMD-3精神分裂症诊断标准,随机分成两组,分别使用阿立哌唑和喹硫平治疗,疗程共8周.采用阳性和阴性症状量表(PANSS)和不良反应症状量表(TESS)进行副反应评定.结果 阿立哌唑组总有效率为93.55%,喹硫平组总有效率为90.63%,差异无统计学意义(P>0.05).阿立哌唑组和喹硫平组两组患者治疗前后PANSS量表评分,差异无统计学意义(P>0.05);阿立哌唑组治疗前后相比,瘦素和三酰甘油水平升高,差异有统计学意义(P<0.05),喹硫平组治疗前后瘦素、催乳素、血糖和三酰甘油水平升

  4. 品管圈活动在帕金森病合并抑郁患者中的应用%Effect of quality control circle activity on improving Parkinson’ s disease patients with depression

    Institute of Scientific and Technical Information of China (English)

    王培芝; 代桂宁; 杨洁; 王彦永

    2014-01-01

    Objective To explore the effect of quality control circle activity on depression and activities of daily living of Parkinson ’ s disease with depression .Methods Totals of 80 patients of Parkinson ’ s disease with depression were divided into treatment group and control group with 40 cases in each group according to the time of admission.Treatment group took part in quality control circle activity for 3 months, two groups were obliged to attend a constant activity with all patients per month , received collective health education .Hamilton depression scale ( HAMD) and Activities of Daily Living ( ADL) were used to measure depression degree and activities of daily living of patients before and after the intervention .Results Three months after the intervention, HAMD score of patients in treatment group was reduced to (8.80 ±2.36), that in control group was (19.47 ±1.85),and the difference was statistically significant (t=22.50,P<0.01).ADL score of patients in treatment group was increased to (89.14 ±2.25), while that score of patients in control group was (58.32 ±2.21), and significantly difference was found between two groups (t =61.81,P <0.01). Conclusions Quality control circle activity can improve the effect of health education through continuously giving the patients and caregivers health education , and establishing an effective social support system . Meanwhile , it can improve the patients ’ depression condition and self management ability , so as to improve the quality of their life .%目的:探讨品管圈活动对帕金森病合并抑郁患者抑郁和日常生活能力的影响。方法将80例帕金森合并抑郁的患者按入院顺序分为干预组和对照组,每组40例,干预组参加3个月的品管圈活动,两组患者及主要家庭照料者均参加每月1次的帕金森病友会,接受集体健康教育。采用汉密尔顿抑郁量表(HAMD)和日常生活能力(ADL)量表比较干预前后两组患者的抑郁

  5. Effect of comprehensive intervention to improve the mood of anxiety and depression in patients with chronic prostatitis%综合干预改善慢性前列腺炎焦虑抑郁情绪的效果

    Institute of Scientific and Technical Information of China (English)

    彭翠香; 王非凡; 韩敏

    2011-01-01

    Objective To investigate the effect of comprehensive intervention to improve the mood the anxiety and depression in patients with chronic prostatieis, in order to improve the chronic prostatitis patients with anxiety and depression mood, improve life quality. Methods Using Zung self-rating anxiety scale SAS and depression rating scale SDS, the SAS score≥47 points or SDS≥45 points in 174 cases of chronic prostatitis patients were randomly divided into intervention group 87 patients and control group 87 patients. For the intervention group patients, get through psychological counseling, cognitive behavioral education, seeking social support and nursing care management, comprehensive intervention, and then compared SAS, SDS values of selfevaluation on the patient admission, discharge with the national norm. Results Admission patients in the intervention group SAS(54±3.09) points, SDS (52±4.34) points, control group SAS ( 53±3.91) points,SDS ( 52±3.86) points, no statistics significant between the two groups(P>0.05), discharge patients in the intervention group SAS (37±3.72) points, SDS(35±2.82) points, control group SAS (48 ± 2.34) points,SDS (47±3.43) points, the two groups had significant difference ( P<0.05).Intervention group scores assessed at discharge are lower than the national norm SAS (42 ±11) points, SDS (37 ± 13) points while the control group scores at discharge decreased slightly, but not statistically significant. Conclusions Patients with chronic prostatitis are affected by many factors, anxiety and depression will affect their life quality and disease rehabilitative. We believe that in the treatment of chronic prostatitis, improve the patient' s anxiety and depression. To improve the life quality of the patients are equally important.%目的 探讨综合干预改善慢性前列腺炎患者的焦虑、抑郁情绪的效果,以提高其生活质量.方法 采用Zung自我评定焦虑量表SAS和抑郁评定量表SDS,将SAS评分≥47

  6. Always Consider the Possibility of Opioid Induced Respiratory Depression in Patients Presenting with Hypercapnic Respiratory Failure Who Fail to Improve as Expected with Appropriate Therapy

    OpenAIRE

    Martin Steynor; Andrew MacDuff

    2015-01-01

    Hypercapnic respiratory failure is a frequently encountered medical emergency. Two common causes are acute exacerbations of chronic obstructive pulmonary disease (COPD) and as a side effect of opioids. The two causes may coexist leading to diagnostic confusion and consequent delay in optimal management. We report a case of what was initially thought to be an exacerbation of COPD. The patient failed to improve with treatment as expected which led to the empirical administration of naloxone res...

  7. Rationale and Baseline Characteristics of PREVENT: A Second-Generation Intervention Trial in Subjects At-Risk (Prodromal) of Developing First-Episode Psychosis Evaluating Cognitive Behavior Therapy, Aripiprazole, and Placebo for the Prevention of Psychosis

    Science.gov (United States)

    Bechdolf, Andreas; Müller, Hendrik; Stützer, Hartmut; Wagner, Michael; Maier, Wolfgang; Lautenschlager, Marion; Heinz, Andreas; de Millas, Walter; Janssen, Birgit; Gaebel, Wolfgang; Michel, Tanja Maria; Schneider, Frank; Lambert, Martin; Naber, Dieter; Brüne, Martin; Krüger-Özgürdal, Seza; Wobrock, Thomas; Riedel, Michael; Klosterkötter, Joachim

    2011-01-01

    Antipsychotics, cognitive behavioral therapy (CBT), and omega-3-fatty acids have been found superior to control conditions as regards prevention of psychosis in people at-risk of first-episode psychosis. However, no large-scale trial evaluating the differential efficacy of CBT and antipsychotics has been performed yet. In PREVENT, we evaluate CBT, aripiprazole, and clinical management (CM) as well as placebo and CM for the prevention of psychosis in a randomized, double-blind, placebo-controlled trial with regard to the antipsychotic intervention and a randomized controlled trial with regard to the CBT intervention with blinded ratings. The hypotheses are first that CBT and aripiprazole and CM are superior to placebo and CM and second that CBT is not inferior to aripiprazole and CM combined. The primary outcome is transition to psychosis. By November 2010, 156 patients were recruited into the trial. The subjects were substantially functionally compromised (Social and Occupational Functioning Assessment Scale mean score 52.5) and 78.3% presented with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition axis I comorbid diagnosis. Prior to randomization, 51.5% of the participants preferred to be randomized into the CBT arm, whereas only 12.9% preferred pharmacological treatment. First, assessments of audiotaped treatment sessions confirmed the application of CBT-specific skills in the CBT condition and the absence of those in CM. The overall quality rating of the CBT techniques applied in the CBT condition was good. When the final results of the trial are available, PREVENT will substantially expand the current limited evidence base for best clinical practice in people at-risk (prodromal) of first-episode psychosis. PMID:21860040

  8. Effects of a Multi-Component Behavioral Intervention (MCI) for Insomnia on Depressive and Insomnia Symptoms in Individuals with High and Low Depression

    OpenAIRE

    Johnson, Kirsten; Sidani, Souraya; Epstein, Dana R.

    2015-01-01

    Insomnia and depression are prevalent and co-occurring conditions that are associated with significant impairment of life. Previous research indicates that cognitive-behavioral interventions for insomnia (CBT-I) can improve both insomnia and depressive symptoms. The aim of this study was to determine whether a multi-component behavioral intervention (MCI) improved both insomnia and depressive symptoms in persons presenting with insomnia and high levels of depression. The sample consisted of 3...

  9. Severe water intoxication and secondary depressive syndrome in relation to delusional infestation

    Directory of Open Access Journals (Sweden)

    Lai J

    2016-02-01

    Full Text Available Jianbo Lai,1 Qiaoqiao Lu,1 Yi Xu,1,2 Shaohua Hu1,2 1Department of Psychiatry, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China; 2The Key Laboratory of Mental Disorder’s Management in Zhejiang Province, Hangzhou, People’s Republic of China Abstract: This study presents a case of severe water intoxication in a female patient with delusional infestation. Self-induced excessive water ingestion is a rare medical condition, which has not been reported in patients with delusional infestation yet. The patient in this case study was a 60-year-old Chinese woman, who was admitted to our hospital because of a feeling of skin infestation. She suffered from loss of consciousness and generalized tonic–clonic seizure after drinking 12 L of water during bowel cleansing before colonoscopy. Sufficient laboratory and imaging examinations were performed to exclude other possible causes of severe hyponatremia, such as hypothyroidism, diabetes insipidus, and syndrome of inappropriate antidiuretic hormone. Besides, the cystic lesion in the posterior pituitary revealed by cranial magnetic resonance imaging was not accountable for her delusional symptoms as well as excessive drinking behavior. Her delusional symptoms were in complete remission with a combination of risperidone and aripiprazole. However, nearly 3 months after discharge, this patient suffered from depressed mood and was diagnosed with depressive syndrome, and even attempted suicide. This case highlights the possibility of self-induced water intoxication in patients with delusional infestation, inevitably adding to the complexity of the disease, and indicates the necessity of precautions for secondary psychotic or mood problems after symptomatological remission. Keywords: delusional infestation, depressive syndrome, suicide, water intoxication

  10. Progress of Researcheson Mechanisms of Acupuncture Underlying Improvement of Depression in the Past Five Years%针刺治疗抑郁症作用机制近5年研究进展

    Institute of Scientific and Technical Information of China (English)

    户丽; 梁佳; 金树英; 韩焱晶; 卢峻; 图娅

    2013-01-01

    Depression is a state of low mood and aversion to activity that has a negative effect on the patient's thoughts,behavior,feelings,and physical well-being.In the past five years,a significant progress has been made in understanding the mechanism of acupuncture therapy for improving depression.In the present paper,the authors summarize mechanisms of acupuncture for depression from 1) upregulating levels of monoamine neurotransmitters,gamma-aminobutyric acid,5-HT1A receptor binding,and hypothalamic neuropeptide Y,β-endorphine,and μ-receptor expression,and down-regulating hippocampal glutamate content,etc.; 2) upregulating expression of hippocampal brain-derived neurotrophic factor protein and mRNA and its receptor TrkB,and activating adenyl eyclase-cAMP-PKA-CREB signaling pathway; 3) increasing hi ppocampal growth-associated protein 43 level and suppressing hippocampal c-Jun N-terminal kinase activation and cellular apoptosis; 4) upregulating expression of glial fibrillary acidic protein (activating glia cells) ; 5) regulating activities of hypothalamus-pituitary-adrenal axis and hypothalamus-pituitary-sex gland axis; 6) down-regulating serum IL-1β,IL-6,and tumor necrosis factor-α levels.Moreover,the authors also put forward some suggestions about the further research on the mechanisms of acupuncture intervention for depression in the future.%近5年来,针刺治疗抑郁症的作用机制研究取得了显著进展,笔者对此进行了综述,主要包括以下几方面:(1)针刺上调海马内单胺类神经递质、γ-氨基丁酸含量和5-羟色胺1A受体结合位点,及下丘脑神经肽Y、β-内啡肽、μ受体的表达,降低海马谷氨酸含量;(2)针刺上调海马脑源性神经营养因子蛋白及基因和相关受体的表达,激活腺苷酸环化酶-环磷酸腺苷(cAMP)-蛋白激酶A-cAMP反应元件结合蛋白信号通路;(3)针刺增加海马生长相关蛋白-43水平,并抑制c-J un氨基末端激酶活性和细胞凋亡;(4)针刺

  11. Collaborative Depression Care Among Latino Patients in Diabetes Disease Management, Los Angeles, 2011–2013

    OpenAIRE

    Wu, Brian; Jin, Haomiao; Vidyanti, Irene; Lee, Pey-Jiuan; Ell, Kathleen; Wu, Shinyi

    2014-01-01

    Introduction The prevalence of comorbid diabetes and depression is high, especially in low-income Hispanic or Latino patients. The complex mix of factors in safety-net care systems impedes the adoption of evidence-based collaborative depression care and results in persistent disparities in depression outcomes. The Diabetes–Depression Care-Management Adoption Trial examined whether the collaborative depression care model is an effective approach in safety-net clinics to improve clinical care o...

  12. Always Consider the Possibility of Opioid Induced Respiratory Depression in Patients Presenting with Hypercapnic Respiratory Failure Who Fail to Improve as Expected with Appropriate Therapy

    Science.gov (United States)

    Steynor, Martin; MacDuff, Andrew

    2015-01-01

    Hypercapnic respiratory failure is a frequently encountered medical emergency. Two common causes are acute exacerbations of chronic obstructive pulmonary disease (COPD) and as a side effect of opioids. The two causes may coexist leading to diagnostic confusion and consequent delay in optimal management. We report a case of what was initially thought to be an exacerbation of COPD. The patient failed to improve with treatment as expected which led to the empirical administration of naloxone resulting in a dramatic reversal of her respiratory failure. The patient was subsequently discovered to be taking regular dihydrocodeine for chronic back pain. PMID:25893118

  13. Always Consider the Possibility of Opioid Induced Respiratory Depression in Patients Presenting with Hypercapnic Respiratory Failure Who Fail to Improve as Expected with Appropriate Therapy

    Directory of Open Access Journals (Sweden)

    Martin Steynor

    2015-01-01

    Full Text Available Hypercapnic respiratory failure is a frequently encountered medical emergency. Two common causes are acute exacerbations of chronic obstructive pulmonary disease (COPD and as a side effect of opioids. The two causes may coexist leading to diagnostic confusion and consequent delay in optimal management. We report a case of what was initially thought to be an exacerbation of COPD. The patient failed to improve with treatment as expected which led to the empirical administration of naloxone resulting in a dramatic reversal of her respiratory failure. The patient was subsequently discovered to be taking regular dihydrocodeine for chronic back pain.

  14. Standardization of depression measurement

    DEFF Research Database (Denmark)

    Wahl, Inka; Löwe, Bernd; Bjørner, Jakob;

    2014-01-01

    OBJECTIVES: To provide a standardized metric for the assessment of depression severity to enable comparability among results of established depression measures. STUDY DESIGN AND SETTING: A common metric for 11 depression questionnaires was developed applying item response theory (IRT) methods. Data...... of 33,844 adults were used for secondary analysis including routine assessments of 23,817 in- and outpatients with mental and/or medical conditions (46% with depressive disorders) and a general population sample of 10,027 randomly selected participants from three representative German household surveys....... RESULTS: A standardized metric for depression severity was defined by 143 items, and scores were normed to a general population mean of 50 (standard deviation = 10) for easy interpretability. It covers the entire range of depression severity assessed by established instruments. The metric allows...

  15. Sphingolipids in Major Depression

    Directory of Open Access Journals (Sweden)

    Peter L. Jernigan

    2015-12-01

    Full Text Available Major depression is one of the most common and severe diseases affecting the world's population. However, the pathogenesis of the disease remains inadequately defined. Previously, a lack of monoaminergic neurotransmitters was the focus of pathophysiological concepts; however, recent concepts focus on a alteration of neurogenesis in the hippocampus. This concept suggests that neurogenesis is decreased in major depression with a rarefication of neuronal networks and a lack of new, immature neurons in the hippocampus, events that may result in the clinical symptoms of major depression. However, molecular targets involved in the pathogenesis of major depression and, in particular, a reduction of neurogenesis, are largely unknown. We have recently discovered that an inhibition of the acid sphingomyelinase/ceramide system mediates the effects of tri- and tetracyclic antidepressants. Moreover, an accumulation of ceramide in the hippocampus results in depression-like symptoms. This suggests the acid sphingomyelinase/ceramide system is very important in the pathogenesis of major depression.

  16. Physical activity & depression

    OpenAIRE

    Tsiantoula E.; Tsiadoula L.; Patsiaouras A.; Kokaridas D.

    2012-01-01

    Depression is a major public health disorder. Clinical depression is the most frequent disability in North America among other countries and by 2020 it is estimated that it will represent the second most common disability worldwide. Physical activity can be used to prevent as well as treat depression. Its characteristics and structure should be individualized to the personality and special needs of the patient as well as to the severity of the disorder. Intensity, duration and the place of pe...

  17. Stress, norepinephrine and depression.

    OpenAIRE

    Leonard, B E

    2001-01-01

    Stress is an important precipitant factor in depression, and the changes in various body systems that occur in depression are similar to those observed in response to stress. This paper discusses the interactions among the immune, endocrine and norepinephrine systems that are evident in patients with depression, as well as those affected by stress. Many of the stress-induced changes can be reversed by antidepressants, particularly norepinephrine reuptake inhibitors.

  18. Fibromyalgia and Depression

    OpenAIRE

    Gracely, Richard H.; M. Catherine Bushnell; Marta Ceko

    2011-01-01

    Fibromyalgia and depression might represent two manifestations of affective spectrum disorder. They share similar pathophysiology and are largely targeted by the same drugs with dual action on serotoninergic and noradrenergic systems. Here, we review evidence for genetic and environmental factors that predispose, precipitate, and perpetuate fibromyalgia and depression and include laboratory findings on the role of depression in fibromyalgia. Further, we comment on several aspects of fibromyal...

  19. Depression in Older Adults

    OpenAIRE

    Fiske, Amy; Wetherell, Julie Loebach; Gatz, Margaret

    2009-01-01

    Depression is less prevalent among older adults than among younger adults but can have serious consequences. Over half of cases represent a first onset in later life. Although suicide rates in the elderly are declining, they are still higher than in younger adults and more closely associated with depression. Depressed older adults are less likely to endorse affective symptoms and more likely to display cognitive changes, somatic symptoms, and loss of interest than are younger adults. Risk fac...

  20. Depression after myocardial infarction.

    Science.gov (United States)

    Ziegelstein, R C

    2001-01-01

    Depression is an independent risk factor for increased postmyocardial infarction morbidity and mortality, even after controlling for the extent of coronary artery disease, infarct size, and the severity of left ventricular dysfunction. This risk factor takes on added significance when one considers that almost half of patients recovering from a myocardial infarction have major or minor depression and that major depression alone occurs in about one in five of these individuals. Despite the well-documented risk of depression, questions remain about the mechanism of the relationship between mood disturbance and adverse outcome. The link may be explained by an association with lower levels of social support, poor adherence to recommended medical therapy and lifestyle changes intended to reduce the risk of subsequent cardiac events, disturbances in autonomic tone, enhanced platelet activation and aggregation, and systemic immune activation. Unfortunately, questions about the pathophysiologic mechanism of depression in this setting are paralleled by uncertainties about the optimal treatment of depression for patients recovering from a myocardial infarction and by a lack of knowledge about whether treating depression lowers the associated increased mortality risk. Ongoing research studies will help to determine the benefits of psychosocial interventions and of antidepressant therapy for patients soon after myocardial infarction. Although the identification of depression as a risk factor may by itself be a reason to incorporate a comprehensive psychological evaluation into the routine care of patients with myocardial infarction, this practice should certainly become standard if studies show that treating depression reduces the increased mortality risk of these patients.

  1. [Sleep in depression].

    Science.gov (United States)

    Pringuey, D; Darcourt, G

    1990-11-28

    Insomnia is a cardinal symptom of depression, side by side with alterations of mood and slowing down of psychomotor activities. It bears witness to a rupture in the built-in circadian rhythm: architectural changes in sleep betray a biological desynchronization. Insomnia is also a failed attempt at finding a solution to depression. Total deprivation of sleep for one night may damp down the depressive disorders, and so does partial sleep deprivation in the second part of the night during several days. This leads to the conclusion that the waking-sleep system participates in the expression of symptoms of depression or even contributes to the genesis of the disease. PMID:2148377

  2. Relaxation training to improve the survey depression patients hospitalized anxiety effect%放松训练改善住院抑郁症病人焦虑情绪效果调查

    Institute of Scientific and Technical Information of China (English)

    褚洪伟; 韩以华; 刘先群; 周华

    2013-01-01

    Objective Depression patients with drug treatment combined with relaxation training ,relaxation training consciously control the psychological physiological activities ,reduce arousal level ,improve the disorder function reduce anxiety emotional distress and physical symptoms . Methods A self-designed questionnaire to conform to the standards of the patient ,relaxed survey questionnaire before and after training .Anxiety and sleep improvement before and after training to relax more .Results The drug therapy combined with relaxation training ,improve patient com-pliance ,reduce anxiety ,improve sleep ,there are obvious differences between them before and after treatment (P ≤ 0.05) .Conclusion Depres-sion is a chronic disease ,medication time is long ,the compliance decreased gradually along with the medication time prolonged ,the obvious anxie-ty ,sleep ,we take the drug therapy combined with relaxation training ,reduce anxiety and improve patient treatment of sleep ,increased confi-dence ,drug therapy combined with relaxation training therapy and so on ,to provide treatment and care fully for the patient .%目的:抑郁症病人通过药物治疗的同时辅以放松训练,通过放松训练有意识地控制自身的心理生理活动,降低唤醒水平,改善机体紊乱功能降低紧张焦虑情绪困扰和躯体症状。方法采用自行设计的调查表对符合标准的病人进行调查,放松训练前后效果问卷调查.放松训练前后焦虑情绪和睡眠改善比较。结果通过药物治疗配合放松训练,病员服药依从性提高,减轻了焦虑情绪、改善睡眠,治疗前后两者之间有明显的差异(P≤0.05)。结论抑郁症是一个慢性病,服药时间长,依从性随服药时间延长逐渐下降,病员焦虑情绪明显,影响睡眠,我们采取药物治疗结合放松训练,减轻焦虑情绪改善病员睡眠,治疗信心增强,药物治疗为主结合放松训练等辅助治疗,

  3. The comparison of blood prolactin in the female patients with psychosis treated by aripiprazole and Sulpiride%阿立哌唑与舒必利对女性患者血清催乳素影响的对照研究

    Institute of Scientific and Technical Information of China (English)

    祖鑫

    2013-01-01

    目的:探讨阿立哌唑与舒必利对女性患者血清催乳素的影响。方法:将64例精神分裂症女性患者随机分为阿立哌唑组和舒必利组,比较两组治疗前后的血清催乳素变化。结果:阿立哌唑与舒必利对女性患者血清催乳素的影响有显著差异。结论:阿立哌唑对女性患者血清催乳素的影响较舒必利不明显。%Objective:To investigate the change of blood prolactin in female patients with p sychosis treated by aripiprazole and Sulpiride .Methods:64 female patients with schizophrenia or schizophrenia form psychosis were randomized to aripiprazole and Sulpiride .The blood prolactin at the baseline and after treatment were compared.Results:There were significant differences in the blood prolactin after treatment between aripiprazole and Sulpiride groups . Conclusions:The change of blood prolactin in the female patients with psychosis caused by aripiprazole was little then Sulpiride .

  4. The Effect of Interpersonal Psychotherapy for Depression on Insomnia Symptoms in a Cohort of Women with Sexual Abuse Histories

    OpenAIRE

    Pigeon, Wilfred R.; May, Pamela E.; Perlis, Michael L.; Ward, Erin A.; Lu, Naiji; Talbot, Nancy L.

    2009-01-01

    Insomnia frequently occurs with trauma exposure and depression, but can ameliorate with improvements in depression. Insomnia was assessed by the insomnia subscale of the Hamilton Rating Scale for Depression in 106 women with childhood sexual abuse (CSA) and major depression receiving Interpersonal Psychotherapy in an uncontrolled pilot (n = 36) and an immediately subsequent randomized controlled trial (n = 70) comparing IPT to treatment as usual. Depression improved in each study and in both ...

  5. Striatal Dopamine D-2/3 Receptor Availability in Treatment Resistant Depression

    NARCIS (Netherlands)

    de Kwaasteniet, Bart P.; Pinto, Chedwa; Ruhe, Eric H. G.; van Wingen, Guido A.; Booij, Jan; Denys, Damiaan

    2014-01-01

    Several studies demonstrated improvement of depressive symptoms in treatment resistant depression (TRD) after administering dopamine agonists which suggest abnormal dopaminergic neurotransmission in TRD. However, the role of dopaminergic signaling through measurement of striatal dopamine D-2/3 recep

  6. Diagnosing major depression in elderly primary care patients: nuances and determinants.

    NARCIS (Netherlands)

    Volkers, A.C.; Nuijen, J.; Verhaak, P.F.M.; Schellevis, F.G.

    2003-01-01

    The researchers studied how general practitioners (GPs) diagnosed elderly patients with depressive symptoms. Sociodemographic factors such as younger age, female sex and more education, clinical characteristics such as severe depression and comorbidity of anxiety disorders are suggested to improve t

  7. Going to Scale: Re-Engineering Systems for Primary Care Treatment of Depression

    OpenAIRE

    Dietrich, Allen J.; Oxman, Thomas E.; Williams, John W.; Kroenke, Kurt; Schulberg, H. Charles; Bruce, Martha; Barry, Sheila L.

    2004-01-01

    BACKGROUND Recent trials have shown improved depression outcomes with chronic care models. We report the methods of a project that assesses the sustainability and transportability of a chronic care model for depression and change strategy.

  8. 换用阿立哌唑对精神分裂症患者代谢的影响%Metabolic effects in treating schizophrenia patients after switching to aripiprazole

    Institute of Scientific and Technical Information of China (English)

    程群; 朱怀轩

    2012-01-01

    目的:探讨换用阿立哌唑治疗后精神分裂症患者各项代谢指标的改善情况. 方法:选择43例换用阿立哌唑治疗的精神分裂症患者,分别在换药前和换药12周对患者的血糖、血脂和体质量等代谢指标进行检测. 结果:换用阿立哌唑12周,患者的体质量(t=3.38,P<0.01)和体质量指数(t=3.07,P<0.01)显著改善,空腹血糖(t=2.96,P<0.01)、2h血糖(=2.58,P<0.01)、糖化血红蛋白(t=3.50,P<0.01)、空腹胰岛素(t=19.71,P<0.01)、和稳态模型评估的胰岛素抵抗系数(t=2.70,P<0.05)均较治疗前显著降低,总胆固醇(t=2.78,P<0.01)、三酰甘油(t=4.38,P<0.01)和低密度脂蛋白(=2.81,P<0.01)亦有显著降低,代谢综合征的患病率(x2=19.07,P<0.01)显著降低. 结论:换用阿立哌唑治疗对精神分裂症患者的代谢有显著改善作用.%Objective: To evaluate extensively the metabolic improvements of switching to aripirzazole in the treatment of schizophrenia. Method :43 patients who had successfully switched to aripirazole with a schizophrenia diagnosis went through an extensive metabolic evaluation, including blood glucose, blood lipids and body weight test at baseline and at 12 weeks post switch. Results: There was significant decreases in body weight(t=3. 38, P< 0.01), body mass index(t =3. 07,P <0. 01) .fasting glucose(t =2. 96,P <0. 01) .glucose at 2 h(t = 2. 58,P<0. 01) .glycated hemoglobin(t = 3. 50, P < 0.01) .fasting insulin(t = 19. 71,P< 0.01),insulin resistance index(t =2. 70,P<0.05) .total cholesterol (t =2. 78,P <0.01), triglycerides (t = 4. 38,P<0.01) and low-density lipoprotein (t =2. 81 ,P<0.01) levels. There was also a significant reduction in the prevalence of metabolic syndrome(χ 2 = 19.07,P <0.01). Conclusion: Switching to aripiprazole can significantly improve metabolic abnormalities in treating schizophrenia.

  9. A model for maternal depression.

    Science.gov (United States)

    Connelly, Cynthia D; Baker-Ericzen, Mary J; Hazen, Andrea L; Landsverk, John; Horwitz, Sarah McCue

    2010-09-01

    With the awareness of maternal depression as a prevalent public health issue and its important link to child physical and mental health, attention has turned to how healthcare providers can respond effectively. Intimate partner violence (IPV) and the use of alcohol, tobacco, and other drugs are strongly related to depression, particularly for low-income women. The American College of Obstetricians and Gynecologists (ACOG) recommends psychosocial screening of pregnant women at least once per trimester, yet screening is uncommonly done. Research suggests that a collaborative care approach improves identification, outcomes, and cost-effectiveness of care. This article presents The Perinatal Mental Health Model, a community-based model that developed screening and referral partnerships for use in community obstetric settings in order to specifically address the psychosocial needs of culturally diverse, low-income mothers. PMID:20718624

  10. Facial recognition of happiness among older adults with active and remitted major depression.

    Science.gov (United States)

    Shiroma, Paulo R; Thuras, Paul; Johns, Brian; Lim, Kelvin O

    2016-09-30

    Biased emotion processing in depression might be a trait characteristic independent of mood improvement and a vulnerable factor to develop further depressive episodes. This phenomenon of among older adults with depression has not been adequately examined. In a 2-year cross-sectional study, 59 older patients with either active or remitted major depression, or never-depressed, completed a facial emotion recognition task (FERT) to probe perceptual bias of happiness. The results showed that depressed patients, compared with never depressed subjects, had a significant lower sensitivity to identify happiness particularly at moderate intensity of facial stimuli. Patients in remission from a previous major depressive episode but with none or minimal symptoms had similar sensitivity rate to identify happy facial expressions as compared to patients with an active depressive episode. Further studies would be necessary to confirm whether recognition of happy expression reflects a persistent perceptual bias of major depression in older adults. PMID:27428081

  11. Depression in the aging: an important health problem in Mexico

    Directory of Open Access Journals (Sweden)

    Jesús RIVERA NAVARRO

    2015-12-01

    Full Text Available Depression is a disease which has an especially worrying impact on old aged people due to the increased risk factors for diseases in this age group. In Mexico there are very few studies on depression in aging. The objectives of our study are: 1 to estimate the prevalence of depressive symptoms in old aged people and; 2 to analyze the relation between depressive symptoms and different risk factors of depression. The research is a cross-sectional population study and was made in Ciudad Victoria, Tamaulipas state. 1,126 elderly were interviewed (455 male and 671 female, which constituted 5.1% of the old age population in Ciudad Victoria. Depression was measured on the Geriatric Depression Scale. The results point out: 1 the prevalence of depressive symptoms was estimated to be 29% of the interviewed subjects; 2 the factors favoring depression were the dependence on daily life activities, cognitive impairment, lack of social support, age, gender, loneliness, poverty, stressful events and subjective perception of health. Decreasing depression is not only related to improvement of health but also to the improvement of the conditions of old age life.

  12. How Should We Treat Depression in Patients with Cardiovascular Disease?

    OpenAIRE

    Kronish, Ian M.; Krupka, David J.; Davidson, Karina W.

    2012-01-01

    Among patients with cardiovascular disease (CVD), depression is highly prevalent and is associated with worse cardiovascular prognosis and lower quality of life. Treatments for depression in CVD patients produce modest, but clinically significant reductions in depressive symptoms and show promise for improving cardiovascular prognosis. While tricyclics should generally be avoided, antidepressants from multiple other classes appear to be safe in cardiac patients. A strategy of engaging patient...

  13. Innovation:CBT-based support groups for postnatal depression.

    Science.gov (United States)

    Alexander, Pat

    Postnatal depression can have serious implications for mother/child bonding and damage relationships between parents. Approaches to treat it need to overcome barriers that have led to high attrition in some group or clinic-based postnatal depression treatment studies. This retrospective evaluation explored the benefits of offering postnatally depressed mothers group support based on cognitive behavioural therapy. It helped to improve women's self-esteem and self-worth and to make them feel safe and supported.

  14. Effectiveness of the workshop "Adolescent depression: What can schools do?"

    OpenAIRE

    Vania eMartinez; Daniel eEspinosa; Pedro eZitko; Rigoberto eMarin; Sara eSchilling; Camila eSchwerter; Graciela eRojas

    2015-01-01

    Introduction: Adolescent depression is associated with serious consequences. School staff is in a unique position to screen and refer adolescents with depression in a timely manner, and can collaborate with healthcare teams to assist in the proper management of the disease. The objective of this paper is to describe the results of a workshop that aims to improve the knowledge of adolescent depression among school staff.Material and methods: This was a single-arm trial with a pre-post design. ...

  15. Studying depression using imaging and machine learning methods

    OpenAIRE

    Patel, Meenal J.; Alexander Khalaf; Aizenstein, Howard J.

    2015-01-01

    Depression is a complex clinical entity that can pose challenges for clinicians regarding both accurate diagnosis and effective timely treatment. These challenges have prompted the development of multiple machine learning methods to help improve the management of this disease. These methods utilize anatomical and physiological data acquired from neuroimaging to create models that can identify depressed patients vs. non-depressed patients and predict treatment outcomes. This article (1) presen...

  16. Treatment of Comorbid Obesity and Major Depressive Disorder: A Prospective Pilot Study for their Combined Treatment

    Directory of Open Access Journals (Sweden)

    Lucy F. Faulconbridge

    2011-01-01

    Full Text Available Background. Obese individuals who suffer from major depressive disorder are routinely screened out of weight loss trials. Treatments targeting obesity and depression concurrently have not been tested. Purpose. To test the short-term efficacy of a treatment that combined behavioral weight management and cognitive behavioral therapy (CBT for obese adults with depression. Methods. Twelve obese females diagnosed with major depressive disorder received weekly group behavioral weight management, combined with CBT for depression, for 16 weeks. Weight, symptoms of depression, and cardiovascular disease (CVD risk factors were measured at baseline and week 16. Results. Participants lost 11.4% of initial weight and achieved significant improvements in symptoms of depression and CVD risk factors. Conclusions. Obese individuals suffering from major depressive disorder can lose weight and achieve improvements in symptoms of depression and CVD risk factors with 16 weeks of combined treatment. A larger randomized controlled trial is needed to establish the efficacy of this treatment.

  17. Depression in Children and Teens

    Science.gov (United States)

    ... Return to Web version Depression in Children and Teens Depression in Children and Teens How are the symptoms ... aafp.org/afp/20001115/2297.html) Childhood and Adolescent Depression by SK Bhatia, M.D., and SC Bhatia, ...

  18. Helping your teen with depression

    Science.gov (United States)

    ... ency/patientinstructions/000646.htm Helping your teen with depression To use the sharing features on this page, please enable JavaScript. Your teen's depression may be treated with talk therapy, anti-depression ...

  19. Depression During and After Pregnancy

    Science.gov (United States)

    ... Depression during and after pregnancy fact sheet ePublications Depression during and after pregnancy fact sheet This information in Spanish (en español) Print this fact sheet Depression during and after pregnancy fact sheet (PDF, 260 ...

  20. Symptoms and Treatment of Depression

    Medline Plus

    Full Text Available ... Prevention (7 items) Treatments (11 items) Symptoms and Treatment of Depression February 1, 2010 People with depression ... why it affects some people but not others. Treatments for depression do work. One type of effective ...

  1. St. John's Wort and Depression

    Science.gov (United States)

    ... W X Y Z St. John's Wort and Depression: In Depth Share: On This Page Introduction Key ... will help ensure coordinated and safe care. About Depression Depression is a medical condition that affects about ...

  2. Sleep deprivation and depression

    NARCIS (Netherlands)

    Elsenga, Simon

    1992-01-01

    The association between depression and sleep disturbances is perhaps as old as makind. In view of the longstanding experience with this association it is amazing that only some 20 years ago, a few depressed patients attracted attention to the fact that Total Sleep Deprivation (TSD) had antidepressan

  3. Memory training in depression

    NARCIS (Netherlands)

    Becker, E.S.; Vanderhasselt, M.A.; Vrijsen, J.N.

    2015-01-01

    Memory biases, that is, general memory impairments as well as specific mood-congruent memory biases, are important vulnerability factors in depression. Recently, computerized memory trainings have been developed to target these biases, reducing rumination and lightening depressive symptoms. This rev

  4. Depression and African Americans

    Science.gov (United States)

    ... is a common, yet serious, medical illness. Clinical depression is a “whole-body” illness that affects your mood, thoughts, body and behavior. Without treatment, symptoms can last for weeks, months or years. Appropriate ... Clinical depression can affect anyone: Anyone can experience ...

  5. Depression following myocardial infarction

    DEFF Research Database (Denmark)

    Larsen, Karen Kjær

    2013-01-01

    Myocardial infarction (MI) is a severe life event that is accompanied by an increased risk of depression. Mounting evidence suggests that post-MI depression is associated with adverse outcomes, but the underlying mechanisms of this association remain unclear, and no previous studies have examined...

  6. Testosterone and Depression

    Directory of Open Access Journals (Sweden)

    Şükrü Kartalcı

    2010-12-01

    Full Text Available Androgens have various effects on human body and mood. Testosterone, a hormone mainly secreted from testes and adrenals, is one of the most potent androgens. Multiple studies have found that testosterone plays a role in regulating sexual activity, libido, social behaviors, aggression, cognitive functions, sleep control and well-being in men and women. Testosterone deficiency in hypogonadic or elderly men leads to neuropsychiatric problems, such as fatigue, loss of libido, irritability, insomnia and depressive mood. Testosterone replacement therapy consistently reverses these sequel in men. On the other hand, hyperandrogenic states in women are related to aggression and antisocial behavior, which might lead to depressive mood. Low testosterone levels may also result in depression among oophorectomized women. Because of such effects, a relationship between testosterone and depression has long been an issue of speculation, but yet very few studies have addressed this relation. Along with clinical studies, experimental and epidemiological studies show that testosterone is related to depression in men and women. But studies of testosterone concentrations in depression have yielded inconsistent results reporting low as well as high testosterone levels associated with depression. In this article, the physiological and psychological effects of testosterone and evidence regarding its relationship to depressive disorders and possible gender differences have been reviewed.

  7. Adjustments and Depression

    Medline Plus

    Full Text Available ... Depression, however, is a serious medical disorder that affects your thoughts, feelings, physical health and behaviors as well as other aspects of your life. Depression can cause physical and psychological symptoms. It can worsen pain, make sleep difficult, cause loss of energy, take away your ...

  8. Postpartum Depression: An Overview.

    Science.gov (United States)

    Albright, Angela

    1993-01-01

    Occurring in about 12 percent of postpartum women, postpartum depression has been focus of considerable research. Variables that have been correlated with postpartum depression range from biological causes, to lack of social support, to relationship with husband, to attributional styles, to psychodynamic explanations. There is need for more…

  9. Antidepressant treatment of the depressed patient with insomnia.

    Science.gov (United States)

    Thase, M E

    1999-01-01

    Sleep disturbances are an integral part of depressive disorder. As such, they are a part of all contemporary sets of diagnostic criteria for major depression and of all major symptom-based rating scales for depression. Insomnia is a particularly frequent complaint, and it is reported by more than 90% of depressed patients. Although the "kindling" or "illness transduction" model of depression remains hypothetical, there is evidence that people with recurrent depression have more pronounced abnormalities of sleep neurophysiology than those experiencing a single or initial episode. Therefore, early relief of insomnia in a depressed patient, in addition to alleviating other symptoms, may increase adherence to treatment and increase daytime performance and overall functioning, while complete relief of insomnia may improve prognosis. Stimulation of serotonin-2 (5-HT2) receptors is thought to underlie insomnia and changes in sleep architecture seen with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). This is the reason why hypnotics or low-dose trazodone are commonly coprescribed at the initiation of the treatment with either the SSRIs or SNRIs. On the other hand, antidepressant drugs with 5-HT2 blocking properties, such as mirtazapine or nefazodone, alleviate insomnia and improve sleep architecture. In depressed patients, mirtazapine produces a significant shortening of sleep-onset latency, increases a total sleep time, and leads to a marked improvement in sleep efficiency. Antidepressants with preferential 5-HT2 blocking properties are therefore a good treatment option for depressed patients with marked insomnia. PMID:10446739

  10. [Severe depression : psychoanalysis].

    Science.gov (United States)

    Bouvet de la Maisonneuve, O

    2009-12-01

    The indication for psychoanalysis in severe depression is not clear. And yet, demands for this type of intervention are increasing, despite the absence of any form of consensus on the subject. Freud considered depression as a failure of analytical efforts and, based on this observation, revised his theory, in particular to include the notions of narcissism and the death drive. Many analysts have been reluctant to follow his teachings on this last point and provide depressed patients with analytical-type therapies aimed at restoring narcissism. Melanie Klein pushed Freud's ideas about depression even further and brought such therapies back to the heart of analytical practice. Jacques Lacan took the debate to another level by proposing an overhaul of the principles on which analysis has been based. Today, while following certain precautionary rules, true psychoanalyses can be proposed to patients with severe depression, whether of the bipolar, recurring or even neurotic type that can reach this level of severity. PMID:20141799

  11. Depression in schizophrenia.

    Science.gov (United States)

    Becker, R E

    1988-12-01

    Depressive syndromes that occur during the course of schizophrenia are not clearly understood but have important implications for the treatment of the schizophrenic patient. In this review of the literature on depression secondary to schizophrenia, the author notes that lack of tested diagnostic criteria has led to a misunderstanding of its relatively high frequency and its association with poor outcome features such as impaired psychosocial functioning, schizophrenic relapse, and suicide. Differential diagnosis, including ruling out akinetic depression, is essential, he believes, partly because the concept of schizophrenic depression as postpsychotic is not supported by evidence. Clinical management must address such increased risk factors as relapse and suicide, but evidence indicates that secondary depression in schizophrenia does not respond to antidepressant medication. PMID:3068116

  12. Lao Depression Inventory.

    Science.gov (United States)

    Davidson-Muskin, M B; Golden, C

    1989-01-01

    There are no measurement tools that accurately measure depression among Lao refugees. The overall purpose of this research was to complete the development and validation procedures for the Lao Depression Inventory (LDI). The study consisted of 216 Ethnic Lao refugees. A clinical interview and 164 true/false questions were administered to identify specific items which could identify depression among the Ethnic Lao people. All items were administered in both English and Lao. Overall, 78 of the 164 items differentiated groups of depressed and nondepressed Lao at the .01 level. Results of validation procedures showed that a 30-item scale had an accuracy rate of 89% in identifying the presence of depression in the validation group; the hit-rate for the same items and cutoff was 92% in the cross-validation group. Potential uses of the scale are discussed. PMID:2918451

  13. [Severe depression : psychoanalysis].

    Science.gov (United States)

    Bouvet de la Maisonneuve, O

    2009-12-01

    The indication for psychoanalysis in severe depression is not clear. And yet, demands for this type of intervention are increasing, despite the absence of any form of consensus on the subject. Freud considered depression as a failure of analytical efforts and, based on this observation, revised his theory, in particular to include the notions of narcissism and the death drive. Many analysts have been reluctant to follow his teachings on this last point and provide depressed patients with analytical-type therapies aimed at restoring narcissism. Melanie Klein pushed Freud's ideas about depression even further and brought such therapies back to the heart of analytical practice. Jacques Lacan took the debate to another level by proposing an overhaul of the principles on which analysis has been based. Today, while following certain precautionary rules, true psychoanalyses can be proposed to patients with severe depression, whether of the bipolar, recurring or even neurotic type that can reach this level of severity.

  14. Depression and Bipolar Support Alliance

    Science.gov (United States)

    ... Series JOINT COMMISSION LAUNCHES EDUCATIONAL CAMPAIGN ON ADULT DEPRESSION Educational Brochure Provides Guidance on Recognizing and Treating Depression [PDF] DBSA 2013–2017 STRATEGIC PLAN Learn how ...

  15. Depression in dialysis patients.

    Science.gov (United States)

    King-Wing Ma, Terry; Kam-Tao Li, Philip

    2016-08-01

    Depression is the most common psychiatric illness in patients with end-stage renal disease (ESRD). The reported prevalence of depression in dialysis population varied from 22.8% (interview-based diagnosis) to 39.3% (self- or clinician-administered rating scales). Such differences were attributed to the overlapping symptoms of uraemia and depression. Systemic review and meta-analysis of observational studies showed that depression was a significant predictor of mortality in dialysis population. The optimal screening tool for depression in dialysis patients remains uncertain. The Beck Depression Inventory (BDI), Patient Health Questionnaire (PHQ) and Center for Epidemiologic Studies Depression Scale (CESD) have been validated for screening purposes. Patients who scored ≥14 using BDI should be referred to a psychiatrist for early evaluation. Structured Clinical Interview for DSM disorders (SCID) remains the gold standard for diagnosis. Non-pharmacological treatment options include cognitive behavioural therapy and exercise training programs. Although frequent haemodialysis may have beneficial effects on patients' physical and mental well-being, it cannot and should not be viewed as a treatment of depression. Selective serotonin reuptake inhibitors (SSRIs) are generally effective and safe in ESRD patients, but most studies were small, non-randomized and uncontrolled. The European Renal Best Practice (ERBP) guideline suggests a trial of SSRI for 8 to 12 weeks in dialysis patients who have moderate-major depression. The treatment effect should be re-evaluated after 12 weeks to avoid prolonging ineffective medication. This review will discuss the current understanding in the diagnosis and management of depression in dialysis patients. PMID:26860073

  16. Dialogues on depression management: the primary care and specialist perspectives.

    Science.gov (United States)

    Collins, Richard L; Escobar, Javier I

    2006-10-01

    Depression is a major public health problem in the United States and is responsible for an enormous economic burden and loss of productivity and quality of life. In many cases, PCPs are well situated to identify and treat unrecognized depression, but an optimal treatment program often comprises both medical and psychotherapeutic interventions. Many collaborative models that integrate the efforts of PCPs, psychiatrists, behavioral health organizations, and workplace assistance programs are being tested and may prove to be the best direction for improving care for patients with depression. Looking ahead, improvement in treatment of depression will depend on numerous factors, including educating health care practitioners to recognize silent depression, expanding current collaborative models to cover more of the population, involving MCOs and payers in the development of effective treatment systems, and improving workplace-support programs to encourage more patients to seek appropriate care.

  17. [Depression in Sub-Saharan Africa].

    Science.gov (United States)

    Perez, S; Junod, A

    1998-01-01

    We now have a better knowledge of the specific features of depression in sub-Saharan Africa. Anthropologically speaking, the Western model is irrelevant. Depression in sub-Saharan Africa involves the relationship of the subject to himself or others in a mode specific to African cultures. Ignoring this fact can lead to simplistic ethnocentrism. From a clinical standpoint, depressive illness characterized by somatic manifestations, delusions of persecution, and anxiety are increasingly uncommon. As African societies modernize, these traditional forms are being gradually supplanted by states with symptoms and prognoses more like those observed in industrialized countries. Hybrid depressive syndromes are now the most widespread. Epidemiologically the notion widely held only a few decades ago that depression is a rare occurrence in Africa has now been dispelled. Many studies have been conducted to determine the exact incidence, age distribution, and sex ratio but more precise data is still needed. This investigation will require improvement in screening and diagnostic methods which must be not only suitable for clinical use but also adaptable to local conditions. This is also true with regard to management which has the same goals as anywhere else in the world. Treatment facilities are different in urban and rural areas but care is often dispensed in unconventional settings and may be combined with traditional methods. Drug availability is limited by problems involving supply and cost. This explains why electro-convulsive therapy which was introduced into sub-Saharan Africa long ago still plays a major role in the treatment of depression.

  18. Physical (in)activity and depression in older people

    NARCIS (Netherlands)

    Wassink-Vossen, S.; Collard, R.M.; Oude Voshaar, R.C.; Comijs, H.C.; Vocht, H.M. de; Naarding, P.

    2014-01-01

    BACKGROUND: Knowledge about characteristics explaining low level of physical activity in late-life depression is needed to develop specific interventions aimed at improving physical health in depressed people above the age of 60. METHODS: This cross-sectional study used data from the Netherlands Stu

  19. Cognitive-Behavioral Therapy for HIV Medication Adherence and Depression

    Science.gov (United States)

    Safren, Steven A.; Hendriksen, Ellen S.; Mayer, Kenneth H.; Mimiaga, Matthew J.; Pickard, Robert; Otto, Michael W.

    2004-01-01

    For patients with HIV, depression is a common, distressing condition that can interfere with a critical self-care behavior--adherence to antiretroviral therapy. The present study describes a cognitive-behavioral treatment designed to integrate cognitive-behavioral therapy for depression with our previously tested approach to improving adherence to…

  20. Depression after Delivery: Risk Factors, Diagnostic and Therapeutic Considerations

    Directory of Open Access Journals (Sweden)

    Debra A. Scrandis

    2007-01-01

    Full Text Available Postpartum mood disorders can negatively affect women, their offspring, and their families when left untreated. The identification and treatment of postpartum depression remains problematic since health care providers may often not differentiate postpartum blues from depression onset. Recent studies found potentially new risk factors, etiologies, and treatments; thus, possibly improving the untreated postpartum depression rates. This integrated review examined several postpartum psychiatric disorders, postpartum blues, generalized anxiety, obsessive compulsive disorder, post-traumatic stress disorder, and postpartum psychosis for current findings on prevalence, etiologies, risk factors, and postpartum depression treatments.

  1. Predictors of depression stigma

    Directory of Open Access Journals (Sweden)

    Jorm Anthony F

    2008-04-01

    Full Text Available Abstract Background To investigate and compare the predictors of personal and perceived stigma associated with depression. Method Three samples were surveyed to investigate the predictors: a national sample of 1,001 Australian adults; a local community sample of 5,572 residents of the Australian Capital Territory and Queanbeyan aged 18 to 50 years; and a psychologically distressed subset (n = 487 of the latter sample. Personal and Perceived Stigma were measured using the two subscales of the Depression Stigma Scale. Potential predictors included demographic variables (age, gender, education, country of birth, remoteness of residence, psychological distress, awareness of Australia's national depression initiative beyondblue, depression literacy and level of exposure to depression. Not all predictors were used for all samples. Results Personal stigma was consistently higher among men, those with less education and those born overseas. It was also associated with greater current psychological distress, lower prior contact with depression, not having heard of a national awareness raising initiative, and lower depression literacy. These findings differed from those for perceived stigma except for psychological distress which was associated with both higher personal and higher perceived stigma. Remoteness of residence was not associated with either type of stigma. Conclusion The findings highlight the importance of treating the concepts of personal and perceived stigma separately in designing measures of stigma, in interpreting the pattern of findings in studies of the predictors of stigma, and in designing, interpreting the impact of and disseminating interventions for stigma.

  2. Depression in hypertensive subjects.

    Science.gov (United States)

    Ramachandran, V; Parikh, G J; Srinivasan, V

    1983-10-01

    168 patients attending hypertension clinic were randomly selected for the study. They were thoroughly investigated using E.C.G., X-ray chest, Urine analysis, Blood sugar, Blood urea, Serum cholesterol, Serum K, Serum Na, Scrum creatinine and Uric acid level. Detailed psychiatric case history and mental examination was carried out. Beck Rating Scale was used to measure the depression. 25% of hypertensive subjects exhibited depressive features and their mean score in Beck Rating scale is 21.76. The mean score of non-depressives is 4.46. All patients were receiving methyl dopa.25 mg. twice or thrice daily with thiazide diuretic. No significant difference in the incidence of depression with the duration of medication was observed.The hypertension was classified into mild, moderate and severe depending on the diastolic pressure. Depression was more frequent in severe hypertensives but not to the statistically significant level.Further hypertensives were classified into:1. Hypertension without organ involvement2. Hypertension with LVH only3. Hypertension with additional organ involvement4. Malignant hypertensionDepression was significantly more frequent in hypertensives with complications and also hypertensives in whom the B.P. remained uncontrolled. As all the patients were on the same drug, the drug effect is common to all; hence, the higher incidence of depression in hypertensives with complications is due to the limitation and distress caused by the illness. PMID:21847301

  3. Epilepsy coexisting with depression.

    Science.gov (United States)

    Błaszczyk, Barbara; Czuczwar, Stanisław J

    2016-10-01

    Depression episodes in epilepsy is the most common commorbidity, affecting between 11% and 62% of patients with epilepsy. Although researchers have documented a strong association between epilepsy and psychiatric comorbidities, the nature of this relationship is poorly understood. The manifestation of depression in epilepsy is a complex issue having many interacting neurobiological and psychosocial determinants, including clinical features of epilepsy (seizure frequency, type, foci, or lateralization of foci) and neurochemical or iatrogenic mechanisms. Other risk factors are a family history of psychiatric illness, particularly depression, a lack of control over the seizures and iatrogenic causes (pharmacologic and surgical). In addition, treatment with antiepileptic drugs (AEDs) as well as social coping and adaptation skills have also been recognised as risk factors of depression associated with epilepsy. Epilepsy may foster the development of depression through being exposed to chronic stress. The uncertainty and unpredictability of seizures may instigate sadness, loneliness, despair, low self-esteem, and self-reproach in patients with epilepsy and lead to social isolation, stigmatization, or disability. Often, depression is viewed as a reaction to epilepsy's stigma and the associated poor quality of life. Moreover, patients with epilepsy display a 4-5 higher rate of depression and suicide compared with healthy population. PMID:27634589

  4. Management of bipolar depression

    Directory of Open Access Journals (Sweden)

    Jae Seung Chang

    2011-01-01

    Full Text Available Patients with bipolar disorder spend more time in a depressed than manic state, even with individualized treatment. To date, bipolar depression is often misdiagnosed and ineffectively managed both for acute episodes and residual symptoms. This review attempts to summarize the current status of available treatment strategies in the treatment of bipolar depression. For acute and prophylactic treatment, a substantial body of evidence supports the antidepressive efficacy of lithium for bipolar disorders and its antisuicidal effects. Among numerous anticonvulsants with mood-stabilizing properties, valproate and lamotrigine could be first-line options for bipolar depression. Due to receptor profile, mood-stabilizing properties of second-generation antipsychotics have been explored, and up to date, quetiapine and olanzapine appear to be a reasonable option for bipolar depression. The usefulness of antidepressants in bipolar depression is still controversial. Current guidelines generally recommend the cautious antidepressant use in combination with mood stabilizers to reduce the risk of mood elevation or cycle acceleration. Results from clinical trials on psychosocial intervention are promising, especially when integrated with pharmacotherapy. Most patients with bipolar depression need individualized and combined treatment, although the published evidence on this type of treatment strategy is limited. Future studies on the utility of currently available agents and modalities including psychosocial intervention are required.

  5. 褪黑素改善抑郁症患者睡眠及抑郁情绪的研究%Melatonin synergizes with sertraline to improve quality of sleep and mood in patients with depressive disorder

    Institute of Scientific and Technical Information of China (English)

    程娟; 窦光茜; 康明秀; 马静; 王勇

    2014-01-01

    Objective To evaluate the effect of melatonin synergizing with sertraline in improving the quality of sleep and mood in patients with depressive disorder .Methods 82 subjects were enrolled in this study from the wards of Dept .Integrative Medicine in Anding hospital , form August 2012 to December 2013, who were also randomly divided into 2 gruops, namely the study group and the controlled one ( 41 for each group );sertraline alone was applied for patients in controlled group , while melatonin , along with sertraline , was for those in the study group;patients from both groups were assessed with HAMD and PQSI at start point , the end of 4 weeks of treatment and the endpoint ( 8 weeks ) .Results Patients form both groups were much better after 8 weeks of treatment;those in the study group were with lower HAMD and PQSI score than the controlled group . Conclusions Melatonin synergizes with sertraline can improve the quality of sleep and mood in patients with depressive disorder .%目的:探讨褪黑素对抑郁患者睡眠及抑郁情绪的改善情况。方法选择自2012年8月至2013年12月于天津安定医院中西医结合科住院患者中符合入组标准的患者82例,随机分为实验组及对照组各41例;对照组患者以舍曲林系统治疗,改善患者抑郁情绪;实验组在服用舍曲林基础上加用褪黑素;两组患者均连续治疗8周,在入组时及治疗后4周末、8周末对两组患者进行汉密顿抑郁量表( HAMD,24项版本)及匹兹堡睡眠质量问卷( PQSI)评估。结果两组患者经8周治疗后,抑郁情绪及睡眠情况均较入组时明显好转;实验组患者在抑郁情绪及睡眠质量的好转上,均优于对照组患者。结论褪黑素可以明显改善抑郁患者睡眠质量,增强舍曲林的临床疗效。

  6. Depression and Obstructive Sleep Apnea (OSA

    Directory of Open Access Journals (Sweden)

    O'Hara Ruth

    2005-06-01

    Full Text Available Abstract For over two decades clinical studies have been conducted which suggest the existence of a relationship between depression and Obstructive Sleep Apnea (OSA. Recently, Ohayon underscored the evidence for a link between these two disorders in the general population, showing that 800 out of 100,000 individuals had both, a breathing-related sleep disorder and a major depressive disorder, with up to 20% of the subjects presenting with one of these disorders also having the other. In some populations, depending on age, gender and other demographic and health characteristics, the prevalence of both disorders may be even higher: OSA may affect more than 50% of individuals over the age of 65, and significant depressive symptoms may be present in as many as 26% of a community-dwelling population of older adults. In clinical practice, the presence of depressive symptomatology is often considered in patients with OSA, and may be accounted for and followed-up when considering treatment approaches and response to treatment. On the other hand, sleep problems and specifically OSA are rarely assessed on a regular basis in patients with a depressive disorder. However, OSA might not only be associated with a depressive syndrome, but its presence may also be responsible for failure to respond to appropriate pharmacological treatment. Furthermore, an undiagnosed OSA might be exacerbated by adjunct treatments to antidepressant medications, such as benzodiazepines. Increased awareness of the relationship between depression and OSA might significantly improve diagnostic accuracy as well as treatment outcome for both disorders. In this review, we will summarize important findings in the current literature regarding the association between depression and OSA, and the possible mechanisms by which both disorders interact. Implications for clinical practice will be discussed.

  7. Depressive prototype narrative. A convergent validation in depressive patients

    OpenAIRE

    Leonardo Yovany Álvarez Ramírez

    2007-01-01

    The present study has the intention of establishing the identification that a group of depressed male subjects does with the narrative prototype of depression compared to a group of depressed female subjects. The sample was made of 65 depressive subjects and 65non depressive subjects for every group according to the genderwith ages between 16 and 40 years. The participants were derived from different centers of psychological attention of the city of Bucaramanga. An additional inclusion criter...

  8. Depression, Pain, and Pain Behavior.

    Science.gov (United States)

    Keefe, Francis J.; And Others

    1986-01-01

    Examined the degree to which depression predicted pain and pain behavior. The Beck Depression Inventory was administered to 207 low back pain patients. Depression and physical findings were the most important predictors of pain and pain behavior. Depression proved significant even after controlling for important demographic and medical status…

  9. Do You Have Major Depression?

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Depression Do You Have Major Depression? Past Issues / Fall 2009 Table of Contents Simple ... member may have major depression. —NIMH Types of Depression Just like other illnesses, such as heart disease, ...

  10. A Treatment-control Study of Aripiprazole and Ziprasidone in Female First-onset Schizophrenia%阿立哌唑与齐拉西酮治疗女性首发精神分裂症对照研究

    Institute of Scientific and Technical Information of China (English)

    许爱琴; 尤加永; 赵长银

    2013-01-01

    Objective:To evaluate the efficacy and adverse reactions of aripiprazole and ziprasidone in female first-onset schizophrenia.Method:31 female first-onset schizophrenia patients met the CCMD-3 diagnosis of schizophrenia were randomly assigned to aripiprazole group (36 patients) and ziprasidone group (35 cases). Positive symptoms and negative syndrome scale(PANSS) and treatment Emergent Symptom Scale(TESS) were used to evaluate the efficacy and safety.Result:There was no significant difference in PANSS scores(P>0.05) before and after 2,4,8 week’treatment between two groups. The two groups had no serious adverse reactions.Conclusion:Aripiprazole and ziprasidone were effective and less adverse reactions in treatment of female first-onset schizophrenia.%目的:评价齐拉西酮与阿立哌唑治疗女性首发精神分裂症的疗效与不良反应。方法:31例符合CCMD-3精神分裂症诊断标准的女性首发患者随机分为阿立哌唑(博思清)组(36例)和齐拉西酮(思贝格)组(35例),采用阳性症状与阴性症状量表(positive symptoms and negative symptoms scale,PANSS)评定疗效,副反应量表(treatment Emergent Symptom Scale,TESS)评价药物安全性。结果:两组患者治疗前及治疗后2、4、8 PANSS评分差异无显著性(P>0.05),两组均无严重不良反应。结论:阿立哌唑和齐拉西酮治疗女性首发精神分裂症有效,且不良反应少。

  11. 阿立哌唑应用于老年精神分裂症临床治疗的疗效和安全性%The clinical therapeutic effect and safety of aripiprazole in clinical treatment of senile schizophrenia

    Institute of Scientific and Technical Information of China (English)

    王琪

    2014-01-01

    目的:探讨阿立哌唑应用于老年精神分裂症临床治疗效果及安全性,总结其治疗经验。方法:2010年1月-2013年10月收治老年精神分裂症患者40例,采用阿立哌唑治疗,平均治疗剂量(18.5±5.5)mg/d,治疗8周后采用简明精神病评定量表(BPRS)评定临床疗效,不良反应量表(TESS)评定安全性。结果:显效率70.0%,有效率87.5%,无明显锥体外系反应,不良反应轻。结论:阿立哌唑应用于老年精神分裂症患者的治疗依从性好、安全性高,可以有效缓解老年精神分裂症的精神病症状,值得临床推广应用。%Objective:To explore the clinical therapeutic effect and safety of aripiprazole in clinical treatment of senile schizophrenia,to summarize the treatment experience.Methods:40 elderly patients with schizophrenia were selected from January 2010 to October 2013.They were treated with aripiprazole.Average dose was (18.5 ± 5.5)mg/day.At 8 weeks after treatment,the clinical efficacy was assessed by the brief psychiatric rating scale(BPRS),and security was assessed by side effects scale(TESS). Results:The significant efficiency rate was 70%,and the efficiency was 87.5%.There was no obvious extrapyramidal reaction,and adverse reaction was light.Conclusion:Treatment compliance of application of aripiprazole in clinical treatment of senile schizophrenia is good,and security is high.It can effectively alleviate psychotic symptoms of senile schizophrenia,and it is worth the clinical promotion.

  12. Adjustments and Depression

    Medline Plus

    Full Text Available ... us anything ⟟ Resources in your area ☇ Fundraise with Team Reeve Need to talk to someone? We’re ... are looking for more information on how to manage depression or have a specific question, our information ...

  13. Suicide and Depression

    Science.gov (United States)

    ... Sign-Up Save. Suicide Awareness Voices of Education Suicide and Depression Q&A Why do people kill ... does not become an option. Do people attempt suicide to prove something or to get sympathy? No. ...

  14. Adjustments and Depression

    Medline Plus

    Full Text Available ... our repository of fact sheets on hundreds of topics ranging from state resources to secondary complications of ... Center (MSKTC) maintains factsheets on a number of topics, including depression with a self-test to help ...

  15. Adjustments and Depression

    Medline Plus

    Full Text Available ... University of Washington provides pamphlets on depression with spinal cord injury and potential ... do I find a rehabilitation facility? How can I locate funding for rehabilitation ...

  16. Adjustments and Depression

    Medline Plus

    Full Text Available ... helplessness and confusion is to arm yourself with information on what a spinal cord injury is, and ... Karp Resources If you are looking for more information on how to manage depression or have a ...

  17. Adjustments and Depression

    Medline Plus

    Full Text Available ... grieving, taking control, talking about your disability, taking care of yourself, and looking ahead. Depression, however, is ... make it difficult for you to take good care of your health. Other symptoms include oversleeping, change ...

  18. Adjustments and Depression

    Medline Plus

    Full Text Available ... behaviors as well as other aspects of your life. Depression can cause physical and psychological symptoms. It ... loss of energy, take away your enjoyment of life and make it difficult for you to take ...

  19. Depression - older adults

    Science.gov (United States)

    ... these steps do not help, medicines to treat depression and talk therapy often help. Doctors often prescribe lower doses of antidepressants to older people, and increase the dose more slowly than in ...

  20. Vision in depressive disorder

    DEFF Research Database (Denmark)

    Bubl, E.; Tebartz Van Elst, L.; Ebert, D.;

    2009-01-01

    Background. Reduced dopaminergic transmission has been implicated in the pathophysiology of major depression. Furthermore, dopaminergic neurotransmission plays an important role in the physiology of visual contrast sensitivity (CS). To test the hypothesis that altered dopaminergic neurotransmissi...

  1. Identifying Depression on Twitter

    OpenAIRE

    Nadeem, Moin

    2016-01-01

    Social media has recently emerged as a premier method to disseminate information online. Through these online networks, tens of millions of individuals communicate their thoughts, personal experiences, and social ideals. We therefore explore the potential of social media to predict, even prior to onset, Major Depressive Disorder (MDD) in online personas. We employ a crowdsourced method to compile a list of Twitter users who profess to being diagnosed with depression. Using up to a year of pri...

  2. Sleep deprivation and depression

    OpenAIRE

    Elsenga, Simon

    1992-01-01

    The association between depression and sleep disturbances is perhaps as old as makind. In view of the longstanding experience with this association it is amazing that only some 20 years ago, a few depressed patients attracted attention to the fact that Total Sleep Deprivation (TSD) had antidepressant effects. A large number of studies have followed these observations. The purpose of the studies presented in this thesis was to evaluate the clinical usefulness of TSD and related procedures for ...

  3. LIFE EVENTS AND DEPRESSION

    OpenAIRE

    R N Chatterjee; Mukherjee, S. P.; Nandi, D.N.

    1981-01-01

    SUMMARY The life events occurring in a 6 month period preceding onset of illness in 50 OPD primary depressives were inquired into by a Life Events Inventory and compared with those in a corresponding time period of 50 matched controls. The relation between life events and the depth of depression at initial interview was also studied. The results are analysed and the probable pitfalls discussed.

  4. DISABILITY AND DEPRESSION AMONG HIGH UTILIZERS OF HEALTH-CARE - A LONGITUDINAL ANALYSIS

    NARCIS (Netherlands)

    VONKORFF, M; ORMEL, J; KATON, W; LIN, EHB

    1992-01-01

    We evaluated, among depressed medical patients who are high utilizers of health care, whether improved vs unimproved depression is associated with differences in the course of functional disability. At baseline, 6 months, and 12 months, depression and disability were assessed among a sample of enrol

  5. Remission of Depression in Parents: Links to Healthy Functioning in Their Children

    Science.gov (United States)

    Garber, Judy; Ciesla, Jeff A.; McCauley, Elizabeth; Diamond, Guy; Schloredt, Kelly A.

    2011-01-01

    This study examined whether improvement in parents' depression was linked with changes in their children's depressive symptoms and functioning. Participants were 223 parents and children ranging in age from 7 to 17 years old (M = 12.13, SD = 2.31); 126 parents were in treatment for depression and 97 parents were nondepressed. Children were…

  6. [Therapeutic education for recurrent depressive disorder].

    Science.gov (United States)

    Carde, Soufiane; Hatif, Séverine; Samama, Diane; Charbonnel, Patricia; Jouvent, Roland

    2016-01-01

    Depression is a serious and recurrent condition which can become chronic. As a complement to other therapeutic approaches, therapeutic patient education (TPE) or psychoeducation is effective. TPE groups led by a multidisciplinary hospitalisation team in a psychiatric department are thereby integrated into the global care in order to reduce relapses and improve patients' quality of life.

  7. Comparative Effectiveness of Psychotherapies for Depressed Elders.

    Science.gov (United States)

    Thompson, Larry W.; And Others

    1987-01-01

    Treated 91 elders with a major depressive disorder (MDD) using behavioral, cognitive, or brief psychodynamic psychotherapy. By the end of six weeks patients in all three treatment conditions showed improvement equally, whereas controls did not. Overall, 52 percent of the treatment sample attained remission by termination. The remainder still met…

  8. Interpersonal Psychotherapy for Postpartum Depression

    OpenAIRE

    Stuart, Scott

    2012-01-01

    Perinatal depression is prevalent and has a great impact on both mother and infant. There are empirically validated treatments for both postpartum depression and depression during pregnancy. Primary among these is interpersonal psychotherapy, which has been shown to be effective for postpartum women across the spectrum from mild to severe depression. At present, interpersonal psychotherapy is the best validated treatment for postpartum depression and should be considered first-line treatment,...

  9. Incidence of Depression and Associated Factors in Patients With Type 2 Diabetes in Quebec, Canada

    OpenAIRE

    Lunghi, Carlotta; Moisan, Jocelyne; Grégoire, Jean-Pierre; Guénette, Line

    2016-01-01

    Abstract It has been reported that the risk of depression is higher among people with type 2 diabetes compared with a nondiabetic population. Among diabetic patients, depression has been associated with worse self-care behaviors, poor glycemic control, and an increased risk of diabetes complications. Identifying factors associated with the occurrence of depression may help physicians identify earlier diabetic patients at a high risk of developing depression, improve prevention, and accelerate...

  10. The role of body image in prenatal and postpartum depression: a critical review of the literature

    OpenAIRE

    Silveira, Marushka L.; Ertel, Karen A.; Dole, Nancy; Chasan-Taber, Lisa

    2015-01-01

    Maternal depression increases risk of adverse perinatal outcomes, and recent evidence suggests that body image may play an important role in depression. This systematic review identifies studies of body image and perinatal depression with the goal of elucidating the complex role that body image plays in prenatal and postpartum depression, improving measurement, and informing next steps in research. We conducted a literature search of the PubMed database (1996– 2014) for English language studi...

  11. Screening for Depression in Hospitalized Pediatric Patients

    OpenAIRE

    Mohammad-Reza ESMAEELI; Reza ERFANI SAYAR; Ali SAGHEBI; ELMI, Saghi; Shagheyegh RAHMANI; Elmi, Sam; Akram RABBANI JAVADI

    2014-01-01

    How to Cite This Article: Esmaeeli M, Erfani Sayar R, Saghebi A, Elmi Saghi, Rahmani Sh, Elmi S, Rabbani Javadi A. Screening for Depression in Hospitalized Pediatric Patients. Iran J Child Neurol. 2014 Winter; 8(1):47-51. ObjectiveIn chronically ill children who are hospitalized, many mood changes occur. For example, in children with cancer or renal failure, prolonged hospitalization and chemotherapy can lead to depression. With the improved survival of childhoodmalignancies, the effect of tr...

  12. USE OF TRANYLCYPROMINE IN SEVERE RESISTANT DEPRESSION : A CASE REPORT

    OpenAIRE

    Maulik, Pallab K.; Das, Sudipto; Saxena, Shekhar

    1999-01-01

    This case report describes the improvement obtained by using tranylcypromine in a patient of severe treatment resistant depression. The adverse effects faced and steps taken to overcome them have also been discussed.

  13. Comparative Study on Aripiprazole and Risperidone in the Treatment of Schizophrenia%阿立哌唑与利培酮治疗精神分裂症的对照研究

    Institute of Scientific and Technical Information of China (English)

    彭红波

    2013-01-01

    目的比较阿立哌唑和利培酮对精神分裂症的疗效,为临床用药提供参考。方法以我院2011年1月~2012年9月收治的120例精神分裂症患者为研究对象,将患者随机分为治疗组和对照组,每组60例。对照组患者应用利培酮,治疗组患者服用阿立哌唑。观察两组的治疗效果以及不良反应。结果治疗组总有效率高于对照组,但是差异不具有统计学意义( P>0.05);两组患者PANSS总分、阳性症状分、阴性症状分、一般精神病理分治疗后明显比治疗前降低(P<0.05),但是组间比较差异不具有统计学意义(P>0.05);治疗组不良反应发生率明显低于对照组(P<0.05)。结论临床对精神分裂症采用阿立哌唑和利培酮治疗效果均较显著,两种药物疗效相似;但是采用阿立哌唑治疗的不良反应发生率少,因此阿立哌唑治可作为临床的首要选择。%Objective Objective To analyze effect of aripiprazole and risperidone in the treatment of schizo-phrenia ,and provide reference for clinical medication choice .Methods 120 cases with schizophrenia from in-patient department in January 2011 to September 2012 were selected .These patients were randomly di-vided into treatment group and control group , 60 cases in each group .Control group received risperidone , and treatment group received aripiprazole .Curative effect and adverse reaction for two groups were observed and compared .Results Total effective rate for treatment group was obviously higher than control group , but there were no significant difference ( P>0 .05 ) .PANSS score , positive symptoms score , negative symp-toms score and general psychopathology score after treatment were obviously lower than the score before treatment ( P0 .05 ) .Incidence of adverse effect was obviously lower than control group ( P<0.05 ) .Conclusion herapeutic effects of aripiprazole and risperi-done in the treatment of

  14. 阿立哌唑和利培酮治疗女性精神分裂症对照研究%Aripiprazole and Risperidone in the Treatment of Female Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    姜丽艳

    2014-01-01

    目的:研究女性精神分裂症患者运用阿立哌唑和利培酮治疗的临床效果。方法2012年4月~2013年4月间诊治的160例女性精神分裂症患者,将其分为两组,组1使用阿立哌唑进行治疗,组2使用利培酮进行治疗,比较两组患者的临床效果。结果通过对两组患者进行比较,组1有效率为87.5%,组2为90.0%,两组患者临床效果未见明…显差异,无统计学意义(P >0.05);但组2患者的体质量增加情况、椎体外系反应的发生率、泌乳以及月经紊乱情况均比组1高,两组患者差异显著,有统计学意义(P <0.05)。结论对于女性精神分裂症治疗上效果上阿立哌唑和利培酮基本一致,但是阿立哌唑更适合用于女性精神分裂症患者。%Objective To study the clinical effect of female schizophrenia with aripiprazole and risperidone in the treatment of patients with. Methods 160 cases of female spirit in 2012 April ~2013 April in the diagnosis and treatment of patients with schizophrenia,it is divided into two groups, group 1 were treated by aripiprazole risperidone group, 2 were treated by comparison of the clinical effects of two groups of patients. Results The two groups of patients were compared, the group has an efficiency of 1 for 87.5%, group 2 to 90%,The patients in the two groups no significant differences in clinical effect, no statistical significance (P>0.05), but the group of 2 patients with body mass increase, extrapyramidal reaction rate, lactation and menstrual disorders are 1 higher than group, the differences between the two groups were significant, with statistical significance (P<0.05). Conclusion For the treatment of female schizophrenia aripiprazole and risperidone effect on basically the same,but aripiprazole is more suitable for female patients with schizophrenia.

  15. Depression in hemodialysis patients

    International Nuclear Information System (INIS)

    To measure the frequency of depression and its risk factors in patients under going hemodialysis. It is a cross-sectional prospective study conducted at Hemodialysis unit of Shalamar Hospital and Shaikh Zayed Hospital, Lahore from 1/sup st/ January 2006 to 30/sup th/ April 2006. All patients getting regular hemodialysis for more than three months were included. Beck's Depression Inventory- II (BDI-II; adapted in Urdu) was administered on all the patients who were able to read or understand it. Blood sample were drawn at the same time for routine hematological, biochemical parameters and viral markers (Anti HCV and HbsAg). Diagnosis was made as per Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM IV) for correlation of psychological variables with clinical, hematological and biochemical parameters. Eighty nine patients were enrolled which included fifty two (58.4%) were male and seventy seven (86.5%) were married. Major causes of renal failure were diabetes, hypertension and chronic glomerulonephrotis. Duration of dialysis was from 03 to 49 months with mean of 19.64 +- 11.7 months. Severity of depression was categorized in to mild, moderate and severe on the basis of BDI score. Majority of the patients fifty (56.1%) were moderately to severely depressed and there was no gender difference in the prevalence of depression. Majority of patients undergoing hemodialysis were depressed. Major risk factors for depression were marital status, illiteracy, number of children, socioeconomic factors, gender, hypertension and hypoalbuminemia. Patients with anemia, hyponatremia and hyperkalemia had suicidal tendency. Patients with hepatitis C and disturbed liver function have strong correlation with psychological parameters. (author)

  16. Poststroke depression: Diagnosis of depression, phenomenology and specificity of depressive symptoms

    Directory of Open Access Journals (Sweden)

    Rabi-Žikić Tamara

    2009-01-01

    Full Text Available The diagnosis of depression. Depressive disorder is nowadays diagnosed by the two widely used diagnostic systems - International Classification of Diseases of the World Health Organization, 10th revision and the Diagnostic and Statistical Manual Criteria of the American Psychiatric Organisation, 4th edition. The criteria for depressive disorder used in these two systems are almost identical. Poststroke depression. The diagnosis of depression may be difficult to establish in stroke patients, especially in patients with aphasia/dysphasia, anosognosia and other cognitive dysfunction. Major vs. minor poststroke depression, specificity and sensitivity of depressive symptoms: The phenomenology of major poststroke depression has been found to be similar to that of primary depression, and it appears that minor and major are not stages of the same continuum, but rather separate entities. Contrary to common opinion, non specific somatic symptoms do not hinder the diagnosis of poststroke depression and can be highly discriminative and crucial in the evaluation of poststroke depression. Validity of the poststroke depression diagnosis Studies have shown that a valid diagnosis of poststroke depression may be established successfully using structured or semi-structured neuropsychiatric interviews, according to the current Diagnostic and Statistical Manual Criteria. Conclusion. It appears that no new diagnostic tools specific for major depression in stroke patients are necessary. The existing diagnostic procedures will fail to diagnose or misdiagnose depression only in few stroke patients.

  17. To observe the clinical effect of aripiprazole and risperidone in the treatment of female schizophrenia%阿立哌唑与利培酮治疗女性精神分裂症的临床效果探讨

    Institute of Scientific and Technical Information of China (English)

    龚日东; 黄书梅

    2014-01-01

    Objective To investigate the clinical effect of aripiprazole and risperidone in the treatment of female schizophrenia. Methods 100 cases of female spirit admitted in our hospital in 2012 January to 2014 January between the schizophrenia patients for clinical research,The patients were randomly divided into aripiprazole group and risperidone group, compared two groups of patients with clinical curative effect. Results In the two groups before treatment PANSS clinical psychopathology, negative symptoms, positive symptoms and score of contrast was no significant statistical difference (P>0.05), the clinical treatment for 2 weeks, 4 weeks of treatment and 8 weeks after the treatment, PANSS psychopathology, negative symptoms, positive symptoms and total score compared with the statistically significant difference (P0.05),临床治疗2周、治疗4周和治疗8周后PANSS精神病理、阴性症状、阳性症状和总分对比差异具有统计学意义(P<0.05)。两组女性精神分裂症患者临床治疗的总有效率和不良反应发生率对比差异具有统计学意义(P<0.05)。结论该次医学研究结果证实,阿立哌唑用于女性精神分裂症的临床治疗,具有更高的有效率和安全性,因而临床推广和应用价值更高。

  18. Major depression and severe weight loss

    Directory of Open Access Journals (Sweden)

    Ntrogkounta Α.

    2015-10-01

    Full Text Available Α 25-year old patient was referred to the casualty department of the Community Mental Health Center of Central Sector of Thessaloniki from the emergency department of the Psychiatric Hospital of Thessaloniki, in order to manage symptoms of depression as long as her life- threating loss of weight. A. appeared to have depressive feelings, lack of appetite, lack of interest, withdrawal, sleep disorders, sexual disorders, low self-esteem and ideas of guilt. There were held 27 conferences. In the beginning there were supportive intervations in order to improve the depressive symptoms and to gain weight. Moreover we applied medication (SSRI's that after 6 months was stopped gradually, without any setback. There was an increase of weight, about 10 kg, which remained until the follow up one year later.

  19. Effect of Sahaj Yoga on depressive disorders.

    Science.gov (United States)

    Sharma, V K; Das, S; Mondal, S; Goswampi, U; Gandhi, A

    2005-01-01

    Sahaj Yoga is a meditative technique that has been found to have beneficial effects in some psycho-somatic illnesses. The study was carried out on 30 cases (19 Males, 11 females, age 18-45 years) of major depression diagnosed on the basis of DSM IV criteria. The patients were then randomly divided into two groups: Group 1: (10 Males & 5 Females) Patients who were practising Sahaj Yoga and also received conventional anti-depressants. Group 2: (9 Males & 6 Females) Patients who were only receiving conventional anti-depressants. Training in Sahaj yoga was conducted under the supervision of a trained Sahaj Yogi for 8 weeks. At start of the study, all the patients were subjected to Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A). Above scales were again assessed after two months of treatment. There was significant improvement in HAM-D as well as HAM-A scores in both Group 1 and Group 2 patients (PYoga was significantly higher than in Group 2 patients. The number of patients who went into remission after two months of intervention were also significantly higher in Group 1 patients (P=0.02). The present study demonstrates that Sahaj Yoga has got a potential role as a component in the management of depressive disorders. PMID:16579401

  20. Magnesium in depression.

    Science.gov (United States)

    Serefko, Anna; Szopa, Aleksandra; Wlaź, Piotr; Nowak, Gabriel; Radziwoń-Zaleska, Maria; Skalski, Michał; Poleszak, Ewa

    2013-01-01

    Magnesium is one of the most essential mineral in the human body, connected with brain biochemistry and the fluidity of neuronal membrane. A variety of neuromuscular and psychiatric symptoms, including different types of depression, was observed in magnesium deficiency. Plasma/serum magnesium levels do not seem to be the appropriate indicators of depressive disorders, since ambiguous outcomes, depending on the study, were obtained. The emergence of a new approach to magnesium compounds in medical practice has been seen. Apart from being administered as components of dietary supplements, they are also perceived as the effective agents in treatment of migraine, alcoholism, asthma, heart diseases, arrhythmias, renal calcium stones, premenstrual tension syndrome etc. Magnesium preparations have an essential place in homeopathy as a remedy for a range of mental health problems. Mechanisms of antidepressant action of magnesium are not fully understood yet. Most probably, magnesium influences several systems associated with development of depression. The first information on the beneficial effect of magnesium sulfate given hypodermically to patients with agitated depression was published almost 100 years ago. Numerous pre-clinical and clinical studies confirmed the initial observations as well as demonstrated the beneficial safety profile of magnesium supplementation. Thus, magnesium preparations seem to be a valuable addition to the pharmacological armamentarium for management of depression. PMID:23950577

  1. The Effects of a Problem Solving-Based Intervention on Depressive Symptoms and HIV Medication Adherence Are Independent

    NARCIS (Netherlands)

    Gross, Robert; Bellamy, Scarlett L.; Chapman, Jennifer; Han, Xiaoyan; O'Duor, Jacqueline; Strom, Brian L.; Houts, Peter S.; Palmer, Steven C.; Coyne, James C.

    2014-01-01

    Depression and depressive symptoms predict poor adherence to medical therapy, but the association is complex, nonspecific, and difficult to interpret. Understanding this association may help to identify the mechanism explaining the results of interventions that improve both medical therapy adherence

  2. Postpartum Blues and Postpartum Depression

    Directory of Open Access Journals (Sweden)

    Erdem Ö et al.

    2009-09-01

    Full Text Available Postpartum blues which is seen during the postpartum period is a transient psychological state. Most of the mothers experience maternity blues in postpartum period. It remains usually unrecognized by the others. Some sensitive families can misattribute these feelings as depression. In this article, we tried to review the characteristics of maternity blues and its differences from depression. We defined depression and presented the incidence and diagnostic criteria, of major depression as well as the risk factors and clinic findings of postpartum depression. Thus, especially at primary care we aimed to prevent misdiagnosis of both maternity blues and depression

  3. Comparison of Efficacy and Prolactin Concentrations between Aripiprazole and Risperidone Treat-ments in Patients with Schizophrenia%阿立哌唑替换利培酮治疗对精神分裂症患者血清催乳素水平的影响

    Institute of Scientific and Technical Information of China (English)

    马筠; 李轶琛; 李毅; 房茂胜; 钟宝亮

    2013-01-01

    Objective: To compare the prolactin concentrations between aripiprazole and risperidone treatment in patients with schizophrenia. Methods: One hundred and twenty-eight schizophrenic patients with hy-perprolactinemia were randomly divided into risperidone group and aripiprazole group. Patients in the risperidone group were treated with risperidone and in the aripiprazole group were treated with aripiprazol instead of risperidone for 8 weeks. The prolactin concentrations were assessed and compared between two groups at weeks 0, 1,2, 4, 6, and 8. The clinical status was assessed by using the positive and negative syndrome scale (PANSS) and the clinical global impressions scale (CGIS) atweeks0 and 8. Results: Fifty-three in the risperidone group and 48 in the aripiprazole group were available for analyzing. Shift risperidone to aripiprazole was effective in reducing serum prolactin levels. The serum prolactin levels in the risperidone group was significantly lower than that in the aripiprazole group at week 8 (P<0.001). No significant changes was found in the PANSS and CGI-S scores between the two groups. Conclusion: Shift risperidone to aripiprazole was effective in reducing serum prolactin levels of schizophrenia patients with hyperprolactinemia.%目的:研究阿立哌唑替换利培酮治疗对精神分裂症患者血清催乳素水平的影响.方法:伴有高催乳素血症的精神分裂症患者128 例,随机分为利培酮组(维持利培酮治疗)和阿立哌唑(阿立哌唑替代利培酮治疗)组,治疗8 周.于第0、1、2、4、6 及8 周测血清催乳素水平及身体质量指数(BMI);在入组时和治疗8 周时采用阳性与阴性症状量表(PANSS)和临床总体印象量表(CGIS)测定疗效.结果:可用于评估的数据101 例,利培酮组53 例,阿立哌唑组48 例.阿立哌唑组替换治疗后第1 周血清催乳素水平即明显下降,第8 周时,显著低于利培酮组(P<0.001);2 组BMI 、PANSS 及CGIS 评分及变化差异无统计

  4. Physical activity & depression

    Directory of Open Access Journals (Sweden)

    Tsiantoula E.

    2012-07-01

    Full Text Available Depression is a major public health disorder. Clinical depression is the most frequent disability in North America among other countries and by 2020 it is estimated that it will represent the second most common disability worldwide. Physical activity can be used to prevent as well as treat depression. Its characteristics and structure should be individualized to the personality and special needs of the patient as well as to the severity of the disorder. Intensity, duration and the place of performance are of special importance. Research has identified neurobiological and psychological paths that can develop between physical activity and well being. More studies although are needed in order to standardize the use of physical activity as a treatment option, mainly in the groups of children and teenagers.

  5. Depression in new fathers.

    Science.gov (United States)

    2016-07-01

    There is a growing awareness about the burden of ill-health experienced by men. Research has shown that fatherhood has a protective effect on men's health. However, the transition can be complex and demanding, and may cause distress, anxiety and increased risk of depression. This article discusses paternal postnatal depression, which is a significant public health issue that is not acknowledged widely or well researched. As a result, men are under-screened, under-diagnosed and under-treated for the condition and other postnatal mental health problems, causing detrimental effects on their health and negative effects on the health and wellbeing of mother and child. Read Paternal postnatal depression: an overview for primary healthcare professionals in Primary Health Care. PMID:27387639

  6. Risk factors for antenatal depression, postnatal depression and parenting stress

    Directory of Open Access Journals (Sweden)

    Milgrom Jeannette

    2008-04-01

    Full Text Available Abstract Background Given that the prevalence of antenatal and postnatal depression is high, with estimates around 13%, and the consequences serious, efforts have been made to identify risk factors to assist in prevention, identification and treatment. Most risk factors associated with postnatal depression have been well researched, whereas predictors of antenatal depression have been less researched. Risk factors associated with early parenting stress have not been widely researched, despite the strong link with depression. The aim of this study was to further elucidate which of some previously identified risk factors are most predictive of three outcome measures: antenatal depression, postnatal depression and parenting stress and to examine the relationship between them. Methods Primipara and multiparae women were recruited antenatally from two major hoitals as part of the beyondblue National Postnatal Depression Program 1. In this subsidiary study, 367 women completed an additional large battery of validated questionnaires to identify risk factors in the antenatal period at 26–32 weeks gestation. A subsample of these women (N = 161 also completed questionnaires at 10–12 weeks postnatally. Depression level was measured by the Beck Depression Inventory (BDI. Results Regression analyses identified significant risk factors for the three outcome measures. (1. Significant predictors for antenatal depression: low self-esteem, antenatal anxiety, low social support, negative cognitive style, major life events, low income and history of abuse. (2. Significant predictors for postnatal depression: antenatal depression and a history of depression while also controlling for concurrent parenting stress, which was a significant variable. Antenatal depression was identified as a mediator between seven of the risk factors and postnatal depression. (3. Postnatal depression was the only significant predictor for parenting stress and also acted as a mediator

  7. Screening for Depression In Hospitalized Pediatric Patients

    Directory of Open Access Journals (Sweden)

    Mohammad-Reza ESMAEELI

    2014-01-01

    Full Text Available How to Cite This Article: Esmaeeli M, Erfani Sayar R, Saghebi A, Elmi Saghi, Rahmani Sh, Elmi S, Rabbani Javadi A. Screening for Depression in Hospitalized Pediatric Patients. Iran J Child Neurol. 2014 Winter; 8(1:47-51. ObjectiveIn chronically ill children who are hospitalized, many mood changes occur. For example, in children with cancer or renal failure, prolonged hospitalization and chemotherapy can lead to depression. With the improved survival of childhoodmalignancies, the effect of treatment on child’s psychosocial well-being becomes increasingly relevant. In this study, we examined the prevalence of depression in hospitalized children with chronic and acute conditions in Dr Sheikh Pediatrics Hospital in Mashhad.Materials & MethodsAfter receiving the approval from the Ethics Committee of Mashhad University of Medical Sciences, we did this cross-sectional descriptive study, from April to June 2012 in Dr Sheikh Pediatric Hospital in Mashhad. Ninety children, aged between 8 to 16 years, were screened for depression. The sampling method was census. Children with a history of depressive or other mental disorders were excluded.Three groups of children (children with chronic renal disease, malignancy, and acute disease were evaluated for depression using standard Children Depression Inventory Questionnaire (CDI. Two specifically trained nurses with the supervisionof a psychiatrist filled out the questionnaires at patients’ bedside. Depression scores were then analyzed by SPSS software.ResultsOf 90 children, 43(47.7% were male and 47(52.2% were female. The Children’s mean age was 11±2.3 years, and the mean length of hospitalization was 8±5.3 days.Depression was detected in various degrees in 63% of patients (N=57, and 36.6% of children (N=32 had no symptoms of depression. Severe depression was not seenin any of the patients with acute illness. More than half of patients with cancer and chronic kidney disease had moderate

  8. STUDY OF DEPRESSION IN SCHIZOPHRENIA

    Directory of Open Access Journals (Sweden)

    Dharmesh V

    2014-06-01

    Full Text Available : BACKGROUND: The presence of depression in schizophrenia has been recognized since the time of Kraepelin and Bleuler. Depressive symptoms associated with schizophrenia have received considerable attention in recent years. It has been suggested that patient may manifest depressive symptoms during the onset of psychotic symptoms, during course of chronic schizophrenia or after the psychotic symptoms has been abated. AIMS & OBJECTIVES: 1. To study the prevalence of depression in schizophrenia. 2. To study the correlation between depression and subtype of schizophrenia. MATERALS & METHODS: 50 consecutive patients suffering from schizophrenia according to DSM-IV criteria, who were brought to psychiatric OPD were selected for this study. Patients between 15-55years age were included in this study. HDRS (Hamilton depression rating scale was administered to all patients to assess severity of depression. RESULTS: Out of 50 patients suffering from schizophrenia, 44% of patients suffering from schizophrenia were depressed. In this study the most common symptoms of depression were depressed mood, loss of interest on pleasure, sleep disturbance, loss of energy/fatigue, psychomotor disturbance, suicidal thought or death wish, feeling of hopelessness. CONCLUSION: Depression is common in patients suffering from schizophrenia. The severity of depression was mild to moderate, no one had severe depression. It is more common in patients who are living in nuclear family, who are divorced, who have paranoid type of schizophrenia, who were not on antipsychotic medicine.

  9. Paroxetine versus other anti-depressive agents for depression

    OpenAIRE

    Cipriani, Andrea; Furukawa, Toshi A.; Veronese, Antonio; Watanabe, Norio; Churchill, Rachel; McGuire, Hugh; Barbui, Corrado

    2007-01-01

    This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the efficacy of paroxetine in comparison with other anti-depressive agents in alleviating the acute symptoms of major depressive disorder.To review acceptability of treatment with paroxetine in comparison with other anti-depressive agents.To investigate the adverse effects of paroxetine in comparison with other anti-depressive agents.

  10. Effects of PDCA nursing model on improving negative emotion and mood state of patients with depression%PDCA护理模式在改善抑郁症患者不良情绪及心境状态中的效果

    Institute of Scientific and Technical Information of China (English)

    高秀君; 王建女; 王颖

    2016-01-01

    Objective To explore the effects of PDCA nursing model on improving negative emotion and mood state of patients with depression. Methods A total of 70 patients with depression in our hospital between January 2013 and June 2014 were randomly divided into control group ( routine depression nursing group) and observation group ( PDCA nursing intervention group) with 35 cases in each group. The emotion and mood state of two groups before and after intervention were evaluated with Zung′s self-rating depression scale ( SDS) , positive and negative affect schedule ( PANAS) and profile of mood state ( POMS) . Results After the intervention, the scores of SDS, PANAS and POMS in the observation group were all improved more than those in the control group at 1w, 2w and 4w. The differences between two groups were statistically significant ( P<0. 05). Conclusions PDCA nursing model can improve the negative emotion and mood state of patients with depression and help recovery of disease.%目的:观察PDCA护理模式在改善抑郁症患者不良情绪与心境状态中的效果。方法选取2013年1月—2014年6月于本院进行诊治的70例抑郁症患者为研究对象,根据随机分配的原则分为对照组(常规抑郁症护理组)和观察组( PDCA护理干预组)各35例,采用Zung抑郁自评量表( SDS)、积极情感消极情感量表( PANAS)及心境状态量表( POMS)评估患者干预前后不同时间点的心理情绪状态及心境状态。结果观察组患者护理干预后1周、2周、4周时各量表评分结果均优于对照组患者,差异有统计学意义(P<0.05)。结论 PDCA护理模式在改善抑郁症患者不良情绪与心境状态中的效果较好,为患者疾病状态的改善奠定了基础。

  11. Dietary Treatment Options for Depression among Diabetic Patient, Focusing on Macronutrients

    Directory of Open Access Journals (Sweden)

    Fahimeh Haghighatdoost

    2013-01-01

    Full Text Available There is a bidirectional adverse association between diabetes and depression. The odds for experiencing depressive symptoms in diabetic patients are two times more than nondiabetic persons, and depression is an independent predictor for the onset of diabetes. However, depression has been approximately unrecognized and untreated in two-thirds of diabetic patients, which may lead to worsened diabetes complications. A cornerstone strategy for managing depression among diabetic patients is the use of diet to improve both health problems. Because of similar pathophysiology for chronic diseases and depression, it seems that similar dietary recommendations could be useful. However, few studies have been conducted among diabetic patients. Regarding the complications of diabetes such as renal diseases and coronary heart diseases, the proper range of various macronutrients should be clarified in depressed diabetic patients as well as the proper type of each macronutrient. In this paper, we reviewed the available data on the treatment of depression in diabetic patients.

  12. Major Depression and Complicated Grief

    Science.gov (United States)

    ... grieving process Symptoms of major depression and complicated grief Depression It’s common for people to have sadness, ... pain or trying to avoid letting go. Complicated grief If normal mourning does not occur, or if ...

  13. Symptoms and Treatment of Depression

    Medline Plus

    Full Text Available ... Autism (12 items) Bipolar Disorder (1 item) Borderline Personality Disorder (3 items) Depression (16 items) Eating Disorders ( ... Autism (12 items) Bipolar Disorder (1 item) Borderline Personality Disorder (3 items) Depression (16 items) Eating Disorders ( ...

  14. Depression Plagues Many with COPD

    Science.gov (United States)

    ... nlm.nih.gov/medlineplus/news/fullstory_159436.html Depression Plagues Many With COPD Studies found 1 in ... pulmonary disorder (COPD) may raise the risk of depression among patients with the incurable respiratory illness, two ...

  15. Depression in an evolutionary context

    OpenAIRE

    Wolpert Lewis

    2008-01-01

    Abstract Sadness and low levels of depression are adaptive since they lead the individual to try and make up a loss. By contrast, severe or clinical depression is not adaptive, but can be thought of as sadness having become malignant.

  16. Symptoms and Treatment of Depression

    Medline Plus

    Full Text Available ... with Traumatic Events (3 items) NIMH (24 items) Symptoms and Treatment of Depression February 1, 2010 People ... is a serious illness that affects many people. Symptoms can vary, but many depressed people lose interest ...

  17. Symptoms and Treatment of Depression

    Medline Plus

    Full Text Available ... items) Autism (12 items) Bipolar Disorder (2 items) Borderline Personality Disorder (3 items) Depression (16 items) Eating ... items) Autism (12 items) Bipolar Disorder (2 items) Borderline Personality Disorder (3 items) Depression (16 items) Eating ...

  18. Depression Plagues Many with COPD

    Science.gov (United States)

    ... page: https://medlineplus.gov/news/fullstory_159436.html Depression Plagues Many With COPD Studies found 1 in ... pulmonary disorder (COPD) may raise the risk of depression among patients with the incurable respiratory illness, two ...

  19. Facebook Bullying Can Cause Depression

    Science.gov (United States)

    ... page: https://medlineplus.gov/news/fullstory_160991.html Facebook Bullying Can Cause Depression Social media attacks have ' ... Sept. 15, 2016 (HealthDay News) -- Negative experiences on Facebook can increase the odds of depression in young ...

  20. Symptoms and Treatment of Depression

    Medline Plus

    Full Text Available ... Hyperactivity Disorder (ADHD) (3 items) Autism (12 items) Bipolar Disorder (2 items) Borderline Personality Disorder (3 items) Depression ( ... Hyperactivity Disorder (ADHD) (3 items) Autism (12 items) Bipolar Disorder (2 items) Borderline Personality Disorder (3 items) Depression ( ...

  1. Postpartum Depression: An Interactional View.

    Science.gov (United States)

    Kraus, Mary Ann; Redman, E. Scott

    1986-01-01

    Postpartum depression is conceptualized as a predictable developmental, family crisis, which occurs when the natural difficulties of childbirth are benignly mishandled. Tactics are illustrated for interdicting maladaptive interpersonal spirals, including normalizing conflicting complaints; reframing depression as positive but costly; regulating…

  2. Racial/Ethnic disparities in depression and its theoretical perspectives.

    Science.gov (United States)

    Kim, Minjeong

    2014-03-01

    The purpose of this review is to look at racial/ethnic disparities in the diagnosis of depression and its treatment and to explain the dynamics and causes of these racial/ethnic disparities in depression by looking at several theories, such as perceived racism, cultural competency, and other theories. Perceived racism is that the perceptions of an environmental stimulus as being racist affects the coping responses of ethnic/racial minorities, which alters psychological and physiological stress responses, and finally affects health outcomes negatively. A lower level of cultural competence can lead to health disparities. In addition, lower socioeconomic status and health care providers' beliefs and behaviors about patients' race/ethnicity and class can affect depressive symptoms as well as diagnosis and treatment. In order to reduce these racial/ethnic disparities in depression, diverse interventions should be developed to improve depression outcomes for ethnic minority populations based on these theoretical perspectives. PMID:23801269

  3. Study of proportion and determinants of depression among college students in Mangalore city

    Directory of Open Access Journals (Sweden)

    Sarah Naushad

    2014-01-01

    Full Text Available Background: Onset of depression is occurring earlier in life today than in past decades. Adolescence being transitional period from childhood to adulthood is a stage of emotional instability resulting from demand for separation and independence. Evidence suggests that early intervention for depression in children can improve long-term outcomes. Materials and Methods: This cross-sectional study was done in January 2010 to find out the prevalence of depression among pre university students in Mangalore city. Prevalence of depression was assessed using Beck′s Depression Inventory II. Data was collected using a self-administered questionnaire. Results: Out of 308 participants, depression was seen among 79.2% students. A majority (41.2% were found to be suffering from moderate followed by mild (26.6% depression. Prevalence of depression (P = 0.027 and severity of depression (P = 0.0357 was found to significantly increase with age of the participants. Students of commerce were found to be significantly more depressed than students of science stream (P = 0.002. No association of depression with gender of participants or with the type of college they were studying in was observed. Conclusion: There is a need for college students to be educated about depression in order to improve recognition and diagnosis. Also student counselling service offering mental health assistance needs to be established at colleges.

  4. Depression in Childhood and Adolescence

    OpenAIRE

    Maughan, Barbara; Collishaw, Stephan; Stringaris, Argyris

    2013-01-01

    Objective: To review recent evidence on child and adolescent depression.Method: Narrative review.Results: Rates of unipolar depression are low before puberty, but rise from the early teens, especially among girls. Concurrent comorbidity with both disruptive and emotional disorders is common, especially among younger children; across age, youth depression may be preceded by both anxiety and disruptive behaviour disorders, and increase risk for alcohol problems. Adolescent depression is associa...

  5. : Socioeconomic position and depression persistence.

    OpenAIRE

    Melchior, Maria; Chastang, Jean-François; Leclerc, Annette; Ribet, Céline; Rouillon, Frédéric

    2010-01-01

    International audience Research examining the association between socioeconomic position and depression course has yielded inconsistent results. We tested the association between low socioeconomic position and 7-year depression persistence among 298 community-based individuals with depression (subset of the GAZEL cohort study based in France). Data were analyzed using Generalized Estimating Equation (GEE models). Low socioeconomic position predicted depression persistence (men: low vs. int...

  6. Depressive Illness: Pervasive Yet Mystifying.

    Science.gov (United States)

    Blai, Boris, Jr.

    Doctors annually treat between approximately four and eight million Americans for depression. Behavioral changes in depressed individuals are characterized by sadness, loneliness, and apathy. Other symptoms include fatigue, early morning insomnia, loss of appetite, and suicide attempts. Underlying depression may mask itself in physical symptoms,…

  7. Depression in Children and Adolescents

    Science.gov (United States)

    Davis, Noel M.

    2005-01-01

    During the past 20 years, depression has been recognized widely in children and adolescents. However, even with what is known today about depression, many children and adolescents remain undiagnosed. Early recognition is imperative to prevent further episodes that may continue into adulthood. Depression in children and adolescents affects social…

  8. Sadness, Depression, and Avoidance Behavior

    Science.gov (United States)

    Leventhal, Allan M.

    2008-01-01

    Research into genetic, psychosocial, and cognitive explanations for depression (biopsychosocial models) provides support for the role of these variables in the etiology of depression. Regularly identified as basic to depression is loss, and the experience of loss has been found to be more influential than genetic factors in the causation of…

  9. Postpartum Depression and Child Development.

    Science.gov (United States)

    Murray, Lynne, Ed.; Cooper, Peter J., Ed.

    Only recently has the research on postpartum depression dealt with the disorder's effects on child development. This book explores the impact of postpartum depression on mother-infant interaction and child development, its treatment, and postpartum psychosis. The chapters are: (1) "The Nature of Postpartum Depressive Disorders" (Michael O'Hara);…

  10. Symptoms and Treatment of Depression

    Medline Plus

    Full Text Available ... items) Treatments (11 items) Symptoms and Treatment of Depression February 1, 2010 People with depression discuss how they got help.   Watch on ... for me to do anything for myself. NARRATOR : Depression is more than just a feeling of being ...

  11. [Toloxatone and depression].

    Science.gov (United States)

    Fernández Labriola, R; Caetano Esquivel, G; Alvarez, M; Servidio, M

    1991-12-01

    One hundred and one depressed inpatients were treated by the authors with a second-generation antidepressive original molecule: Toloxatone, a specific and reversible MAO A inhibitor. Upon admission, all 101 patients with depressive illness did not score higher than 20 on Hamilton's Scale, and did not score lower than 4 on Fischer, Fernández Labriola and Rodríguez Casanova's Endogeneity Test. Biological profiles (Phenyl-ethylamine, NA, and MHPG) were available on 57 subjects. At the beginning of the experiment: (a) No subject was taking antidepressives, (b) Patients' age averaged 46; (c) The 6-week experiment was a double-blind vs. placebo type. Daily toloxatone dose was standardized in a 400 mg intake. Significant modifications were detected in 51 subjects. Among the 59 subjects that were administered active substance, 37 achieved either "excellent" or "good" outcomes. Biological markers pointed out a profile of patients with a better response to Toloxatone: Namely, patients with a lower noradrenergic activity. Anxiety-free depression as well as inhibited depressions are a psychiatrist's choice for administering Toloxatone. PMID:1843597

  12. Genetic Determinants of Depression

    NARCIS (Netherlands)

    S. López León (Sandra)

    2008-01-01

    textabstractThe aim of the studies in this genetic epidemiological thesis was to investigate candidate genes that play a role in the etiology of depression and to obtain new insights about biological pathways that may be involved in this disorder. The introduction of the thesis presents a review of

  13. Depressive Stories for Children

    Science.gov (United States)

    Tucker, Nicholas

    2006-01-01

    While stories with a depressing message are now common for teenagers, resistance to them remains where smaller children are concerned. But is this more a case of the publishers and providers concerned protecting their own particular image of childhood? This article looks at the case for books that also convey a sense of sadness to infants,…

  14. Adjustments and Depression

    Medline Plus

    Full Text Available ... what it means in terms of short-term planning and long-range goals. However, depression can be ... Ask us anything Get a peer mentor Find resources in your area Join ... Department of Health and Human Services, Washington, D.C. 20201. Grantees undertaking projects ...

  15. Plain Talk about Depression. Plain Talk Series.

    Science.gov (United States)

    Sargent, Marilyn

    Depression is defined as a "whole-body" illness, involving the body, mood, and thoughts. Three of the most prevalent types of depressive disorders are described: major depression, dysthymia, and bipolar disorders (formerly called manic-depressive illness). Eleven symptoms of depression and 10 symptoms of mania are listed. Causes of depression are…

  16. Cushing's Syndrome Masquerading as Treatment Resistant Depression

    OpenAIRE

    Anil Kumar, B. N.; Sandeep Grover

    2016-01-01

    Treatment resistant depression (TRD) is a common clinical occurrence among patients treated for major depressive disorder. A significant proportion of patients remain significantly depressed in spite of aggressive pharmacological and psychotherapeutic approaches. Management of patient with treatment resistant depression requires thorough evaluation for physical causes. We report a case of recurrent depressive disorder, who presented with severe depressive episode without psychotic symptoms, n...

  17. Apathy, alexithymia, and depressive symptoms: Points of convergence and divergence.

    Science.gov (United States)

    Ready, Rebecca E; Mather, Molly A; Santorelli, Gennarina D; Santospago, Breanna P

    2016-10-30

    This study determined convergence and divergence in the constructs of alexithymia, apathy, and depressive symptoms. Understanding of similarities and differences between these constructs will improve diagnostic accuracy for clinical and research purposes. Community-dwelling participants (N=622, M age=35.6 years, SD=13.1) completed online measures of alexithymia, depression, and apathy; 12.2% were alexithymic, 37.8% reported significant depressive symptoms, and 24.9% reported significant apathy. Exploratory Factor Analyses (EFAs) determined the best factor structure for the apathy, alexithymia, and depressive symptoms was comprised of three factors and accounted for 45.1% of item variance. The Depression, Apathy, and Alexithymia factors were defined most strongly by item content that is at the core of each construct. Depression was defined most highly by items assessing sadness, low self-esteem, and loneliness. The strongest item loadings for Alexithymia were difficulty identifying and describing feelings. Apathy was characterized by poor motivation, low interest, and lack of initiative. However, each of these core and defining features had significant cross-loadings on one of the other two factors. Negative affect shared variance with Apathy, low motivation shared variance with Depression, and difficulty describing and identify feelings shared variance with Depression and Apathy. Clinical and research implications are discussed. PMID:27512920

  18. Dependency and self-criticism in treatments for depression.

    Science.gov (United States)

    Chui, Harold; Zilcha-Mano, Sigal; Dinger, Ulrike; Barrett, Marna S; Barber, Jacques P

    2016-07-01

    Dependency and self-criticism are vulnerability factors for depression. How these personality factors change with treatment for depression and how they relate to symptom change across different types of treatment require further research. In addition, cultural differences that interact with the dependency/self-criticism-depression relation remain underinvestigated. We randomly assigned 149 adults with major depression to receive active medication (MED; n = 50), supportive-expressive therapy (SET; n = 49), or placebo pill (PBO; n = 50). Participants completed the Depressive Experiences Questionnaire (DEQ; Blatt, D'Afflitti, & Quinlan, 1976) before and after treatment and completed the Hamilton Rating Scale for Depression (Hamilton, 1967) throughout the course of treatment. Self-criticism as measured on the DEQ decreased with treatment similarly across conditions. DEQ Dependency decreased in MED but remained unchanged in SET and PBO. Higher initial dependency, but not higher initial self-criticism, predicted poor treatment response across conditions. Greater reduction in self-criticism was associated with greater reduction in depressive symptoms, but the effect was weaker for racial minorities (vs. White). Increase in connectedness, an adaptive form of dependency, was associated with symptom improvement in SET but not MED. Hence, different pathways of change seem to be implicated in the treatment of depression depending on culture and type of intervention. Implications for future research are discussed. (PsycINFO Database Record PMID:26866638

  19. Depression risk in patients with coronary heart disease in Germany

    Science.gov (United States)

    Konrad, Marcel; Jacob, Louis; Rapp, Michael A; Kostev, Karel

    2016-01-01

    AIM To determine the prevalence of depression and its risk factors among patients with coronary heart disease (CHD) treated in German primary care practices. METHODS Longitudinal data from nationwide general practices in Germany (n = 1072) were analyzed. Individuals initially diagnosed with CHD (2009-2013) were identified, and 59992 patients were included and matched (1:1) to 59992 controls. The primary outcome measure was an initial diagnosis of depression within five years after the index date among patients with and without CHD. Cox proportional hazards models were used to adjust for confounders. RESULTS Mean age was equal to 68.0 years (SD = 11.3). A total of 55.9% of patients were men. After a five-year follow-up, 21.8% of the CHD group and 14.2% of the control group were diagnosed with depression (P risk factor for developing depression (HR = 1.54, 95%CI: 1.49-1.59, P risk of developing depression. Interestingly, older patients and women were also more likely to be diagnosed with depression compared with younger patients and men, respectively. CONCLUSION The risk of depression is significantly increased among patients with CHD compared with patients without CHD treated in primary care practices in Germany. CHD patients should be routinely screened for depression to ensure improved treatment and management.

  20. Depression and bulimia: the link between depression and bulimic cognitions.

    Science.gov (United States)

    Schlesier-Carter, B; Hamilton, S A; O'Neil, P M; Lydiard, R B; Malcolm, R

    1989-08-01

    This study assessed the link between bulimic and depressive cognitions. Twenty-nine bulimics and 16 controls from the general population were first assessed on levels of depression using the Schedule for Affective Disorders and Schizophrenia-Change Version and the Beck Depression Inventory (BDI). Bulimics were significantly more depressed than controls. Bulimics differed significantly from controls on all cognitive measures associated with depression (Automatic Thoughts Questionnaire, Dysfunctional Attitude Scale, and Attributional Style Questionnaire), but differences on these measures were nonsignificant when depression, as measured by the BDI, was controlled. Bulimics differed from controls regardless of level of depression on the three scales of the Restraint Inventory, the Rationalization and All-or-None scales of the Thoughts About Eating Inventory, and most of the eight scales of the Eating Disorders Inventory. Bulimics showed more maladaptive thinking associated with depression, but these differences likely reflect the levels of depression for each group. The differences on the measures of cognitive and behavioral symptoms of bulimia remained when the level of depression was controlled statistically. This suggests that although depression can be frequently diagnosed in a bulimic sample, specific maladaptive cognitions and behaviors reflect a distinct disorder (bulimia) and are not simply the expression of an affective disorder. PMID:2768669